id	sid	tid	token	lemma	pos
dpc-4248	1	1	dermatology	dermatology	NOUN
dpc-4248	1	2	:	:	PUNCT
dpc-4248	1	3	practical	practical	ADJ
dpc-4248	1	4	and	and	CCONJ
dpc-4248	1	5	conceptual	conceptual	ADJ
dpc-4248	1	6	original	original	ADJ
dpc-4248	1	7	article	article	NOUN
dpc-4248	1	8	|	|	ADV
dpc-4248	1	9	dermatol	dermatol	ADJ
dpc-4248	1	10	pract	pract	NOUN
dpc-4248	1	11	concept	concept	NOUN
dpc-4248	1	12	.	.	PUNCT
dpc-4248	2	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	2	2	1	1	NUM
dpc-4248	2	3	long	long	ADJ
dpc-4248	2	4	-	-	PUNCT
dpc-4248	2	5	term	term	NOUN
dpc-4248	2	6	effectiveness	effectiveness	NOUN
dpc-4248	2	7	of	of	ADP
dpc-4248	2	8	brodalumab	brodalumab	NOUN
dpc-4248	2	9	for	for	ADP
dpc-4248	2	10	 	 	SPACE
dpc-4248	2	11	the	the	DET
dpc-4248	2	12	 	 	SPACE
dpc-4248	2	13	treatment	treatment	NOUN
dpc-4248	2	14	of	of	ADP
dpc-4248	2	15	moderate	moderate	ADJ
dpc-4248	2	16	-	-	PUNCT
dpc-4248	2	17	to	to	ADP
dpc-4248	2	18	-	-	PUNCT
dpc-4248	2	19	severe	severe	ADJ
dpc-4248	2	20	psoriasis	psoriasis	NOUN
dpc-4248	2	21	:	:	PUNCT
dpc-4248	2	22	a	a	DET
dpc-4248	2	23	real	real	ADJ
dpc-4248	2	24	-	-	PUNCT
dpc-4248	2	25	life	life	NOUN
dpc-4248	2	26	multicenter	multicenter	NOUN
dpc-4248	2	27	study	study	NOUN
dpc-4248	2	28	of	of	ADP
dpc-4248	2	29	up	up	ADP
dpc-4248	2	30	to	to	PART
dpc-4248	2	31	3	3	NUM
dpc-4248	2	32	years	year	NOUN
dpc-4248	2	33	in	in	ADP
dpc-4248	2	34	 	 	SPACE
dpc-4248	2	35	a	a	DET
dpc-4248	2	36	 	 	SPACE
dpc-4248	2	37	real	real	ADJ
dpc-4248	2	38	-	-	PUNCT
dpc-4248	2	39	life	life	NOUN
dpc-4248	2	40	italian	italian	ADJ
dpc-4248	2	41	cohort	cohort	NOUN
dpc-4248	2	42	giacomo	giacomo	PROPN
dpc-4248	2	43	caldarola1,2	caldarola1,2	PROPN
dpc-4248	2	44	,	,	PUNCT
dpc-4248	2	45	marco	marco	PROPN
dpc-4248	2	46	galluzzo3,4	galluzzo3,4	PROPN
dpc-4248	2	47	,	,	PUNCT
dpc-4248	2	48	nicoletta	nicoletta	PROPN
dpc-4248	2	49	bernardini5	bernardini5	PROPN
dpc-4248	2	50	,	,	PUNCT
dpc-4248	2	51	elisabetta	elisabetta	PROPN
dpc-4248	2	52	botti4	botti4	PROPN
dpc-4248	2	53	,	,	PUNCT
dpc-4248	2	54	eleonora	eleonora	PROPN
dpc-4248	2	55	de	de	PROPN
dpc-4248	2	56	luca1,2	luca1,2	PROPN
dpc-4248	2	57	,	,	PUNCT
dpc-4248	2	58	clara	clara	PROPN
dpc-4248	2	59	de	de	PROPN
dpc-4248	2	60	simone1,2	simone1,2	PROPN
dpc-4248	2	61	,	,	PUNCT
dpc-4248	2	62	marco	marco	PROPN
dpc-4248	2	63	mariani6	mariani6	PROPN
dpc-4248	2	64	,	,	PUNCT
dpc-4248	2	65	gaia	gaia	PROPN
dpc-4248	2	66	moretta7	moretta7	PROPN
dpc-4248	2	67	,	,	PUNCT
dpc-4248	2	68	sabatino	sabatino	PROPN
dpc-4248	2	69	pallotta7	pallotta7	PROPN
dpc-4248	2	70	,	,	PUNCT
dpc-4248	2	71	elena	elena	NOUN
dpc-4248	3	1	campione3,4	campione3,4	PROPN
dpc-4248	3	2	,	,	PUNCT
dpc-4248	3	3	ketty	ketty	PROPN
dpc-4248	3	4	peris1,2	peris1,2	PROPN
dpc-4248	3	5	1	1	NUM
dpc-4248	3	6	uoc	uoc	PROPN
dpc-4248	3	7	di	di	NOUN
dpc-4248	3	8	dermatologia	dermatologia	PROPN
dpc-4248	3	9	,	,	PUNCT
dpc-4248	3	10	dipartimento	dipartimento	ADP
dpc-4248	3	11	di	di	PROPN
dpc-4248	3	12	scienze	scienze	PROPN
dpc-4248	3	13	mediche	mediche	PROPN
dpc-4248	3	14	e	e	PROPN
dpc-4248	3	15	chirurgiche	chirurgiche	PROPN
dpc-4248	3	16	,	,	PUNCT
dpc-4248	3	17	fondazione	fondazione	PROPN
dpc-4248	3	18	policlinico	policlinico	PROPN
dpc-4248	3	19	universitario	universitario	PROPN
dpc-4248	3	20	a.	a.	PROPN
dpc-4248	3	21	gemelli	gemelli	PROPN
dpc-4248	3	22	irccs	irccs	PROPN
dpc-4248	3	23	,	,	PUNCT
dpc-4248	3	24	rome	rome	PROPN
dpc-4248	3	25	,	,	PUNCT
dpc-4248	3	26	italy	italy	PROPN
dpc-4248	3	27	2	2	NUM
dpc-4248	3	28	dermatologia	dermatologia	NOUN
dpc-4248	3	29	,	,	PUNCT
dpc-4248	3	30	dipartimento	dipartimento	ADP
dpc-4248	3	31	di	di	NOUN
dpc-4248	3	32	medicina	medicina	PROPN
dpc-4248	3	33	e	e	PROPN
dpc-4248	3	34	chirurgia	chirurgia	PROPN
dpc-4248	3	35	traslazionale	traslazionale	PROPN
dpc-4248	3	36	,	,	PUNCT
dpc-4248	3	37	università	università	PROPN
dpc-4248	3	38	cattolica	cattolica	PROPN
dpc-4248	3	39	del	del	PROPN
dpc-4248	3	40	sacro	sacro	PROPN
dpc-4248	3	41	cuore	cuore	PROPN
dpc-4248	3	42	,	,	PUNCT
dpc-4248	3	43	rome	rome	PROPN
dpc-4248	3	44	,	,	PUNCT
dpc-4248	3	45	italy	italy	PROPN
dpc-4248	3	46	3	3	NUM
dpc-4248	3	47	department	department	PROPN
dpc-4248	3	48	of	of	ADP
dpc-4248	3	49	systems	system	NOUN
dpc-4248	3	50	medicine	medicine	NOUN
dpc-4248	3	51	,	,	PUNCT
dpc-4248	3	52	university	university	NOUN
dpc-4248	3	53	of	of	ADP
dpc-4248	3	54	rome	rome	PROPN
dpc-4248	3	55	“	"	PUNCT
dpc-4248	3	56	tor	tor	PROPN
dpc-4248	3	57	vergata	vergata	NOUN
dpc-4248	3	58	”	"	PUNCT
dpc-4248	3	59	,	,	PUNCT
dpc-4248	3	60	rome	rome	PROPN
dpc-4248	3	61	,	,	PUNCT
dpc-4248	3	62	italy	italy	PROPN
dpc-4248	3	63	4	4	NUM
dpc-4248	3	64	dermatology	dermatology	NOUN
dpc-4248	3	65	unit	unit	NOUN
dpc-4248	3	66	,	,	PUNCT
dpc-4248	3	67	azienda	azienda	PROPN
dpc-4248	3	68	ospedaliera	ospedaliera	PROPN
dpc-4248	3	69	universitaria	universitaria	PROPN
dpc-4248	3	70	“	"	PUNCT
dpc-4248	3	71	policlinico	policlinico	NOUN
dpc-4248	3	72	tor	tor	NOUN
dpc-4248	3	73	vergata	vergata	NOUN
dpc-4248	3	74	”	"	PUNCT
dpc-4248	3	75	,	,	PUNCT
dpc-4248	3	76	rome	rome	PROPN
dpc-4248	3	77	,	,	PUNCT
dpc-4248	3	78	italy	italy	PROPN
dpc-4248	3	79	5	5	NUM
dpc-4248	3	80	department	department	PROPN
dpc-4248	3	81	of	of	ADP
dpc-4248	3	82	medical	medical	ADJ
dpc-4248	3	83	-	-	PUNCT
dpc-4248	3	84	surgical	surgical	ADJ
dpc-4248	3	85	sciences	science	NOUN
dpc-4248	3	86	and	and	CCONJ
dpc-4248	3	87	biotechnologies	biotechnology	NOUN
dpc-4248	3	88	,	,	PUNCT
dpc-4248	3	89	sapienza	sapienza	PROPN
dpc-4248	3	90	university	university	PROPN
dpc-4248	3	91	dermatology	dermatology	NOUN
dpc-4248	3	92	unit	unit	NOUN
dpc-4248	3	93	“	"	PUNCT
dpc-4248	3	94	daniele	daniele	PROPN
dpc-4248	3	95	innocenzi	innocenzi	PROPN
dpc-4248	3	96	”	"	PUNCT
dpc-4248	3	97	,	,	PUNCT
dpc-4248	3	98	asl	asl	PROPN
dpc-4248	3	99	latina	latina	PROPN
dpc-4248	3	100	,	,	PUNCT
dpc-4248	3	101	italy	italy	PROPN
dpc-4248	3	102	6	6	NUM
dpc-4248	3	103	section	section	NOUN
dpc-4248	3	104	of	of	ADP
dpc-4248	3	105	hygiene	hygiene	NOUN
dpc-4248	3	106	,	,	PUNCT
dpc-4248	3	107	university	university	NOUN
dpc-4248	3	108	department	department	PROPN
dpc-4248	3	109	of	of	ADP
dpc-4248	3	110	health	health	PROPN
dpc-4248	3	111	sciences	sciences	PROPN
dpc-4248	3	112	and	and	CCONJ
dpc-4248	3	113	public	public	ADJ
dpc-4248	3	114	health	health	NOUN
dpc-4248	3	115	,	,	PUNCT
dpc-4248	3	116	università	università	PROPN
dpc-4248	3	117	cattolica	cattolica	PROPN
dpc-4248	3	118	del	del	PROPN
dpc-4248	3	119	sacro	sacro	PROPN
dpc-4248	3	120	cuore	cuore	PROPN
dpc-4248	3	121	,	,	PUNCT
dpc-4248	3	122	rome	rome	PROPN
dpc-4248	3	123	,	,	PUNCT
dpc-4248	3	124	italy	italy	PROPN
dpc-4248	3	125	7	7	NUM
dpc-4248	3	126	dermatology	dermatology	NOUN
dpc-4248	3	127	unit	unit	NOUN
dpc-4248	3	128	,	,	PUNCT
dpc-4248	3	129	istituto	istituto	PROPN
dpc-4248	3	130	dermopatico	dermopatico	PROPN
dpc-4248	3	131	dell’immacolata	dell’immacolata	VERB
dpc-4248	3	132	idi	idi	PROPN
dpc-4248	3	133	-	-	PUNCT
dpc-4248	3	134	irccs	irccs	PROPN
dpc-4248	3	135	,	,	PUNCT
dpc-4248	3	136	rome	rome	PROPN
dpc-4248	3	137	,	,	PUNCT
dpc-4248	3	138	italy	italy	PROPN
dpc-4248	3	139	key	key	ADJ
dpc-4248	3	140	words	word	NOUN
dpc-4248	3	141	:	:	PUNCT
dpc-4248	3	142	biologics	biologic	NOUN
dpc-4248	3	143	,	,	PUNCT
dpc-4248	3	144	brodalumab	brodalumab	NOUN
dpc-4248	3	145	,	,	PUNCT
dpc-4248	3	146	drug	drug	NOUN
dpc-4248	3	147	survival	survival	NOUN
dpc-4248	3	148	,	,	PUNCT
dpc-4248	3	149	il-17	il-17	ADP
dpc-4248	3	150	inhibitors	inhibitor	NOUN
dpc-4248	3	151	,	,	PUNCT
dpc-4248	3	152	psoriasis	psoriasis	NOUN
dpc-4248	3	153	,	,	PUNCT
dpc-4248	3	154	real	real	ADJ
dpc-4248	3	155	-	-	PUNCT
dpc-4248	3	156	life	life	NOUN
dpc-4248	3	157	effectiveness	effectiveness	NOUN
dpc-4248	3	158	citation	citation	NOUN
dpc-4248	3	159	:	:	PUNCT
dpc-4248	3	160	caldarola	caldarola	PROPN
dpc-4248	3	161	g	g	PROPN
dpc-4248	3	162	,	,	PUNCT
dpc-4248	3	163	galluzzo	galluzzo	PROPN
dpc-4248	3	164	m	m	PROPN
dpc-4248	3	165	,	,	PUNCT
dpc-4248	3	166	bernardini	bernardini	PROPN
dpc-4248	3	167	n	n	CCONJ
dpc-4248	3	168	,	,	PUNCT
dpc-4248	3	169	et	et	PROPN
dpc-4248	3	170	al	al	PROPN
dpc-4248	3	171	.	.	PUNCT
dpc-4248	4	1	long	long	ADJ
dpc-4248	4	2	-	-	PUNCT
dpc-4248	4	3	term	term	NOUN
dpc-4248	4	4	effectiveness	effectiveness	NOUN
dpc-4248	4	5	of	of	ADP
dpc-4248	4	6	brodalumab	brodalumab	NOUN
dpc-4248	4	7	for	for	ADP
dpc-4248	4	8	the	the	DET
dpc-4248	4	9	treatment	treatment	NOUN
dpc-4248	4	10	of	of	ADP
dpc-4248	4	11	moderate	moderate	ADJ
dpc-4248	4	12	-	-	PUNCT
dpc-4248	4	13	to	to	ADP
dpc-4248	4	14	-	-	PUNCT
dpc-4248	4	15	severe	severe	ADJ
dpc-4248	4	16	psoriasis	psoriasis	NOUN
dpc-4248	4	17	:	:	PUNCT
dpc-4248	4	18	a	a	DET
dpc-4248	4	19	real	real	ADJ
dpc-4248	4	20	-	-	PUNCT
dpc-4248	4	21	life	life	NOUN
dpc-4248	4	22	multicenter	multicenter	NOUN
dpc-4248	4	23	study	study	NOUN
dpc-4248	4	24	of	of	ADP
dpc-4248	4	25	up	up	ADP
dpc-4248	4	26	to	to	PART
dpc-4248	4	27	3	3	NUM
dpc-4248	4	28	years	year	NOUN
dpc-4248	4	29	in	in	ADP
dpc-4248	4	30	a	a	DET
dpc-4248	4	31	real	real	ADJ
dpc-4248	4	32	-	-	PUNCT
dpc-4248	4	33	life	life	NOUN
dpc-4248	4	34	italian	italian	ADJ
dpc-4248	4	35	cohort	cohort	NOUN
dpc-4248	4	36	.	.	PUNCT
dpc-4248	5	1	dermatol	dermatol	NOUN
dpc-4248	5	2	pract	pract	PROPN
dpc-4248	5	3	concept	concept	NOUN
dpc-4248	5	4	.	.	PUNCT
dpc-4248	6	1	2024;14(2):e2024152	2024;14(2):e2024152	X
dpc-4248	6	2	.	.	PUNCT
dpc-4248	6	3	doi	doi	PROPN
dpc-4248	6	4	:	:	PUNCT
dpc-4248	6	5	https://doi.org/10.5826/dpc.1402a152	https://doi.org/10.5826/dpc.1402a152	PROPN
dpc-4248	6	6	accepted	accept	VERB
dpc-4248	6	7	:	:	PUNCT
dpc-4248	6	8	april	april	PROPN
dpc-4248	6	9	15	15	NUM
dpc-4248	6	10	,	,	PUNCT
dpc-4248	6	11	2024	2024	NUM
dpc-4248	6	12	;	;	PUNCT
dpc-4248	6	13	published	publish	VERB
dpc-4248	6	14	:	:	PUNCT
dpc-4248	7	1	april	april	PROPN
dpc-4248	7	2	2024	2024	NUM
dpc-4248	7	3	copyright	copyright	NOUN
dpc-4248	7	4	:	:	PUNCT
dpc-4248	7	5	©	©	PROPN
dpc-4248	7	6	2024	2024	NUM
dpc-4248	7	7	caldarola	caldarola	PROPN
dpc-4248	7	8	et	et	PROPN
dpc-4248	7	9	al	al	PROPN
dpc-4248	7	10	.	.	PUNCT
dpc-4248	8	1	this	this	PRON
dpc-4248	8	2	is	be	AUX
dpc-4248	8	3	an	an	DET
dpc-4248	8	4	open	open	ADJ
dpc-4248	8	5	-	-	PUNCT
dpc-4248	8	6	access	access	NOUN
dpc-4248	8	7	article	article	NOUN
dpc-4248	8	8	distributed	distribute	VERB
dpc-4248	8	9	under	under	ADP
dpc-4248	8	10	the	the	DET
dpc-4248	8	11	terms	term	NOUN
dpc-4248	8	12	of	of	ADP
dpc-4248	8	13	the	the	DET
dpc-4248	8	14	creative	creative	ADJ
dpc-4248	8	15	commons	common	NOUN
dpc-4248	8	16	attributionnoncommercial	attributionnoncommercial	ADJ
dpc-4248	8	17	license	license	NOUN
dpc-4248	8	18	(	(	PUNCT
dpc-4248	8	19	by	by	ADP
dpc-4248	8	20	-	-	PUNCT
dpc-4248	8	21	nc-4.0	nc-4.0	NOUN
dpc-4248	8	22	)	)	PUNCT
dpc-4248	8	23	,	,	PUNCT
dpc-4248	8	24	https://creativecommons.org/licenses/by-nc/4.0/	https://creativecommons.org/licenses/by-nc/4.0/	PROPN
dpc-4248	8	25	,	,	PUNCT
dpc-4248	8	26	which	which	PRON
dpc-4248	8	27	permits	permit	VERB
dpc-4248	8	28	unrestricted	unrestricted	ADJ
dpc-4248	8	29	noncommercial	noncommercial	ADJ
dpc-4248	8	30	use	use	NOUN
dpc-4248	8	31	,	,	PUNCT
dpc-4248	8	32	distribution	distribution	NOUN
dpc-4248	8	33	,	,	PUNCT
dpc-4248	8	34	and	and	CCONJ
dpc-4248	8	35	reproduction	reproduction	NOUN
dpc-4248	8	36	in	in	ADP
dpc-4248	8	37	any	any	DET
dpc-4248	8	38	medium	medium	NOUN
dpc-4248	8	39	,	,	PUNCT
dpc-4248	8	40	provided	provide	VERB
dpc-4248	8	41	the	the	DET
dpc-4248	8	42	original	original	ADJ
dpc-4248	8	43	authors	author	NOUN
dpc-4248	8	44	and	and	CCONJ
dpc-4248	8	45	source	source	NOUN
dpc-4248	8	46	are	be	AUX
dpc-4248	8	47	credited	credit	VERB
dpc-4248	8	48	.	.	PUNCT
dpc-4248	9	1	funding	funding	NOUN
dpc-4248	9	2	:	:	PUNCT
dpc-4248	9	3	none	none	NOUN
dpc-4248	9	4	.	.	PUNCT
dpc-4248	10	1	competing	compete	VERB
dpc-4248	10	2	interests	interest	NOUN
dpc-4248	10	3	:	:	PUNCT
dpc-4248	10	4	g	g	PROPN
dpc-4248	10	5	caldarola	caldarola	PROPN
dpc-4248	10	6	has	have	AUX
dpc-4248	10	7	received	receive	VERB
dpc-4248	10	8	consulting	consulting	NOUN
dpc-4248	10	9	fees	fee	NOUN
dpc-4248	10	10	,	,	PUNCT
dpc-4248	10	11	honoraria	honorarium	NOUN
dpc-4248	10	12	and	and	CCONJ
dpc-4248	10	13	support	support	NOUN
dpc-4248	10	14	for	for	ADP
dpc-4248	10	15	attending	attend	VERB
dpc-4248	10	16	meetings	meeting	NOUN
dpc-4248	10	17	from	from	ADP
dpc-4248	10	18	abbvie	abbvie	PROPN
dpc-4248	10	19	,	,	PUNCT
dpc-4248	10	20	lilly	lilly	PROPN
dpc-4248	10	21	,	,	PUNCT
dpc-4248	10	22	janssen	janssen	PROPN
dpc-4248	10	23	,	,	PUNCT
dpc-4248	10	24	ucb	ucb	PROPN
dpc-4248	10	25	,	,	PUNCT
dpc-4248	10	26	novartis	novartis	PROPN
dpc-4248	10	27	and	and	CCONJ
dpc-4248	10	28	leopharma	leopharma	PROPN
dpc-4248	10	29	;	;	PUNCT
dpc-4248	10	30	c	c	PROPN
dpc-4248	10	31	de	de	X
dpc-4248	10	32	simone	simone	PROPN
dpc-4248	10	33	has	have	AUX
dpc-4248	10	34	received	receive	VERB
dpc-4248	10	35	support	support	NOUN
dpc-4248	10	36	for	for	ADP
dpc-4248	10	37	consulting	consulting	NOUN
dpc-4248	10	38	fees	fee	NOUN
dpc-4248	10	39	,	,	PUNCT
dpc-4248	10	40	honoraria	honorarium	NOUN
dpc-4248	10	41	and	and	CCONJ
dpc-4248	10	42	support	support	NOUN
dpc-4248	10	43	for	for	ADP
dpc-4248	10	44	attending	attend	VERB
dpc-4248	10	45	meetings	meeting	NOUN
dpc-4248	10	46	from	from	ADP
dpc-4248	10	47	abbvie	abbvie	PROPN
dpc-4248	10	48	,	,	PUNCT
dpc-4248	10	49	lilly	lilly	PROPN
dpc-4248	10	50	,	,	PUNCT
dpc-4248	10	51	janssen	janssen	PROPN
dpc-4248	10	52	,	,	PUNCT
dpc-4248	10	53	ucb	ucb	PROPN
dpc-4248	10	54	,	,	PUNCT
dpc-4248	10	55	novartis	novartis	PROPN
dpc-4248	10	56	,	,	PUNCT
dpc-4248	10	57	leopharma	leopharma	PROPN
dpc-4248	10	58	,	,	PUNCT
dpc-4248	10	59	sanofi	sanofi	PROPN
dpc-4248	10	60	and	and	CCONJ
dpc-4248	10	61	almiral	almiral	ADJ
dpc-4248	10	62	;	;	PUNCT
dpc-4248	10	63	k	k	PROPN
dpc-4248	10	64	peris	peris	PROPN
dpc-4248	10	65	has	have	AUX
dpc-4248	10	66	received	receive	VERB
dpc-4248	10	67	support	support	NOUN
dpc-4248	10	68	for	for	ADP
dpc-4248	10	69	consulting	consult	VERB
dpc-4248	10	70	fees	fee	NOUN
dpc-4248	10	71	and	and	CCONJ
dpc-4248	10	72	honoraria	honorarium	NOUN
dpc-4248	10	73	from	from	ADP
dpc-4248	10	74	abbvie	abbvie	PROPN
dpc-4248	10	75	,	,	PUNCT
dpc-4248	10	76	almirall	almirall	ADJ
dpc-4248	10	77	,	,	PUNCT
dpc-4248	10	78	biogen	biogen	PROPN
dpc-4248	10	79	,	,	PUNCT
dpc-4248	10	80	celgene	celgene	NOUN
dpc-4248	10	81	,	,	PUNCT
dpc-4248	10	82	janssen	janssen	PROPN
dpc-4248	10	83	galderma	galderma	PROPN
dpc-4248	10	84	,	,	PUNCT
dpc-4248	10	85	novartis	novartis	PROPN
dpc-4248	10	86	,	,	PUNCT
dpc-4248	10	87	lilly	lilly	PROPN
dpc-4248	10	88	,	,	PUNCT
dpc-4248	10	89	novartis	novartis	PROPN
dpc-4248	10	90	,	,	PUNCT
dpc-4248	10	91	pierre	pierre	PROPN
dpc-4248	10	92	fabre	fabre	PROPN
dpc-4248	10	93	,	,	PUNCT
dpc-4248	10	94	sandoz	sandoz	PROPN
dpc-4248	10	95	,	,	PUNCT
dpc-4248	10	96	sanofi	sanofi	PROPN
dpc-4248	10	97	and	and	CCONJ
dpc-4248	10	98	sun	sun	PROPN
dpc-4248	10	99	pharma	pharma	PROPN
dpc-4248	10	100	.	.	PUNCT
dpc-4248	11	1	m	m	AUX
dpc-4248	11	2	galluzzo	galluzzo	NOUN
dpc-4248	11	3	declare	declare	VERB
dpc-4248	11	4	to	to	PART
dpc-4248	11	5	have	have	AUX
dpc-4248	11	6	acted	act	VERB
dpc-4248	11	7	as	as	ADP
dpc-4248	11	8	speakers	speaker	NOUN
dpc-4248	11	9	and/or	and/or	CCONJ
dpc-4248	11	10	consultants	consultant	NOUN
dpc-4248	11	11	for	for	ADP
dpc-4248	11	12	abbvie	abbvie	NOUN
dpc-4248	11	13	,	,	PUNCT
dpc-4248	11	14	almirall	almirall	ADJ
dpc-4248	11	15	,	,	PUNCT
dpc-4248	11	16	eli	eli	PROPN
dpc-4248	11	17	-	-	PUNCT
dpc-4248	11	18	lilly	lilly	PROPN
dpc-4248	11	19	,	,	PUNCT
dpc-4248	11	20	janssen	janssen	NOUN
dpc-4248	11	21	-	-	PUNCT
dpc-4248	11	22	cilag	cilag	PROPN
dpc-4248	11	23	,	,	PUNCT
dpc-4248	11	24	leopharma	leopharma	PROPN
dpc-4248	11	25	,	,	PUNCT
dpc-4248	11	26	novartis	novartis	PROPN
dpc-4248	11	27	and	and	CCONJ
dpc-4248	11	28	sanofi	sanofi	PROPN
dpc-4248	11	29	,	,	PUNCT
dpc-4248	11	30	outside	outside	ADP
dpc-4248	11	31	the	the	DET
dpc-4248	11	32	submitted	submit	VERB
dpc-4248	11	33	work	work	NOUN
dpc-4248	11	34	.	.	PUNCT
dpc-4248	12	1	e	e	X
dpc-4248	12	2	campione	campione	PROPN
dpc-4248	12	3	served	serve	VERB
dpc-4248	12	4	as	as	ADP
dpc-4248	12	5	a	a	DET
dpc-4248	12	6	consultant	consultant	NOUN
dpc-4248	12	7	for	for	ADP
dpc-4248	12	8	almirall	almirall	NOUN
dpc-4248	12	9	,	,	PUNCT
dpc-4248	12	10	bms	bms	PROPN
dpc-4248	12	11	,	,	PUNCT
dpc-4248	12	12	amgen	amgen	PROPN
dpc-4248	12	13	,	,	PUNCT
dpc-4248	12	14	and	and	CCONJ
dpc-4248	12	15	ucb	ucb	PROPN
dpc-4248	12	16	.	.	PUNCT
dpc-4248	13	1	g	g	PROPN
dpc-4248	13	2	moretta	moretta	PROPN
dpc-4248	13	3	has	have	AUX
dpc-4248	13	4	received	receive	VERB
dpc-4248	13	5	consulting	consulting	NOUN
dpc-4248	13	6	fees	fee	NOUN
dpc-4248	13	7	,	,	PUNCT
dpc-4248	13	8	honoraria	honorarium	NOUN
dpc-4248	13	9	and	and	CCONJ
dpc-4248	13	10	support	support	NOUN
dpc-4248	13	11	for	for	ADP
dpc-4248	13	12	attending	attend	VERB
dpc-4248	13	13	meetings	meeting	NOUN
dpc-4248	13	14	from	from	ADP
dpc-4248	13	15	abbvie	abbvie	PROPN
dpc-4248	13	16	,	,	PUNCT
dpc-4248	13	17	leopharma	leopharma	PROPN
dpc-4248	13	18	,	,	PUNCT
dpc-4248	13	19	sanofi	sanofi	NOUN
dpc-4248	13	20	and	and	CCONJ
dpc-4248	13	21	lilly	lilly	PROPN
dpc-4248	13	22	.	.	PUNCT
dpc-4248	14	1	all	all	DET
dpc-4248	14	2	other	other	ADJ
dpc-4248	14	3	authors	author	NOUN
dpc-4248	14	4	declare	declare	VERB
dpc-4248	14	5	that	that	SCONJ
dpc-4248	14	6	they	they	PRON
dpc-4248	14	7	have	have	VERB
dpc-4248	14	8	no	no	DET
dpc-4248	14	9	conflicts	conflict	NOUN
dpc-4248	14	10	of	of	ADP
dpc-4248	14	11	interest	interest	NOUN
dpc-4248	14	12	relevant	relevant	ADJ
dpc-4248	14	13	to	to	ADP
dpc-4248	14	14	this	this	DET
dpc-4248	14	15	manuscript	manuscript	NOUN
dpc-4248	14	16	.	.	PUNCT
dpc-4248	15	1	authorship	authorship	NOUN
dpc-4248	15	2	:	:	PUNCT
dpc-4248	15	3	g.	g.	PROPN
dpc-4248	15	4	caldarola	caldarola	PROPN
dpc-4248	15	5	and	and	CCONJ
dpc-4248	15	6	m.	m.	NOUN
dpc-4248	15	7	galluzzo	galluzzo	NOUN
dpc-4248	15	8	contributed	contribute	VERB
dpc-4248	15	9	equally	equally	ADV
dpc-4248	15	10	to	to	ADP
dpc-4248	15	11	this	this	DET
dpc-4248	15	12	manuscript	manuscript	NOUN
dpc-4248	15	13	.	.	PUNCT
dpc-4248	16	1	all	all	DET
dpc-4248	16	2	authors	author	NOUN
dpc-4248	16	3	have	have	AUX
dpc-4248	16	4	contributed	contribute	VERB
dpc-4248	16	5	significantly	significantly	ADV
dpc-4248	16	6	to	to	ADP
dpc-4248	16	7	this	this	DET
dpc-4248	16	8	publication	publication	NOUN
dpc-4248	16	9	.	.	PUNCT
dpc-4248	17	1	corresponding	correspond	VERB
dpc-4248	17	2	author	author	NOUN
dpc-4248	17	3	:	:	PUNCT
dpc-4248	17	4	eleonora	eleonora	PROPN
dpc-4248	17	5	de	de	X
dpc-4248	17	6	luca	luca	PROPN
dpc-4248	17	7	,	,	PUNCT
dpc-4248	17	8	uoc	uoc	PROPN
dpc-4248	17	9	di	di	PROPN
dpc-4248	17	10	dermatologia	dermatologia	PROPN
dpc-4248	17	11	,	,	PUNCT
dpc-4248	17	12	università	università	PROPN
dpc-4248	17	13	cattolica	cattolica	PROPN
dpc-4248	17	14	del	del	PROPN
dpc-4248	17	15	sacro	sacro	PROPN
dpc-4248	17	16	cuore	cuore	PROPN
dpc-4248	17	17	,	,	PUNCT
dpc-4248	17	18	l.go	l.go	PROPN
dpc-4248	17	19	f.	f.	PROPN
dpc-4248	17	20	vito	vito	PROPN
dpc-4248	17	21	1	1	NUM
dpc-4248	17	22	00135	00135	NUM
dpc-4248	17	23	roma	roma	PROPN
dpc-4248	17	24	,	,	PUNCT
dpc-4248	17	25	italy	italy	PROPN
dpc-4248	17	26	.	.	PUNCT
dpc-4248	18	1	phone	phone	NOUN
dpc-4248	18	2	:	:	PUNCT
dpc-4248	18	3	+39	+39	PROPN
dpc-4248	18	4	(	(	PUNCT
dpc-4248	18	5	0)6	0)6	PROPN
dpc-4248	18	6	3015	3015	NUM
dpc-4248	18	7	4227	4227	NUM
dpc-4248	19	1	e	e	NOUN
dpc-4248	19	2	-	-	NOUN
dpc-4248	19	3	mail	mail	NOUN
dpc-4248	19	4	:	:	PUNCT
dpc-4248	19	5	deluca.eleonora94@gmail.com	deluca.eleonora94@gmail.com	X
dpc-4248	19	6	2	2	NUM
dpc-4248	19	7	original	original	ADJ
dpc-4248	19	8	article	article	NOUN
dpc-4248	19	9	|	|	ADV
dpc-4248	19	10	dermatol	dermatol	ADJ
dpc-4248	19	11	pract	pract	NOUN
dpc-4248	19	12	concept	concept	NOUN
dpc-4248	19	13	.	.	PUNCT
dpc-4248	20	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	20	2	introduction	introduction	NOUN
dpc-4248	20	3	the	the	DET
dpc-4248	20	4	management	management	NOUN
dpc-4248	20	5	of	of	ADP
dpc-4248	20	6	psoriasis	psoriasis	NOUN
dpc-4248	20	7	has	have	AUX
dpc-4248	20	8	improved	improve	VERB
dpc-4248	20	9	in	in	ADP
dpc-4248	20	10	recent	recent	ADJ
dpc-4248	20	11	years	year	NOUN
dpc-4248	20	12	due	due	ADP
dpc-4248	20	13	to	to	ADP
dpc-4248	20	14	the	the	DET
dpc-4248	20	15	expansion	expansion	NOUN
dpc-4248	20	16	of	of	ADP
dpc-4248	20	17	available	available	ADJ
dpc-4248	20	18	systemic	systemic	ADJ
dpc-4248	20	19	therapies	therapy	NOUN
dpc-4248	20	20	.	.	PUNCT
dpc-4248	21	1	biologic	biologic	NOUN
dpc-4248	21	2	drugs	drug	NOUN
dpc-4248	21	3	target	target	VERB
dpc-4248	21	4	specific	specific	ADJ
dpc-4248	21	5	immune	immune	ADJ
dpc-4248	21	6	system	system	NOUN
dpc-4248	21	7	pathways	pathway	NOUN
dpc-4248	21	8	involved	involve	VERB
dpc-4248	21	9	in	in	ADP
dpc-4248	21	10	psoriasis	psoriasis	NOUN
dpc-4248	21	11	,	,	PUNCT
dpc-4248	21	12	allowing	allow	VERB
dpc-4248	21	13	for	for	ADP
dpc-4248	21	14	the	the	DET
dpc-4248	21	15	optimization	optimization	NOUN
dpc-4248	21	16	of	of	ADP
dpc-4248	21	17	clinical	clinical	ADJ
dpc-4248	21	18	responses	response	NOUN
dpc-4248	21	19	and	and	CCONJ
dpc-4248	21	20	the	the	DET
dpc-4248	21	21	long	long	ADJ
dpc-4248	21	22	-	-	PUNCT
dpc-4248	21	23	term	term	NOUN
dpc-4248	21	24	management	management	NOUN
dpc-4248	21	25	of	of	ADP
dpc-4248	21	26	patients	patient	NOUN
dpc-4248	21	27	.	.	PUNCT
dpc-4248	22	1	the	the	DET
dpc-4248	22	2	remarkable	remarkable	ADJ
dpc-4248	22	3	pharmaceutical	pharmaceutical	ADJ
dpc-4248	22	4	improvement	improvement	NOUN
dpc-4248	22	5	in	in	ADP
dpc-4248	22	6	recent	recent	ADJ
dpc-4248	22	7	years	year	NOUN
dpc-4248	22	8	has	have	AUX
dpc-4248	22	9	led	lead	VERB
dpc-4248	22	10	to	to	ADP
dpc-4248	22	11	the	the	DET
dpc-4248	22	12	development	development	NOUN
dpc-4248	22	13	of	of	ADP
dpc-4248	22	14	new	new	ADJ
dpc-4248	22	15	biologic	biologic	NOUN
dpc-4248	22	16	therapies	therapy	NOUN
dpc-4248	22	17	that	that	PRON
dpc-4248	22	18	target	target	VERB
dpc-4248	22	19	interleukins	interleukin	VERB
dpc-4248	22	20	(	(	PUNCT
dpc-4248	22	21	il	il	PROPN
dpc-4248	22	22	)	)	PUNCT
dpc-4248	22	23	17	17	NUM
dpc-4248	22	24	and	and	CCONJ
dpc-4248	22	25	23	23	NUM
dpc-4248	22	26	,	,	PUNCT
dpc-4248	22	27	allowing	allow	VERB
dpc-4248	22	28	to	to	PART
dpc-4248	22	29	achieve	achieve	VERB
dpc-4248	22	30	higher	high	ADJ
dpc-4248	22	31	skin	skin	NOUN
dpc-4248	22	32	clearance	clearance	NOUN
dpc-4248	22	33	with	with	ADP
dpc-4248	22	34	a	a	DET
dpc-4248	22	35	good	good	ADJ
dpc-4248	22	36	safety	safety	NOUN
dpc-4248	22	37	profile	profile	NOUN
dpc-4248	22	38	.	.	PUNCT
dpc-4248	23	1	brodalumab	brodalumab	NOUN
dpc-4248	23	2	is	be	AUX
dpc-4248	23	3	a	a	DET
dpc-4248	23	4	fully	fully	ADV
dpc-4248	23	5	human	human	ADJ
dpc-4248	23	6	monoclonal	monoclonal	NOUN
dpc-4248	23	7	antibody	antibody	NOUN
dpc-4248	23	8	that	that	PRON
dpc-4248	23	9	specifically	specifically	ADV
dpc-4248	23	10	targets	target	VERB
dpc-4248	23	11	the	the	DET
dpc-4248	23	12	interleukin-17	interleukin-17	PROPN
dpc-4248	23	13	receptor	receptor	NOUN
dpc-4248	23	14	a	a	DET
dpc-4248	23	15	(	(	PUNCT
dpc-4248	23	16	il-17ra	il-17ra	PROPN
dpc-4248	23	17	)	)	PUNCT
dpc-4248	23	18	,	,	PUNCT
dpc-4248	23	19	inhibiting	inhibit	VERB
dpc-4248	23	20	the	the	DET
dpc-4248	23	21	signaling	signal	VERB
dpc-4248	23	22	pathway	pathway	NOUN
dpc-4248	23	23	of	of	ADP
dpc-4248	23	24	several	several	ADJ
dpc-4248	23	25	il-17	il-17	NUM
dpc-4248	23	26	isoforms	isoform	NOUN
dpc-4248	23	27	(	(	PUNCT
dpc-4248	23	28	instead	instead	ADV
dpc-4248	23	29	of	of	ADP
dpc-4248	23	30	(	(	PUNCT
dpc-4248	23	31	il-17isoforms	il-17isoform	NOUN
dpc-4248	23	32	)	)	PUNCT
dpc-4248	23	33	involved	involve	VERB
dpc-4248	23	34	in	in	ADP
dpc-4248	23	35	psoriasis	psoriasis	NOUN
dpc-4248	23	36	pathogenesis	pathogenesis	NOUN
dpc-4248	23	37	[	[	X
dpc-4248	23	38	1,2	1,2	NUM
dpc-4248	23	39	]	]	PUNCT
dpc-4248	23	40	.	.	PUNCT
dpc-4248	24	1	the	the	DET
dpc-4248	24	2	rapid	rapid	ADJ
dpc-4248	24	3	action	action	NOUN
dpc-4248	24	4	and	and	CCONJ
dpc-4248	24	5	high	high	ADJ
dpc-4248	24	6	efficacy	efficacy	NOUN
dpc-4248	24	7	of	of	ADP
dpc-4248	24	8	brodalumab	brodalumab	NOUN
dpc-4248	24	9	have	have	AUX
dpc-4248	24	10	already	already	ADV
dpc-4248	24	11	been	be	AUX
dpc-4248	24	12	demonstrated	demonstrate	VERB
dpc-4248	24	13	in	in	ADP
dpc-4248	24	14	three	three	NUM
dpc-4248	24	15	phase	phase	NOUN
dpc-4248	24	16	3	3	NUM
dpc-4248	24	17	randomized	randomize	VERB
dpc-4248	24	18	double	double	ADJ
dpc-4248	24	19	-	-	PUNCT
dpc-4248	24	20	blind	blind	ADJ
dpc-4248	24	21	trials	trial	NOUN
dpc-4248	24	22	(	(	PUNCT
dpc-4248	24	23	rcts	rct	NOUN
dpc-4248	24	24	):	):	PUNCT
dpc-4248	24	25	amagine-1	amagine-1	PROPN
dpc-4248	24	26	,	,	PUNCT
dpc-4248	24	27	amagine-2	amagine-2	PROPN
dpc-4248	24	28	,	,	PUNCT
dpc-4248	24	29	and	and	CCONJ
dpc-4248	24	30	amagine-3	amagine-3	NUM
dpc-4248	25	1	[	[	X
dpc-4248	25	2	3	3	NUM
dpc-4248	25	3	,	,	PUNCT
dpc-4248	25	4	4	4	NUM
dpc-4248	25	5	,	,	PUNCT
dpc-4248	25	6	5	5	NUM
dpc-4248	25	7	]	]	PUNCT
dpc-4248	25	8	,	,	PUNCT
dpc-4248	25	9	as	as	ADV
dpc-4248	25	10	well	well	ADV
dpc-4248	25	11	as	as	ADP
dpc-4248	25	12	in	in	ADP
dpc-4248	25	13	real	real	ADJ
dpc-4248	25	14	-	-	PUNCT
dpc-4248	25	15	life	life	NOUN
dpc-4248	25	16	settings	setting	NOUN
dpc-4248	25	17	[	[	X
dpc-4248	25	18	6	6	NUM
dpc-4248	25	19	,	,	PUNCT
dpc-4248	25	20	7	7	NUM
dpc-4248	25	21	,	,	PUNCT
dpc-4248	25	22	8	8	NUM
dpc-4248	25	23	,	,	PUNCT
dpc-4248	25	24	9	9	NUM
dpc-4248	25	25	,	,	PUNCT
dpc-4248	25	26	10	10	NUM
dpc-4248	25	27	]	]	PUNCT
dpc-4248	25	28	.	.	PUNCT
dpc-4248	26	1	for	for	ADP
dpc-4248	26	2	the	the	DET
dpc-4248	26	3	long	long	ADJ
dpc-4248	26	4	-	-	PUNCT
dpc-4248	26	5	term	term	NOUN
dpc-4248	26	6	management	management	NOUN
dpc-4248	26	7	of	of	ADP
dpc-4248	26	8	psoriasis	psoriasis	NOUN
dpc-4248	26	9	,	,	PUNCT
dpc-4248	26	10	evaluating	evaluate	VERB
dpc-4248	26	11	brodalumab	brodalumab	NOUN
dpc-4248	26	12	’s	’s	PART
dpc-4248	26	13	drug	drug	NOUN
dpc-4248	26	14	survival	survival	NOUN
dpc-4248	26	15	might	might	AUX
dpc-4248	26	16	help	help	VERB
dpc-4248	26	17	to	to	PART
dpc-4248	26	18	assess	assess	VERB
dpc-4248	26	19	its	its	PRON
dpc-4248	26	20	real	real	ADJ
dpc-4248	26	21	-	-	PUNCT
dpc-4248	26	22	world	world	NOUN
dpc-4248	26	23	success	success	NOUN
dpc-4248	26	24	and	and	CCONJ
dpc-4248	26	25	patient	patient	NOUN
dpc-4248	26	26	’s	’s	PART
dpc-4248	26	27	adherence	adherence	NOUN
dpc-4248	26	28	to	to	ADP
dpc-4248	26	29	the	the	DET
dpc-4248	26	30	treatment	treatment	NOUN
dpc-4248	26	31	,	,	PUNCT
dpc-4248	26	32	but	but	CCONJ
dpc-4248	26	33	to	to	ADP
dpc-4248	26	34	date	date	NOUN
dpc-4248	26	35	data	datum	NOUN
dpc-4248	26	36	in	in	ADP
dpc-4248	26	37	literature	literature	NOUN
dpc-4248	26	38	are	be	AUX
dpc-4248	26	39	scanty	scanty	ADJ
dpc-4248	26	40	.	.	PUNCT
dpc-4248	27	1	herein	herein	NOUN
dpc-4248	27	2	we	we	PRON
dpc-4248	27	3	present	present	VERB
dpc-4248	27	4	a	a	DET
dpc-4248	27	5	retrospective	retrospective	ADJ
dpc-4248	27	6	real	real	ADJ
dpc-4248	27	7	-	-	PUNCT
dpc-4248	27	8	life	life	NOUN
dpc-4248	27	9	multicenter	multicenter	NOUN
dpc-4248	27	10	study	study	NOUN
dpc-4248	27	11	conducted	conduct	VERB
dpc-4248	27	12	in	in	ADP
dpc-4248	27	13	a	a	DET
dpc-4248	27	14	real	real	ADJ
dpc-4248	27	15	life	life	NOUN
dpc-4248	27	16	italian	italian	ADJ
dpc-4248	27	17	cohort	cohort	NOUN
dpc-4248	27	18	,	,	PUNCT
dpc-4248	27	19	involving	involve	VERB
dpc-4248	27	20	patients	patient	NOUN
dpc-4248	27	21	with	with	ADP
dpc-4248	27	22	moderate	moderate	ADJ
dpc-4248	27	23	to	to	ADP
dpc-4248	27	24	severe	severe	ADJ
dpc-4248	27	25	psoriasis	psoriasis	NOUN
dpc-4248	27	26	who	who	PRON
dpc-4248	27	27	were	be	AUX
dpc-4248	27	28	treated	treat	VERB
dpc-4248	27	29	with	with	ADP
dpc-4248	27	30	brodalumab	brodalumab	NOUN
dpc-4248	27	31	for	for	ADP
dpc-4248	27	32	a	a	DET
dpc-4248	27	33	period	period	NOUN
dpc-4248	27	34	up	up	ADP
dpc-4248	27	35	to	to	PART
dpc-4248	27	36	3	3	NUM
dpc-4248	27	37	years	year	NOUN
dpc-4248	27	38	.	.	PUNCT
dpc-4248	28	1	method	method	NOUN
dpc-4248	28	2	we	we	PRON
dpc-4248	28	3	conducted	conduct	VERB
dpc-4248	28	4	a	a	DET
dpc-4248	28	5	multicenter	multicenter	NOUN
dpc-4248	28	6	,	,	PUNCT
dpc-4248	28	7	retrospective	retrospective	ADJ
dpc-4248	28	8	,	,	PUNCT
dpc-4248	28	9	observational	observational	ADJ
dpc-4248	28	10	study	study	NOUN
dpc-4248	28	11	in	in	ADP
dpc-4248	28	12	patients	patient	NOUN
dpc-4248	28	13	with	with	ADP
dpc-4248	28	14	psoriasis	psoriasis	NOUN
dpc-4248	28	15	who	who	PRON
dpc-4248	28	16	started	start	VERB
dpc-4248	28	17	brodalumab	brodalumab	NOUN
dpc-4248	28	18	therapy	therapy	NOUN
dpc-4248	28	19	between	between	ADP
dpc-4248	28	20	may	may	PROPN
dpc-4248	28	21	2019	2019	NUM
dpc-4248	28	22	and	and	CCONJ
dpc-4248	28	23	january	january	PROPN
dpc-4248	28	24	2021	2021	NUM
dpc-4248	28	25	.	.	PUNCT
dpc-4248	29	1	we	we	PRON
dpc-4248	29	2	included	include	VERB
dpc-4248	29	3	patients	patient	NOUN
dpc-4248	29	4	of	of	ADP
dpc-4248	29	5	age	age	NOUN
dpc-4248	29	6	>	>	SYM
dpc-4248	29	7	18	18	NUM
dpc-4248	29	8	years	year	NOUN
dpc-4248	29	9	from	from	ADP
dpc-4248	29	10	the	the	DET
dpc-4248	29	11	following	follow	VERB
dpc-4248	29	12	dermatology	dermatology	NOUN
dpc-4248	29	13	units	unit	NOUN
dpc-4248	29	14	in	in	ADP
dpc-4248	29	15	italy	italy	PROPN
dpc-4248	29	16	:	:	PUNCT
dpc-4248	29	17	‘	'	PUNCT
dpc-4248	29	18	tor	tor	NOUN
dpc-4248	29	19	vergata	vergata	NOUN
dpc-4248	29	20	’	'	PUNCT
dpc-4248	29	21	university	university	PROPN
dpc-4248	29	22	of	of	ADP
dpc-4248	29	23	rome	rome	PROPN
dpc-4248	29	24	,	,	PUNCT
dpc-4248	29	25	catholic	catholic	PROPN
dpc-4248	29	26	university	university	PROPN
dpc-4248	29	27	of	of	ADP
dpc-4248	29	28	the	the	DET
dpc-4248	29	29	sacred	sacred	ADJ
dpc-4248	29	30	heart	heart	NOUN
dpc-4248	29	31	in	in	ADP
dpc-4248	29	32	rome	rome	PROPN
dpc-4248	29	33	irccs	irccs	NOUN
dpc-4248	29	34	,	,	PUNCT
dpc-4248	29	35	‘	'	PUNCT
dpc-4248	29	36	daniele	daniele	PROPN
dpc-4248	29	37	innocenzi	innocenzi	NOUN
dpc-4248	29	38	’	'	PUNCT
dpc-4248	29	39	of	of	ADP
dpc-4248	29	40	university	university	PROPN
dpc-4248	29	41	of	of	ADP
dpc-4248	29	42	rome	rome	PROPN
dpc-4248	29	43	‘	'	PUNCT
dpc-4248	29	44	la	la	X
dpc-4248	29	45	sapienza	sapienza	NOUN
dpc-4248	29	46	,	,	PUNCT
dpc-4248	29	47	’	'	PUNCT
dpc-4248	29	48	polo	polo	NOUN
dpc-4248	29	49	pontino	pontino	NOUN
dpc-4248	29	50	and	and	CCONJ
dpc-4248	29	51	istituto	istituto	ADJ
dpc-4248	29	52	dermopatico	dermopatico	NOUN
dpc-4248	29	53	dell’immacolata	dell’immacolata	NOUN
dpc-4248	29	54	–	–	PUNCT
dpc-4248	29	55	irccs	irccs	NOUN
dpc-4248	29	56	,	,	PUNCT
dpc-4248	29	57	rome	rome	PROPN
dpc-4248	29	58	.	.	PUNCT
dpc-4248	30	1	exclusion	exclusion	NOUN
dpc-4248	30	2	criteria	criterion	NOUN
dpc-4248	30	3	were	be	AUX
dpc-4248	30	4	generalized	generalize	VERB
dpc-4248	30	5	,	,	PUNCT
dpc-4248	30	6	palmoplantar	palmoplantar	NOUN
dpc-4248	30	7	pustular	pustular	ADJ
dpc-4248	30	8	psoriasis	psoriasis	NOUN
dpc-4248	30	9	,	,	PUNCT
dpc-4248	30	10	use	use	NOUN
dpc-4248	30	11	of	of	ADP
dpc-4248	30	12	additional	additional	ADJ
dpc-4248	30	13	systemic	systemic	ADJ
dpc-4248	30	14	therapies	therapy	NOUN
dpc-4248	30	15	for	for	ADP
dpc-4248	30	16	psoriasis	psoriasis	NOUN
dpc-4248	30	17	,	,	PUNCT
dpc-4248	30	18	and	and	CCONJ
dpc-4248	30	19	participation	participation	NOUN
dpc-4248	30	20	in	in	ADP
dpc-4248	30	21	clinical	clinical	ADJ
dpc-4248	30	22	trials	trial	NOUN
dpc-4248	30	23	.	.	PUNCT
dpc-4248	31	1	patients	patient	NOUN
dpc-4248	31	2	were	be	AUX
dpc-4248	31	3	treated	treat	VERB
dpc-4248	31	4	with	with	ADP
dpc-4248	31	5	brodalumab	brodalumab	NOUN
dpc-4248	31	6	at	at	ADP
dpc-4248	31	7	the	the	DET
dpc-4248	31	8	european	european	PROPN
dpc-4248	31	9	medicines	medicines	PROPN
dpc-4248	31	10	agency	agency	NOUN
dpc-4248	31	11	(	(	PUNCT
dpc-4248	31	12	ema)-approved	ema)-approve	VERB
dpc-4248	31	13	dosage	dosage	NOUN
dpc-4248	31	14	.	.	PUNCT
dpc-4248	32	1	we	we	PRON
dpc-4248	32	2	collected	collect	VERB
dpc-4248	32	3	data	datum	NOUN
dpc-4248	32	4	related	relate	VERB
dpc-4248	32	5	to	to	ADP
dpc-4248	32	6	the	the	DET
dpc-4248	32	7	characteristics	characteristic	NOUN
dpc-4248	32	8	of	of	ADP
dpc-4248	32	9	the	the	DET
dpc-4248	32	10	patients	patient	NOUN
dpc-4248	32	11	(	(	PUNCT
dpc-4248	32	12	age	age	NOUN
dpc-4248	32	13	,	,	PUNCT
dpc-4248	32	14	sex	sex	NOUN
dpc-4248	32	15	,	,	PUNCT
dpc-4248	32	16	body	body	NOUN
dpc-4248	32	17	mass	mass	NOUN
dpc-4248	32	18	index	index	NOUN
dpc-4248	32	19	[	[	X
dpc-4248	32	20	bmi	bmi	X
dpc-4248	32	21	]	]	X
dpc-4248	32	22	,	,	PUNCT
dpc-4248	32	23	comorbidities	comorbiditie	NOUN
dpc-4248	32	24	,	,	PUNCT
dpc-4248	32	25	smoking	smoking	NOUN
dpc-4248	32	26	habits	habit	NOUN
dpc-4248	32	27	)	)	PUNCT
dpc-4248	32	28	and	and	CCONJ
dpc-4248	32	29	of	of	ADP
dpc-4248	32	30	the	the	DET
dpc-4248	32	31	disease	disease	NOUN
dpc-4248	32	32	(	(	PUNCT
dpc-4248	32	33	age	age	NOUN
dpc-4248	32	34	at	at	ADP
dpc-4248	32	35	onset	onset	NOUN
dpc-4248	32	36	,	,	PUNCT
dpc-4248	32	37	previous	previous	ADJ
dpc-4248	32	38	therapies	therapy	NOUN
dpc-4248	32	39	,	,	PUNCT
dpc-4248	32	40	and	and	CCONJ
dpc-4248	32	41	special	special	ADJ
dpc-4248	32	42	-	-	PUNCT
dpc-4248	32	43	site	site	NOUN
dpc-4248	32	44	involvement	involvement	NOUN
dpc-4248	32	45	)	)	PUNCT
dpc-4248	32	46	.	.	PUNCT
dpc-4248	33	1	the	the	DET
dpc-4248	33	2	severity	severity	NOUN
dpc-4248	33	3	of	of	ADP
dpc-4248	33	4	psoriasis	psoriasis	NOUN
dpc-4248	33	5	was	be	AUX
dpc-4248	33	6	measured	measure	VERB
dpc-4248	33	7	with	with	ADP
dpc-4248	33	8	the	the	DET
dpc-4248	33	9	psoriasis	psoriasis	NOUN
dpc-4248	33	10	area	area	NOUN
dpc-4248	33	11	and	and	CCONJ
dpc-4248	33	12	severity	severity	NOUN
dpc-4248	33	13	index	index	NOUN
dpc-4248	33	14	(	(	PUNCT
dpc-4248	33	15	pasi	pasi	NOUN
dpc-4248	33	16	)	)	PUNCT
dpc-4248	33	17	score	score	NOUN
dpc-4248	33	18	at	at	ADP
dpc-4248	33	19	baseline	baseline	NOUN
dpc-4248	33	20	and	and	CCONJ
dpc-4248	33	21	after	after	ADP
dpc-4248	33	22	4	4	NUM
dpc-4248	33	23	,	,	PUNCT
dpc-4248	33	24	12	12	NUM
dpc-4248	33	25	,	,	PUNCT
dpc-4248	33	26	24	24	NUM
dpc-4248	33	27	,	,	PUNCT
dpc-4248	33	28	52	52	NUM
dpc-4248	33	29	,	,	PUNCT
dpc-4248	33	30	104	104	NUM
dpc-4248	33	31	,	,	PUNCT
dpc-4248	33	32	and	and	CCONJ
dpc-4248	33	33	156	156	NUM
dpc-4248	33	34	weeks	week	NOUN
dpc-4248	33	35	of	of	ADP
dpc-4248	33	36	treatment	treatment	NOUN
dpc-4248	33	37	.	.	PUNCT
dpc-4248	34	1	patients	patient	NOUN
dpc-4248	34	2	obtaining	obtain	VERB
dpc-4248	34	3	a	a	DET
dpc-4248	34	4	pasi	pasi	NOUN
dpc-4248	34	5	90	90	NUM
dpc-4248	34	6	improvement	improvement	NOUN
dpc-4248	34	7	at	at	ADP
dpc-4248	34	8	week	week	NOUN
dpc-4248	34	9	4	4	NUM
dpc-4248	34	10	were	be	AUX
dpc-4248	34	11	defined	define	VERB
dpc-4248	34	12	fast	fast	ADJ
dpc-4248	34	13	responders	responder	NOUN
dpc-4248	34	14	.	.	PUNCT
dpc-4248	35	1	reasons	reason	NOUN
dpc-4248	35	2	for	for	ADP
dpc-4248	35	3	withdrawal	withdrawal	NOUN
dpc-4248	35	4	of	of	ADP
dpc-4248	35	5	brodalumab	brodalumab	NOUN
dpc-4248	35	6	and	and	CCONJ
dpc-4248	35	7	any	any	DET
dpc-4248	35	8	adverse	adverse	ADJ
dpc-4248	35	9	event	event	NOUN
dpc-4248	35	10	that	that	PRON
dpc-4248	35	11	occurred	occur	VERB
dpc-4248	35	12	during	during	ADP
dpc-4248	35	13	treatment	treatment	NOUN
dpc-4248	35	14	were	be	AUX
dpc-4248	35	15	recorded	record	VERB
dpc-4248	35	16	.	.	PUNCT
dpc-4248	36	1	discontinuation	discontinuation	NOUN
dpc-4248	36	2	of	of	ADP
dpc-4248	36	3	therapy	therapy	NOUN
dpc-4248	36	4	was	be	AUX
dpc-4248	36	5	defined	define	VERB
dpc-4248	36	6	as	as	ADP
dpc-4248	36	7	interruption	interruption	NOUN
dpc-4248	36	8	of	of	ADP
dpc-4248	36	9	brodalumab	brodalumab	NOUN
dpc-4248	36	10	administration	administration	NOUN
dpc-4248	36	11	for	for	ADP
dpc-4248	36	12	more	more	ADJ
dpc-4248	36	13	than	than	ADP
dpc-4248	36	14	90	90	NUM
dpc-4248	36	15	days	day	NOUN
dpc-4248	36	16	.	.	PUNCT
dpc-4248	37	1	descriptive	descriptive	ADJ
dpc-4248	37	2	statistics	statistic	NOUN
dpc-4248	37	3	for	for	ADP
dpc-4248	37	4	continuous	continuous	ADJ
dpc-4248	37	5	variables	variable	NOUN
dpc-4248	37	6	were	be	AUX
dpc-4248	37	7	reported	report	VERB
dpc-4248	37	8	as	as	ADP
dpc-4248	37	9	medians	median	NOUN
dpc-4248	37	10	/	/	SYM
dpc-4248	37	11	means	mean	NOUN
dpc-4248	37	12	and	and	CCONJ
dpc-4248	37	13	interquartile	interquartile	VERB
dpc-4248	37	14	ranges	range	NOUN
dpc-4248	37	15	(	(	PUNCT
dpc-4248	37	16	ir)/	ir)/	X
dpc-4248	37	17	standard	standard	ADJ
dpc-4248	37	18	deviations	deviation	NOUN
dpc-4248	37	19	(	(	PUNCT
dpc-4248	37	20	sd	sd	NOUN
dpc-4248	37	21	)	)	PUNCT
dpc-4248	37	22	,	,	PUNCT
dpc-4248	37	23	dichotomous	dichotomous	ADJ
dpc-4248	37	24	variables	variable	NOUN
dpc-4248	37	25	were	be	AUX
dpc-4248	37	26	described	describe	VERB
dpc-4248	37	27	using	use	VERB
dpc-4248	37	28	absolute	absolute	ADJ
dpc-4248	37	29	and	and	CCONJ
dpc-4248	37	30	relative	relative	ADJ
dpc-4248	37	31	(	(	PUNCT
dpc-4248	37	32	%	%	INTJ
dpc-4248	37	33	)	)	PUNCT
dpc-4248	37	34	frequencies	frequency	NOUN
dpc-4248	37	35	.	.	PUNCT
dpc-4248	38	1	the	the	DET
dpc-4248	38	2	drug	drug	NOUN
dpc-4248	38	3	survival	survival	NOUN
dpc-4248	38	4	analysis	analysis	NOUN
dpc-4248	38	5	was	be	AUX
dpc-4248	38	6	descriptively	descriptively	ADV
dpc-4248	38	7	analyzed	analyze	VERB
dpc-4248	38	8	using	use	VERB
dpc-4248	38	9	introduction	introduction	NOUN
dpc-4248	38	10	:	:	PUNCT
dpc-4248	38	11	data	datum	NOUN
dpc-4248	38	12	about	about	ADP
dpc-4248	38	13	the	the	DET
dpc-4248	38	14	long	long	ADJ
dpc-4248	38	15	-	-	PUNCT
dpc-4248	38	16	term	term	NOUN
dpc-4248	38	17	effectiveness	effectiveness	NOUN
dpc-4248	38	18	of	of	ADP
dpc-4248	38	19	brodalumab	brodalumab	NOUN
dpc-4248	38	20	could	could	AUX
dpc-4248	38	21	be	be	AUX
dpc-4248	38	22	valuable	valuable	ADJ
dpc-4248	38	23	in	in	ADP
dpc-4248	38	24	assessing	assess	VERB
dpc-4248	38	25	patient	patient	ADJ
dpc-4248	38	26	adherence	adherence	NOUN
dpc-4248	38	27	to	to	ADP
dpc-4248	38	28	treatment	treatment	NOUN
dpc-4248	38	29	and	and	CCONJ
dpc-4248	38	30	improving	improve	VERB
dpc-4248	38	31	psoriasis	psoriasis	NOUN
dpc-4248	38	32	management	management	NOUN
dpc-4248	38	33	.	.	PUNCT
dpc-4248	39	1	objective	objective	NOUN
dpc-4248	39	2	:	:	PUNCT
dpc-4248	39	3	the	the	DET
dpc-4248	39	4	aim	aim	NOUN
dpc-4248	39	5	of	of	ADP
dpc-4248	39	6	our	our	PRON
dpc-4248	39	7	study	study	NOUN
dpc-4248	39	8	was	be	AUX
dpc-4248	39	9	to	to	PART
dpc-4248	39	10	evaluate	evaluate	VERB
dpc-4248	39	11	the	the	DET
dpc-4248	39	12	drug	drug	NOUN
dpc-4248	39	13	survival	survival	NOUN
dpc-4248	39	14	of	of	ADP
dpc-4248	39	15	brodalumab	brodalumab	NOUN
dpc-4248	39	16	and	and	CCONJ
dpc-4248	39	17	identify	identify	VERB
dpc-4248	39	18	any	any	DET
dpc-4248	39	19	predictive	predictive	ADJ
dpc-4248	39	20	factors	factor	NOUN
dpc-4248	39	21	for	for	ADP
dpc-4248	39	22	discontinuation	discontinuation	NOUN
dpc-4248	39	23	.	.	PUNCT
dpc-4248	40	1	methods	method	NOUN
dpc-4248	40	2	:	:	PUNCT
dpc-4248	40	3	a	a	DET
dpc-4248	40	4	multicenter	multicenter	ADJ
dpc-4248	40	5	retrospective	retrospective	ADJ
dpc-4248	40	6	study	study	NOUN
dpc-4248	40	7	was	be	AUX
dpc-4248	40	8	conducted	conduct	VERB
dpc-4248	40	9	in	in	ADP
dpc-4248	40	10	patients	patient	NOUN
dpc-4248	40	11	with	with	ADP
dpc-4248	40	12	moderate	moderate	ADJ
dpc-4248	40	13	-	-	PUNCT
dpc-4248	40	14	to	to	ADP
dpc-4248	40	15	-	-	PUNCT
dpc-4248	40	16	severe	severe	ADJ
dpc-4248	40	17	psoriasis	psoriasis	NOUN
dpc-4248	40	18	who	who	PRON
dpc-4248	40	19	were	be	AUX
dpc-4248	40	20	treated	treat	VERB
dpc-4248	40	21	for	for	ADP
dpc-4248	40	22	up	up	ADP
dpc-4248	40	23	to	to	PART
dpc-4248	40	24	3	3	NUM
dpc-4248	40	25	years	year	NOUN
dpc-4248	40	26	.	.	PUNCT
dpc-4248	41	1	we	we	PRON
dpc-4248	41	2	extracted	extract	VERB
dpc-4248	41	3	data	datum	NOUN
dpc-4248	41	4	from	from	ADP
dpc-4248	41	5	patient	patient	ADJ
dpc-4248	41	6	files	file	NOUN
dpc-4248	41	7	,	,	PUNCT
dpc-4248	41	8	related	relate	VERB
dpc-4248	41	9	to	to	ADP
dpc-4248	41	10	the	the	DET
dpc-4248	41	11	characteristics	characteristic	NOUN
dpc-4248	41	12	of	of	ADP
dpc-4248	41	13	the	the	DET
dpc-4248	41	14	patients	patient	NOUN
dpc-4248	41	15	and	and	CCONJ
dpc-4248	41	16	the	the	DET
dpc-4248	41	17	disease	disease	NOUN
dpc-4248	41	18	.	.	PUNCT
dpc-4248	42	1	drug	drug	NOUN
dpc-4248	42	2	survival	survival	NOUN
dpc-4248	42	3	analysis	analysis	NOUN
dpc-4248	42	4	was	be	AUX
dpc-4248	42	5	descriptively	descriptively	ADV
dpc-4248	42	6	analyzed	analyze	VERB
dpc-4248	42	7	using	use	VERB
dpc-4248	42	8	kaplan	kaplan	PROPN
dpc-4248	42	9	–	–	PUNCT
dpc-4248	42	10	meier	meier	PROPN
dpc-4248	42	11	survival	survival	NOUN
dpc-4248	42	12	curves	curve	NOUN
dpc-4248	42	13	.	.	PUNCT
dpc-4248	43	1	univariable	univariable	ADJ
dpc-4248	43	2	and	and	CCONJ
dpc-4248	43	3	multivariable	multivariable	ADJ
dpc-4248	43	4	analyses	analysis	NOUN
dpc-4248	43	5	were	be	AUX
dpc-4248	43	6	performed	perform	VERB
dpc-4248	43	7	to	to	PART
dpc-4248	43	8	assess	assess	VERB
dpc-4248	43	9	baseline	baseline	ADJ
dpc-4248	43	10	patient	patient	ADJ
dpc-4248	43	11	characteristics	characteristic	NOUN
dpc-4248	43	12	that	that	PRON
dpc-4248	43	13	predicted	predict	VERB
dpc-4248	43	14	clinical	clinical	ADJ
dpc-4248	43	15	response	response	NOUN
dpc-4248	43	16	.	.	PUNCT
dpc-4248	44	1	results	result	NOUN
dpc-4248	44	2	:	:	PUNCT
dpc-4248	44	3	the	the	DET
dpc-4248	44	4	study	study	NOUN
dpc-4248	44	5	included	include	VERB
dpc-4248	44	6	90	90	NUM
dpc-4248	44	7	patients	patient	NOUN
dpc-4248	44	8	.	.	PUNCT
dpc-4248	45	1	among	among	ADP
dpc-4248	45	2	them	they	PRON
dpc-4248	45	3	,	,	PUNCT
dpc-4248	45	4	28	28	NUM
dpc-4248	45	5	(	(	PUNCT
dpc-4248	45	6	31.1	31.1	NUM
dpc-4248	45	7	%	%	NOUN
dpc-4248	45	8	)	)	PUNCT
dpc-4248	45	9	suspended	suspend	VERB
dpc-4248	45	10	brodalumab	brodalumab	NOUN
dpc-4248	45	11	through	through	ADP
dpc-4248	45	12	the	the	DET
dpc-4248	45	13	observation	observation	NOUN
dpc-4248	45	14	period	period	NOUN
dpc-4248	45	15	.	.	PUNCT
dpc-4248	46	1	at	at	ADP
dpc-4248	46	2	weeks	week	NOUN
dpc-4248	46	3	52	52	NUM
dpc-4248	46	4	,	,	PUNCT
dpc-4248	46	5	104	104	NUM
dpc-4248	46	6	and	and	CCONJ
dpc-4248	46	7	156	156	NUM
dpc-4248	46	8	the	the	DET
dpc-4248	46	9	median	median	ADJ
dpc-4248	46	10	pasi	pasi	NOUN
dpc-4248	46	11	score	score	NOUN
dpc-4248	46	12	were	be	AUX
dpc-4248	46	13	0.0	0.0	NUM
dpc-4248	46	14	[	[	X
dpc-4248	46	15	0.0	0.0	NUM
dpc-4248	46	16	–	–	PUNCT
dpc-4248	46	17	0.8	0.8	NUM
dpc-4248	46	18	]	]	PUNCT
dpc-4248	46	19	,	,	PUNCT
dpc-4248	46	20	0.0	0.0	NUM
dpc-4248	46	21	[	[	X
dpc-4248	46	22	0.0	0.0	NUM
dpc-4248	46	23	–	–	PUNCT
dpc-4248	46	24	1.0	1.0	NUM
dpc-4248	46	25	]	]	PUNCT
dpc-4248	46	26	and	and	CCONJ
dpc-4248	46	27	0.0	0.0	NUM
dpc-4248	46	28	[	[	SYM
dpc-4248	46	29	0.0	0.0	NUM
dpc-4248	46	30	–	–	PUNCT
dpc-4248	46	31	0.0	0.0	NUM
dpc-4248	46	32	]	]	PUNCT
dpc-4248	46	33	,	,	PUNCT
dpc-4248	46	34	respectively	respectively	ADV
dpc-4248	46	35	.	.	PUNCT
dpc-4248	47	1	the	the	DET
dpc-4248	47	2	estimated	estimate	VERB
dpc-4248	47	3	cumulative	cumulative	ADJ
dpc-4248	47	4	survival	survival	NOUN
dpc-4248	47	5	rates	rate	NOUN
dpc-4248	47	6	at	at	ADP
dpc-4248	47	7	weeks	week	NOUN
dpc-4248	47	8	52	52	NUM
dpc-4248	47	9	and	and	CCONJ
dpc-4248	47	10	104	104	NUM
dpc-4248	47	11	were	be	AUX
dpc-4248	47	12	86.32	86.32	NUM
dpc-4248	47	13	%	%	NOUN
dpc-4248	47	14	and	and	CCONJ
dpc-4248	47	15	78.09	78.09	NUM
dpc-4248	47	16	%	%	NOUN
dpc-4248	47	17	,	,	PUNCT
dpc-4248	47	18	respectively	respectively	ADV
dpc-4248	47	19	.	.	PUNCT
dpc-4248	48	1	in	in	ADP
dpc-4248	48	2	the	the	DET
dpc-4248	48	3	multivariable	multivariable	ADJ
dpc-4248	48	4	survival	survival	NOUN
dpc-4248	48	5	analysis	analysis	NOUN
dpc-4248	48	6	,	,	PUNCT
dpc-4248	48	7	predictor	predictor	NOUN
dpc-4248	48	8	factors	factor	NOUN
dpc-4248	48	9	for	for	ADP
dpc-4248	48	10	overall	overall	ADJ
dpc-4248	48	11	discontinuation	discontinuation	NOUN
dpc-4248	48	12	included	include	VERB
dpc-4248	48	13	body	body	NOUN
dpc-4248	48	14	mass	mass	NOUN
dpc-4248	48	15	index	index	NOUN
dpc-4248	48	16	(	(	PUNCT
dpc-4248	48	17	bmi	bmi	PROPN
dpc-4248	48	18	)	)	PUNCT
dpc-4248	48	19	(	(	PUNCT
dpc-4248	48	20	or	or	CCONJ
dpc-4248	48	21	1.10	1.10	NUM
dpc-4248	48	22	,	,	PUNCT
dpc-4248	48	23	95	95	NUM
dpc-4248	48	24	%	%	NOUN
dpc-4248	48	25	ci	ci	NOUN
dpc-4248	48	26	1.03	1.03	NUM
dpc-4248	48	27	1.18	1.18	NUM
dpc-4248	48	28	)	)	PUNCT
dpc-4248	48	29	,	,	PUNCT
dpc-4248	48	30	baseline	baseline	NOUN
dpc-4248	48	31	pasi	pasi	NOUN
dpc-4248	48	32	(	(	PUNCT
dpc-4248	48	33	or	or	CCONJ
dpc-4248	48	34	1.06	1.06	NUM
dpc-4248	48	35	,	,	PUNCT
dpc-4248	48	36	95	95	NUM
dpc-4248	48	37	%	%	NOUN
dpc-4248	48	38	ci	ci	NOUN
dpc-4248	48	39	1.02	1.02	NUM
dpc-4248	48	40	1.10	1.10	NUM
dpc-4248	48	41	)	)	PUNCT
dpc-4248	48	42	,	,	PUNCT
dpc-4248	48	43	and	and	CCONJ
dpc-4248	48	44	psoriatic	psoriatic	ADJ
dpc-4248	48	45	arthritis	arthritis	NOUN
dpc-4248	48	46	(	(	PUNCT
dpc-4248	48	47	or	or	CCONJ
dpc-4248	48	48	5.05	5.05	NUM
dpc-4248	48	49	,	,	PUNCT
dpc-4248	48	50	95	95	NUM
dpc-4248	48	51	%	%	NOUN
dpc-4248	48	52	ci	ci	NOUN
dpc-4248	48	53	0.89	0.89	NUM
dpc-4248	48	54	13.50	13.50	NUM
dpc-4248	48	55	)	)	PUNCT
dpc-4248	48	56	.	.	PUNCT
dpc-4248	49	1	conclusions	conclusion	NOUN
dpc-4248	49	2	:	:	PUNCT
dpc-4248	49	3	brodalumab	brodalumab	NOUN
dpc-4248	49	4	has	have	AUX
dpc-4248	49	5	shown	show	VERB
dpc-4248	49	6	long	long	ADJ
dpc-4248	49	7	-	-	PUNCT
dpc-4248	49	8	term	term	NOUN
dpc-4248	49	9	effectiveness	effectiveness	NOUN
dpc-4248	49	10	for	for	ADP
dpc-4248	49	11	up	up	ADP
dpc-4248	49	12	to	to	PART
dpc-4248	49	13	3	3	NUM
dpc-4248	49	14	years	year	NOUN
dpc-4248	49	15	.	.	PUNCT
dpc-4248	50	1	considering	consider	VERB
dpc-4248	50	2	baseline	baseline	NOUN
dpc-4248	50	3	disease	disease	NOUN
dpc-4248	50	4	severity	severity	NOUN
dpc-4248	50	5	and	and	CCONJ
dpc-4248	50	6	patient	patient	ADJ
dpc-4248	50	7	characteristics	characteristic	NOUN
dpc-4248	50	8	could	could	AUX
dpc-4248	50	9	aid	aid	VERB
dpc-4248	50	10	in	in	ADP
dpc-4248	50	11	optimizing	optimize	VERB
dpc-4248	50	12	the	the	DET
dpc-4248	50	13	long	long	ADJ
dpc-4248	50	14	-	-	PUNCT
dpc-4248	50	15	term	term	NOUN
dpc-4248	50	16	management	management	NOUN
dpc-4248	50	17	of	of	ADP
dpc-4248	50	18	psoriasis	psoriasis	NOUN
dpc-4248	50	19	.	.	PUNCT
dpc-4248	51	1	abstract	abstract	ADJ
dpc-4248	51	2	original	original	ADJ
dpc-4248	51	3	article	article	NOUN
dpc-4248	51	4	|	|	ADV
dpc-4248	51	5	dermatol	dermatol	ADJ
dpc-4248	51	6	pract	pract	NOUN
dpc-4248	51	7	concept	concept	NOUN
dpc-4248	51	8	.	.	PUNCT
dpc-4248	52	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	52	2	3	3	NUM
dpc-4248	52	3	kaplan	kaplan	PROPN
dpc-4248	52	4	–	–	PUNCT
dpc-4248	52	5	meier	meier	PROPN
dpc-4248	52	6	survival	survival	NOUN
dpc-4248	52	7	curves	curve	NOUN
dpc-4248	52	8	.	.	PUNCT
dpc-4248	53	1	three	three	NUM
dpc-4248	53	2	“	"	PUNCT
dpc-4248	53	3	events	event	NOUN
dpc-4248	53	4	”	"	PUNCT
dpc-4248	53	5	for	for	ADP
dpc-4248	53	6	drug	drug	NOUN
dpc-4248	53	7	survival	survival	NOUN
dpc-4248	53	8	were	be	AUX
dpc-4248	53	9	defined	define	VERB
dpc-4248	53	10	and	and	CCONJ
dpc-4248	53	11	analyzed	analyze	VERB
dpc-4248	53	12	separately	separately	ADV
dpc-4248	53	13	.	.	PUNCT
dpc-4248	54	1	(	(	PUNCT
dpc-4248	54	2	i.e.	i.e.	X
dpc-4248	54	3	overall	overall	ADJ
dpc-4248	54	4	discontinuation	discontinuation	NOUN
dpc-4248	54	5	;	;	PUNCT
dpc-4248	54	6	discontinuation	discontinuation	NOUN
dpc-4248	54	7	because	because	SCONJ
dpc-4248	54	8	of	of	ADP
dpc-4248	54	9	brodalumab	brodalumab	NOUN
dpc-4248	54	10	ineffectiveness	ineffectiveness	NOUN
dpc-4248	54	11	;	;	PUNCT
dpc-4248	54	12	adverse	adverse	ADJ
dpc-4248	54	13	events	event	NOUN
dpc-4248	54	14	or	or	CCONJ
dpc-4248	54	15	other	other	ADJ
dpc-4248	54	16	type	type	NOUN
dpc-4248	54	17	of	of	ADP
dpc-4248	54	18	events	event	NOUN
dpc-4248	54	19	other	other	ADJ
dpc-4248	54	20	than	than	ADP
dpc-4248	54	21	ineffectiveness	ineffectiveness	NOUN
dpc-4248	54	22	)	)	PUNCT
dpc-4248	54	23	.	.	PUNCT
dpc-4248	55	1	patients	patient	NOUN
dpc-4248	55	2	were	be	AUX
dpc-4248	55	3	censored	censor	VERB
dpc-4248	55	4	when	when	SCONJ
dpc-4248	55	5	lost	lose	VERB
dpc-4248	55	6	to	to	PART
dpc-4248	55	7	follow	follow	VERB
dpc-4248	55	8	-	-	PUNCT
dpc-4248	55	9	up	up	NOUN
dpc-4248	55	10	,	,	PUNCT
dpc-4248	55	11	discontinued	discontinue	VERB
dpc-4248	55	12	due	due	ADP
dpc-4248	55	13	to	to	ADP
dpc-4248	55	14	an	an	DET
dpc-4248	55	15	event	event	NOUN
dpc-4248	55	16	other	other	ADJ
dpc-4248	55	17	than	than	ADP
dpc-4248	55	18	the	the	DET
dpc-4248	55	19	events	event	NOUN
dpc-4248	55	20	of	of	ADP
dpc-4248	55	21	interest	interest	NOUN
dpc-4248	55	22	,	,	PUNCT
dpc-4248	55	23	or	or	CCONJ
dpc-4248	55	24	when	when	SCONJ
dpc-4248	55	25	the	the	DET
dpc-4248	55	26	database	database	NOUN
dpc-4248	55	27	was	be	AUX
dpc-4248	55	28	extracted	extract	VERB
dpc-4248	55	29	,	,	PUNCT
dpc-4248	55	30	and	and	CCONJ
dpc-4248	55	31	patients	patient	NOUN
dpc-4248	55	32	were	be	AUX
dpc-4248	55	33	actively	actively	ADV
dpc-4248	55	34	undergoing	undergo	VERB
dpc-4248	55	35	their	their	PRON
dpc-4248	55	36	treatment	treatment	NOUN
dpc-4248	55	37	with	with	ADP
dpc-4248	55	38	the	the	DET
dpc-4248	55	39	drug	drug	NOUN
dpc-4248	55	40	of	of	ADP
dpc-4248	55	41	interest	interest	NOUN
dpc-4248	55	42	at	at	ADP
dpc-4248	55	43	that	that	DET
dpc-4248	55	44	moment	moment	NOUN
dpc-4248	55	45	.	.	PUNCT
dpc-4248	56	1	univariable	univariable	ADJ
dpc-4248	56	2	and	and	CCONJ
dpc-4248	56	3	multivariable	multivariable	ADJ
dpc-4248	56	4	cox	cox	PROPN
dpc-4248	56	5	regression	regression	PROPN
dpc-4248	56	6	analyses	analysis	NOUN
dpc-4248	56	7	were	be	AUX
dpc-4248	56	8	carried	carry	VERB
dpc-4248	56	9	out	out	ADP
dpc-4248	56	10	using	use	VERB
dpc-4248	56	11	variables	variable	NOUN
dpc-4248	56	12	considered	consider	VERB
dpc-4248	56	13	of	of	ADP
dpc-4248	56	14	clinical	clinical	ADJ
dpc-4248	56	15	importance	importance	NOUN
dpc-4248	56	16	.	.	PUNCT
dpc-4248	57	1	statistical	statistical	ADJ
dpc-4248	57	2	significance	significance	NOUN
dpc-4248	57	3	was	be	AUX
dpc-4248	57	4	set	set	VERB
dpc-4248	57	5	at	at	ADP
dpc-4248	57	6	p	p	NOUN
dpc-4248	57	7	-	-	PUNCT
dpc-4248	57	8	value	value	NOUN
dpc-4248	57	9	<	<	NOUN
dpc-4248	57	10	0.05	0.05	NUM
dpc-4248	57	11	.	.	PUNCT
dpc-4248	58	1	analyses	analysis	NOUN
dpc-4248	58	2	were	be	AUX
dpc-4248	58	3	performed	perform	VERB
dpc-4248	58	4	in	in	ADP
dpc-4248	58	5	may	may	PROPN
dpc-4248	58	6	2023	2023	NUM
dpc-4248	58	7	by	by	ADP
dpc-4248	58	8	using	use	VERB
dpc-4248	58	9	stata	stata	NOUN
dpc-4248	58	10	13.0	13.0	NUM
dpc-4248	58	11	software	software	NOUN
dpc-4248	58	12	(	(	PUNCT
dpc-4248	58	13	statacorp	statacorp	PROPN
dpc-4248	58	14	,	,	PUNCT
dpc-4248	58	15	texas	texas	PROPN
dpc-4248	58	16	)	)	PUNCT
dpc-4248	58	17	.	.	PUNCT
dpc-4248	59	1	the	the	DET
dpc-4248	59	2	protocol	protocol	NOUN
dpc-4248	59	3	was	be	AUX
dpc-4248	59	4	reviewed	review	VERB
dpc-4248	59	5	and	and	CCONJ
dpc-4248	59	6	approved	approve	VERB
dpc-4248	59	7	by	by	ADP
dpc-4248	59	8	fondazione	fondazione	PROPN
dpc-4248	59	9	policlinico	policlinico	PROPN
dpc-4248	59	10	universitario	universitario	PROPN
dpc-4248	59	11	agostino	agostino	PROPN
dpc-4248	59	12	gemelli	gemelli	PROPN
dpc-4248	59	13	irccs	ircc	VERB
dpc-4248	59	14	università	università	PROPN
dpc-4248	59	15	cattolica	cattolica	PROPN
dpc-4248	59	16	del	del	PROPN
dpc-4248	59	17	sacro	sacro	PROPN
dpc-4248	59	18	cuore	cuore	PROPN
dpc-4248	59	19	,	,	PUNCT
dpc-4248	59	20	prot	prot	NOUN
dpc-4248	59	21	n.	n.	NOUN
dpc-4248	59	22	:	:	PUNCT
dpc-4248	59	23	15188/23	15188/23	NUM
dpc-4248	59	24	.	.	PUNCT
dpc-4248	60	1	all	all	DET
dpc-4248	60	2	patients	patient	NOUN
dpc-4248	60	3	signed	sign	VERB
dpc-4248	60	4	a	a	DET
dpc-4248	60	5	hospital	hospital	NOUN
dpc-4248	60	6	-	-	PUNCT
dpc-4248	60	7	based	base	VERB
dpc-4248	60	8	informed	informed	ADJ
dpc-4248	60	9	consent	consent	NOUN
dpc-4248	60	10	.	.	PUNCT
dpc-4248	61	1	the	the	DET
dpc-4248	61	2	study	study	NOUN
dpc-4248	61	3	was	be	AUX
dpc-4248	61	4	performed	perform	VERB
dpc-4248	61	5	following	follow	VERB
dpc-4248	61	6	the	the	DET
dpc-4248	61	7	principles	principle	NOUN
dpc-4248	61	8	of	of	ADP
dpc-4248	61	9	the	the	DET
dpc-4248	61	10	declaration	declaration	NOUN
dpc-4248	61	11	of	of	ADP
dpc-4248	61	12	helsinki	helsinki	PROPN
dpc-4248	61	13	.	.	PUNCT
dpc-4248	62	1	results	result	VERB
dpc-4248	62	2	ninety	ninety	NUM
dpc-4248	62	3	patients	patient	NOUN
dpc-4248	62	4	with	with	ADP
dpc-4248	62	5	moderatetosevere	moderatetosevere	ADP
dpc-4248	62	6	plaque	plaque	NOUN
dpc-4248	62	7	psoriasis	psoriasis	NOUN
dpc-4248	62	8	treated	treat	VERB
dpc-4248	62	9	with	with	ADP
dpc-4248	62	10	brodalumab	brodalumab	NOUN
dpc-4248	62	11	were	be	AUX
dpc-4248	62	12	included	include	VERB
dpc-4248	62	13	.	.	PUNCT
dpc-4248	63	1	mean	mean	VERB
dpc-4248	63	2	age	age	NOUN
dpc-4248	63	3	of	of	ADP
dpc-4248	63	4	patients	patient	NOUN
dpc-4248	63	5	was	be	AUX
dpc-4248	63	6	52.2	52.2	NUM
dpc-4248	63	7	(	(	PUNCT
dpc-4248	63	8	sd	sd	ADP
dpc-4248	63	9	15.0	15.0	NUM
dpc-4248	63	10	)	)	PUNCT
dpc-4248	63	11	years	year	NOUN
dpc-4248	63	12	,	,	PUNCT
dpc-4248	63	13	and	and	CCONJ
dpc-4248	63	14	the	the	DET
dpc-4248	63	15	majority	majority	NOUN
dpc-4248	63	16	(	(	PUNCT
dpc-4248	63	17	67.8	67.8	NUM
dpc-4248	63	18	%	%	NOUN
dpc-4248	63	19	)	)	PUNCT
dpc-4248	63	20	were	be	AUX
dpc-4248	63	21	males	male	NOUN
dpc-4248	63	22	.	.	PUNCT
dpc-4248	64	1	median	median	ADJ
dpc-4248	64	2	pasi	pasi	PROPN
dpc-4248	64	3	score	score	NOUN
dpc-4248	64	4	at	at	ADP
dpc-4248	64	5	baseline	baseline	NOUN
dpc-4248	64	6	was	be	AUX
dpc-4248	64	7	15.0	15.0	NUM
dpc-4248	64	8	(	(	PUNCT
dpc-4248	64	9	ir	ir	PROPN
dpc-4248	64	10	10.0	10.0	NUM
dpc-4248	64	11	22.0	22.0	NUM
dpc-4248	64	12	)	)	PUNCT
dpc-4248	64	13	.	.	PUNCT
dpc-4248	65	1	other	other	ADJ
dpc-4248	65	2	baseline	baseline	PROPN
dpc-4248	65	3	characteristics	characteristic	NOUN
dpc-4248	65	4	of	of	ADP
dpc-4248	65	5	patients	patient	NOUN
dpc-4248	65	6	are	be	AUX
dpc-4248	65	7	presented	present	VERB
dpc-4248	65	8	in	in	ADP
dpc-4248	65	9	table	table	NOUN
dpc-4248	65	10	1	1	NUM
dpc-4248	65	11	.	.	PUNCT
dpc-4248	66	1	data	datum	NOUN
dpc-4248	66	2	about	about	ADP
dpc-4248	66	3	the	the	DET
dpc-4248	66	4	first	first	ADJ
dpc-4248	66	5	52	52	NUM
dpc-4248	66	6	weeks	week	NOUN
dpc-4248	66	7	of	of	ADP
dpc-4248	66	8	treatment	treatment	NOUN
dpc-4248	66	9	have	have	AUX
dpc-4248	66	10	been	be	AUX
dpc-4248	66	11	already	already	ADV
dpc-4248	66	12	reported	report	VERB
dpc-4248	66	13	[	[	X
dpc-4248	66	14	11	11	NUM
dpc-4248	66	15	]	]	PUNCT
dpc-4248	66	16	.	.	PUNCT
dpc-4248	67	1	in	in	ADP
dpc-4248	67	2	particular	particular	ADJ
dpc-4248	67	3	,	,	PUNCT
dpc-4248	67	4	29/90	29/90	NUM
dpc-4248	67	5	(	(	PUNCT
dpc-4248	67	6	32.2	32.2	NUM
dpc-4248	67	7	%	%	NOUN
dpc-4248	67	8	)	)	PUNCT
dpc-4248	67	9	patients	patient	NOUN
dpc-4248	67	10	achieved	achieve	VERB
dpc-4248	67	11	pasi	pasi	NOUN
dpc-4248	67	12	90	90	NUM
dpc-4248	67	13	at	at	ADP
dpc-4248	67	14	week	week	NOUN
dpc-4248	67	15	4	4	NUM
dpc-4248	67	16	and	and	CCONJ
dpc-4248	67	17	were	be	AUX
dpc-4248	67	18	considered	consider	VERB
dpc-4248	67	19	fast	fast	ADJ
dpc-4248	67	20	responders	responder	NOUN
dpc-4248	67	21	.	.	PUNCT
dpc-4248	68	1	among	among	ADP
dpc-4248	68	2	90	90	NUM
dpc-4248	68	3	enrolled	enrol	VERB
dpc-4248	68	4	patients	patient	NOUN
dpc-4248	68	5	,	,	PUNCT
dpc-4248	68	6	28	28	NUM
dpc-4248	68	7	(	(	PUNCT
dpc-4248	68	8	31.1	31.1	NUM
dpc-4248	68	9	%	%	NOUN
dpc-4248	68	10	)	)	PUNCT
dpc-4248	68	11	suspended	suspend	VERB
dpc-4248	68	12	brodalumab	brodalumab	NOUN
dpc-4248	68	13	through	through	ADP
dpc-4248	68	14	the	the	DET
dpc-4248	68	15	observation	observation	NOUN
dpc-4248	68	16	period	period	NOUN
dpc-4248	68	17	.	.	PUNCT
dpc-4248	69	1	at	at	ADP
dpc-4248	69	2	weeks	week	NOUN
dpc-4248	69	3	52	52	NUM
dpc-4248	69	4	,	,	PUNCT
dpc-4248	69	5	104	104	NUM
dpc-4248	69	6	,	,	PUNCT
dpc-4248	69	7	and	and	CCONJ
dpc-4248	69	8	156	156	NUM
dpc-4248	69	9	the	the	DET
dpc-4248	69	10	median	median	ADJ
dpc-4248	69	11	pasi	pasi	NOUN
dpc-4248	69	12	score	score	NOUN
dpc-4248	69	13	were	be	AUX
dpc-4248	69	14	0.0	0.0	NUM
dpc-4248	69	15	[	[	X
dpc-4248	69	16	0.0	0.0	NUM
dpc-4248	69	17	–	–	PUNCT
dpc-4248	69	18	0.8	0.8	NUM
dpc-4248	69	19	]	]	PUNCT
dpc-4248	69	20	,	,	PUNCT
dpc-4248	69	21	0.0	0.0	NUM
dpc-4248	69	22	[	[	X
dpc-4248	69	23	0.0	0.0	NUM
dpc-4248	69	24	–	–	PUNCT
dpc-4248	69	25	1.0	1.0	NUM
dpc-4248	69	26	]	]	PUNCT
dpc-4248	69	27	and	and	CCONJ
dpc-4248	69	28	0.0	0.0	NUM
dpc-4248	69	29	[	[	SYM
dpc-4248	69	30	0.0	0.0	NUM
dpc-4248	69	31	–	–	PUNCT
dpc-4248	69	32	0.0	0.0	NUM
dpc-4248	69	33	]	]	PUNCT
dpc-4248	69	34	,	,	PUNCT
dpc-4248	69	35	respectively	respectively	ADV
dpc-4248	69	36	.	.	PUNCT
dpc-4248	70	1	the	the	DET
dpc-4248	70	2	reasons	reason	NOUN
dpc-4248	70	3	for	for	ADP
dpc-4248	70	4	discontinuation	discontinuation	NOUN
dpc-4248	70	5	were	be	AUX
dpc-4248	70	6	adverse	adverse	ADJ
dpc-4248	70	7	events	event	NOUN
dpc-4248	70	8	in	in	ADP
dpc-4248	70	9	8	8	NUM
dpc-4248	70	10	patients	patient	NOUN
dpc-4248	70	11	(	(	PUNCT
dpc-4248	70	12	8.9	8.9	NUM
dpc-4248	70	13	%	%	NOUN
dpc-4248	70	14	)	)	PUNCT
dpc-4248	70	15	,	,	PUNCT
dpc-4248	70	16	ineffectiveness	ineffectiveness	NOUN
dpc-4248	70	17	in	in	ADP
dpc-4248	70	18	15	15	NUM
dpc-4248	70	19	patients	patient	NOUN
dpc-4248	70	20	(	(	PUNCT
dpc-4248	70	21	16.7	16.7	NUM
dpc-4248	70	22	%	%	NOUN
dpc-4248	70	23	)	)	PUNCT
dpc-4248	70	24	and	and	CCONJ
dpc-4248	70	25	loss	loss	NOUN
dpc-4248	70	26	to	to	PART
dpc-4248	70	27	follow	follow	VERB
dpc-4248	70	28	-	-	PUNCT
dpc-4248	70	29	up	up	NOUN
dpc-4248	70	30	in	in	ADP
dpc-4248	70	31	5	5	NUM
dpc-4248	70	32	patient	patient	NOUN
dpc-4248	70	33	(	(	PUNCT
dpc-4248	70	34	5.6	5.6	NUM
dpc-4248	70	35	%	%	NOUN
dpc-4248	70	36	)	)	PUNCT
dpc-4248	70	37	.	.	PUNCT
dpc-4248	71	1	discontinuation	discontinuation	NOUN
dpc-4248	71	2	for	for	ADP
dpc-4248	71	3	adverse	adverse	ADJ
dpc-4248	71	4	events	event	NOUN
dpc-4248	71	5	were	be	AUX
dpc-4248	71	6	due	due	ADJ
dpc-4248	71	7	to	to	ADP
dpc-4248	71	8	eczematous	eczematous	ADJ
dpc-4248	71	9	eruptions	eruption	NOUN
dpc-4248	71	10	in	in	ADP
dpc-4248	71	11	2	2	NUM
dpc-4248	71	12	patients	patient	NOUN
dpc-4248	71	13	,	,	PUNCT
dpc-4248	71	14	and	and	CCONJ
dpc-4248	71	15	in	in	ADP
dpc-4248	71	16	singular	singular	ADJ
dpc-4248	71	17	cases	case	NOUN
dpc-4248	71	18	to	to	PART
dpc-4248	71	19	recurrent	recurrent	VERB
dpc-4248	71	20	candidiasis	candidiasis	NOUN
dpc-4248	71	21	,	,	PUNCT
dpc-4248	71	22	lower	low	ADJ
dpc-4248	71	23	limb	limb	NOUN
dpc-4248	71	24	myalgia	myalgia	NOUN
dpc-4248	71	25	,	,	PUNCT
dpc-4248	71	26	myocardial	myocardial	ADJ
dpc-4248	71	27	infarction	infarction	NOUN
dpc-4248	71	28	,	,	PUNCT
dpc-4248	71	29	cerebral	cerebral	ADJ
dpc-4248	71	30	ischemia	ischemia	NOUN
dpc-4248	71	31	,	,	PUNCT
dpc-4248	71	32	concomitant	concomitant	ADJ
dpc-4248	71	33	anemia	anemia	NOUN
dpc-4248	71	34	and	and	CCONJ
dpc-4248	71	35	transaminase	transaminase	NOUN
dpc-4248	71	36	increase	increase	NOUN
dpc-4248	71	37	due	due	ADP
dpc-4248	71	38	to	to	ADP
dpc-4248	71	39	alcohol	alcohol	NOUN
dpc-4248	71	40	abuse	abuse	NOUN
dpc-4248	71	41	,	,	PUNCT
dpc-4248	71	42	and	and	CCONJ
dpc-4248	71	43	to	to	PART
dpc-4248	71	44	recurrent	recurrent	VERB
dpc-4248	71	45	upper	upper	ADJ
dpc-4248	71	46	respiratory	respiratory	ADJ
dpc-4248	71	47	tract	tract	NOUN
dpc-4248	71	48	infection	infection	NOUN
dpc-4248	71	49	.	.	PUNCT
dpc-4248	72	1	median	median	ADJ
dpc-4248	72	2	time	time	NOUN
dpc-4248	72	3	of	of	ADP
dpc-4248	72	4	observation	observation	NOUN
dpc-4248	72	5	among	among	ADP
dpc-4248	72	6	those	those	PRON
dpc-4248	72	7	who	who	PRON
dpc-4248	72	8	discontinued	discontinue	VERB
dpc-4248	72	9	brodalumab	brodalumab	NOUN
dpc-4248	72	10	was	be	AUX
dpc-4248	72	11	62.5	62.5	NUM
dpc-4248	72	12	(	(	PUNCT
dpc-4248	72	13	ir	ir	PROPN
dpc-4248	72	14	32.0	32.0	NUM
dpc-4248	72	15	–	–	PUNCT
dpc-4248	72	16	111.0	111.0	NUM
dpc-4248	72	17	)	)	PUNCT
dpc-4248	72	18	weeks	week	NOUN
dpc-4248	72	19	after	after	ADP
dpc-4248	72	20	the	the	DET
dpc-4248	72	21	start	start	NOUN
dpc-4248	72	22	of	of	ADP
dpc-4248	72	23	the	the	DET
dpc-4248	72	24	drug	drug	NOUN
dpc-4248	72	25	.	.	PUNCT
dpc-4248	73	1	the	the	DET
dpc-4248	73	2	overall	overall	ADJ
dpc-4248	73	3	drug	drug	NOUN
dpc-4248	73	4	survival	survival	NOUN
dpc-4248	73	5	is	be	AUX
dpc-4248	73	6	reported	report	VERB
dpc-4248	73	7	in	in	ADP
dpc-4248	73	8	figure	figure	NOUN
dpc-4248	73	9	1a	1a	NOUN
dpc-4248	73	10	.	.	PUNCT
dpc-4248	74	1	overall	overall	ADV
dpc-4248	74	2	,	,	PUNCT
dpc-4248	74	3	a	a	DET
dpc-4248	74	4	total	total	NOUN
dpc-4248	74	5	of	of	ADP
dpc-4248	74	6	86.32	86.32	NUM
dpc-4248	74	7	%	%	NOUN
dpc-4248	74	8	,	,	PUNCT
dpc-4248	74	9	78.09	78.09	NUM
dpc-4248	74	10	%	%	NOUN
dpc-4248	74	11	 	 	SPACE
dpc-4248	74	12	of	of	ADP
dpc-4248	74	13	patients	patient	NOUN
dpc-4248	74	14	was	be	AUX
dpc-4248	74	15	under	under	ADP
dpc-4248	74	16	treatment	treatment	NOUN
dpc-4248	74	17	at	at	ADP
dpc-4248	74	18	weeks	week	NOUN
dpc-4248	74	19	52	52	NUM
dpc-4248	74	20	and	and	CCONJ
dpc-4248	74	21	104	104	NUM
dpc-4248	74	22	respectively	respectively	ADV
dpc-4248	74	23	.	.	PUNCT
dpc-4248	75	1	the	the	DET
dpc-4248	75	2	drug	drug	NOUN
dpc-4248	75	3	survival	survival	NOUN
dpc-4248	75	4	rate	rate	NOUN
dpc-4248	75	5	for	for	ADP
dpc-4248	75	6	discontinuation	discontinuation	NOUN
dpc-4248	75	7	due	due	ADP
dpc-4248	75	8	to	to	ADP
dpc-4248	75	9	adverse	adverse	ADJ
dpc-4248	75	10	events	event	NOUN
dpc-4248	75	11	was	be	AUX
dpc-4248	75	12	93.69	93.69	NUM
dpc-4248	75	13	%	%	NOUN
dpc-4248	75	14	(	(	PUNCT
dpc-4248	75	15	confidence	confidence	NOUN
dpc-4248	75	16	interval	interval	NOUN
dpc-4248	75	17	[	[	X
dpc-4248	75	18	ci	ci	X
dpc-4248	75	19	]	]	X
dpc-4248	75	20	85.35	85.35	NUM
dpc-4248	75	21	-	-	SYM
dpc-4248	75	22	97.35	97.35	NUM
dpc-4248	75	23	)	)	PUNCT
dpc-4248	75	24	,	,	PUNCT
dpc-4248	75	25	and	and	CCONJ
dpc-4248	75	26	92.04	92.04	NUM
dpc-4248	75	27	%	%	NOUN
dpc-4248	75	28	(	(	PUNCT
dpc-4248	75	29	ci	ci	PROPN
dpc-4248	75	30	82.93	82.93	NUM
dpc-4248	75	31	-	-	SYM
dpc-4248	75	32	96.39	96.39	NUM
dpc-4248	75	33	)	)	PUNCT
dpc-4248	75	34	after	after	ADP
dpc-4248	75	35	52	52	NUM
dpc-4248	75	36	and	and	CCONJ
dpc-4248	75	37	104	104	NUM
dpc-4248	75	38	weeks	week	NOUN
dpc-4248	75	39	,	,	PUNCT
dpc-4248	75	40	respectively	respectively	ADV
dpc-4248	75	41	(	(	PUNCT
dpc-4248	75	42	figure	figure	NOUN
dpc-4248	75	43	1b	1b	NUM
dpc-4248	75	44	)	)	PUNCT
dpc-4248	75	45	.	.	PUNCT
dpc-4248	76	1	the	the	DET
dpc-4248	76	2	drug	drug	NOUN
dpc-4248	76	3	survival	survival	NOUN
dpc-4248	76	4	rate	rate	NOUN
dpc-4248	76	5	for	for	ADP
dpc-4248	76	6	discontinuation	discontinuation	NOUN
dpc-4248	76	7	due	due	ADP
dpc-4248	76	8	to	to	ADP
dpc-4248	76	9	ineffectiveness	ineffectiveness	NOUN
dpc-4248	76	10	was	be	AUX
dpc-4248	76	11	table	table	NOUN
dpc-4248	76	12	1	1	NUM
dpc-4248	76	13	.	.	PUNCT
dpc-4248	77	1	clinical	clinical	ADJ
dpc-4248	77	2	and	and	CCONJ
dpc-4248	77	3	demographic	demographic	ADJ
dpc-4248	77	4	characteristics	characteristic	NOUN
dpc-4248	77	5	of	of	ADP
dpc-4248	77	6	the	the	DET
dpc-4248	77	7	study	study	NOUN
dpc-4248	77	8	population	population	NOUN
dpc-4248	77	9	.	.	PUNCT
dpc-4248	78	1	demographic	demographic	ADJ
dpc-4248	78	2	or	or	CCONJ
dpc-4248	78	3	clinical	clinical	ADJ
dpc-4248	78	4	characteristic	characteristic	NOUN
dpc-4248	78	5	(	(	PUNCT
dpc-4248	78	6	total	total	NOUN
dpc-4248	78	7	n	n	NOUN
dpc-4248	78	8	=	=	SYM
dpc-4248	78	9	90	90	NUM
dpc-4248	78	10	)	)	PUNCT
dpc-4248	78	11	n	n	PROPN
dpc-4248	78	12	(	(	PUNCT
dpc-4248	78	13	%	%	INTJ
dpc-4248	78	14	)	)	PUNCT
dpc-4248	78	15	;	;	PUNCT
dpc-4248	78	16	mean	mean	X
dpc-4248	78	17	(	(	PUNCT
dpc-4248	78	18	sd	sd	NOUN
dpc-4248	78	19	)	)	PUNCT
dpc-4248	78	20	,	,	PUNCT
dpc-4248	78	21	median	median	PROPN
dpc-4248	78	22	[	[	X
dpc-4248	78	23	iqr	iqr	X
dpc-4248	78	24	]	]	X
dpc-4248	78	25	sex	sex	NOUN
dpc-4248	78	26	males	male	NOUN
dpc-4248	78	27	29	29	NUM
dpc-4248	78	28	(	(	PUNCT
dpc-4248	78	29	32.22	32.22	NUM
dpc-4248	78	30	)	)	PUNCT
dpc-4248	78	31	females	female	NOUN
dpc-4248	78	32	61	61	NUM
dpc-4248	78	33	(	(	PUNCT
dpc-4248	78	34	67.78	67.78	NUM
dpc-4248	78	35	)	)	PUNCT
dpc-4248	78	36	age	age	NOUN
dpc-4248	78	37	52.22	52.22	NUM
dpc-4248	78	38	(	(	PUNCT
dpc-4248	78	39	15.03	15.03	NUM
dpc-4248	78	40	)	)	PUNCT
dpc-4248	78	41	age	age	NOUN
dpc-4248	78	42	of	of	ADP
dpc-4248	78	43	onset	onset	NOUN
dpc-4248	78	44	29.45	29.45	NUM
dpc-4248	78	45	(	(	PUNCT
dpc-4248	78	46	15.64	15.64	NUM
dpc-4248	78	47	)	)	PUNCT
dpc-4248	78	48	arthritic	arthritic	ADJ
dpc-4248	78	49	psoriasis	psoriasis	NOUN
dpc-4248	78	50	yes	yes	INTJ
dpc-4248	78	51	21	21	NUM
dpc-4248	78	52	(	(	PUNCT
dpc-4248	78	53	23.33	23.33	NUM
dpc-4248	78	54	)	)	PUNCT
dpc-4248	78	55	no	no	PRON
dpc-4248	78	56	69	69	NUM
dpc-4248	78	57	(	(	PUNCT
dpc-4248	78	58	76.67	76.67	NUM
dpc-4248	78	59	)	)	PUNCT
dpc-4248	78	60	bmi	bmi	VERB
dpc-4248	78	61	26.73	26.73	NUM
dpc-4248	79	1	[	[	X
dpc-4248	79	2	24.10	24.10	NUM
dpc-4248	79	3	–	–	PUNCT
dpc-4248	79	4	29.41	29.41	NUM
dpc-4248	79	5	]	]	PUNCT
dpc-4248	79	6	scalp	scalp	NOUN
dpc-4248	79	7	psoriasis	psoriasis	NOUN
dpc-4248	79	8	yes	yes	INTJ
dpc-4248	79	9	44	44	NUM
dpc-4248	79	10	(	(	PUNCT
dpc-4248	79	11	48.89	48.89	NUM
dpc-4248	79	12	)	)	PUNCT
dpc-4248	79	13	no	no	DET
dpc-4248	79	14	46	46	NUM
dpc-4248	79	15	(	(	PUNCT
dpc-4248	79	16	51.11	51.11	NUM
dpc-4248	79	17	)	)	PUNCT
dpc-4248	79	18	nail	nail	NOUN
dpc-4248	79	19	psoriasis	psoriasis	NOUN
dpc-4248	80	1	yes	yes	INTJ
dpc-4248	80	2	23	23	NUM
dpc-4248	80	3	(	(	PUNCT
dpc-4248	80	4	25.65	25.65	NUM
dpc-4248	80	5	)	)	PUNCT
dpc-4248	80	6	no	no	PRON
dpc-4248	80	7	67	67	NUM
dpc-4248	80	8	(	(	PUNCT
dpc-4248	80	9	74.44	74.44	NUM
dpc-4248	80	10	)	)	PUNCT
dpc-4248	80	11	palmoplantar	palmoplantar	NOUN
dpc-4248	80	12	psoriasis	psoriasis	NOUN
dpc-4248	81	1	yes	yes	INTJ
dpc-4248	81	2	12	12	NUM
dpc-4248	81	3	(	(	PUNCT
dpc-4248	81	4	13.33	13.33	NUM
dpc-4248	81	5	)	)	PUNCT
dpc-4248	81	6	no	no	DET
dpc-4248	81	7	78	78	NUM
dpc-4248	81	8	(	(	PUNCT
dpc-4248	81	9	86.67	86.67	NUM
dpc-4248	81	10	)	)	PUNCT
dpc-4248	81	11	genital	genital	ADJ
dpc-4248	81	12	psoriasis	psoriasis	NOUN
dpc-4248	82	1	yes	yes	INTJ
dpc-4248	82	2	25	25	NUM
dpc-4248	82	3	(	(	PUNCT
dpc-4248	82	4	27.78	27.78	NUM
dpc-4248	82	5	)	)	PUNCT
dpc-4248	83	1	no	no	DET
dpc-4248	83	2	65	65	NUM
dpc-4248	83	3	(	(	PUNCT
dpc-4248	83	4	72.22	72.22	NUM
dpc-4248	83	5	)	)	PUNCT
dpc-4248	83	6	previous	previous	ADJ
dpc-4248	83	7	biological	biological	ADJ
dpc-4248	83	8	treatments	treatment	NOUN
dpc-4248	83	9	yes	yes	INTJ
dpc-4248	83	10	47	47	NUM
dpc-4248	83	11	(	(	PUNCT
dpc-4248	83	12	52.22	52.22	NUM
dpc-4248	83	13	)	)	PUNCT
dpc-4248	83	14	no	no	DET
dpc-4248	83	15	43	43	NUM
dpc-4248	83	16	(	(	PUNCT
dpc-4248	83	17	47.78	47.78	NUM
dpc-4248	83	18	)	)	PUNCT
dpc-4248	83	19	other	other	ADJ
dpc-4248	83	20	anti	anti	NOUN
dpc-4248	83	21	il17	il17	PROPN
dpc-4248	83	22	use	use	VERB
dpc-4248	83	23	yes	yes	INTJ
dpc-4248	83	24	19	19	NUM
dpc-4248	83	25	(	(	PUNCT
dpc-4248	83	26	21.11	21.11	NUM
dpc-4248	83	27	)	)	PUNCT
dpc-4248	83	28	no	no	DET
dpc-4248	83	29	71	71	NUM
dpc-4248	83	30	(	(	PUNCT
dpc-4248	83	31	78.89	78.89	NUM
dpc-4248	83	32	)	)	PUNCT
dpc-4248	83	33	pasi	pasi	NOUN
dpc-4248	83	34	at	at	ADP
dpc-4248	83	35	baseline	baseline	NOUN
dpc-4248	83	36	15.0	15.0	NUM
dpc-4248	83	37	[	[	X
dpc-4248	83	38	10.0	10.0	NUM
dpc-4248	83	39	–	–	PUNCT
dpc-4248	83	40	22.0	22.0	NUM
dpc-4248	83	41	]	]	PUNCT
dpc-4248	83	42	pasi	pasi	NOUN
dpc-4248	83	43	week	week	PROPN
dpc-4248	83	44	12	12	NUM
dpc-4248	83	45	(	(	PUNCT
dpc-4248	83	46	n=90	n=90	NUM
dpc-4248	83	47	)	)	PUNCT
dpc-4248	83	48	0.0	0.0	NUM
dpc-4248	84	1	[	[	PUNCT
dpc-4248	84	2	0.0	0.0	NUM
dpc-4248	84	3	–	–	SYM
dpc-4248	84	4	2.0	2.0	NUM
dpc-4248	84	5	]	]	PUNCT
dpc-4248	84	6	pasi	pasi	NOUN
dpc-4248	84	7	week	week	NOUN
dpc-4248	84	8	52	52	NUM
dpc-4248	84	9	(	(	PUNCT
dpc-4248	84	10	n=85	n=85	PROPN
dpc-4248	84	11	)	)	PUNCT
dpc-4248	84	12	0.0	0.0	NUM
dpc-4248	85	1	[	[	PUNCT
dpc-4248	85	2	0.0	0.0	NUM
dpc-4248	85	3	–	–	PUNCT
dpc-4248	85	4	0.8	0.8	NUM
dpc-4248	85	5	]	]	PUNCT
dpc-4248	85	6	pasi	pasi	NOUN
dpc-4248	85	7	week	week	PROPN
dpc-4248	85	8	104	104	NUM
dpc-4248	85	9	(	(	PUNCT
dpc-4248	85	10	n=73	n=73	NOUN
dpc-4248	85	11	)	)	PUNCT
dpc-4248	85	12	0.0	0.0	NUM
dpc-4248	86	1	[	[	PUNCT
dpc-4248	86	2	0.0	0.0	NUM
dpc-4248	86	3	–	–	SYM
dpc-4248	86	4	1.0	1.0	NUM
dpc-4248	86	5	]	]	PUNCT
dpc-4248	86	6	pasi	pasi	NOUN
dpc-4248	86	7	week	week	PROPN
dpc-4248	86	8	156	156	NUM
dpc-4248	86	9	(	(	PUNCT
dpc-4248	86	10	n=24	n=24	PROPN
dpc-4248	86	11	)	)	PUNCT
dpc-4248	86	12	0.0	0.0	NUM
dpc-4248	87	1	[	[	PUNCT
dpc-4248	87	2	0.0	0.0	NUM
dpc-4248	87	3	–	–	SYM
dpc-4248	87	4	0.0	0.0	NUM
dpc-4248	87	5	]	]	PUNCT
dpc-4248	87	6	fast	fast	ADJ
dpc-4248	87	7	responder	responder	NOUN
dpc-4248	87	8	*	*	PUNCT
dpc-4248	87	9	no	no	DET
dpc-4248	87	10	61	61	NUM
dpc-4248	87	11	(	(	PUNCT
dpc-4248	87	12	67.78	67.78	NUM
dpc-4248	87	13	)	)	PUNCT
dpc-4248	87	14	yes	yes	INTJ
dpc-4248	87	15	29	29	NUM
dpc-4248	87	16	(	(	PUNCT
dpc-4248	87	17	32.22	32.22	NUM
dpc-4248	87	18	)	)	PUNCT
dpc-4248	87	19	*	*	PUNCT
dpc-4248	87	20	patients	patient	NOUN
dpc-4248	87	21	achieving	achieve	VERB
dpc-4248	87	22	pasi	pasi	NOUN
dpc-4248	87	23	90	90	NUM
dpc-4248	87	24	at	at	ADP
dpc-4248	87	25	week	week	NOUN
dpc-4248	87	26	4	4	NUM
dpc-4248	87	27	.	.	PUNCT
dpc-4248	87	28	bmi	bmi	NOUN
dpc-4248	87	29	=	=	SYM
dpc-4248	87	30	body	body	PROPN
dpc-4248	87	31	mass	mass	PROPN
dpc-4248	87	32	index	index	NOUN
dpc-4248	87	33	;	;	PUNCT
dpc-4248	87	34	iqr	iqr	PROPN
dpc-4248	87	35	=	=	NOUN
dpc-4248	87	36	interquartile	interquartile	NOUN
dpc-4248	87	37	range	range	NOUN
dpc-4248	87	38	;	;	PUNCT
dpc-4248	87	39	pasi	pasi	NOUN
dpc-4248	87	40	=	=	SYM
dpc-4248	87	41	psoriasis	psoriasis	NOUN
dpc-4248	87	42	area	area	NOUN
dpc-4248	87	43	and	and	CCONJ
dpc-4248	87	44	severity	severity	NOUN
dpc-4248	87	45	index	index	NOUN
dpc-4248	87	46	;	;	PUNCT
dpc-4248	87	47	sd	sd	NOUN
dpc-4248	87	48	=	=	SYM
dpc-4248	87	49	standard	standard	ADJ
dpc-4248	87	50	deviation	deviation	NOUN
dpc-4248	87	51	.	.	PUNCT
dpc-4248	88	1	93.44	93.44	NUM
dpc-4248	88	2	%	%	NOUN
dpc-4248	88	3	(	(	PUNCT
dpc-4248	88	4	ic	ic	PROPN
dpc-4248	88	5	84.81	84.81	NUM
dpc-4248	88	6	-	-	SYM
dpc-4248	88	7	97.24	97.24	NUM
dpc-4248	88	8	)	)	PUNCT
dpc-4248	88	9	and	and	CCONJ
dpc-4248	88	10	87.94	87.94	NUM
dpc-4248	88	11	%	%	NOUN
dpc-4248	88	12	(	(	PUNCT
dpc-4248	88	13	ic	ic	PROPN
dpc-4248	88	14	76.95	76.95	NUM
dpc-4248	88	15	-	-	SYM
dpc-4248	88	16	93.90	93.90	NUM
dpc-4248	88	17	)	)	PUNCT
dpc-4248	88	18	after	after	ADP
dpc-4248	88	19	52	52	NUM
dpc-4248	88	20	and	and	CCONJ
dpc-4248	88	21	104	104	NUM
dpc-4248	88	22	weeks	week	NOUN
dpc-4248	88	23	,	,	PUNCT
dpc-4248	88	24	respectively	respectively	ADV
dpc-4248	88	25	(	(	PUNCT
dpc-4248	88	26	figure	figure	NOUN
dpc-4248	88	27	1c	1c	NOUN
dpc-4248	88	28	)	)	PUNCT
dpc-4248	88	29	.	.	PUNCT
dpc-4248	89	1	data	datum	NOUN
dpc-4248	89	2	about	about	ADV
dpc-4248	89	3	156	156	NUM
dpc-4248	89	4	weeks	week	NOUN
dpc-4248	89	5	were	be	AUX
dpc-4248	89	6	not	not	PART
dpc-4248	89	7	reported	report	VERB
dpc-4248	89	8	because	because	SCONJ
dpc-4248	89	9	only	only	ADV
dpc-4248	89	10	24	24	NUM
dpc-4248	89	11	patients	patient	NOUN
dpc-4248	89	12	reached	reach	VERB
dpc-4248	89	13	this	this	DET
dpc-4248	89	14	timepoint	timepoint	NOUN
dpc-4248	89	15	.	.	PUNCT
dpc-4248	90	1	4	4	NUM
dpc-4248	90	2	original	original	ADJ
dpc-4248	90	3	article	article	NOUN
dpc-4248	90	4	|	|	ADV
dpc-4248	90	5	dermatol	dermatol	ADJ
dpc-4248	90	6	pract	pract	NOUN
dpc-4248	90	7	concept	concept	NOUN
dpc-4248	90	8	.	.	PUNCT
dpc-4248	91	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	91	2	figure	figure	NOUN
dpc-4248	91	3	1	1	NUM
dpc-4248	91	4	.	.	PUNCT
dpc-4248	92	1	kaplan	kaplan	PROPN
dpc-4248	92	2	–	–	PUNCT
dpc-4248	92	3	meier	meier	PROPN
dpc-4248	92	4	curves	curve	NOUN
dpc-4248	92	5	of	of	ADP
dpc-4248	92	6	(	(	PUNCT
dpc-4248	92	7	a	a	X
dpc-4248	92	8	)	)	PUNCT
dpc-4248	92	9	overall	overall	ADJ
dpc-4248	92	10	drug	drug	NOUN
dpc-4248	92	11	survival	survival	NOUN
dpc-4248	92	12	;	;	PUNCT
dpc-4248	92	13	(	(	PUNCT
dpc-4248	92	14	b	b	X
dpc-4248	92	15	)	)	PUNCT
dpc-4248	92	16	discontinuation	discontinuation	NOUN
dpc-4248	92	17	because	because	SCONJ
dpc-4248	92	18	of	of	ADP
dpc-4248	92	19	adverse	adverse	ADJ
dpc-4248	92	20	events	event	NOUN
dpc-4248	92	21	or	or	CCONJ
dpc-4248	92	22	other	other	ADJ
dpc-4248	92	23	events	event	NOUN
dpc-4248	92	24	;	;	PUNCT
dpc-4248	92	25	and	and	CCONJ
dpc-4248	92	26	(	(	PUNCT
dpc-4248	92	27	c	c	NOUN
dpc-4248	92	28	)	)	PUNCT
dpc-4248	92	29	discontinuation	discontinuation	NOUN
dpc-4248	92	30	because	because	SCONJ
dpc-4248	92	31	of	of	ADP
dpc-4248	92	32	a	a	DET
dpc-4248	92	33	lack	lack	NOUN
dpc-4248	92	34	or	or	CCONJ
dpc-4248	92	35	loss	loss	NOUN
dpc-4248	92	36	of	of	ADP
dpc-4248	92	37	efficacy	efficacy	NOUN
dpc-4248	92	38	(	(	PUNCT
dpc-4248	92	39	confidence	confidence	NOUN
dpc-4248	92	40	interval	interval	NOUN
dpc-4248	92	41	[	[	X
dpc-4248	92	42	ci	ci	X
dpc-4248	92	43	]	]	X
dpc-4248	92	44	in	in	ADP
dpc-4248	92	45	light	light	ADJ
dpc-4248	92	46	gray	gray	ADJ
dpc-4248	92	47	)	)	PUNCT
dpc-4248	92	48	.	.	PUNCT
dpc-4248	93	1	an	an	DET
dpc-4248	93	2	univariable	univariable	ADJ
dpc-4248	93	3	logistic	logistic	ADJ
dpc-4248	93	4	regression	regression	NOUN
dpc-4248	93	5	was	be	AUX
dpc-4248	93	6	performed	perform	VERB
dpc-4248	93	7	and	and	CCONJ
dpc-4248	93	8	results	result	NOUN
dpc-4248	93	9	are	be	AUX
dpc-4248	93	10	reported	report	VERB
dpc-4248	93	11	in	in	ADP
dpc-4248	93	12	table	table	NOUN
dpc-4248	93	13	2	2	NUM
dpc-4248	93	14	.	.	PUNCT
dpc-4248	94	1	in	in	ADP
dpc-4248	94	2	detail	detail	NOUN
dpc-4248	94	3	,	,	PUNCT
dpc-4248	94	4	predictive	predictive	ADJ
dpc-4248	94	5	factors	factor	NOUN
dpc-4248	94	6	for	for	ADP
dpc-4248	94	7	overall	overall	ADJ
dpc-4248	94	8	drug	drug	NOUN
dpc-4248	94	9	discontinuation	discontinuation	NOUN
dpc-4248	94	10	were	be	AUX
dpc-4248	94	11	psoriatic	psoriatic	ADJ
dpc-4248	94	12	arthritis	arthritis	NOUN
dpc-4248	94	13	or	or	CCONJ
dpc-4248	94	14	2.93	2.93	NUM
dpc-4248	94	15	(	(	PUNCT
dpc-4248	94	16	95	95	NUM
dpc-4248	94	17	%	%	NOUN
dpc-4248	94	18	ci	ci	NOUN
dpc-4248	94	19	,	,	PUNCT
dpc-4248	94	20	1.30	1.30	NUM
dpc-4248	94	21	–	–	PUNCT
dpc-4248	94	22	6.61	6.61	NUM
dpc-4248	94	23	)	)	PUNCT
dpc-4248	94	24	,	,	PUNCT
dpc-4248	94	25	bmi	bmi	VERB
dpc-4248	94	26	with	with	ADP
dpc-4248	94	27	an	an	DET
dpc-4248	94	28	or	or	CCONJ
dpc-4248	94	29	of	of	ADP
dpc-4248	94	30	1.07	1.07	NUM
dpc-4248	94	31	(	(	PUNCT
dpc-4248	94	32	95	95	NUM
dpc-4248	94	33	%	%	NOUN
dpc-4248	94	34	ci	ci	NOUN
dpc-4248	94	35	,	,	PUNCT
dpc-4248	94	36	1.02	1.02	NUM
dpc-4248	94	37	–	–	PUNCT
dpc-4248	94	38	1.13	1.13	NUM
dpc-4248	94	39	)	)	PUNCT
dpc-4248	94	40	and	and	CCONJ
dpc-4248	94	41	baseline	baseline	NOUN
dpc-4248	94	42	pasi	pasi	NOUN
dpc-4248	94	43	or	or	CCONJ
dpc-4248	94	44	1.05	1.05	NUM
dpc-4248	94	45	(	(	PUNCT
dpc-4248	94	46	95	95	NUM
dpc-4248	94	47	%	%	NOUN
dpc-4248	94	48	ci	ci	NOUN
dpc-4248	94	49	,	,	PUNCT
dpc-4248	94	50	1.02	1.02	NUM
dpc-4248	94	51	–	–	PUNCT
dpc-4248	94	52	1.09	1.09	NUM
dpc-4248	94	53	)	)	PUNCT
dpc-4248	94	54	.	.	PUNCT
dpc-4248	95	1	at	at	ADP
dpc-4248	95	2	the	the	DET
dpc-4248	95	3	multivariable	multivariable	ADJ
dpc-4248	95	4	survival	survival	NOUN
dpc-4248	95	5	analysis	analysis	NOUN
dpc-4248	95	6	(	(	PUNCT
dpc-4248	95	7	table	table	NOUN
dpc-4248	95	8	3	3	NUM
dpc-4248	95	9	)	)	PUNCT
dpc-4248	95	10	,	,	PUNCT
dpc-4248	95	11	positive	positive	ADJ
dpc-4248	95	12	predictor	predictor	NOUN
dpc-4248	95	13	factors	factor	NOUN
dpc-4248	95	14	for	for	ADP
dpc-4248	95	15	overall	overall	ADJ
dpc-4248	95	16	discontinuation	discontinuation	NOUN
dpc-4248	95	17	resulted	result	VERB
dpc-4248	95	18	bmi	bmi	NOUN
dpc-4248	95	19	or	or	CCONJ
dpc-4248	95	20	 	 	SPACE
dpc-4248	95	21	1.10	1.10	NUM
dpc-4248	95	22	(	(	PUNCT
dpc-4248	95	23	1.03	1.03	NUM
dpc-4248	95	24	–	–	SYM
dpc-4248	95	25	1.18	1.18	NUM
dpc-4248	95	26	)	)	PUNCT
dpc-4248	95	27	)	)	PUNCT
dpc-4248	95	28	,	,	PUNCT
dpc-4248	95	29	baseline	baseline	NOUN
dpc-4248	95	30	pasi	pasi	NOUN
dpc-4248	95	31	or	or	CCONJ
dpc-4248	95	32	1.06	1.06	NUM
dpc-4248	95	33	(	(	PUNCT
dpc-4248	95	34	95	95	NUM
dpc-4248	95	35	%	%	NOUN
dpc-4248	95	36	ci	ci	NOUN
dpc-4248	95	37	,	,	PUNCT
dpc-4248	95	38	1.02	1.02	NUM
dpc-4248	95	39	–	–	PUNCT
dpc-4248	95	40	1.10	1.10	NUM
dpc-4248	95	41	)	)	PUNCT
dpc-4248	95	42	and	and	CCONJ
dpc-4248	95	43	psoriatic	psoriatic	ADJ
dpc-4248	95	44	arthritis	arthritis	NOUN
dpc-4248	95	45	or	or	CCONJ
dpc-4248	95	46	5.05	5.05	NUM
dpc-4248	95	47	(	(	PUNCT
dpc-4248	95	48	95	95	NUM
dpc-4248	95	49	%	%	NOUN
dpc-4248	95	50	ci	ci	NOUN
dpc-4248	95	51	,	,	PUNCT
dpc-4248	95	52	.89	.89	NUM
dpc-4248	95	53	–	–	PUNCT
dpc-4248	95	54	13.50	13.50	NUM
dpc-4248	95	55	)	)	PUNCT
dpc-4248	95	56	.	.	PUNCT
dpc-4248	96	1	factors	factor	NOUN
dpc-4248	96	2	associated	associate	VERB
dpc-4248	96	3	with	with	ADP
dpc-4248	96	4	suspension	suspension	NOUN
dpc-4248	96	5	for	for	ADP
dpc-4248	96	6	ineffectiveness	ineffectiveness	NOUN
dpc-4248	96	7	were	be	AUX
dpc-4248	96	8	bmi	bmi	NOUN
dpc-4248	96	9	or	or	CCONJ
dpc-4248	96	10	1.11	1.11	NUM
dpc-4248	96	11	(	(	PUNCT
dpc-4248	96	12	95	95	NUM
dpc-4248	96	13	%	%	NOUN
dpc-4248	96	14	ci	ci	NOUN
dpc-4248	96	15	,	,	PUNCT
dpc-4248	96	16	1.01	1.01	NUM
dpc-4248	96	17	–	–	PUNCT
dpc-4248	96	18	1.23	1.23	NUM
dpc-4248	96	19	)	)	PUNCT
dpc-4248	96	20	,	,	PUNCT
dpc-4248	96	21	baseline	baseline	NOUN
dpc-4248	96	22	pasi	pasi	NOUN
dpc-4248	96	23	or	or	CCONJ
dpc-4248	96	24	1.07	1.07	NUM
dpc-4248	96	25	(	(	PUNCT
dpc-4248	96	26	95%ci	95%ci	NUM
dpc-4248	96	27	,	,	PUNCT
dpc-4248	96	28	1.02	1.02	NUM
dpc-4248	96	29	–	–	PUNCT
dpc-4248	96	30	1.13	1.13	NUM
dpc-4248	96	31	)	)	PUNCT
dpc-4248	96	32	and	and	CCONJ
dpc-4248	96	33	psoriatic	psoriatic	ADJ
dpc-4248	96	34	arthritis	arthritis	NOUN
dpc-4248	96	35	or	or	CCONJ
dpc-4248	96	36	11.65	11.65	NUM
dpc-4248	96	37	(	(	PUNCT
dpc-4248	96	38	95	95	NUM
dpc-4248	96	39	%	%	NOUN
dpc-4248	96	40	ci	ci	NOUN
dpc-4248	96	41	,	,	PUNCT
dpc-4248	96	42	2.92	2.92	NUM
dpc-4248	96	43	–	–	PUNCT
dpc-4248	96	44	46.46	46.46	NUM
dpc-4248	96	45	)	)	PUNCT
dpc-4248	96	46	.	.	PUNCT
dpc-4248	97	1	no	no	DET
dpc-4248	97	2	significant	significant	ADJ
dpc-4248	97	3	predictive	predictive	ADJ
dpc-4248	97	4	factors	factor	NOUN
dpc-4248	97	5	emerged	emerge	VERB
dpc-4248	97	6	for	for	ADP
dpc-4248	97	7	discontinuation	discontinuation	NOUN
dpc-4248	97	8	for	for	ADP
dpc-4248	97	9	adverse	adverse	ADJ
dpc-4248	97	10	events	event	NOUN
dpc-4248	97	11	.	.	PUNCT
dpc-4248	98	1	detailed	detailed	ADJ
dpc-4248	98	2	report	report	NOUN
dpc-4248	98	3	of	of	ADP
dpc-4248	98	4	cases	case	NOUN
dpc-4248	98	5	of	of	ADP
dpc-4248	98	6	special	special	ADJ
dpc-4248	98	7	interest	interest	NOUN
dpc-4248	98	8	patient	patient	NOUN
dpc-4248	98	9	#	#	SYM
dpc-4248	98	10	1	1	NUM
dpc-4248	98	11	:	:	PUNCT
dpc-4248	98	12	patient	patient	ADJ
dpc-4248	98	13	with	with	ADP
dpc-4248	98	14	multi	multi	ADJ
dpc-4248	98	15	-	-	ADJ
dpc-4248	98	16	drug	drug	ADJ
dpc-4248	98	17	resistance	resistance	NOUN
dpc-4248	98	18	,	,	PUNCT
dpc-4248	98	19	comorbidities	comorbiditie	NOUN
dpc-4248	98	20	,	,	PUNCT
dpc-4248	98	21	and	and	CCONJ
dpc-4248	98	22	bmi	bmi	PROPN
dpc-4248	98	23	≥40	≥40	PROPN
dpc-4248	98	24	.	.	PUNCT
dpc-4248	99	1	we	we	PRON
dpc-4248	99	2	present	present	VERB
dpc-4248	99	3	the	the	DET
dpc-4248	99	4	case	case	NOUN
dpc-4248	99	5	of	of	ADP
dpc-4248	99	6	a	a	DET
dpc-4248	99	7	56	56	NUM
dpc-4248	99	8	-	-	PUNCT
dpc-4248	99	9	year	year	NOUN
dpc-4248	99	10	-	-	PUNCT
dpc-4248	99	11	old	old	ADJ
dpc-4248	99	12	male	male	NOUN
dpc-4248	99	13	,	,	PUNCT
dpc-4248	99	14	with	with	ADP
dpc-4248	99	15	class	class	NOUN
dpc-4248	99	16	iii	iii	NUM
dpc-4248	99	17	obesity	obesity	NOUN
dpc-4248	99	18	,	,	PUNCT
dpc-4248	99	19	arterial	arterial	NOUN
dpc-4248	99	20	hypertension	hypertension	NOUN
dpc-4248	99	21	,	,	PUNCT
dpc-4248	99	22	hyperuricemia	hyperuricemia	ADV
dpc-4248	99	23	,	,	PUNCT
dpc-4248	99	24	type	type	NOUN
dpc-4248	99	25	ii	ii	NOUN
dpc-4248	99	26	diabetes	diabetes	NOUN
dpc-4248	99	27	,	,	PUNCT
dpc-4248	99	28	hypercholesterolemia	hypercholesterolemia	NOUN
dpc-4248	99	29	and	and	CCONJ
dpc-4248	99	30	a	a	DET
dpc-4248	99	31	history	history	NOUN
dpc-4248	99	32	of	of	ADP
dpc-4248	99	33	psoriasis	psoriasis	NOUN
dpc-4248	99	34	from	from	ADP
dpc-4248	99	35	the	the	DET
dpc-4248	99	36	age	age	NOUN
dpc-4248	99	37	of	of	ADP
dpc-4248	99	38	32	32	NUM
dpc-4248	99	39	.	.	PUNCT
dpc-4248	100	1	he	he	PRON
dpc-4248	100	2	was	be	AUX
dpc-4248	100	3	in	in	ADP
dpc-4248	100	4	therapy	therapy	NOUN
dpc-4248	100	5	from	from	ADP
dpc-4248	100	6	2001	2001	NUM
dpc-4248	100	7	to	to	ADP
dpc-4248	100	8	2002	2002	NUM
dpc-4248	100	9	with	with	ADP
dpc-4248	100	10	cyclosporine	cyclosporine	NOUN
dpc-4248	100	11	discontinued	discontinue	VERB
dpc-4248	100	12	for	for	ADP
dpc-4248	100	13	inefficacy	inefficacy	NOUN
dpc-4248	100	14	.	.	PUNCT
dpc-4248	101	1	then	then	ADV
dpc-4248	101	2	,	,	PUNCT
dpc-4248	101	3	for	for	ADP
dpc-4248	101	4	more	more	ADJ
dpc-4248	101	5	than	than	ADP
dpc-4248	101	6	10	10	NUM
dpc-4248	101	7	years	year	NOUN
dpc-4248	101	8	he	he	PRON
dpc-4248	101	9	was	be	AUX
dpc-4248	101	10	treated	treat	VERB
dpc-4248	101	11	only	only	ADV
dpc-4248	101	12	with	with	ADP
dpc-4248	101	13	topical	topical	ADJ
dpc-4248	101	14	treatments	treatment	NOUN
dpc-4248	101	15	.	.	PUNCT
dpc-4248	102	1	in	in	ADP
dpc-4248	102	2	june	june	PROPN
dpc-4248	102	3	2016	2016	NUM
dpc-4248	102	4	,	,	PUNCT
dpc-4248	102	5	ustekinumab	ustekinumab	NOUN
dpc-4248	102	6	was	be	AUX
dpc-4248	102	7	administered	administer	VERB
dpc-4248	102	8	(	(	PUNCT
dpc-4248	102	9	pasi	pasi	VERB
dpc-4248	102	10	score=42	score=42	NOUN
dpc-4248	102	11	)	)	PUNCT
dpc-4248	102	12	,	,	PUNCT
dpc-4248	102	13	and	and	CCONJ
dpc-4248	102	14	then	then	ADV
dpc-4248	102	15	discontinued	discontinue	VERB
dpc-4248	102	16	after	after	ADP
dpc-4248	102	17	90	90	NUM
dpc-4248	102	18	weeks	week	NOUN
dpc-4248	102	19	for	for	ADP
dpc-4248	102	20	persistence	persistence	NOUN
dpc-4248	102	21	of	of	ADP
dpc-4248	102	22	psoriasis	psoriasis	NOUN
dpc-4248	102	23	(	(	PUNCT
dpc-4248	102	24	residual	residual	ADJ
dpc-4248	102	25	pasi=15	pasi=15	NOUN
dpc-4248	102	26	)	)	PUNCT
dpc-4248	102	27	.	.	PUNCT
dpc-4248	103	1	in	in	ADP
dpc-4248	103	2	may	may	PROPN
dpc-4248	103	3	2018	2018	NUM
dpc-4248	103	4	,	,	PUNCT
dpc-4248	103	5	therapy	therapy	NOUN
dpc-4248	103	6	with	with	ADP
dpc-4248	103	7	secukinumab	secukinumab	NOUN
dpc-4248	103	8	was	be	AUX
dpc-4248	103	9	started	start	VERB
dpc-4248	103	10	,	,	PUNCT
dpc-4248	103	11	with	with	ADP
dpc-4248	103	12	a	a	DET
dpc-4248	103	13	lack	lack	NOUN
dpc-4248	103	14	of	of	ADP
dpc-4248	103	15	response	response	NOUN
dpc-4248	103	16	,	,	PUNCT
dpc-4248	103	17	and	and	CCONJ
dpc-4248	103	18	therefore	therefore	ADV
dpc-4248	103	19	switched	switch	VERB
dpc-4248	103	20	to	to	ADP
dpc-4248	103	21	guselkumab	guselkumab	NOUN
dpc-4248	103	22	after	after	ADP
dpc-4248	103	23	42	42	NUM
dpc-4248	103	24	weeks	week	NOUN
dpc-4248	103	25	of	of	ADP
dpc-4248	103	26	treatment	treatment	NOUN
dpc-4248	103	27	(	(	PUNCT
dpc-4248	103	28	march	march	PROPN
dpc-4248	103	29	2019	2019	NUM
dpc-4248	103	30	,	,	PUNCT
dpc-4248	103	31	pasi	pasi	NOUN
dpc-4248	103	32	score=15	score=15	ADV
dpc-4248	103	33	)	)	PUNCT
dpc-4248	103	34	.	.	PUNCT
dpc-4248	104	1	even	even	ADV
dpc-4248	104	2	with	with	ADP
dpc-4248	104	3	this	this	DET
dpc-4248	104	4	last	last	ADJ
dpc-4248	104	5	therapy	therapy	NOUN
dpc-4248	104	6	,	,	PUNCT
dpc-4248	104	7	no	no	DET
dpc-4248	104	8	improvement	improvement	NOUN
dpc-4248	104	9	was	be	AUX
dpc-4248	104	10	observed	observe	VERB
dpc-4248	104	11	after	after	ADP
dpc-4248	104	12	108	108	NUM
dpc-4248	104	13	weeks	week	NOUN
dpc-4248	104	14	(	(	PUNCT
dpc-4248	104	15	pasi	pasi	NOUN
dpc-4248	104	16	score=15	score=15	ADV
dpc-4248	104	17	)	)	PUNCT
dpc-4248	104	18	.	.	PUNCT
dpc-4248	105	1	finally	finally	ADV
dpc-4248	105	2	,	,	PUNCT
dpc-4248	105	3	in	in	ADP
dpc-4248	105	4	april	april	PROPN
dpc-4248	105	5	2021	2021	NUM
dpc-4248	105	6	,	,	PUNCT
dpc-4248	105	7	brodalumab	brodalumab	NOUN
dpc-4248	105	8	treatment	treatment	NOUN
dpc-4248	105	9	was	be	AUX
dpc-4248	105	10	started	start	VERB
dpc-4248	105	11	(	(	PUNCT
dpc-4248	105	12	figure	figure	NOUN
dpc-4248	105	13	2a	2a	NUM
dpc-4248	105	14	)	)	PUNCT
dpc-4248	105	15	,	,	PUNCT
dpc-4248	105	16	with	with	ADP
dpc-4248	105	17	a	a	DET
dpc-4248	105	18	rapid	rapid	ADJ
dpc-4248	105	19	improvement	improvement	NOUN
dpc-4248	105	20	after	after	ADP
dpc-4248	105	21	6	6	NUM
dpc-4248	105	22	weeks	week	NOUN
dpc-4248	105	23	(	(	PUNCT
dpc-4248	105	24	pasi	pasi	NOUN
dpc-4248	105	25	score=	score=	NUM
dpc-4248	105	26	6	6	NUM
dpc-4248	105	27	,	,	PUNCT
dpc-4248	105	28	figure	figure	NOUN
dpc-4248	105	29	2b	2b	NOUN
dpc-4248	105	30	)	)	PUNCT
dpc-4248	105	31	and	and	CCONJ
dpc-4248	105	32	a	a	DET
dpc-4248	105	33	complete	complete	ADJ
dpc-4248	105	34	remission	remission	NOUN
dpc-4248	105	35	after	after	ADP
dpc-4248	105	36	12	12	NUM
dpc-4248	105	37	weeks	week	NOUN
dpc-4248	105	38	.	.	PUNCT
dpc-4248	106	1	currently	currently	ADV
dpc-4248	106	2	,	,	PUNCT
dpc-4248	106	3	the	the	DET
dpc-4248	106	4	patient	patient	NOUN
dpc-4248	106	5	has	have	AUX
dpc-4248	106	6	reached	reach	VERB
dpc-4248	106	7	the	the	DET
dpc-4248	106	8	second	second	ADJ
dpc-4248	106	9	year	year	NOUN
dpc-4248	106	10	of	of	ADP
dpc-4248	106	11	treatment	treatment	NOUN
dpc-4248	106	12	with	with	ADP
dpc-4248	106	13	brodalumab	brodalumab	NOUN
dpc-4248	106	14	,	,	PUNCT
dpc-4248	106	15	maintaining	maintain	VERB
dpc-4248	106	16	a	a	DET
dpc-4248	106	17	complete	complete	ADJ
dpc-4248	106	18	remission	remission	NOUN
dpc-4248	106	19	of	of	ADP
dpc-4248	106	20	the	the	DET
dpc-4248	106	21	disease	disease	NOUN
dpc-4248	106	22	(	(	PUNCT
dpc-4248	106	23	figure	figure	NOUN
dpc-4248	106	24	2c	2c	NUM
dpc-4248	106	25	)	)	PUNCT
dpc-4248	106	26	.	.	PUNCT
dpc-4248	107	1	patient	patient	ADJ
dpc-4248	107	2	#	#	SYM
dpc-4248	107	3	2	2	NUM
dpc-4248	107	4	:	:	PUNCT
dpc-4248	107	5	a	a	DET
dpc-4248	107	6	complex	complex	ADJ
dpc-4248	107	7	oncological	oncological	ADJ
dpc-4248	107	8	history	history	NOUN
dpc-4248	107	9	and	and	CCONJ
dpc-4248	107	10	multiple	multiple	ADJ
dpc-4248	107	11	treatment	treatment	NOUN
dpc-4248	107	12	suspensions	suspension	NOUN
dpc-4248	107	13	without	without	ADP
dpc-4248	107	14	recurrences	recurrence	NOUN
dpc-4248	107	15	.	.	PUNCT
dpc-4248	108	1	a	a	DET
dpc-4248	108	2	48	48	NUM
dpc-4248	108	3	-	-	PUNCT
dpc-4248	108	4	year	year	NOUN
dpc-4248	108	5	-	-	PUNCT
dpc-4248	108	6	old	old	ADJ
dpc-4248	108	7	woman	woman	NOUN
dpc-4248	108	8	was	be	AUX
dpc-4248	108	9	affected	affect	VERB
dpc-4248	108	10	by	by	ADP
dpc-4248	108	11	moderate	moderate	ADJ
dpc-4248	108	12	-	-	PUNCT
dpc-4248	108	13	severe	severe	ADJ
dpc-4248	108	14	psoriasis	psoriasis	NOUN
dpc-4248	108	15	for	for	ADP
dpc-4248	108	16	nearly	nearly	ADV
dpc-4248	108	17	30	30	NUM
dpc-4248	108	18	years	year	NOUN
dpc-4248	108	19	and	and	CCONJ
dpc-4248	108	20	had	have	AUX
dpc-4248	108	21	undergone	undergo	VERB
dpc-4248	108	22	various	various	ADJ
dpc-4248	108	23	therapies	therapy	NOUN
dpc-4248	108	24	over	over	ADP
dpc-4248	108	25	time	time	NOUN
dpc-4248	108	26	,	,	PUNCT
dpc-4248	108	27	including	include	VERB
dpc-4248	108	28	topical	topical	ADJ
dpc-4248	108	29	treatments	treatment	NOUN
dpc-4248	108	30	,	,	PUNCT
dpc-4248	108	31	cyclosporine	cyclosporine	NOUN
dpc-4248	108	32	,	,	PUNCT
dpc-4248	108	33	and	and	CCONJ
dpc-4248	108	34	nb	nb	NOUN
dpc-4248	108	35	-	-	PUNCT
dpc-4248	108	36	uvb	uvb	ADJ
dpc-4248	108	37	phototherapy	phototherapy	NOUN
dpc-4248	108	38	,	,	PUNCT
dpc-4248	108	39	with	with	ADP
dpc-4248	108	40	partial	partial	ADJ
dpc-4248	108	41	benefit	benefit	NOUN
dpc-4248	108	42	.	.	PUNCT
dpc-4248	109	1	two	two	NUM
dpc-4248	109	2	years	year	NOUN
dpc-4248	109	3	earlier	early	ADV
dpc-4248	109	4	the	the	DET
dpc-4248	109	5	patient	patient	NOUN
dpc-4248	109	6	underwent	undergo	VERB
dpc-4248	109	7	a	a	DET
dpc-4248	109	8	conization	conization	NOUN
dpc-4248	109	9	procedure	procedure	NOUN
dpc-4248	109	10	for	for	ADP
dpc-4248	109	11	cervical	cervical	ADJ
dpc-4248	109	12	intraepithelial	intraepithelial	ADJ
dpc-4248	109	13	neoplasia	neoplasia	NOUN
dpc-4248	109	14	iii	iii	X
dpc-4248	109	15	(	(	PUNCT
dpc-4248	109	16	cin	cin	PROPN
dpc-4248	109	17	iii	iii	PROPN
dpc-4248	109	18	)	)	PUNCT
dpc-4248	109	19	.	.	PUNCT
dpc-4248	110	1	however	however	ADV
dpc-4248	110	2	,	,	PUNCT
dpc-4248	110	3	she	she	PRON
dpc-4248	110	4	was	be	AUX
dpc-4248	110	5	in	in	ADP
dpc-4248	110	6	general	general	ADJ
dpc-4248	110	7	good	good	ADJ
dpc-4248	110	8	health	health	NOUN
dpc-4248	110	9	.	.	PUNCT
dpc-4248	111	1	at	at	ADP
dpc-4248	111	2	the	the	DET
dpc-4248	111	3	time	time	NOUN
dpc-4248	111	4	of	of	ADP
dpc-4248	111	5	our	our	PRON
dpc-4248	111	6	observation	observation	NOUN
dpc-4248	111	7	,	,	PUNCT
dpc-4248	111	8	in	in	ADP
dpc-4248	111	9	december	december	PROPN
dpc-4248	111	10	2019	2019	NUM
dpc-4248	111	11	,	,	PUNCT
dpc-4248	111	12	the	the	DET
dpc-4248	111	13	patient	patient	NOUN
dpc-4248	111	14	presented	present	VERB
dpc-4248	111	15	a	a	DET
dpc-4248	111	16	pasi	pasi	NOUN
dpc-4248	111	17	score	score	NOUN
dpc-4248	111	18	of	of	ADP
dpc-4248	111	19	13	13	NUM
dpc-4248	111	20	and	and	CCONJ
dpc-4248	111	21	dlqi	dlqi	VERB
dpc-4248	111	22	of	of	ADP
dpc-4248	111	23	12	12	NUM
dpc-4248	111	24	(	(	PUNCT
dpc-4248	111	25	figure	figure	NOUN
dpc-4248	111	26	3a	3a	NUM
dpc-4248	111	27	)	)	PUNCT
dpc-4248	111	28	.	.	PUNCT
dpc-4248	112	1	she	she	PRON
dpc-4248	112	2	was	be	AUX
dpc-4248	112	3	prescribed	prescribe	VERB
dpc-4248	112	4	brodalumab	brodalumab	NOUN
dpc-4248	112	5	,	,	PUNCT
dpc-4248	112	6	which	which	PRON
dpc-4248	112	7	led	lead	VERB
dpc-4248	112	8	to	to	ADP
dpc-4248	112	9	a	a	DET
dpc-4248	112	10	complete	complete	ADJ
dpc-4248	112	11	remission	remission	NOUN
dpc-4248	112	12	of	of	ADP
dpc-4248	112	13	psoriasis	psoriasis	NOUN
dpc-4248	112	14	(	(	PUNCT
dpc-4248	112	15	pasi	pasi	NOUN
dpc-4248	112	16	0	0	NUM
dpc-4248	112	17	)	)	PUNCT
dpc-4248	112	18	and	and	CCONJ
dpc-4248	112	19	pruritus	pruritus	PROPN
dpc-4248	112	20	after	after	ADP
dpc-4248	112	21	4	4	NUM
dpc-4248	112	22	weeks	week	NOUN
dpc-4248	112	23	,	,	PUNCT
dpc-4248	112	24	along	along	ADP
dpc-4248	112	25	with	with	ADP
dpc-4248	112	26	a	a	DET
dpc-4248	112	27	significant	significant	ADJ
dpc-4248	112	28	improvement	improvement	NOUN
dpc-4248	112	29	in	in	ADP
dpc-4248	112	30	her	her	PRON
dpc-4248	112	31	quality	quality	NOUN
dpc-4248	112	32	of	of	ADP
dpc-4248	112	33	life	life	NOUN
dpc-4248	112	34	(	(	PUNCT
dpc-4248	112	35	dlqi	dlqi	VERB
dpc-4248	112	36	4	4	NUM
dpc-4248	112	37	)	)	PUNCT
dpc-4248	112	38	.	.	PUNCT
dpc-4248	113	1	after	after	ADP
dpc-4248	113	2	9	9	NUM
dpc-4248	113	3	months	month	NOUN
dpc-4248	113	4	of	of	ADP
dpc-4248	113	5	therapy	therapy	NOUN
dpc-4248	113	6	,	,	PUNCT
dpc-4248	113	7	the	the	DET
dpc-4248	113	8	patient	patient	NOUN
dpc-4248	113	9	was	be	AUX
dpc-4248	113	10	diagnosed	diagnose	VERB
dpc-4248	113	11	with	with	ADP
dpc-4248	113	12	a	a	DET
dpc-4248	113	13	right	right	ADJ
dpc-4248	113	14	fronto	fronto	NOUN
dpc-4248	113	15	-	-	PUNCT
dpc-4248	113	16	temporal	temporal	ADJ
dpc-4248	113	17	meningioma	meningioma	NOUN
dpc-4248	113	18	.	.	PUNCT
dpc-4248	114	1	consequently	consequently	ADV
dpc-4248	114	2	,	,	PUNCT
dpc-4248	114	3	she	she	PRON
dpc-4248	114	4	discontinued	discontinue	VERB
dpc-4248	114	5	brodalumab	brodalumab	NOUN
dpc-4248	114	6	and	and	CCONJ
dpc-4248	114	7	underwent	undergo	VERB
dpc-4248	114	8	neurosurgery	neurosurgery	NOUN
dpc-4248	114	9	to	to	PART
dpc-4248	114	10	remove	remove	VERB
dpc-4248	114	11	the	the	DET
dpc-4248	114	12	tumor	tumor	NOUN
dpc-4248	114	13	.	.	PUNCT
dpc-4248	115	1	despite	despite	SCONJ
dpc-4248	115	2	discontinuing	discontinue	VERB
dpc-4248	115	3	the	the	DET
dpc-4248	115	4	biological	biological	ADJ
dpc-4248	115	5	therapy	therapy	NOUN
dpc-4248	115	6	,	,	PUNCT
dpc-4248	115	7	the	the	DET
dpc-4248	115	8	patient	patient	NOUN
dpc-4248	115	9	did	do	AUX
dpc-4248	115	10	not	not	PART
dpc-4248	115	11	experience	experience	VERB
dpc-4248	115	12	a	a	DET
dpc-4248	115	13	relapse	relapse	NOUN
dpc-4248	115	14	of	of	ADP
dpc-4248	115	15	psoriasis	psoriasis	NOUN
dpc-4248	115	16	until	until	ADP
dpc-4248	115	17	3	3	NUM
dpc-4248	115	18	months	month	NOUN
dpc-4248	115	19	after	after	ADP
dpc-4248	115	20	the	the	DET
dpc-4248	115	21	neurosurgical	neurosurgical	ADJ
dpc-4248	115	22	intervention	intervention	NOUN
dpc-4248	115	23	,	,	PUNCT
dpc-4248	115	24	when	when	SCONJ
dpc-4248	115	25	she	she	PRON
dpc-4248	115	26	had	have	VERB
dpc-4248	115	27	a	a	DET
dpc-4248	115	28	recurrence	recurrence	NOUN
dpc-4248	115	29	localized	localize	VERB
dpc-4248	115	30	to	to	ADP
dpc-4248	115	31	the	the	DET
dpc-4248	115	32	scalp	scalp	NOUN
dpc-4248	115	33	(	(	PUNCT
dpc-4248	115	34	figure	figure	NOUN
dpc-4248	115	35	3b	3b	NUM
dpc-4248	115	36	)	)	PUNCT
dpc-4248	115	37	.	.	PUNCT
dpc-4248	116	1	subsequently	subsequently	ADV
dpc-4248	116	2	,	,	PUNCT
dpc-4248	116	3	the	the	DET
dpc-4248	116	4	patient	patient	NOUN
dpc-4248	116	5	resumed	resume	VERB
dpc-4248	116	6	brodalumab	brodalumab	NOUN
dpc-4248	116	7	after	after	ADP
dpc-4248	116	8	consultation	consultation	NOUN
dpc-4248	116	9	with	with	ADP
dpc-4248	116	10	the	the	DET
dpc-4248	116	11	neurosurgeon	neurosurgeon	NOUN
dpc-4248	116	12	,	,	PUNCT
dpc-4248	116	13	achieving	achieve	VERB
dpc-4248	116	14	again	again	ADV
dpc-4248	116	15	the	the	DET
dpc-4248	116	16	remission	remission	NOUN
dpc-4248	116	17	of	of	ADP
dpc-4248	116	18	her	her	PRON
dpc-4248	116	19	psoriasis	psoriasis	NOUN
dpc-4248	116	20	.	.	PUNCT
dpc-4248	117	1	original	original	ADJ
dpc-4248	117	2	article	article	NOUN
dpc-4248	117	3	|	|	ADV
dpc-4248	117	4	dermatol	dermatol	ADJ
dpc-4248	117	5	pract	pract	NOUN
dpc-4248	117	6	concept	concept	NOUN
dpc-4248	117	7	.	.	PUNCT
dpc-4248	118	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	118	2	5	5	NUM
dpc-4248	118	3	table	table	NOUN
dpc-4248	118	4	2	2	NUM
dpc-4248	118	5	.	.	X
dpc-4248	118	6	univariable	univariable	ADJ
dpc-4248	118	7	drug	drug	NOUN
dpc-4248	118	8	survival	survival	NOUN
dpc-4248	118	9	analysis	analysis	NOUN
dpc-4248	118	10	.	.	PUNCT
dpc-4248	119	1	overall	overall	ADJ
dpc-4248	119	2	ineffectiveness	ineffectiveness	NOUN
dpc-4248	119	3	adverse	adverse	ADJ
dpc-4248	119	4	events	event	NOUN
dpc-4248	119	5	or	or	CCONJ
dpc-4248	119	6	(	(	PUNCT
dpc-4248	119	7	95	95	NUM
dpc-4248	119	8	%	%	NOUN
dpc-4248	119	9	ci	ci	NOUN
dpc-4248	119	10	)	)	PUNCT
dpc-4248	119	11	p	p	NOUN
dpc-4248	119	12	-	-	PUNCT
dpc-4248	119	13	value	value	NOUN
dpc-4248	119	14	or	or	CCONJ
dpc-4248	119	15	(	(	PUNCT
dpc-4248	119	16	95	95	NUM
dpc-4248	119	17	%	%	NOUN
dpc-4248	119	18	ci	ci	NOUN
dpc-4248	119	19	)	)	PUNCT
dpc-4248	119	20	p	p	NOUN
dpc-4248	119	21	-	-	PUNCT
dpc-4248	119	22	value	value	NOUN
dpc-4248	119	23	or	or	CCONJ
dpc-4248	119	24	(	(	PUNCT
dpc-4248	119	25	95	95	NUM
dpc-4248	119	26	%	%	NOUN
dpc-4248	119	27	ci	ci	NOUN
dpc-4248	119	28	)	)	PUNCT
dpc-4248	119	29	p	p	NOUN
dpc-4248	119	30	-	-	PUNCT
dpc-4248	119	31	value	value	NOUN
dpc-4248	119	32	sex	sex	NOUN
dpc-4248	119	33	female	female	ADJ
dpc-4248	119	34	ref	ref	NOUN
dpc-4248	119	35	ref	ref	NOUN
dpc-4248	119	36	ref	ref	NOUN
dpc-4248	119	37	males	male	NOUN
dpc-4248	119	38	1.43	1.43	NUM
dpc-4248	119	39	(	(	PUNCT
dpc-4248	119	40	0.60	0.60	NUM
dpc-4248	119	41	–	–	PUNCT
dpc-4248	119	42	3.44	3.44	NUM
dpc-4248	119	43	)	)	PUNCT
dpc-4248	119	44	0.419	0.419	NUM
dpc-4248	119	45	1.15	1.15	NUM
dpc-4248	119	46	(	(	PUNCT
dpc-4248	119	47	0.39	0.39	NUM
dpc-4248	119	48	–	–	PUNCT
dpc-4248	119	49	3.37	3.37	NUM
dpc-4248	119	50	)	)	PUNCT
dpc-4248	119	51	0.802	0.802	NUM
dpc-4248	119	52	1.59	1.59	NUM
dpc-4248	119	53	(	(	PUNCT
dpc-4248	119	54	0.32	0.32	NUM
dpc-4248	119	55	–	–	PUNCT
dpc-4248	119	56	7.89	7.89	NUM
dpc-4248	119	57	)	)	PUNCT
dpc-4248	119	58	0.571	0.571	NUM
dpc-4248	119	59	age	age	NOUN
dpc-4248	119	60	1.00	1.00	NUM
dpc-4248	119	61	(	(	PUNCT
dpc-4248	119	62	0.97	0.97	NUM
dpc-4248	119	63	–	–	PUNCT
dpc-4248	119	64	1.03	1.03	NUM
dpc-4248	119	65	)	)	PUNCT
dpc-4248	119	66	0.933	0.933	NUM
dpc-4248	119	67	1.01	1.01	NUM
dpc-4248	119	68	(	(	PUNCT
dpc-4248	119	69	0.97	0.97	NUM
dpc-4248	119	70	–	–	PUNCT
dpc-4248	119	71	1.04	1.04	NUM
dpc-4248	119	72	)	)	PUNCT
dpc-4248	119	73	0.750	0.750	NUM
dpc-4248	119	74	0.99	0.99	NUM
dpc-4248	119	75	(	(	PUNCT
dpc-4248	119	76	0.94	0.94	NUM
dpc-4248	119	77	–	–	PUNCT
dpc-4248	119	78	1.04	1.04	NUM
dpc-4248	119	79	)	)	PUNCT
dpc-4248	119	80	0.636	0.636	NUM
dpc-4248	119	81	arthritic	arthritic	ADJ
dpc-4248	119	82	psoriasis	psoriasis	NOUN
dpc-4248	120	1	no	no	DET
dpc-4248	120	2	ref	ref	NOUN
dpc-4248	120	3	ref	ref	NOUN
dpc-4248	120	4	ref	ref	NOUN
dpc-4248	120	5	yes	yes	INTJ
dpc-4248	120	6	2.93	2.93	NUM
dpc-4248	120	7	(	(	PUNCT
dpc-4248	120	8	1.30	1.30	NUM
dpc-4248	120	9	–	–	PUNCT
dpc-4248	120	10	6.61	6.61	NUM
dpc-4248	120	11	)	)	PUNCT
dpc-4248	120	12	0.010	0.010	NUM
dpc-4248	120	13	5.60	5.60	NUM
dpc-4248	120	14	(	(	PUNCT
dpc-4248	120	15	1.94	1.94	NUM
dpc-4248	120	16	–	–	SYM
dpc-4248	120	17	16.17	16.17	NUM
dpc-4248	120	18	)	)	PUNCT
dpc-4248	120	19	0.001	0.001	NUM
dpc-4248	120	20	1.29	1.29	NUM
dpc-4248	120	21	(	(	PUNCT
dpc-4248	120	22	0.26	0.26	NUM
dpc-4248	120	23	–	–	PUNCT
dpc-4248	120	24	6.40	6.40	NUM
dpc-4248	120	25	)	)	PUNCT
dpc-4248	120	26	0.756	0.756	NUM
dpc-4248	120	27	bmi	bmi	NOUN
dpc-4248	120	28	1.07	1.07	NUM
dpc-4248	120	29	(	(	PUNCT
dpc-4248	120	30	1.02	1.02	NUM
dpc-4248	120	31	–	–	SYM
dpc-4248	120	32	1.13	1.13	NUM
dpc-4248	120	33	)	)	PUNCT
dpc-4248	120	34	0.004	0.004	NUM
dpc-4248	120	35	1.07	1.07	NUM
dpc-4248	120	36	(	(	PUNCT
dpc-4248	120	37	0.99	0.99	NUM
dpc-4248	120	38	–	–	PUNCT
dpc-4248	120	39	1.14	1.14	NUM
dpc-4248	120	40	)	)	PUNCT
dpc-4248	120	41	0.056	0.056	NUM
dpc-4248	120	42	1.09	1.09	NUM
dpc-4248	120	43	(	(	PUNCT
dpc-4248	120	44	1.00	1.00	NUM
dpc-4248	120	45	–	–	SYM
dpc-4248	120	46	1.18	1.18	NUM
dpc-4248	120	47	)	)	PUNCT
dpc-4248	120	48	0.049	0.049	NUM
dpc-4248	120	49	scalp	scalp	NOUN
dpc-4248	120	50	psoriasis	psoriasis	NOUN
dpc-4248	121	1	no	no	DET
dpc-4248	121	2	ref	ref	NOUN
dpc-4248	121	3	ref	ref	NOUN
dpc-4248	121	4	ref	ref	NOUN
dpc-4248	121	5	yes	yes	INTJ
dpc-4248	121	6	3.27	3.27	NUM
dpc-4248	121	7	(	(	PUNCT
dpc-4248	121	8	1.36	1.36	NUM
dpc-4248	121	9	–	–	PUNCT
dpc-4248	121	10	7.86	7.86	NUM
dpc-4248	121	11	)	)	PUNCT
dpc-4248	121	12	0.080	0.080	NUM
dpc-4248	121	13	1.96	1.96	NUM
dpc-4248	121	14	(	(	PUNCT
dpc-4248	121	15	0.70	0.70	NUM
dpc-4248	121	16	–	–	PUNCT
dpc-4248	121	17	5.53	5.53	NUM
dpc-4248	121	18	)	)	PUNCT
dpc-4248	121	19	0.203	0.203	NUM
dpc-4248	121	20	8.56	8.56	NUM
dpc-4248	121	21	(	(	PUNCT
dpc-4248	121	22	1.05	1.05	NUM
dpc-4248	121	23	–	–	PUNCT
dpc-4248	121	24	69.76	69.76	NUM
dpc-4248	121	25	)	)	PUNCT
dpc-4248	121	26	0.045	0.045	NUM
dpc-4248	121	27	nail	nail	NOUN
dpc-4248	121	28	psoriasis	psoriasis	NOUN
dpc-4248	121	29	:	:	PUNCT
dpc-4248	122	1	no	no	INTJ
dpc-4248	122	2	no	no	DET
dpc-4248	122	3	ref	ref	NOUN
dpc-4248	122	4	ref	ref	NOUN
dpc-4248	122	5	ref	ref	NOUN
dpc-4248	122	6	yes	yes	INTJ
dpc-4248	122	7	2.38	2.38	NUM
dpc-4248	122	8	(	(	PUNCT
dpc-4248	122	9	0.95	0.95	NUM
dpc-4248	122	10	–	–	PUNCT
dpc-4248	122	11	5.96	5.96	NUM
dpc-4248	122	12	)	)	PUNCT
dpc-4248	122	13	0.064	0.064	NUM
dpc-4248	122	14	2.63	2.63	NUM
dpc-4248	122	15	(	(	PUNCT
dpc-4248	122	16	0.78	0.78	NUM
dpc-4248	122	17	–	–	PUNCT
dpc-4248	122	18	8.80	8.80	NUM
dpc-4248	122	19	)	)	PUNCT
dpc-4248	122	20	0.117	0.117	NUM
dpc-4248	122	21	3.00	3.00	NUM
dpc-4248	122	22	(	(	PUNCT
dpc-4248	122	23	0.67	0.67	NUM
dpc-4248	122	24	–	–	PUNCT
dpc-4248	122	25	13.57	13.57	NUM
dpc-4248	122	26	)	)	PUNCT
dpc-4248	122	27	0.152	0.152	NUM
dpc-4248	122	28	palmoplantar	palmoplantar	NOUN
dpc-4248	122	29	psoriasis	psoriasis	NOUN
dpc-4248	122	30	no	no	DET
dpc-4248	122	31	ref	ref	NOUN
dpc-4248	122	32	ref	ref	NOUN
dpc-4248	123	1	ref	ref	NOUN
dpc-4248	124	1	yes	yes	INTJ
dpc-4248	124	2	0.40	0.40	NUM
dpc-4248	124	3	(	(	PUNCT
dpc-4248	124	4	0.06	0.06	NUM
dpc-4248	124	5	–	–	PUNCT
dpc-4248	124	6	2.96	2.96	NUM
dpc-4248	124	7	)	)	PUNCT
dpc-4248	124	8	0.368	0.368	NUM
dpc-4248	124	9	0.75	0.75	NUM
dpc-4248	124	10	(	(	PUNCT
dpc-4248	124	11	0.10	0.10	NUM
dpc-4248	124	12	–	–	SYM
dpc-4248	124	13	5.76	5.76	NUM
dpc-4248	124	14	)	)	PUNCT
dpc-4248	124	15	0.781	0.781	NUM
dpc-4248	124	16	n.c	n.c	PROPN
dpc-4248	124	17	.	.	PROPN
dpc-4248	124	18	n.c	n.c	PROPN
dpc-4248	124	19	.	.	PROPN
dpc-4248	124	20	genital	genital	ADJ
dpc-4248	124	21	psoriasis	psoriasis	NOUN
dpc-4248	125	1	no	no	DET
dpc-4248	125	2	ref	ref	NOUN
dpc-4248	125	3	ref	ref	NOUN
dpc-4248	125	4	ref	ref	NOUN
dpc-4248	125	5	yes	yes	INTJ
dpc-4248	125	6	2.13	2.13	NUM
dpc-4248	125	7	(	(	PUNCT
dpc-4248	125	8	0.95	0.95	NUM
dpc-4248	125	9	–	–	SYM
dpc-4248	125	10	4.81	4.81	NUM
dpc-4248	125	11	)	)	PUNCT
dpc-4248	125	12	0.068	0.068	NUM
dpc-4248	125	13	1.21	1.21	NUM
dpc-4248	125	14	(	(	PUNCT
dpc-4248	125	15	0.38	0.38	NUM
dpc-4248	125	16	–	–	PUNCT
dpc-4248	125	17	3.87	3.87	NUM
dpc-4248	125	18	)	)	PUNCT
dpc-4248	125	19	0.748	0.748	NUM
dpc-4248	125	20	4.94	4.94	NUM
dpc-4248	125	21	(	(	PUNCT
dpc-4248	125	22	1.75	1.75	NUM
dpc-4248	125	23	–	–	PUNCT
dpc-4248	125	24	20.75	20.75	NUM
dpc-4248	125	25	)	)	PUNCT
dpc-4248	125	26	0.029	0.029	NUM
dpc-4248	125	27	other	other	ADJ
dpc-4248	125	28	anti	anti	X
dpc-4248	125	29	il-17	il-17	AUX
dpc-4248	125	30	use	use	VERB
dpc-4248	125	31	no	no	DET
dpc-4248	125	32	ref	ref	NOUN
dpc-4248	125	33	ref	ref	NOUN
dpc-4248	125	34	ref	ref	NOUN
dpc-4248	126	1	yes	yes	INTJ
dpc-4248	126	2	0.88	0.88	NUM
dpc-4248	126	3	(	(	PUNCT
dpc-4248	126	4	0.30	0.30	NUM
dpc-4248	126	5	–	–	PUNCT
dpc-4248	126	6	2.59	2.59	NUM
dpc-4248	126	7	)	)	PUNCT
dpc-4248	126	8	0.821	0.821	NUM
dpc-4248	126	9	1.25	1.25	NUM
dpc-4248	126	10	(	(	PUNCT
dpc-4248	126	11	0.35	0.35	NUM
dpc-4248	126	12	–	–	PUNCT
dpc-4248	126	13	4.48	4.48	NUM
dpc-4248	126	14	)	)	PUNCT
dpc-4248	126	15	0.737	0.737	NUM
dpc-4248	126	16	0.60	0.60	NUM
dpc-4248	126	17	(	(	PUNCT
dpc-4248	126	18	0.07	0.07	NUM
dpc-4248	126	19	–	–	PUNCT
dpc-4248	126	20	4.91	4.91	NUM
dpc-4248	126	21	)	)	PUNCT
dpc-4248	126	22	0.637	0.637	NUM
dpc-4248	126	23	previous	previous	ADJ
dpc-4248	126	24	biological	biological	ADJ
dpc-4248	126	25	drug	drug	NOUN
dpc-4248	127	1	no	no	DET
dpc-4248	127	2	ref	ref	NOUN
dpc-4248	127	3	ref	ref	NOUN
dpc-4248	127	4	ref	ref	NOUN
dpc-4248	127	5	yes	yes	INTJ
dpc-4248	127	6	1.47	1.47	NUM
dpc-4248	127	7	(	(	PUNCT
dpc-4248	127	8	0.65	0.65	NUM
dpc-4248	127	9	–	–	PUNCT
dpc-4248	127	10	3.30	3.30	NUM
dpc-4248	127	11	)	)	PUNCT
dpc-4248	127	12	0.358	0.358	NUM
dpc-4248	127	13	1.95	1.95	NUM
dpc-4248	127	14	(	(	PUNCT
dpc-4248	127	15	0.65	0.65	NUM
dpc-4248	127	16	–	–	PUNCT
dpc-4248	127	17	5.83	5.83	NUM
dpc-4248	127	18	)	)	PUNCT
dpc-4248	127	19	0.233	0.233	NUM
dpc-4248	127	20	1.66	1.66	NUM
dpc-4248	127	21	0.40	0.40	NUM
dpc-4248	127	22	–	–	PUNCT
dpc-4248	127	23	6.98	6.98	NUM
dpc-4248	127	24	(	(	PUNCT
dpc-4248	127	25	)	)	PUNCT
dpc-4248	127	26	0.487	0.487	NUM
dpc-4248	127	27	fast	fast	ADJ
dpc-4248	127	28	responder	responder	NOUN
dpc-4248	128	1	no	no	DET
dpc-4248	128	2	ref	ref	NOUN
dpc-4248	128	3	ref	ref	NOUN
dpc-4248	128	4	ref	ref	NOUN
dpc-4248	128	5	yes	yes	INTJ
dpc-4248	128	6	1.57	1.57	NUM
dpc-4248	128	7	(	(	PUNCT
dpc-4248	128	8	0.71	0.71	NUM
dpc-4248	128	9	–	–	PUNCT
dpc-4248	128	10	3.48	3.48	NUM
dpc-4248	128	11	)	)	PUNCT
dpc-4248	128	12	0.261	0.261	NUM
dpc-4248	128	13	1.78	1.78	NUM
dpc-4248	128	14	(	(	PUNCT
dpc-4248	128	15	0.61	0.61	NUM
dpc-4248	128	16	–	–	PUNCT
dpc-4248	128	17	4.73	4.73	NUM
dpc-4248	128	18	)	)	PUNCT
dpc-4248	128	19	0.302	0.302	NUM
dpc-4248	128	20	1.24	1.24	NUM
dpc-4248	128	21	(	(	PUNCT
dpc-4248	128	22	0.30	0.30	NUM
dpc-4248	128	23	–	–	PUNCT
dpc-4248	128	24	5.21	5.21	NUM
dpc-4248	128	25	)	)	PUNCT
dpc-4248	128	26	0.765	0.765	NUM
dpc-4248	128	27	pasi	pasi	NOUN
dpc-4248	128	28	at	at	ADP
dpc-4248	128	29	baseline	baseline	NOUN
dpc-4248	128	30	1.05	1.05	NUM
dpc-4248	128	31	(	(	PUNCT
dpc-4248	128	32	1.02	1.02	NUM
dpc-4248	128	33	–	–	SYM
dpc-4248	128	34	1.09	1.09	NUM
dpc-4248	128	35	)	)	PUNCT
dpc-4248	128	36	0.003	0.003	NUM
dpc-4248	128	37	1.05	1.05	NUM
dpc-4248	128	38	(	(	PUNCT
dpc-4248	128	39	1.00	1.00	NUM
dpc-4248	128	40	–	–	SYM
dpc-4248	128	41	1.10	1.10	NUM
dpc-4248	128	42	)	)	PUNCT
dpc-4248	128	43	0.036	0.036	NUM
dpc-4248	128	44	1.06	1.06	NUM
dpc-4248	128	45	(	(	PUNCT
dpc-4248	128	46	0.99	0.99	NUM
dpc-4248	128	47	–	–	PUNCT
dpc-4248	128	48	1.11	1.11	NUM
dpc-4248	128	49	)	)	PUNCT
dpc-4248	128	50	0.053	0.053	NUM
dpc-4248	128	51	bmi	bmi	NOUN
dpc-4248	128	52	=	=	PUNCT
dpc-4248	128	53	body	body	NOUN
dpc-4248	128	54	mass	mass	PROPN
dpc-4248	128	55	index	index	NOUN
dpc-4248	128	56	;	;	PUNCT
dpc-4248	128	57	ci	ci	NOUN
dpc-4248	128	58	=	=	NOUN
dpc-4248	128	59	confidence	confidence	NOUN
dpc-4248	128	60	interval	interval	NOUN
dpc-4248	128	61	;	;	PUNCT
dpc-4248	128	62	or	or	CCONJ
dpc-4248	128	63	=	=	NOUN
dpc-4248	128	64	odds	odd	NOUN
dpc-4248	128	65	ratio	ratio	NOUN
dpc-4248	128	66	;	;	PUNCT
dpc-4248	128	67	n.c	n.c	PROPN
dpc-4248	128	68	.	.	PROPN
dpc-4248	128	69	,	,	PUNCT
dpc-4248	128	70	non	non	PROPN
dpc-4248	128	71	computable	computable	ADJ
dpc-4248	128	72	;	;	PUNCT
dpc-4248	128	73	pasi	pasi	NOUN
dpc-4248	128	74	=	=	SYM
dpc-4248	128	75	psoriasis	psoriasis	NOUN
dpc-4248	128	76	area	area	NOUN
dpc-4248	128	77	and	and	CCONJ
dpc-4248	128	78	severity	severity	NOUN
dpc-4248	128	79	index	index	NOUN
dpc-4248	128	80	.	.	PUNCT
dpc-4248	129	1	table	table	NOUN
dpc-4248	129	2	3	3	NUM
dpc-4248	129	3	.	.	PUNCT
dpc-4248	129	4	multivariable	multivariable	ADJ
dpc-4248	129	5	survival	survival	NOUN
dpc-4248	129	6	analysis	analysis	NOUN
dpc-4248	129	7	.	.	PUNCT
dpc-4248	130	1	overall	overall	ADJ
dpc-4248	130	2	ineffectiveness	ineffectiveness	NOUN
dpc-4248	130	3	adverse	adverse	ADJ
dpc-4248	130	4	events	event	NOUN
dpc-4248	130	5	or	or	CCONJ
dpc-4248	130	6	(	(	PUNCT
dpc-4248	130	7	95	95	NUM
dpc-4248	130	8	%	%	NOUN
dpc-4248	130	9	ci	ci	NOUN
dpc-4248	130	10	)	)	PUNCT
dpc-4248	130	11	p	p	NOUN
dpc-4248	130	12	-	-	PUNCT
dpc-4248	130	13	value	value	NOUN
dpc-4248	130	14	or	or	CCONJ
dpc-4248	130	15	(	(	PUNCT
dpc-4248	130	16	95	95	NUM
dpc-4248	130	17	%	%	NOUN
dpc-4248	130	18	ci	ci	NOUN
dpc-4248	130	19	)	)	PUNCT
dpc-4248	130	20	p	p	NOUN
dpc-4248	130	21	-	-	PUNCT
dpc-4248	130	22	value	value	NOUN
dpc-4248	130	23	or	or	CCONJ
dpc-4248	130	24	(	(	PUNCT
dpc-4248	130	25	95	95	NUM
dpc-4248	130	26	%	%	NOUN
dpc-4248	130	27	ci	ci	NOUN
dpc-4248	130	28	)	)	PUNCT
dpc-4248	130	29	p	p	NOUN
dpc-4248	130	30	-	-	PUNCT
dpc-4248	130	31	value	value	NOUN
dpc-4248	130	32	sex	sex	NOUN
dpc-4248	130	33	female	female	ADJ
dpc-4248	130	34	ref	ref	NOUN
dpc-4248	130	35	ref	ref	NOUN
dpc-4248	130	36	ref	ref	NOUN
dpc-4248	130	37	males	male	NOUN
dpc-4248	130	38	0.70	0.70	NUM
dpc-4248	130	39	(	(	PUNCT
dpc-4248	130	40	0.26	0.26	NUM
dpc-4248	130	41	–	–	PUNCT
dpc-4248	130	42	1.85	1.85	NUM
dpc-4248	130	43	)	)	PUNCT
dpc-4248	130	44	0.466	0.466	NUM
dpc-4248	130	45	0.46	0.46	NUM
dpc-4248	130	46	(	(	PUNCT
dpc-4248	130	47	0.13	0.13	NUM
dpc-4248	130	48	–	–	PUNCT
dpc-4248	130	49	1.66	1.66	NUM
dpc-4248	130	50	)	)	PUNCT
dpc-4248	130	51	0.237	0.237	NUM
dpc-4248	130	52	0.87	0.87	NUM
dpc-4248	130	53	(	(	PUNCT
dpc-4248	130	54	0.15	0.15	NUM
dpc-4248	130	55	–	–	PUNCT
dpc-4248	130	56	5.00	5.00	NUM
dpc-4248	130	57	)	)	PUNCT
dpc-4248	130	58	0.878	0.878	NUM
dpc-4248	130	59	age	age	NOUN
dpc-4248	130	60	0.99	0.99	NUM
dpc-4248	130	61	(	(	PUNCT
dpc-4248	130	62	0.95	0.95	NUM
dpc-4248	130	63	–	–	PUNCT
dpc-4248	130	64	1.02	1.02	NUM
dpc-4248	130	65	)	)	PUNCT
dpc-4248	130	66	0.443	0.443	NUM
dpc-4248	130	67	0.99	0.99	NUM
dpc-4248	130	68	(	(	PUNCT
dpc-4248	130	69	0.94	0.94	NUM
dpc-4248	130	70	–	–	PUNCT
dpc-4248	130	71	1.03	1.03	NUM
dpc-4248	130	72	)	)	PUNCT
dpc-4248	130	73	0.533	0.533	NUM
dpc-4248	130	74	0.98	0.98	NUM
dpc-4248	130	75	(	(	PUNCT
dpc-4248	130	76	0.93	0.93	NUM
dpc-4248	130	77	–	–	SYM
dpc-4248	130	78	1.04	1.04	NUM
dpc-4248	130	79	)	)	PUNCT
dpc-4248	130	80	0.497	0.497	NUM
dpc-4248	130	81	bmi	bmi	NOUN
dpc-4248	130	82	1.10	1.10	NUM
dpc-4248	130	83	(	(	PUNCT
dpc-4248	130	84	1.03	1.03	NUM
dpc-4248	130	85	–	–	SYM
dpc-4248	130	86	1.18	1.18	NUM
dpc-4248	130	87	)	)	PUNCT
dpc-4248	130	88	0.003	0.003	NUM
dpc-4248	130	89	1.11	1.11	NUM
dpc-4248	130	90	(	(	PUNCT
dpc-4248	130	91	1.01	1.01	NUM
dpc-4248	130	92	–	–	PUNCT
dpc-4248	130	93	1.23	1.23	NUM
dpc-4248	130	94	)	)	PUNCT
dpc-4248	130	95	0.032	0.032	NUM
dpc-4248	130	96	1.09(0.98	1.09(0.98	NUM
dpc-4248	130	97	–	–	PUNCT
dpc-4248	130	98	1.20	1.20	NUM
dpc-4248	130	99	)	)	PUNCT
dpc-4248	130	100	0.106	0.106	NUM
dpc-4248	130	101	baseline	baseline	NOUN
dpc-4248	130	102	pasi	pasi	NOUN
dpc-4248	130	103	no	no	DET
dpc-4248	130	104	1.06	1.06	NUM
dpc-4248	130	105	(	(	PUNCT
dpc-4248	130	106	1.02	1.02	NUM
dpc-4248	130	107	–	–	SYM
dpc-4248	130	108	1.10	1.10	NUM
dpc-4248	130	109	)	)	PUNCT
dpc-4248	130	110	0.002	0.002	NUM
dpc-4248	130	111	1.07	1.07	NUM
dpc-4248	130	112	(	(	PUNCT
dpc-4248	130	113	1.02	1.02	NUM
dpc-4248	130	114	–	–	SYM
dpc-4248	130	115	1.13	1.13	NUM
dpc-4248	130	116	)	)	PUNCT
dpc-4248	130	117	0.010	0.010	NUM
dpc-4248	130	118	1.06	1.06	NUM
dpc-4248	130	119	(	(	PUNCT
dpc-4248	130	120	1.00	1.00	NUM
dpc-4248	130	121	–	–	SYM
dpc-4248	130	122	1.12	1.12	NUM
dpc-4248	130	123	)	)	PUNCT
dpc-4248	130	124	0.046	0.046	NUM
dpc-4248	130	125	arthritic	arthritic	ADJ
dpc-4248	130	126	psoriasis	psoriasis	NOUN
dpc-4248	130	127	no	no	DET
dpc-4248	130	128	ref	ref	NOUN
dpc-4248	130	129	ref	ref	NOUN
dpc-4248	130	130	ref	ref	NOUN
dpc-4248	130	131	yes	yes	INTJ
dpc-4248	130	132	5.05	5.05	NUM
dpc-4248	130	133	(	(	PUNCT
dpc-4248	130	134	1.89	1.89	NUM
dpc-4248	130	135	–	–	SYM
dpc-4248	130	136	13.50	13.50	NUM
dpc-4248	130	137	)	)	PUNCT
dpc-4248	130	138	0.001	0.001	NUM
dpc-4248	130	139	11.65	11.65	NUM
dpc-4248	130	140	(	(	PUNCT
dpc-4248	130	141	2.92	2.92	NUM
dpc-4248	130	142	–	–	PUNCT
dpc-4248	130	143	46.46	46.46	NUM
dpc-4248	130	144	)	)	PUNCT
dpc-4248	130	145	0.001	0.001	NUM
dpc-4248	130	146	1.71	1.71	NUM
dpc-4248	130	147	(	(	PUNCT
dpc-4248	130	148	0.29	0.29	NUM
dpc-4248	130	149	–	–	PUNCT
dpc-4248	130	150	10.08	10.08	NUM
dpc-4248	130	151	)	)	PUNCT
dpc-4248	130	152	0.554	0.554	NUM
dpc-4248	130	153	previous	previous	ADJ
dpc-4248	130	154	biological	biological	ADJ
dpc-4248	130	155	drug	drug	NOUN
dpc-4248	130	156	no	no	DET
dpc-4248	130	157	ref	ref	NOUN
dpc-4248	130	158	ref	ref	NOUN
dpc-4248	130	159	ref	ref	NOUN
dpc-4248	131	1	yes	yes	INTJ
dpc-4248	131	2	0.88	0.88	NUM
dpc-4248	131	3	(	(	PUNCT
dpc-4248	131	4	0.34	0.34	NUM
dpc-4248	131	5	–	–	PUNCT
dpc-4248	131	6	2.23	2.23	NUM
dpc-4248	131	7	)	)	PUNCT
dpc-4248	131	8	0.791	0.791	NUM
dpc-4248	131	9	0.87	0.87	NUM
dpc-4248	131	10	(	(	PUNCT
dpc-4248	131	11	0.25	0.25	NUM
dpc-4248	131	12	–	–	SYM
dpc-4248	131	13	3.04	3.04	NUM
dpc-4248	131	14	)	)	PUNCT
dpc-4248	131	15	0.957	0.957	NUM
dpc-4248	131	16	1.67	1.67	NUM
dpc-4248	131	17	(	(	PUNCT
dpc-4248	131	18	0.31	0.31	NUM
dpc-4248	131	19	–	–	PUNCT
dpc-4248	131	20	8.94	8.94	NUM
dpc-4248	131	21	)	)	PUNCT
dpc-4248	131	22	0.552	0.552	NUM
dpc-4248	131	23	fast	fast	ADJ
dpc-4248	131	24	responder	responder	NOUN
dpc-4248	131	25	no	no	DET
dpc-4248	131	26	ref	ref	NOUN
dpc-4248	131	27	ref	ref	NOUN
dpc-4248	131	28	ref	ref	NOUN
dpc-4248	131	29	yes	yes	INTJ
dpc-4248	131	30	1.63	1.63	NUM
dpc-4248	131	31	(	(	PUNCT
dpc-4248	131	32	0.71	0.71	NUM
dpc-4248	131	33	–	–	PUNCT
dpc-4248	131	34	3.74	3.74	NUM
dpc-4248	131	35	)	)	PUNCT
dpc-4248	131	36	0.249	0.249	NUM
dpc-4248	131	37	1.94	1.94	NUM
dpc-4248	131	38	(	(	PUNCT
dpc-4248	131	39	0.65	0.65	NUM
dpc-4248	131	40	–	–	PUNCT
dpc-4248	131	41	5.78	5.78	NUM
dpc-4248	131	42	)	)	PUNCT
dpc-4248	132	1	0.233	0.233	NUM
dpc-4248	132	2	1.08	1.08	NUM
dpc-4248	132	3	(	(	PUNCT
dpc-4248	132	4	0.23	0.23	NUM
dpc-4248	132	5	–	–	PUNCT
dpc-4248	132	6	5.06	5.06	NUM
dpc-4248	132	7	)	)	PUNCT
dpc-4248	132	8	0.926	0.926	NUM
dpc-4248	132	9	bmi	bmi	NOUN
dpc-4248	132	10	=	=	SYM
dpc-4248	132	11	body	body	NOUN
dpc-4248	132	12	mass	mass	PROPN
dpc-4248	132	13	index	index	NOUN
dpc-4248	132	14	;	;	PUNCT
dpc-4248	132	15	ci	ci	NOUN
dpc-4248	132	16	=	=	NOUN
dpc-4248	132	17	confidence	confidence	NOUN
dpc-4248	132	18	interval	interval	NOUN
dpc-4248	132	19	;	;	PUNCT
dpc-4248	132	20	or	or	CCONJ
dpc-4248	132	21	=	=	NOUN
dpc-4248	132	22	odds	odd	NOUN
dpc-4248	132	23	ratio	ratio	NOUN
dpc-4248	132	24	;	;	PUNCT
dpc-4248	132	25	pasi	pasi	NOUN
dpc-4248	132	26	=	=	SYM
dpc-4248	132	27	psoriasis	psoriasis	NOUN
dpc-4248	132	28	area	area	NOUN
dpc-4248	132	29	and	and	CCONJ
dpc-4248	132	30	severity	severity	NOUN
dpc-4248	132	31	index	index	NOUN
dpc-4248	132	32	.	.	PUNCT
dpc-4248	133	1	6	6	NUM
dpc-4248	133	2	original	original	ADJ
dpc-4248	133	3	article	article	NOUN
dpc-4248	133	4	|	|	ADV
dpc-4248	133	5	dermatol	dermatol	ADJ
dpc-4248	133	6	pract	pract	NOUN
dpc-4248	133	7	concept	concept	NOUN
dpc-4248	133	8	.	.	PUNCT
dpc-4248	134	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	134	2	figure	figure	NOUN
dpc-4248	134	3	2	2	NUM
dpc-4248	134	4	.	.	PUNCT
dpc-4248	134	5	patient	patient	ADJ
dpc-4248	134	6	#	#	SYM
dpc-4248	134	7	1	1	NUM
dpc-4248	134	8	.	.	PUNCT
dpc-4248	135	1	(	(	PUNCT
dpc-4248	135	2	a	a	X
dpc-4248	135	3	)	)	PUNCT
dpc-4248	135	4	at	at	ADP
dpc-4248	135	5	baseline	baseline	NOUN
dpc-4248	135	6	.	.	PUNCT
dpc-4248	136	1	(	(	PUNCT
dpc-4248	136	2	b	b	X
dpc-4248	136	3	)	)	PUNCT
dpc-4248	136	4	at	at	ADP
dpc-4248	136	5	week	week	NOUN
dpc-4248	136	6	6	6	NUM
dpc-4248	136	7	.	.	PUNCT
dpc-4248	137	1	(	(	PUNCT
dpc-4248	137	2	c	c	X
dpc-4248	137	3	)	)	PUNCT
dpc-4248	137	4	at	at	ADP
dpc-4248	137	5	week	week	NOUN
dpc-4248	137	6	108	108	NUM
dpc-4248	137	7	.	.	PUNCT
dpc-4248	138	1	two	two	NUM
dpc-4248	138	2	years	year	NOUN
dpc-4248	138	3	later	later	ADV
dpc-4248	138	4	,	,	PUNCT
dpc-4248	138	5	the	the	DET
dpc-4248	138	6	patient	patient	NOUN
dpc-4248	138	7	received	receive	VERB
dpc-4248	138	8	a	a	DET
dpc-4248	138	9	diagnosis	diagnosis	NOUN
dpc-4248	138	10	of	of	ADP
dpc-4248	138	11	left	left	ADJ
dpc-4248	138	12	ovarian	ovarian	ADJ
dpc-4248	138	13	fibrothecoma	fibrothecoma	NOUN
dpc-4248	138	14	and	and	CCONJ
dpc-4248	138	15	underwent	undergo	VERB
dpc-4248	138	16	bilateral	bilateral	ADJ
dpc-4248	138	17	ovariectomy	ovariectomy	NOUN
dpc-4248	138	18	and	and	CCONJ
dpc-4248	138	19	adnexectomy	adnexectomy	NOUN
dpc-4248	138	20	.	.	PUNCT
dpc-4248	139	1	additionally	additionally	ADV
dpc-4248	139	2	,	,	PUNCT
dpc-4248	139	3	due	due	ADP
dpc-4248	139	4	to	to	ADP
dpc-4248	139	5	the	the	DET
dpc-4248	139	6	detection	detection	NOUN
dpc-4248	139	7	of	of	ADP
dpc-4248	139	8	breast	breast	NOUN
dpc-4248	139	9	calcifications	calcification	NOUN
dpc-4248	139	10	,	,	PUNCT
dpc-4248	139	11	multiple	multiple	ADJ
dpc-4248	139	12	biopsies	biopsy	NOUN
dpc-4248	139	13	were	be	AUX
dpc-4248	139	14	performed	perform	VERB
dpc-4248	139	15	,	,	PUNCT
dpc-4248	139	16	leading	lead	VERB
dpc-4248	139	17	to	to	ADP
dpc-4248	139	18	a	a	DET
dpc-4248	139	19	diagnosis	diagnosis	NOUN
dpc-4248	139	20	of	of	ADP
dpc-4248	139	21	atypical	atypical	ADJ
dpc-4248	139	22	ductal	ductal	ADJ
dpc-4248	139	23	hyperplasia	hyperplasia	NOUN
dpc-4248	139	24	.	.	PUNCT
dpc-4248	140	1	as	as	ADP
dpc-4248	140	2	a	a	DET
dpc-4248	140	3	result	result	NOUN
dpc-4248	140	4	,	,	PUNCT
dpc-4248	140	5	the	the	DET
dpc-4248	140	6	patient	patient	NOUN
dpc-4248	140	7	must	must	AUX
dpc-4248	140	8	undergo	undergo	VERB
dpc-4248	140	9	regular	regular	ADJ
dpc-4248	140	10	clinical	clinical	ADJ
dpc-4248	140	11	and	and	CCONJ
dpc-4248	140	12	instrumental	instrumental	ADJ
dpc-4248	140	13	follow	follow	NOUN
dpc-4248	140	14	-	-	PUNCT
dpc-4248	140	15	ups	up	NOUN
dpc-4248	140	16	.	.	PUNCT
dpc-4248	141	1	during	during	ADP
dpc-4248	141	2	these	these	DET
dpc-4248	141	3	assessments	assessment	NOUN
dpc-4248	141	4	and	and	CCONJ
dpc-4248	141	5	surgical	surgical	ADJ
dpc-4248	141	6	procedures	procedure	NOUN
dpc-4248	141	7	,	,	PUNCT
dpc-4248	141	8	the	the	DET
dpc-4248	141	9	patient	patient	NOUN
dpc-4248	141	10	temporarily	temporarily	ADV
dpc-4248	141	11	discontinued	discontinue	VERB
dpc-4248	141	12	brodalumab	brodalumab	NOUN
dpc-4248	141	13	therapy	therapy	NOUN
dpc-4248	141	14	without	without	ADP
dpc-4248	141	15	experiencing	experience	VERB
dpc-4248	141	16	a	a	DET
dpc-4248	141	17	recurrence	recurrence	NOUN
dpc-4248	141	18	of	of	ADP
dpc-4248	141	19	psoriasis	psoriasis	NOUN
dpc-4248	141	20	.	.	PUNCT
dpc-4248	142	1	upon	upon	SCONJ
dpc-4248	142	2	advice	advice	NOUN
dpc-4248	142	3	from	from	ADP
dpc-4248	142	4	oncology	oncology	NOUN
dpc-4248	142	5	specialists	specialist	NOUN
dpc-4248	142	6	,	,	PUNCT
dpc-4248	142	7	she	she	PRON
dpc-4248	142	8	resumed	resume	VERB
dpc-4248	142	9	treatment	treatment	NOUN
dpc-4248	142	10	with	with	ADP
dpc-4248	142	11	the	the	DET
dpc-4248	142	12	maintenance	maintenance	NOUN
dpc-4248	142	13	dosage	dosage	NOUN
dpc-4248	142	14	regimen	regiman	NOUN
dpc-4248	142	15	.	.	PUNCT
dpc-4248	143	1	to	to	ADP
dpc-4248	143	2	date	date	NOUN
dpc-4248	143	3	,	,	PUNCT
dpc-4248	143	4	the	the	DET
dpc-4248	143	5	patient	patient	NOUN
dpc-4248	143	6	remains	remain	VERB
dpc-4248	143	7	in	in	ADP
dpc-4248	143	8	clinical	clinical	ADJ
dpc-4248	143	9	remission	remission	NOUN
dpc-4248	143	10	for	for	ADP
dpc-4248	143	11	psoriasis	psoriasis	NOUN
dpc-4248	143	12	and	and	CCONJ
dpc-4248	143	13	has	have	AUX
dpc-4248	143	14	not	not	PART
dpc-4248	143	15	experienced	experience	VERB
dpc-4248	143	16	a	a	DET
dpc-4248	143	17	recurrence	recurrence	NOUN
dpc-4248	143	18	of	of	ADP
dpc-4248	143	19	cervical	cervical	ADJ
dpc-4248	143	20	intraepithelial	intraepithelial	ADJ
dpc-4248	143	21	neoplasia	neoplasia	NOUN
dpc-4248	143	22	or	or	CCONJ
dpc-4248	143	23	meningioma	meningioma	NOUN
dpc-4248	143	24	(	(	PUNCT
dpc-4248	143	25	figure	figure	NOUN
dpc-4248	143	26	3c	3c	NUM
dpc-4248	143	27	)	)	PUNCT
dpc-4248	143	28	.	.	PUNCT
dpc-4248	144	1	patient	patient	ADJ
dpc-4248	144	2	#	#	SYM
dpc-4248	144	3	3	3	NUM
dpc-4248	144	4	:	:	PUNCT
dpc-4248	144	5	an	an	DET
dpc-4248	144	6	obese	obese	ADJ
dpc-4248	144	7	patient	patient	NOUN
dpc-4248	144	8	with	with	ADP
dpc-4248	144	9	latent	latent	NOUN
dpc-4248	144	10	tuberculosis	tuberculosis	NOUN
dpc-4248	144	11	.	.	PUNCT
dpc-4248	145	1	we	we	PRON
dpc-4248	145	2	present	present	VERB
dpc-4248	145	3	the	the	DET
dpc-4248	145	4	clinical	clinical	ADJ
dpc-4248	145	5	case	case	NOUN
dpc-4248	145	6	of	of	ADP
dpc-4248	145	7	a	a	DET
dpc-4248	145	8	52	52	NUM
dpc-4248	145	9	-	-	PUNCT
dpc-4248	145	10	year	year	NOUN
dpc-4248	145	11	-	-	PUNCT
dpc-4248	145	12	old	old	ADJ
dpc-4248	145	13	caucasian	caucasian	ADJ
dpc-4248	145	14	male	male	NOUN
dpc-4248	145	15	,	,	PUNCT
dpc-4248	145	16	a	a	DET
dpc-4248	145	17	workman	workman	NOUN
dpc-4248	145	18	and	and	CCONJ
dpc-4248	145	19	habitual	habitual	ADJ
dpc-4248	145	20	smoker	smoker	NOUN
dpc-4248	145	21	with	with	ADP
dpc-4248	145	22	hypertension	hypertension	NOUN
dpc-4248	145	23	,	,	PUNCT
dpc-4248	145	24	dyslipidemia	dyslipidemia	NOUN
dpc-4248	145	25	,	,	PUNCT
dpc-4248	145	26	and	and	CCONJ
dpc-4248	145	27	class	class	PROPN
dpc-4248	145	28	ii	ii	PROPN
dpc-4248	145	29	obesity	obesity	NOUN
dpc-4248	145	30	(	(	PUNCT
dpc-4248	145	31	bmi	bmi	PROPN
dpc-4248	145	32	37.04	37.04	NUM
dpc-4248	145	33	)	)	PUNCT
dpc-4248	145	34	.	.	PUNCT
dpc-4248	146	1	the	the	DET
dpc-4248	146	2	patient	patient	NOUN
dpc-4248	146	3	had	have	VERB
dpc-4248	146	4	a	a	DET
dpc-4248	146	5	positive	positive	ADJ
dpc-4248	146	6	family	family	NOUN
dpc-4248	146	7	history	history	NOUN
dpc-4248	146	8	of	of	ADP
dpc-4248	146	9	psoriasis	psoriasis	NOUN
dpc-4248	146	10	and	and	CCONJ
dpc-4248	146	11	was	be	AUX
dpc-4248	146	12	affected	affect	VERB
dpc-4248	146	13	from	from	ADP
dpc-4248	146	14	plaque	plaque	NOUN
dpc-4248	146	15	psoriasis	psoriasis	NOUN
dpc-4248	146	16	since	since	SCONJ
dpc-4248	146	17	the	the	DET
dpc-4248	146	18	age	age	NOUN
dpc-4248	146	19	of	of	ADP
dpc-4248	146	20	16	16	NUM
dpc-4248	146	21	,	,	PUNCT
dpc-4248	146	22	and	and	CCONJ
dpc-4248	146	23	psoriatic	psoriatic	ADJ
dpc-4248	146	24	arthritis	arthritis	NOUN
dpc-4248	146	25	for	for	ADP
dpc-4248	146	26	the	the	DET
dpc-4248	146	27	last	last	ADJ
dpc-4248	146	28	20	20	NUM
dpc-4248	146	29	years	year	NOUN
dpc-4248	146	30	.	.	PUNCT
dpc-4248	147	1	his	his	PRON
dpc-4248	147	2	clinical	clinical	ADJ
dpc-4248	147	3	presentation	presentation	NOUN
dpc-4248	147	4	was	be	AUX
dpc-4248	147	5	characterized	characterize	VERB
dpc-4248	147	6	by	by	ADP
dpc-4248	147	7	psoriatic	psoriatic	ADJ
dpc-4248	147	8	plaques	plaque	NOUN
dpc-4248	147	9	mainly	mainly	ADV
dpc-4248	147	10	located	locate	VERB
dpc-4248	147	11	on	on	ADP
dpc-4248	147	12	the	the	DET
dpc-4248	147	13	trunk	trunk	NOUN
dpc-4248	147	14	and	and	CCONJ
dpc-4248	147	15	hands	hand	NOUN
dpc-4248	147	16	,	,	PUNCT
dpc-4248	147	17	with	with	ADP
dpc-4248	147	18	a	a	DET
dpc-4248	147	19	pasi	pasi	NOUN
dpc-4248	147	20	of	of	ADP
dpc-4248	147	21	36	36	NUM
dpc-4248	147	22	and	and	CCONJ
dpc-4248	147	23	a	a	DET
dpc-4248	147	24	dlqi	dlqi	ADJ
dpc-4248	147	25	score	score	NOUN
dpc-4248	147	26	of	of	ADP
dpc-4248	147	27	18	18	NUM
dpc-4248	147	28	(	(	PUNCT
dpc-4248	147	29	figure	figure	NOUN
dpc-4248	147	30	4a	4a	NUM
dpc-4248	147	31	)	)	PUNCT
dpc-4248	147	32	.	.	PUNCT
dpc-4248	148	1	due	due	ADP
dpc-4248	148	2	to	to	ADP
dpc-4248	148	3	the	the	DET
dpc-4248	148	4	high	high	ADJ
dpc-4248	148	5	pasi	pasi	NOUN
dpc-4248	148	6	score	score	NOUN
dpc-4248	148	7	and	and	CCONJ
dpc-4248	148	8	the	the	DET
dpc-4248	148	9	presence	presence	NOUN
dpc-4248	148	10	of	of	ADP
dpc-4248	148	11	comorbidities	comorbiditie	NOUN
dpc-4248	148	12	,	,	PUNCT
dpc-4248	148	13	original	original	ADJ
dpc-4248	148	14	article	article	NOUN
dpc-4248	148	15	|	|	ADV
dpc-4248	148	16	dermatol	dermatol	ADJ
dpc-4248	148	17	pract	pract	NOUN
dpc-4248	148	18	concept	concept	NOUN
dpc-4248	148	19	.	.	PUNCT
dpc-4248	149	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	149	2	7	7	NUM
dpc-4248	149	3	figure	figure	NOUN
dpc-4248	149	4	3	3	NUM
dpc-4248	149	5	.	.	PUNCT
dpc-4248	149	6	patient	patient	ADJ
dpc-4248	149	7	#	#	SYM
dpc-4248	149	8	2	2	NUM
dpc-4248	149	9	.	.	PUNCT
dpc-4248	150	1	(	(	PUNCT
dpc-4248	150	2	a	a	X
dpc-4248	150	3	)	)	PUNCT
dpc-4248	150	4	at	at	ADP
dpc-4248	150	5	baseline	baseline	NOUN
dpc-4248	150	6	.	.	PUNCT
dpc-4248	151	1	(	(	PUNCT
dpc-4248	151	2	b	b	X
dpc-4248	151	3	)	)	PUNCT
dpc-4248	151	4	recurrence	recurrence	NOUN
dpc-4248	151	5	of	of	ADP
dpc-4248	151	6	psoriasis	psoriasis	NOUN
dpc-4248	151	7	on	on	ADP
dpc-4248	151	8	the	the	DET
dpc-4248	151	9	scalp	scalp	NOUN
dpc-4248	151	10	after	after	ADP
dpc-4248	151	11	neurosurgical	neurosurgical	ADJ
dpc-4248	151	12	intervention	intervention	NOUN
dpc-4248	151	13	and	and	CCONJ
dpc-4248	151	14	3	3	NUM
dpc-4248	151	15	months	month	NOUN
dpc-4248	151	16	after	after	ADP
dpc-4248	151	17	brodalumab	brodalumab	NOUN
dpc-4248	151	18	discontinuation	discontinuation	NOUN
dpc-4248	151	19	.	.	PUNCT
dpc-4248	152	1	(	(	PUNCT
dpc-4248	152	2	c	c	X
dpc-4248	152	3	)	)	PUNCT
dpc-4248	152	4	at	at	ADP
dpc-4248	152	5	week	week	NOUN
dpc-4248	152	6	160	160	NUM
dpc-4248	152	7	.	.	PUNCT
dpc-4248	153	1	the	the	DET
dpc-4248	153	2	patient	patient	NOUN
dpc-4248	153	3	was	be	AUX
dpc-4248	153	4	screened	screen	VERB
dpc-4248	153	5	to	to	PART
dpc-4248	153	6	start	start	VERB
dpc-4248	153	7	biologic	biologic	NOUN
dpc-4248	153	8	therapy	therapy	NOUN
dpc-4248	153	9	.	.	PUNCT
dpc-4248	154	1	infectious	infectious	ADJ
dpc-4248	154	2	examinations	examination	NOUN
dpc-4248	154	3	revealed	reveal	VERB
dpc-4248	154	4	a	a	DET
dpc-4248	154	5	positive	positive	ADJ
dpc-4248	154	6	result	result	NOUN
dpc-4248	154	7	for	for	ADP
dpc-4248	154	8	quantiferon	quantiferon	PROPN
dpc-4248	154	9	tb	tb	ADP
dpc-4248	154	10	gold	gold	NOUN
dpc-4248	154	11	,	,	PUNCT
dpc-4248	154	12	indicating	indicate	VERB
dpc-4248	154	13	latent	latent	NOUN
dpc-4248	154	14	tuberculosis	tuberculosis	NOUN
dpc-4248	154	15	infection	infection	NOUN
dpc-4248	154	16	.	.	PUNCT
dpc-4248	155	1	therefore	therefore	ADV
dpc-4248	155	2	,	,	PUNCT
dpc-4248	155	3	isoniazid	isoniazid	NOUN
dpc-4248	155	4	prophylaxis	prophylaxis	NOUN
dpc-4248	155	5	was	be	AUX
dpc-4248	155	6	initiated	initiate	VERB
dpc-4248	155	7	,	,	PUNCT
dpc-4248	155	8	but	but	CCONJ
dpc-4248	155	9	after	after	ADP
dpc-4248	155	10	only	only	ADV
dpc-4248	155	11	15	15	NUM
dpc-4248	155	12	days	day	NOUN
dpc-4248	155	13	,	,	PUNCT
dpc-4248	155	14	it	it	PRON
dpc-4248	155	15	induced	induce	VERB
dpc-4248	155	16	an	an	DET
dpc-4248	155	17	increase	increase	NOUN
dpc-4248	155	18	in	in	ADP
dpc-4248	155	19	liver	liver	NOUN
dpc-4248	155	20	enzymes	enzyme	NOUN
dpc-4248	155	21	.	.	PUNCT
dpc-4248	156	1	after	after	ADP
dpc-4248	156	2	an	an	DET
dpc-4248	156	3	infectious	infectious	ADJ
dpc-4248	156	4	disease	disease	NOUN
dpc-4248	156	5	consultation	consultation	NOUN
dpc-4248	156	6	,	,	PUNCT
dpc-4248	156	7	the	the	DET
dpc-4248	156	8	tuberculosis	tuberculosis	NOUN
dpc-4248	156	9	prophylaxis	prophylaxis	NOUN
dpc-4248	156	10	was	be	AUX
dpc-4248	156	11	switched	switch	VERB
dpc-4248	156	12	to	to	ADP
dpc-4248	156	13	rifampicin	rifampicin	VERB
dpc-4248	156	14	.	.	PUNCT
dpc-4248	157	1	after	after	ADP
dpc-4248	157	2	30	30	NUM
dpc-4248	157	3	days	day	NOUN
dpc-4248	157	4	of	of	ADP
dpc-4248	157	5	starting	start	VERB
dpc-4248	157	6	tuberculosis	tuberculosis	NOUN
dpc-4248	157	7	prophylaxis	prophylaxis	NOUN
dpc-4248	157	8	and	and	CCONJ
dpc-4248	157	9	after	after	SCONJ
dpc-4248	157	10	liver	liver	NOUN
dpc-4248	157	11	enzyme	enzyme	NOUN
dpc-4248	157	12	increase	increase	NOUN
dpc-4248	157	13	was	be	AUX
dpc-4248	157	14	resolved	resolve	VERB
dpc-4248	157	15	,	,	PUNCT
dpc-4248	157	16	the	the	DET
dpc-4248	157	17	patient	patient	NOUN
dpc-4248	157	18	began	begin	VERB
dpc-4248	157	19	treatment	treatment	NOUN
dpc-4248	157	20	with	with	ADP
dpc-4248	157	21	brodalumab	brodalumab	NOUN
dpc-4248	157	22	.	.	PUNCT
dpc-4248	158	1	12	12	NUM
dpc-4248	158	2	weeks	week	NOUN
dpc-4248	158	3	later	later	ADV
dpc-4248	158	4	,	,	PUNCT
dpc-4248	158	5	patients	patient	NOUN
dpc-4248	158	6	achieved	achieve	VERB
dpc-4248	158	7	complete	complete	ADJ
dpc-4248	158	8	resolution	resolution	NOUN
dpc-4248	158	9	of	of	ADP
dpc-4248	158	10	psoriasis	psoriasis	NOUN
dpc-4248	158	11	,	,	PUNCT
dpc-4248	158	12	including	include	VERB
dpc-4248	158	13	the	the	DET
dpc-4248	158	14	challenging	challenging	ADJ
dpc-4248	158	15	lesions	lesion	NOUN
dpc-4248	158	16	of	of	ADP
dpc-4248	158	17	the	the	DET
dpc-4248	158	18	hands	hand	NOUN
dpc-4248	158	19	(	(	PUNCT
dpc-4248	158	20	figure	figure	NOUN
dpc-4248	158	21	4b	4b	PROPN
dpc-4248	158	22	)	)	PUNCT
dpc-4248	158	23	.	.	PUNCT
dpc-4248	159	1	the	the	DET
dpc-4248	159	2	patient	patient	NOUN
dpc-4248	159	3	has	have	AUX
dpc-4248	159	4	currently	currently	ADV
dpc-4248	159	5	completed	complete	VERB
dpc-4248	159	6	three	three	NUM
dpc-4248	159	7	years	year	NOUN
dpc-4248	159	8	of	of	ADP
dpc-4248	159	9	brodalumab	brodalumab	NOUN
dpc-4248	159	10	treatment	treatment	NOUN
dpc-4248	159	11	,	,	PUNCT
dpc-4248	159	12	without	without	ADP
dpc-4248	159	13	any	any	DET
dpc-4248	159	14	recurrence	recurrence	NOUN
dpc-4248	159	15	of	of	ADP
dpc-4248	159	16	psoriasis	psoriasis	NOUN
dpc-4248	159	17	.	.	PUNCT
dpc-4248	160	1	patient	patient	ADJ
dpc-4248	160	2	#	#	SYM
dpc-4248	160	3	4	4	NUM
dpc-4248	160	4	:	:	PUNCT
dpc-4248	160	5	brodalumab	brodalumab	NOUN
dpc-4248	160	6	after	after	ADP
dpc-4248	160	7	failure	failure	NOUN
dpc-4248	160	8	of	of	ADP
dpc-4248	160	9	anti	anti	ADJ
dpc-4248	160	10	-	-	ADJ
dpc-4248	160	11	il-17	il-17	ADV
dpc-4248	160	12	secukinumab	secukinumab	NOUN
dpc-4248	160	13	.	.	PUNCT
dpc-4248	161	1	we	we	PRON
dpc-4248	161	2	present	present	VERB
dpc-4248	161	3	the	the	DET
dpc-4248	161	4	case	case	NOUN
dpc-4248	161	5	of	of	ADP
dpc-4248	161	6	a	a	DET
dpc-4248	161	7	38	38	NUM
dpc-4248	161	8	-	-	PUNCT
dpc-4248	161	9	year	year	NOUN
dpc-4248	161	10	-	-	PUNCT
dpc-4248	161	11	old	old	ADJ
dpc-4248	161	12	male	male	ADJ
dpc-4248	161	13	patient	patient	NOUN
dpc-4248	161	14	with	with	ADP
dpc-4248	161	15	an	an	DET
dpc-4248	161	16	11	11	NUM
dpc-4248	161	17	-	-	PUNCT
dpc-4248	161	18	year	year	NOUN
dpc-4248	161	19	history	history	NOUN
dpc-4248	161	20	of	of	ADP
dpc-4248	161	21	psoriasis	psoriasis	NOUN
dpc-4248	161	22	.	.	PUNCT
dpc-4248	162	1	the	the	DET
dpc-4248	162	2	patient	patient	NOUN
dpc-4248	162	3	was	be	AUX
dpc-4248	162	4	obese	obese	ADJ
dpc-4248	162	5	(	(	PUNCT
dpc-4248	162	6	bmi	bmi	PROPN
dpc-4248	162	7	34.7	34.7	NUM
dpc-4248	162	8	)	)	PUNCT
dpc-4248	162	9	,	,	PUNCT
dpc-4248	162	10	dyslipidemic	dyslipidemic	ADJ
dpc-4248	162	11	and	and	CCONJ
dpc-4248	162	12	smoker	smoker	ADJ
dpc-4248	162	13	(	(	PUNCT
dpc-4248	162	14	20	20	NUM
dpc-4248	162	15	cigarettes	cigarette	NOUN
dpc-4248	162	16	per	per	ADP
dpc-4248	162	17	day	day	NOUN
dpc-4248	162	18	)	)	PUNCT
dpc-4248	162	19	.	.	PUNCT
dpc-4248	163	1	previously	previously	ADV
dpc-4248	163	2	,	,	PUNCT
dpc-4248	163	3	he	he	PRON
dpc-4248	163	4	had	have	AUX
dpc-4248	163	5	been	be	AUX
dpc-4248	163	6	unsuccessfully	unsuccessfully	ADV
dpc-4248	163	7	treated	treat	VERB
dpc-4248	163	8	with	with	ADP
dpc-4248	163	9	ciclosporin	ciclosporin	NOUN
dpc-4248	163	10	(	(	PUNCT
dpc-4248	163	11	suspended	suspend	VERB
dpc-4248	163	12	due	due	ADP
dpc-4248	163	13	to	to	ADP
dpc-4248	163	14	hypertension	hypertension	NOUN
dpc-4248	163	15	)	)	PUNCT
dpc-4248	163	16	,	,	PUNCT
dpc-4248	163	17	etanercept	etanercept	NOUN
dpc-4248	163	18	(	(	PUNCT
dpc-4248	163	19	suspended	suspend	VERB
dpc-4248	163	20	due	due	ADP
dpc-4248	163	21	to	to	ADP
dpc-4248	163	22	ineffectiveness	ineffectiveness	NOUN
dpc-4248	163	23	)	)	PUNCT
dpc-4248	163	24	,	,	PUNCT
dpc-4248	163	25	and	and	CCONJ
dpc-4248	163	26	secukinumab	secukinumab	NOUN
dpc-4248	163	27	(	(	PUNCT
dpc-4248	163	28	suspended	suspend	VERB
dpc-4248	163	29	due	due	ADP
dpc-4248	163	30	to	to	ADP
dpc-4248	163	31	lack	lack	NOUN
dpc-4248	163	32	of	of	ADP
dpc-4248	163	33	efficacy	efficacy	NOUN
dpc-4248	163	34	after	after	ADP
dpc-4248	163	35	2	2	NUM
dpc-4248	163	36	years	year	NOUN
dpc-4248	163	37	)	)	PUNCT
dpc-4248	163	38	.	.	PUNCT
dpc-4248	164	1	after	after	ADP
dpc-4248	164	2	a	a	DET
dpc-4248	164	3	partial	partial	ADJ
dpc-4248	164	4	remission	remission	NOUN
dpc-4248	164	5	with	with	ADP
dpc-4248	164	6	secukinumab	secukinumab	NOUN
dpc-4248	164	7	,	,	PUNCT
dpc-4248	164	8	the	the	DET
dpc-4248	164	9	patient	patient	NOUN
dpc-4248	164	10	experienced	experience	VERB
dpc-4248	164	11	a	a	DET
dpc-4248	164	12	recurrence	recurrence	NOUN
dpc-4248	164	13	of	of	ADP
dpc-4248	164	14	the	the	DET
dpc-4248	164	15	disease	disease	NOUN
dpc-4248	164	16	in	in	ADP
dpc-4248	164	17	november	november	PROPN
dpc-4248	164	18	2019	2019	NUM
dpc-4248	164	19	,	,	PUNCT
dpc-4248	164	20	localized	localize	VERB
dpc-4248	164	21	on	on	ADP
dpc-4248	164	22	the	the	DET
dpc-4248	164	23	legs	leg	NOUN
dpc-4248	164	24	,	,	PUNCT
dpc-4248	164	25	trunk	trunk	NOUN
dpc-4248	164	26	,	,	PUNCT
dpc-4248	164	27	and	and	CCONJ
dpc-4248	164	28	scalp	scalp	NOUN
dpc-4248	164	29	.	.	PUNCT
dpc-4248	165	1	consequently	consequently	ADV
dpc-4248	165	2	,	,	PUNCT
dpc-4248	165	3	we	we	PRON
dpc-4248	165	4	decided	decide	VERB
dpc-4248	165	5	to	to	PART
dpc-4248	165	6	initiate	initiate	VERB
dpc-4248	165	7	brodalumab	brodalumab	NOUN
dpc-4248	165	8	treatment	treatment	NOUN
dpc-4248	165	9	,	,	PUNCT
dpc-4248	165	10	considering	consider	VERB
dpc-4248	165	11	its	its	PRON
dpc-4248	165	12	rapid	rapid	ADJ
dpc-4248	165	13	action	action	NOUN
dpc-4248	165	14	.	.	PUNCT
dpc-4248	166	1	remarkably	remarkably	ADV
dpc-4248	166	2	,	,	PUNCT
dpc-4248	166	3	after	after	ADP
dpc-4248	166	4	only	only	ADV
dpc-4248	166	5	4	4	NUM
dpc-4248	166	6	weeks	week	NOUN
dpc-4248	166	7	,	,	PUNCT
dpc-4248	166	8	we	we	PRON
dpc-4248	166	9	observed	observe	VERB
dpc-4248	166	10	a	a	DET
dpc-4248	166	11	near	near	ADV
dpc-4248	166	12	-	-	PUNCT
dpc-4248	166	13	complete	complete	ADJ
dpc-4248	166	14	resolution	resolution	NOUN
dpc-4248	166	15	of	of	ADP
dpc-4248	166	16	the	the	DET
dpc-4248	166	17	disease	disease	NOUN
dpc-4248	166	18	,	,	PUNCT
dpc-4248	166	19	with	with	SCONJ
dpc-4248	166	20	the	the	DET
dpc-4248	166	21	pasi	pasi	NOUN
dpc-4248	166	22	score	score	NOUN
dpc-4248	166	23	decreasing	decrease	VERB
dpc-4248	166	24	from	from	ADP
dpc-4248	166	25	10	10	NUM
dpc-4248	166	26	(	(	PUNCT
dpc-4248	166	27	at	at	ADP
dpc-4248	166	28	baseline	baseline	NOUN
dpc-4248	166	29	)	)	PUNCT
dpc-4248	166	30	8	8	NUM
dpc-4248	166	31	original	original	ADJ
dpc-4248	166	32	article	article	NOUN
dpc-4248	166	33	|	|	ADV
dpc-4248	166	34	dermatol	dermatol	ADJ
dpc-4248	166	35	pract	pract	NOUN
dpc-4248	166	36	concept	concept	NOUN
dpc-4248	166	37	.	.	PUNCT
dpc-4248	167	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	167	2	figure	figure	VERB
dpc-4248	167	3	4	4	NUM
dpc-4248	167	4	.	.	PUNCT
dpc-4248	167	5	patient	patient	ADJ
dpc-4248	167	6	#	#	SYM
dpc-4248	167	7	3	3	NUM
dpc-4248	167	8	.	.	PUNCT
dpc-4248	168	1	(	(	PUNCT
dpc-4248	168	2	a	a	X
dpc-4248	168	3	)	)	PUNCT
dpc-4248	168	4	at	at	ADP
dpc-4248	168	5	baseline	baseline	NOUN
dpc-4248	168	6	.	.	PUNCT
dpc-4248	169	1	(	(	PUNCT
dpc-4248	169	2	b	b	X
dpc-4248	169	3	)	)	PUNCT
dpc-4248	169	4	at	at	ADP
dpc-4248	169	5	week	week	NOUN
dpc-4248	169	6	12	12	NUM
dpc-4248	169	7	.	.	PUNCT
dpc-4248	170	1	figure	figure	NOUN
dpc-4248	170	2	5	5	NUM
dpc-4248	170	3	.	.	PUNCT
dpc-4248	170	4	patient	patient	ADJ
dpc-4248	170	5	#	#	SYM
dpc-4248	170	6	4	4	NUM
dpc-4248	170	7	,	,	PUNCT
dpc-4248	170	8	at	at	ADP
dpc-4248	170	9	baseline	baseline	NOUN
dpc-4248	170	10	and	and	CCONJ
dpc-4248	170	11	after	after	ADP
dpc-4248	170	12	4	4	NUM
dpc-4248	170	13	weeks	week	NOUN
dpc-4248	170	14	and	and	CCONJ
dpc-4248	170	15	3	3	NUM
dpc-4248	170	16	years	year	NOUN
dpc-4248	170	17	of	of	ADP
dpc-4248	170	18	treatment	treatment	NOUN
dpc-4248	170	19	with	with	ADP
dpc-4248	170	20	brodalumab	brodalumab	NOUN
dpc-4248	170	21	.	.	PUNCT
dpc-4248	171	1	the	the	DET
dpc-4248	171	2	hyperchromic	hyperchromic	ADJ
dpc-4248	171	3	patches	patch	NOUN
dpc-4248	171	4	can	can	AUX
dpc-4248	171	5	be	be	AUX
dpc-4248	171	6	attributed	attribute	VERB
dpc-4248	171	7	to	to	ADP
dpc-4248	171	8	post	post	ADJ
dpc-4248	171	9	-	-	ADJ
dpc-4248	171	10	inflammatory	inflammatory	ADJ
dpc-4248	171	11	hyperpigmented	hyperpigmented	ADJ
dpc-4248	171	12	outcomes	outcome	NOUN
dpc-4248	171	13	.	.	PUNCT
dpc-4248	172	1	to	to	ADP
dpc-4248	172	2	1	1	NUM
dpc-4248	172	3	(	(	PUNCT
dpc-4248	172	4	figure	figure	NOUN
dpc-4248	172	5	5	5	NUM
dpc-4248	172	6	)	)	PUNCT
dpc-4248	172	7	.	.	PUNCT
dpc-4248	173	1	after	after	ADP
dpc-4248	173	2	3	3	NUM
dpc-4248	173	3	years	year	NOUN
dpc-4248	173	4	,	,	PUNCT
dpc-4248	173	5	the	the	DET
dpc-4248	173	6	patient	patient	NOUN
dpc-4248	173	7	continues	continue	VERB
dpc-4248	173	8	to	to	PART
dpc-4248	173	9	receive	receive	VERB
dpc-4248	173	10	brodalumab	brodalumab	NOUN
dpc-4248	173	11	treatment	treatment	NOUN
dpc-4248	173	12	with	with	ADP
dpc-4248	173	13	complete	complete	ADJ
dpc-4248	173	14	clearance	clearance	NOUN
dpc-4248	173	15	of	of	ADP
dpc-4248	173	16	psoriasis	psoriasis	NOUN
dpc-4248	173	17	and	and	CCONJ
dpc-4248	173	18	no	no	DET
dpc-4248	173	19	impact	impact	NOUN
dpc-4248	173	20	on	on	ADP
dpc-4248	173	21	his	his	PRON
dpc-4248	173	22	quality	quality	NOUN
dpc-4248	173	23	of	of	ADP
dpc-4248	173	24	life	life	NOUN
dpc-4248	173	25	(	(	PUNCT
dpc-4248	173	26	pasi	pasi	NOUN
dpc-4248	173	27	0	0	NUM
dpc-4248	173	28	;	;	PUNCT
dpc-4248	173	29	dlqi	dlqi	VERB
dpc-4248	173	30	0	0	NUM
dpc-4248	173	31	)	)	PUNCT
dpc-4248	173	32	(	(	PUNCT
dpc-4248	173	33	figure	figure	NOUN
dpc-4248	173	34	5	5	NUM
dpc-4248	173	35	)	)	PUNCT
dpc-4248	173	36	.	.	PUNCT
dpc-4248	174	1	drug	drug	NOUN
dpc-4248	174	2	survival	survival	NOUN
dpc-4248	174	3	is	be	AUX
dpc-4248	174	4	a	a	DET
dpc-4248	174	5	real	real	ADJ
dpc-4248	174	6	-	-	PUNCT
dpc-4248	174	7	life	life	NOUN
dpc-4248	174	8	indicator	indicator	NOUN
dpc-4248	174	9	of	of	ADP
dpc-4248	174	10	treatment	treatment	NOUN
dpc-4248	174	11	success	success	NOUN
dpc-4248	174	12	over	over	ADP
dpc-4248	174	13	the	the	DET
dpc-4248	174	14	long	long	ADJ
dpc-4248	174	15	-	-	PUNCT
dpc-4248	174	16	term	term	NOUN
dpc-4248	174	17	,	,	PUNCT
dpc-4248	174	18	encompassing	encompass	VERB
dpc-4248	174	19	factors	factor	NOUN
dpc-4248	174	20	such	such	ADJ
dpc-4248	174	21	as	as	ADP
dpc-4248	174	22	drug	drug	NOUN
dpc-4248	174	23	efficacy	efficacy	NOUN
dpc-4248	174	24	,	,	PUNCT
dpc-4248	174	25	safety	safety	NOUN
dpc-4248	174	26	and	and	CCONJ
dpc-4248	174	27	patient	patient	ADJ
dpc-4248	174	28	adherence	adherence	NOUN
dpc-4248	174	29	.	.	PUNCT
dpc-4248	175	1	considering	consider	VERB
dpc-4248	175	2	the	the	DET
dpc-4248	175	3	diverse	diverse	ADJ
dpc-4248	175	4	range	range	NOUN
dpc-4248	175	5	of	of	ADP
dpc-4248	175	6	systemic	systemic	ADJ
dpc-4248	175	7	therapies	therapy	NOUN
dpc-4248	175	8	available	available	ADJ
dpc-4248	175	9	for	for	ADP
dpc-4248	175	10	psoriasis	psoriasis	NOUN
dpc-4248	175	11	,	,	PUNCT
dpc-4248	175	12	drug	drug	NOUN
dpc-4248	175	13	survival	survival	NOUN
dpc-4248	175	14	plays	play	VERB
dpc-4248	175	15	a	a	DET
dpc-4248	175	16	crucial	crucial	ADJ
dpc-4248	175	17	role	role	NOUN
dpc-4248	175	18	in	in	ADP
dpc-4248	175	19	guiding	guide	VERB
dpc-4248	175	20	us	we	PRON
dpc-4248	175	21	in	in	ADP
dpc-4248	175	22	the	the	DET
dpc-4248	175	23	selection	selection	NOUN
dpc-4248	175	24	of	of	ADP
dpc-4248	175	25	the	the	DET
dpc-4248	175	26	most	most	ADV
dpc-4248	175	27	suitable	suitable	ADJ
dpc-4248	175	28	treatment	treatment	NOUN
dpc-4248	175	29	option	option	NOUN
dpc-4248	175	30	for	for	ADP
dpc-4248	175	31	patients	patient	NOUN
dpc-4248	175	32	[	[	X
dpc-4248	175	33	12	12	NUM
dpc-4248	175	34	]	]	PUNCT
dpc-4248	175	35	.	.	PUNCT
dpc-4248	176	1	in	in	ADP
dpc-4248	176	2	this	this	DET
dpc-4248	176	3	study	study	NOUN
dpc-4248	176	4	we	we	PRON
dpc-4248	176	5	assessed	assess	VERB
dpc-4248	176	6	the	the	DET
dpc-4248	176	7	drug	drug	NOUN
dpc-4248	176	8	survival	survival	NOUN
dpc-4248	176	9	of	of	ADP
dpc-4248	176	10	brodalumab	brodalumab	NOUN
dpc-4248	176	11	,	,	PUNCT
dpc-4248	176	12	a	a	DET
dpc-4248	176	13	monoclonal	monoclonal	NOUN
dpc-4248	176	14	antibody	antibody	NOUN
dpc-4248	176	15	targeting	target	VERB
dpc-4248	176	16	the	the	DET
dpc-4248	176	17	interleukin-17	interleukin-17	PROPN
dpc-4248	176	18	receptor	receptor	NOUN
dpc-4248	176	19	a	a	DET
dpc-4248	176	20	(	(	PUNCT
dpc-4248	176	21	il-17ra	il-17ra	PROPN
dpc-4248	176	22	)	)	PUNCT
dpc-4248	176	23	,	,	PUNCT
dpc-4248	176	24	in	in	ADP
dpc-4248	176	25	patients	patient	NOUN
dpc-4248	176	26	with	with	ADP
dpc-4248	176	27	moderate	moderate	ADJ
dpc-4248	176	28	to	to	ADP
dpc-4248	176	29	severe	severe	ADJ
dpc-4248	176	30	psoriasis	psoriasis	NOUN
dpc-4248	176	31	.	.	PUNCT
dpc-4248	177	1	the	the	DET
dpc-4248	177	2	data	datum	NOUN
dpc-4248	177	3	collected	collect	VERB
dpc-4248	177	4	over	over	ADP
dpc-4248	177	5	a	a	DET
dpc-4248	177	6	3	3	NUM
dpc-4248	177	7	-	-	PUNCT
dpc-4248	177	8	year	year	NOUN
dpc-4248	177	9	period	period	NOUN
dpc-4248	177	10	provided	provide	VERB
dpc-4248	177	11	valuable	valuable	ADJ
dpc-4248	177	12	insights	insight	NOUN
dpc-4248	177	13	into	into	ADP
dpc-4248	177	14	the	the	DET
dpc-4248	177	15	long	long	ADJ
dpc-4248	177	16	-	-	PUNCT
dpc-4248	177	17	term	term	NOUN
dpc-4248	177	18	effectiveness	effectiveness	NOUN
dpc-4248	177	19	of	of	ADP
dpc-4248	177	20	the	the	DET
dpc-4248	177	21	drug	drug	NOUN
dpc-4248	177	22	.	.	PUNCT
dpc-4248	178	1	in	in	ADP
dpc-4248	178	2	detail	detail	NOUN
dpc-4248	178	3	,	,	PUNCT
dpc-4248	178	4	after	after	ADP
dpc-4248	178	5	52	52	NUM
dpc-4248	178	6	and	and	CCONJ
dpc-4248	178	7	104	104	NUM
dpc-4248	178	8	weeks	week	NOUN
dpc-4248	178	9	,	,	PUNCT
dpc-4248	178	10	86.32	86.32	NUM
dpc-4248	178	11	%	%	NOUN
dpc-4248	178	12	and	and	CCONJ
dpc-4248	178	13	78.09	78.09	NUM
dpc-4248	178	14	%	%	NOUN
dpc-4248	178	15	of	of	ADP
dpc-4248	178	16	patients	patient	NOUN
dpc-4248	178	17	,	,	PUNCT
dpc-4248	178	18	respectively	respectively	ADV
dpc-4248	178	19	,	,	PUNCT
dpc-4248	178	20	were	be	AUX
dpc-4248	178	21	still	still	ADV
dpc-4248	178	22	receiving	receive	VERB
dpc-4248	178	23	brodalumab	brodalumab	NOUN
dpc-4248	178	24	.	.	PUNCT
dpc-4248	179	1	these	these	DET
dpc-4248	179	2	results	result	NOUN
dpc-4248	179	3	demonstrated	demonstrate	VERB
dpc-4248	179	4	a	a	DET
dpc-4248	179	5	favorable	favorable	ADJ
dpc-4248	179	6	drug	drug	NOUN
dpc-4248	179	7	survival	survival	NOUN
dpc-4248	179	8	rate	rate	NOUN
dpc-4248	179	9	,	,	PUNCT
dpc-4248	179	10	with	with	ADP
dpc-4248	179	11	a	a	DET
dpc-4248	179	12	significant	significant	ADJ
dpc-4248	179	13	proportion	proportion	NOUN
dpc-4248	179	14	of	of	ADP
dpc-4248	179	15	patients	patient	NOUN
dpc-4248	179	16	remaining	remain	VERB
dpc-4248	179	17	on	on	ADP
dpc-4248	179	18	the	the	DET
dpc-4248	179	19	treatment	treatment	NOUN
dpc-4248	179	20	throughout	throughout	ADP
dpc-4248	179	21	the	the	DET
dpc-4248	179	22	observation	observation	NOUN
dpc-4248	179	23	period	period	NOUN
dpc-4248	179	24	.	.	PUNCT
dpc-4248	180	1	there	there	PRON
dpc-4248	180	2	are	be	VERB
dpc-4248	180	3	currently	currently	ADV
dpc-4248	180	4	limited	limited	ADJ
dpc-4248	180	5	studies	study	NOUN
dpc-4248	180	6	available	available	ADJ
dpc-4248	180	7	that	that	PRON
dpc-4248	180	8	report	report	VERB
dpc-4248	180	9	the	the	DET
dpc-4248	180	10	long	long	ADJ
dpc-4248	180	11	-	-	PUNCT
dpc-4248	180	12	term	term	NOUN
dpc-4248	180	13	survival	survival	NOUN
dpc-4248	180	14	rate	rate	NOUN
dpc-4248	180	15	of	of	ADP
dpc-4248	180	16	brodalumab	brodalumab	NOUN
dpc-4248	180	17	and	and	CCONJ
dpc-4248	180	18	they	they	PRON
dpc-4248	180	19	report	report	VERB
dpc-4248	180	20	conflicting	conflicting	ADJ
dpc-4248	180	21	data	datum	NOUN
dpc-4248	180	22	and	and	CCONJ
dpc-4248	180	23	differences	difference	NOUN
dpc-4248	180	24	between	between	ADP
dpc-4248	180	25	various	various	ADJ
dpc-4248	180	26	anti	anti	ADJ
dpc-4248	180	27	il17	il17	PROPN
dpc-4248	180	28	agents	agent	NOUN
dpc-4248	180	29	[	[	X
dpc-4248	180	30	7	7	NUM
dpc-4248	180	31	,	,	PUNCT
dpc-4248	180	32	13	13	NUM
dpc-4248	180	33	,	,	PUNCT
dpc-4248	180	34	14	14	NUM
dpc-4248	180	35	,	,	PUNCT
dpc-4248	180	36	15	15	NUM
dpc-4248	180	37	,	,	PUNCT
dpc-4248	180	38	16	16	NUM
dpc-4248	180	39	]	]	PUNCT
dpc-4248	180	40	.	.	PUNCT
dpc-4248	181	1	elgaard	elgaard	PROPN
dpc-4248	181	2	et	et	PROPN
dpc-4248	181	3	al	al	PROPN
dpc-4248	181	4	.	.	PROPN
dpc-4248	181	5	reported	report	VERB
dpc-4248	181	6	a	a	DET
dpc-4248	181	7	low	low	ADJ
dpc-4248	181	8	brodalumab	brodalumab	NOUN
dpc-4248	181	9	survival	survival	NOUN
dpc-4248	181	10	rate	rate	NOUN
dpc-4248	181	11	,	,	PUNCT
dpc-4248	181	12	in	in	ADP
dpc-4248	181	13	detail	detail	NOUN
dpc-4248	181	14	65.7	65.7	NUM
dpc-4248	181	15	%	%	NOUN
dpc-4248	181	16	and	and	CCONJ
dpc-4248	181	17	57.2	57.2	NUM
dpc-4248	181	18	%	%	NOUN
dpc-4248	181	19	after	after	ADP
dpc-4248	181	20	1	1	NUM
dpc-4248	181	21	and	and	CCONJ
dpc-4248	181	22	2	2	NUM
dpc-4248	181	23	years	year	NOUN
dpc-4248	181	24	respectively	respectively	ADV
dpc-4248	181	25	.	.	PUNCT
dpc-4248	182	1	however	however	ADV
dpc-4248	182	2	,	,	PUNCT
dpc-4248	182	3	this	this	DET
dpc-4248	182	4	datum	datum	NOUN
dpc-4248	182	5	may	may	AUX
dpc-4248	182	6	be	be	AUX
dpc-4248	182	7	explained	explain	VERB
dpc-4248	182	8	by	by	ADP
dpc-4248	182	9	the	the	DET
dpc-4248	182	10	very	very	ADV
dpc-4248	182	11	high	high	ADJ
dpc-4248	182	12	percentage	percentage	NOUN
dpc-4248	182	13	of	of	ADP
dpc-4248	182	14	bio	bio	NOUN
dpc-4248	182	15	-	-	ADJ
dpc-4248	182	16	experienced	experienced	ADJ
dpc-4248	182	17	patients	patient	NOUN
dpc-4248	182	18	(	(	PUNCT
dpc-4248	182	19	>	>	SYM
dpc-4248	182	20	90	90	NUM
dpc-4248	182	21	%	%	NOUN
dpc-4248	182	22	)	)	PUNCT
dpc-4248	182	23	and	and	CCONJ
dpc-4248	182	24	by	by	ADP
dpc-4248	182	25	the	the	DET
dpc-4248	182	26	low	low	ADJ
dpc-4248	182	27	number	number	NOUN
dpc-4248	182	28	of	of	ADP
dpc-4248	182	29	patients	patient	NOUN
dpc-4248	182	30	followed	follow	VERB
dpc-4248	182	31	original	original	ADJ
dpc-4248	182	32	article	article	NOUN
dpc-4248	182	33	|	|	ADV
dpc-4248	182	34	dermatol	dermatol	ADJ
dpc-4248	182	35	pract	pract	NOUN
dpc-4248	182	36	concept	concept	NOUN
dpc-4248	182	37	.	.	PUNCT
dpc-4248	183	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	183	2	9	9	NUM
dpc-4248	183	3	the	the	DET
dpc-4248	183	4	optimal	optimal	ADJ
dpc-4248	183	5	safety	safety	NOUN
dpc-4248	183	6	profile	profile	NOUN
dpc-4248	183	7	of	of	ADP
dpc-4248	183	8	brodalumab	brodalumab	NOUN
dpc-4248	183	9	has	have	AUX
dpc-4248	183	10	been	be	AUX
dpc-4248	183	11	also	also	ADV
dpc-4248	183	12	confirmed	confirm	VERB
dpc-4248	183	13	by	by	ADP
dpc-4248	183	14	its	its	PRON
dpc-4248	183	15	successful	successful	ADJ
dpc-4248	183	16	use	use	NOUN
dpc-4248	183	17	in	in	ADP
dpc-4248	183	18	our	our	PRON
dpc-4248	183	19	reported	report	VERB
dpc-4248	183	20	patients	patient	NOUN
dpc-4248	183	21	with	with	ADP
dpc-4248	183	22	a	a	DET
dpc-4248	183	23	complex	complex	ADJ
dpc-4248	183	24	medical	medical	ADJ
dpc-4248	183	25	history	history	NOUN
dpc-4248	183	26	,	,	PUNCT
dpc-4248	183	27	such	such	ADJ
dpc-4248	183	28	as	as	ADP
dpc-4248	183	29	those	those	PRON
dpc-4248	183	30	with	with	ADP
dpc-4248	183	31	latent	latent	NOUN
dpc-4248	183	32	tuberculosis	tuberculosis	NOUN
dpc-4248	183	33	and	and	CCONJ
dpc-4248	183	34	multiple	multiple	ADJ
dpc-4248	183	35	neoplasms	neoplasm	NOUN
dpc-4248	183	36	(	(	PUNCT
dpc-4248	183	37	cases	case	NOUN
dpc-4248	183	38	2	2	NUM
dpc-4248	183	39	and	and	CCONJ
dpc-4248	183	40	3	3	NUM
dpc-4248	183	41	,	,	PUNCT
dpc-4248	183	42	respectively	respectively	ADV
dpc-4248	183	43	)	)	PUNCT
dpc-4248	183	44	.	.	PUNCT
dpc-4248	184	1	moreover	moreover	ADV
dpc-4248	184	2	,	,	PUNCT
dpc-4248	184	3	we	we	PRON
dpc-4248	184	4	analyzed	analyze	VERB
dpc-4248	184	5	predictive	predictive	ADJ
dpc-4248	184	6	factors	factor	NOUN
dpc-4248	184	7	for	for	ADP
dpc-4248	184	8	drug	drug	NOUN
dpc-4248	184	9	survival	survival	NOUN
dpc-4248	184	10	.	.	PUNCT
dpc-4248	185	1	psoriatic	psoriatic	ADJ
dpc-4248	185	2	arthritis	arthritis	NOUN
dpc-4248	185	3	and	and	CCONJ
dpc-4248	185	4	pasi	pasi	NOUN
dpc-4248	185	5	at	at	ADP
dpc-4248	185	6	baseline	baseline	PROPN
dpc-4248	185	7	were	be	AUX
dpc-4248	185	8	identified	identify	VERB
dpc-4248	185	9	as	as	ADP
dpc-4248	185	10	positive	positive	ADJ
dpc-4248	185	11	predictive	predictive	ADJ
dpc-4248	185	12	factors	factor	NOUN
dpc-4248	185	13	for	for	ADP
dpc-4248	185	14	overall	overall	ADJ
dpc-4248	185	15	discontinuation	discontinuation	NOUN
dpc-4248	185	16	and	and	CCONJ
dpc-4248	185	17	suspension	suspension	NOUN
dpc-4248	185	18	due	due	ADP
dpc-4248	185	19	to	to	ADP
dpc-4248	185	20	ineffectiveness	ineffectiveness	NOUN
dpc-4248	185	21	.	.	PUNCT
dpc-4248	186	1	psoriatic	psoriatic	ADJ
dpc-4248	186	2	arthritis	arthritis	NOUN
dpc-4248	186	3	affects	affect	VERB
dpc-4248	186	4	approximately	approximately	ADV
dpc-4248	186	5	30	30	NUM
dpc-4248	186	6	%	%	NOUN
dpc-4248	186	7	of	of	ADP
dpc-4248	186	8	patients	patient	NOUN
dpc-4248	186	9	with	with	ADP
dpc-4248	186	10	psoriasis	psoriasis	NOUN
dpc-4248	186	11	[	[	X
dpc-4248	186	12	25	25	NUM
dpc-4248	186	13	]	]	PUNCT
dpc-4248	186	14	and	and	CCONJ
dpc-4248	186	15	therefore	therefore	ADV
dpc-4248	186	16	the	the	DET
dpc-4248	186	17	ability	ability	NOUN
dpc-4248	186	18	of	of	ADP
dpc-4248	186	19	a	a	DET
dpc-4248	186	20	drug	drug	NOUN
dpc-4248	186	21	to	to	PART
dpc-4248	186	22	manage	manage	VERB
dpc-4248	186	23	the	the	DET
dpc-4248	186	24	articular	articular	ADJ
dpc-4248	186	25	component	component	NOUN
dpc-4248	186	26	is	be	AUX
dpc-4248	186	27	important	important	ADJ
dpc-4248	186	28	when	when	SCONJ
dpc-4248	186	29	choosing	choose	VERB
dpc-4248	186	30	among	among	ADP
dpc-4248	186	31	the	the	DET
dpc-4248	186	32	available	available	ADJ
dpc-4248	186	33	therapeutic	therapeutic	ADJ
dpc-4248	186	34	options	option	NOUN
dpc-4248	186	35	.	.	PUNCT
dpc-4248	187	1	brodalumab	brodalumab	NOUN
dpc-4248	187	2	showed	show	VERB
dpc-4248	187	3	good	good	ADJ
dpc-4248	187	4	results	result	NOUN
dpc-4248	187	5	in	in	ADP
dpc-4248	187	6	clinical	clinical	ADJ
dpc-4248	187	7	trials	trial	NOUN
dpc-4248	187	8	for	for	ADP
dpc-4248	187	9	psoriatic	psoriatic	ADJ
dpc-4248	187	10	arthritis	arthritis	NOUN
dpc-4248	187	11	[	[	X
dpc-4248	187	12	26	26	NUM
dpc-4248	187	13	]	]	PUNCT
dpc-4248	187	14	,	,	PUNCT
dpc-4248	187	15	but	but	CCONJ
dpc-4248	187	16	evidence	evidence	NOUN
dpc-4248	187	17	in	in	ADP
dpc-4248	187	18	real	real	ADJ
dpc-4248	187	19	-	-	PUNCT
dpc-4248	187	20	world	world	NOUN
dpc-4248	187	21	is	be	AUX
dpc-4248	187	22	currently	currently	ADV
dpc-4248	187	23	limited	limit	VERB
dpc-4248	187	24	[	[	X
dpc-4248	187	25	17	17	NUM
dpc-4248	187	26	]	]	PUNCT
dpc-4248	187	27	.	.	PUNCT
dpc-4248	188	1	in	in	ADP
dpc-4248	188	2	contrast	contrast	NOUN
dpc-4248	188	3	to	to	ADP
dpc-4248	188	4	our	our	PRON
dpc-4248	188	5	result	result	NOUN
dpc-4248	188	6	,	,	PUNCT
dpc-4248	188	7	in	in	ADP
dpc-4248	188	8	the	the	DET
dpc-4248	188	9	study	study	NOUN
dpc-4248	188	10	of	of	ADP
dpc-4248	188	11	kojanova	kojanova	PROPN
dpc-4248	188	12	et	et	PROPN
dpc-4248	188	13	al	al	PROPN
dpc-4248	188	14	and	and	CCONJ
dpc-4248	188	15	of	of	ADP
dpc-4248	188	16	gkanti	gkanti	PROPN
dpc-4248	188	17	et	et	PROPN
dpc-4248	188	18	al	al	PROPN
dpc-4248	188	19	,	,	PUNCT
dpc-4248	188	20	psoriatic	psoriatic	ADJ
dpc-4248	188	21	arthritis	arthritis	NOUN
dpc-4248	188	22	resulted	result	VERB
dpc-4248	188	23	associated	associate	VERB
dpc-4248	188	24	to	to	ADP
dpc-4248	188	25	a	a	DET
dpc-4248	188	26	longer	long	ADJ
dpc-4248	188	27	drug	drug	NOUN
dpc-4248	188	28	survival	survival	NOUN
dpc-4248	189	1	[	[	X
dpc-4248	189	2	18	18	NUM
dpc-4248	189	3	,	,	PUNCT
dpc-4248	189	4	27	27	NUM
dpc-4248	189	5	]	]	PUNCT
dpc-4248	189	6	.	.	PUNCT
dpc-4248	190	1	pasi	pasi	NOUN
dpc-4248	190	2	at	at	ADP
dpc-4248	190	3	baseline	baseline	PROPN
dpc-4248	190	4	can	can	AUX
dpc-4248	190	5	have	have	VERB
dpc-4248	190	6	an	an	DET
dpc-4248	190	7	impact	impact	NOUN
dpc-4248	190	8	on	on	ADP
dpc-4248	190	9	the	the	DET
dpc-4248	190	10	efficacy	efficacy	NOUN
dpc-4248	190	11	of	of	ADP
dpc-4248	190	12	treatments	treatment	NOUN
dpc-4248	190	13	for	for	ADP
dpc-4248	190	14	psoriasis	psoriasis	NOUN
dpc-4248	190	15	[	[	X
dpc-4248	190	16	28	28	NUM
dpc-4248	190	17	]	]	PUNCT
dpc-4248	190	18	.	.	PUNCT
dpc-4248	191	1	patients	patient	NOUN
dpc-4248	191	2	with	with	ADP
dpc-4248	191	3	higher	high	ADJ
dpc-4248	191	4	baseline	baseline	NOUN
dpc-4248	191	5	pasi	pasi	NOUN
dpc-4248	191	6	may	may	AUX
dpc-4248	191	7	experience	experience	VERB
dpc-4248	191	8	a	a	DET
dpc-4248	191	9	reduced	reduce	VERB
dpc-4248	191	10	responsiveness	responsiveness	NOUN
dpc-4248	191	11	or	or	CCONJ
dpc-4248	191	12	a	a	DET
dpc-4248	191	13	loss	loss	NOUN
dpc-4248	191	14	of	of	ADP
dpc-4248	191	15	efficacy	efficacy	NOUN
dpc-4248	191	16	to	to	ADP
dpc-4248	191	17	biological	biological	ADJ
dpc-4248	191	18	treatments	treatment	NOUN
dpc-4248	191	19	.	.	PUNCT
dpc-4248	192	1	in	in	ADP
dpc-4248	192	2	fact	fact	NOUN
dpc-4248	192	3	,	,	PUNCT
dpc-4248	192	4	although	although	SCONJ
dpc-4248	192	5	it	it	PRON
dpc-4248	192	6	has	have	AUX
dpc-4248	192	7	not	not	PART
dpc-4248	192	8	yet	yet	ADV
dpc-4248	192	9	been	be	AUX
dpc-4248	192	10	reported	report	VERB
dpc-4248	192	11	in	in	ADP
dpc-4248	192	12	drug	drug	NOUN
dpc-4248	192	13	survival	survival	NOUN
dpc-4248	192	14	analyses	analyse	VERB
dpc-4248	192	15	specific	specific	ADJ
dpc-4248	192	16	on	on	ADP
dpc-4248	192	17	brodalumab	brodalumab	NOUN
dpc-4248	192	18	,	,	PUNCT
dpc-4248	192	19	higher	high	ADJ
dpc-4248	192	20	baseline	baseline	NOUN
dpc-4248	192	21	pasi	pasi	NOUN
dpc-4248	192	22	was	be	AUX
dpc-4248	192	23	identified	identify	VERB
dpc-4248	192	24	as	as	ADP
dpc-4248	192	25	a	a	DET
dpc-4248	192	26	predictor	predictor	NOUN
dpc-4248	192	27	of	of	ADP
dpc-4248	192	28	drug	drug	NOUN
dpc-4248	192	29	discontinuation	discontinuation	NOUN
dpc-4248	192	30	in	in	ADP
dpc-4248	192	31	the	the	DET
dpc-4248	192	32	drug	drug	NOUN
dpc-4248	192	33	survival	survival	NOUN
dpc-4248	192	34	analysis	analysis	NOUN
dpc-4248	192	35	of	of	ADP
dpc-4248	192	36	il	il	PROPN
dpc-4248	192	37	17	17	NUM
dpc-4248	192	38	and	and	CCONJ
dpc-4248	192	39	il	il	PROPN
dpc-4248	192	40	23	23	NUM
dpc-4248	192	41	inhibitors	inhibitor	NOUN
dpc-4248	192	42	by	by	ADP
dpc-4248	192	43	torres	torre	NOUN
dpc-4248	192	44	et	et	NOUN
dpc-4248	192	45	al	al	PROPN
dpc-4248	193	1	[	[	X
dpc-4248	193	2	19	19	NUM
dpc-4248	193	3	]	]	PUNCT
dpc-4248	193	4	.	.	PUNCT
dpc-4248	194	1	this	this	DET
dpc-4248	194	2	finding	finding	NOUN
dpc-4248	194	3	aligns	align	VERB
dpc-4248	194	4	with	with	ADP
dpc-4248	194	5	our	our	PRON
dpc-4248	194	6	result	result	NOUN
dpc-4248	194	7	and	and	CCONJ
dpc-4248	194	8	confirms	confirm	VERB
dpc-4248	194	9	that	that	SCONJ
dpc-4248	194	10	patients	patient	NOUN
dpc-4248	194	11	with	with	ADP
dpc-4248	194	12	a	a	DET
dpc-4248	194	13	more	more	ADV
dpc-4248	194	14	severe	severe	ADJ
dpc-4248	194	15	disease	disease	NOUN
dpc-4248	194	16	at	at	ADP
dpc-4248	194	17	baseline	baseline	NOUN
dpc-4248	194	18	may	may	AUX
dpc-4248	194	19	have	have	VERB
dpc-4248	194	20	a	a	DET
dpc-4248	194	21	lower	low	ADJ
dpc-4248	194	22	drug	drug	NOUN
dpc-4248	194	23	survival	survival	NOUN
dpc-4248	194	24	.	.	PUNCT
dpc-4248	195	1	moreover	moreover	ADV
dpc-4248	195	2	,	,	PUNCT
dpc-4248	195	3	although	although	SCONJ
dpc-4248	195	4	two	two	NUM
dpc-4248	195	5	of	of	ADP
dpc-4248	195	6	the	the	DET
dpc-4248	195	7	reported	report	VERB
dpc-4248	195	8	cases	case	NOUN
dpc-4248	195	9	showed	show	VERB
dpc-4248	195	10	a	a	DET
dpc-4248	195	11	high	high	ADJ
dpc-4248	195	12	effectiveness	effectiveness	NOUN
dpc-4248	195	13	of	of	ADP
dpc-4248	195	14	brodalumab	brodalumab	NOUN
dpc-4248	195	15	in	in	ADP
dpc-4248	195	16	very	very	ADV
dpc-4248	195	17	obese	obese	ADJ
dpc-4248	195	18	patients	patient	NOUN
dpc-4248	195	19	,	,	PUNCT
dpc-4248	195	20	at	at	ADP
dpc-4248	195	21	the	the	DET
dpc-4248	195	22	multivariable	multivariable	ADJ
dpc-4248	195	23	analysis	analysis	NOUN
dpc-4248	195	24	bmi	bmi	NOUN
dpc-4248	195	25	resulted	result	VERB
dpc-4248	195	26	associated	associate	VERB
dpc-4248	195	27	with	with	ADP
dpc-4248	195	28	a	a	DET
dpc-4248	195	29	mild	mild	ADJ
dpc-4248	195	30	increase	increase	NOUN
dpc-4248	195	31	risk	risk	NOUN
dpc-4248	195	32	(	(	PUNCT
dpc-4248	195	33	or	or	CCONJ
dpc-4248	195	34	1.10	1.10	NUM
dpc-4248	195	35	)	)	PUNCT
dpc-4248	195	36	of	of	ADP
dpc-4248	195	37	discontinuation	discontinuation	NOUN
dpc-4248	195	38	for	for	ADP
dpc-4248	195	39	all	all	DET
dpc-4248	195	40	reasons	reason	NOUN
dpc-4248	195	41	and	and	CCONJ
dpc-4248	195	42	for	for	ADP
dpc-4248	195	43	ineffectiveness	ineffectiveness	NOUN
dpc-4248	195	44	[	[	X
dpc-4248	195	45	29	29	NUM
dpc-4248	195	46	]	]	PUNCT
dpc-4248	195	47	.	.	PUNCT
dpc-4248	196	1	although	although	SCONJ
dpc-4248	196	2	in	in	ADP
dpc-4248	196	3	the	the	DET
dpc-4248	196	4	post	post	X
dpc-4248	196	5	hoc	hoc	X
dpc-4248	196	6	analysis	analysis	NOUN
dpc-4248	196	7	of	of	ADP
dpc-4248	196	8	amagine	amagine	ADJ
dpc-4248	196	9	2/3	2/3	NUM
dpc-4248	196	10	trials	trial	NOUN
dpc-4248	196	11	bmi	bmi	NOUN
dpc-4248	196	12	was	be	AUX
dpc-4248	196	13	not	not	PART
dpc-4248	196	14	associated	associate	VERB
dpc-4248	196	15	to	to	ADP
dpc-4248	196	16	a	a	DET
dpc-4248	196	17	lower	low	ADJ
dpc-4248	196	18	efficacy	efficacy	NOUN
dpc-4248	196	19	of	of	ADP
dpc-4248	196	20	brodalumab	brodalumab	NOUN
dpc-4248	196	21	[	[	X
dpc-4248	196	22	30	30	NUM
dpc-4248	196	23	]	]	PUNCT
dpc-4248	196	24	,	,	PUNCT
dpc-4248	196	25	in	in	ADP
dpc-4248	196	26	the	the	DET
dpc-4248	196	27	real	real	ADJ
dpc-4248	196	28	-	-	PUNCT
dpc-4248	196	29	world	world	NOUN
dpc-4248	196	30	setting	set	VERB
dpc-4248	196	31	this	this	DET
dpc-4248	196	32	finding	finding	NOUN
dpc-4248	196	33	is	be	AUX
dpc-4248	196	34	not	not	PART
dpc-4248	196	35	always	always	ADV
dpc-4248	196	36	confirmed	confirm	VERB
dpc-4248	196	37	and	and	CCONJ
dpc-4248	196	38	obesity	obesity	NOUN
dpc-4248	196	39	in	in	ADP
dpc-4248	196	40	some	some	DET
dpc-4248	196	41	studies	study	NOUN
dpc-4248	196	42	seems	seem	VERB
dpc-4248	196	43	to	to	PART
dpc-4248	196	44	be	be	AUX
dpc-4248	196	45	related	relate	VERB
dpc-4248	196	46	to	to	ADP
dpc-4248	196	47	lower	low	ADJ
dpc-4248	196	48	efficacy	efficacy	NOUN
dpc-4248	196	49	and	and	CCONJ
dpc-4248	196	50	drug	drug	NOUN
dpc-4248	196	51	survival	survival	NOUN
dpc-4248	197	1	[	[	X
dpc-4248	197	2	14	14	NUM
dpc-4248	197	3	,	,	PUNCT
dpc-4248	197	4	17	17	NUM
dpc-4248	197	5	,	,	PUNCT
dpc-4248	197	6	18	18	NUM
dpc-4248	197	7	]	]	PUNCT
dpc-4248	197	8	.	.	PUNCT
dpc-4248	198	1	for	for	ADP
dpc-4248	198	2	this	this	DET
dpc-4248	198	3	reason	reason	NOUN
dpc-4248	198	4	,	,	PUNCT
dpc-4248	198	5	a	a	DET
dpc-4248	198	6	trial	trial	NOUN
dpc-4248	198	7	is	be	AUX
dpc-4248	198	8	currently	currently	ADV
dpc-4248	198	9	ongoing	ongoing	ADJ
dpc-4248	198	10	to	to	PART
dpc-4248	198	11	investigate	investigate	VERB
dpc-4248	198	12	the	the	DET
dpc-4248	198	13	administration	administration	NOUN
dpc-4248	198	14	of	of	ADP
dpc-4248	198	15	a	a	DET
dpc-4248	198	16	higher	high	ADJ
dpc-4248	198	17	dosage	dosage	NOUN
dpc-4248	198	18	of	of	ADP
dpc-4248	198	19	brodalumab	brodalumab	NOUN
dpc-4248	198	20	in	in	ADP
dpc-4248	198	21	patients	patient	NOUN
dpc-4248	198	22	with	with	ADP
dpc-4248	198	23	an	an	DET
dpc-4248	198	24	increased	increase	VERB
dpc-4248	198	25	bmi	bmi	NOUN
dpc-4248	198	26	(	(	PUNCT
dpc-4248	198	27	nct04306315	nct04306315	NOUN
dpc-4248	198	28	)	)	PUNCT
dpc-4248	198	29	.	.	PUNCT
dpc-4248	199	1	finally	finally	ADV
dpc-4248	199	2	,	,	PUNCT
dpc-4248	199	3	we	we	PRON
dpc-4248	199	4	did	do	AUX
dpc-4248	199	5	not	not	PART
dpc-4248	199	6	find	find	VERB
dpc-4248	199	7	significant	significant	ADJ
dpc-4248	199	8	difference	difference	NOUN
dpc-4248	199	9	in	in	ADP
dpc-4248	199	10	effectiveness	effectiveness	NOUN
dpc-4248	199	11	between	between	ADP
dpc-4248	199	12	biologic	biologic	NOUN
dpc-4248	199	13	-	-	PUNCT
dpc-4248	199	14	naive	naive	ADJ
dpc-4248	199	15	and	and	CCONJ
dpc-4248	199	16	bio	bio	ADJ
dpc-4248	199	17	-	-	ADJ
dpc-4248	199	18	experienced	experienced	ADJ
dpc-4248	199	19	patients	patient	NOUN
dpc-4248	199	20	.	.	PUNCT
dpc-4248	200	1	this	this	DET
dpc-4248	200	2	datum	datum	NOUN
dpc-4248	200	3	is	be	AUX
dpc-4248	200	4	worthy	worthy	ADJ
dpc-4248	200	5	of	of	ADP
dpc-4248	200	6	note	note	NOUN
dpc-4248	200	7	since	since	SCONJ
dpc-4248	200	8	,	,	PUNCT
dpc-4248	200	9	in	in	ADP
dpc-4248	200	10	the	the	DET
dpc-4248	200	11	real	real	ADJ
dpc-4248	200	12	-	-	PUNCT
dpc-4248	200	13	world	world	NOUN
dpc-4248	200	14	setting	setting	NOUN
dpc-4248	200	15	,	,	PUNCT
dpc-4248	200	16	bio	bio	ADJ
dpc-4248	200	17	-	-	ADJ
dpc-4248	200	18	experienced	experienced	ADJ
dpc-4248	200	19	patients	patient	NOUN
dpc-4248	200	20	represent	represent	VERB
dpc-4248	200	21	a	a	DET
dpc-4248	200	22	therapeutic	therapeutic	ADJ
dpc-4248	200	23	challenge	challenge	NOUN
dpc-4248	200	24	because	because	SCONJ
dpc-4248	200	25	they	they	PRON
dpc-4248	200	26	may	may	AUX
dpc-4248	200	27	have	have	AUX
dpc-4248	200	28	developed	develop	VERB
dpc-4248	200	29	resistance	resistance	NOUN
dpc-4248	200	30	or	or	CCONJ
dpc-4248	200	31	inefficacy	inefficacy	NOUN
dpc-4248	200	32	to	to	ADP
dpc-4248	200	33	prior	prior	ADJ
dpc-4248	200	34	biologic	biologic	NOUN
dpc-4248	200	35	treatments	treatment	NOUN
dpc-4248	200	36	.	.	PUNCT
dpc-4248	201	1	in	in	ADP
dpc-4248	201	2	fact	fact	NOUN
dpc-4248	201	3	,	,	PUNCT
dpc-4248	201	4	therapies	therapy	NOUN
dpc-4248	201	5	for	for	ADP
dpc-4248	201	6	psoriasis	psoriasis	NOUN
dpc-4248	201	7	often	often	ADV
dpc-4248	201	8	have	have	VERB
dpc-4248	201	9	a	a	DET
dpc-4248	201	10	faster	fast	ADJ
dpc-4248	201	11	,	,	PUNCT
dpc-4248	201	12	greater	great	ADJ
dpc-4248	201	13	efficacy	efficacy	NOUN
dpc-4248	201	14	and	and	CCONJ
dpc-4248	201	15	longer	long	ADJ
dpc-4248	201	16	drug	drug	NOUN
dpc-4248	201	17	survival	survival	NOUN
dpc-4248	201	18	in	in	ADP
dpc-4248	201	19	patients	patient	NOUN
dpc-4248	201	20	who	who	PRON
dpc-4248	201	21	are	be	AUX
dpc-4248	201	22	naive	naive	ADJ
dpc-4248	201	23	to	to	ADP
dpc-4248	201	24	biologics	biologic	NOUN
dpc-4248	201	25	[	[	X
dpc-4248	201	26	31	31	NUM
dpc-4248	201	27	,	,	PUNCT
dpc-4248	201	28	32	32	NUM
dpc-4248	201	29	,	,	PUNCT
dpc-4248	201	30	33	33	NUM
dpc-4248	201	31	]	]	PUNCT
dpc-4248	201	32	.	.	PUNCT
dpc-4248	202	1	the	the	DET
dpc-4248	202	2	efficacy	efficacy	NOUN
dpc-4248	202	3	of	of	ADP
dpc-4248	202	4	brodalumab	brodalumab	NOUN
dpc-4248	202	5	in	in	ADP
dpc-4248	202	6	bio	bio	ADJ
dpc-4248	202	7	-	-	ADJ
dpc-4248	202	8	experienced	experienced	ADJ
dpc-4248	202	9	patients	patient	NOUN
dpc-4248	202	10	may	may	AUX
dpc-4248	202	11	be	be	AUX
dpc-4248	202	12	explained	explain	VERB
dpc-4248	202	13	with	with	ADP
dpc-4248	202	14	its	its	PRON
dpc-4248	202	15	unique	unique	ADJ
dpc-4248	202	16	mechanism	mechanism	NOUN
dpc-4248	202	17	of	of	ADP
dpc-4248	202	18	action	action	NOUN
dpc-4248	202	19	that	that	PRON
dpc-4248	202	20	inhibits	inhibit	VERB
dpc-4248	202	21	the	the	DET
dpc-4248	202	22	il17	il17	PROPN
dpc-4248	202	23	-	-	PUNCT
dpc-4248	202	24	receptor	receptor	NOUN
dpc-4248	202	25	.	.	PUNCT
dpc-4248	203	1	this	this	PRON
dpc-4248	203	2	is	be	AUX
dpc-4248	203	3	in	in	ADP
dpc-4248	203	4	line	line	NOUN
dpc-4248	203	5	with	with	ADP
dpc-4248	203	6	our	our	PRON
dpc-4248	203	7	cases	case	NOUN
dpc-4248	203	8	1	1	NUM
dpc-4248	203	9	and	and	CCONJ
dpc-4248	203	10	4	4	NUM
dpc-4248	203	11	,	,	PUNCT
dpc-4248	203	12	pivotal	pivotal	ADJ
dpc-4248	203	13	trials	trial	NOUN
dpc-4248	203	14	and	and	CCONJ
dpc-4248	203	15	real	real	ADJ
dpc-4248	203	16	-	-	PUNCT
dpc-4248	203	17	world	world	NOUN
dpc-4248	203	18	studies	study	NOUN
dpc-4248	203	19	showing	show	VERB
dpc-4248	203	20	that	that	SCONJ
dpc-4248	203	21	brodalumab	brodalumab	NOUN
dpc-4248	203	22	resulted	result	VERB
dpc-4248	203	23	effective	effective	ADJ
dpc-4248	203	24	also	also	ADV
dpc-4248	203	25	in	in	ADP
dpc-4248	203	26	patients	patient	NOUN
dpc-4248	203	27	previously	previously	ADV
dpc-4248	203	28	treated	treat	VERB
dpc-4248	203	29	with	with	ADP
dpc-4248	203	30	other	other	ADJ
dpc-4248	203	31	biologics	biologic	NOUN
dpc-4248	203	32	anti	anti	X
dpc-4248	203	33	il-17a	il-17a	PROPN
dpc-4248	203	34	.	.	PUNCT
dpc-4248	204	1	(	(	PUNCT
dpc-4248	204	2	amagine1	amagine1	NOUN
dpc-4248	204	3	-	-	PUNCT
dpc-4248	204	4	2	2	NUM
dpc-4248	204	5	-	-	SYM
dpc-4248	204	6	3	3	NUM
dpc-4248	204	7	)	)	PUNCT
dpc-4248	205	1	[	[	X
dpc-4248	205	2	34	34	NUM
dpc-4248	205	3	,	,	PUNCT
dpc-4248	205	4	35	35	NUM
dpc-4248	205	5	]	]	PUNCT
dpc-4248	205	6	.	.	PUNCT
dpc-4248	206	1	up	up	ADP
dpc-4248	206	2	for	for	ADP
dpc-4248	206	3	the	the	DET
dpc-4248	206	4	whole	whole	ADJ
dpc-4248	206	5	period	period	NOUN
dpc-4248	206	6	of	of	ADP
dpc-4248	206	7	the	the	DET
dpc-4248	206	8	study	study	NOUN
dpc-4248	206	9	.	.	PUNCT
dpc-4248	207	1	moreover	moreover	ADV
dpc-4248	207	2	,	,	PUNCT
dpc-4248	207	3	gaudet	gaudet	PROPN
dpc-4248	207	4	et	et	PROPN
dpc-4248	207	5	al	al	PROPN
dpc-4248	207	6	.	.	PROPN
dpc-4248	207	7	reported	report	VERB
dpc-4248	207	8	similar	similar	ADJ
dpc-4248	207	9	results	result	NOUN
dpc-4248	207	10	and	and	CCONJ
dpc-4248	207	11	,	,	PUNCT
dpc-4248	207	12	in	in	ADP
dpc-4248	207	13	particular	particular	ADJ
dpc-4248	207	14	,	,	PUNCT
dpc-4248	207	15	a	a	DET
dpc-4248	207	16	1	1	NUM
dpc-4248	207	17	-	-	PUNCT
dpc-4248	207	18	year	year	NOUN
dpc-4248	207	19	survival	survival	NOUN
dpc-4248	207	20	rate	rate	NOUN
dpc-4248	207	21	of	of	ADP
dpc-4248	207	22	70	70	NUM
dpc-4248	207	23	%	%	NOUN
dpc-4248	207	24	,	,	PUNCT
dpc-4248	207	25	analyzing	analyze	VERB
dpc-4248	207	26	data	datum	NOUN
dpc-4248	207	27	collected	collect	VERB
dpc-4248	207	28	through	through	ADP
dpc-4248	207	29	the	the	DET
dpc-4248	207	30	brodalumab	brodalumab	NOUN
dpc-4248	207	31	patient	patient	NOUN
dpc-4248	207	32	support	support	NOUN
dpc-4248	207	33	program	program	NOUN
dpc-4248	207	34	in	in	ADP
dpc-4248	207	35	canada	canada	PROPN
dpc-4248	208	1	[	[	X
dpc-4248	208	2	11	11	NUM
dpc-4248	208	3	,	,	PUNCT
dpc-4248	208	4	17	17	NUM
dpc-4248	208	5	]	]	PUNCT
dpc-4248	208	6	.	.	PUNCT
dpc-4248	209	1	our	our	PRON
dpc-4248	209	2	results	result	NOUN
dpc-4248	209	3	are	be	AUX
dpc-4248	209	4	in	in	ADP
dpc-4248	209	5	line	line	NOUN
dpc-4248	209	6	with	with	ADP
dpc-4248	209	7	the	the	DET
dpc-4248	209	8	studies	study	NOUN
dpc-4248	209	9	by	by	ADP
dpc-4248	209	10	other	other	ADJ
dpc-4248	209	11	authors	author	NOUN
dpc-4248	209	12	that	that	PRON
dpc-4248	209	13	reported	report	VERB
dpc-4248	209	14	survival	survival	NOUN
dpc-4248	209	15	rates	rate	NOUN
dpc-4248	209	16	at	at	ADP
dpc-4248	209	17	1	1	NUM
dpc-4248	209	18	year	year	NOUN
dpc-4248	209	19	ranging	range	VERB
dpc-4248	209	20	from	from	ADP
dpc-4248	209	21	85	85	NUM
dpc-4248	209	22	to	to	PART
dpc-4248	209	23	89.9	89.9	NUM
dpc-4248	209	24	%	%	NOUN
dpc-4248	209	25	and	and	CCONJ
dpc-4248	209	26	at	at	ADP
dpc-4248	209	27	2	2	NUM
dpc-4248	209	28	years	year	NOUN
dpc-4248	209	29	from	from	ADP
dpc-4248	209	30	77.32	77.32	NUM
dpc-4248	209	31	to	to	ADP
dpc-4248	209	32	80.0	80.0	NUM
dpc-4248	209	33	%	%	NOUN
dpc-4248	209	34	.	.	PUNCT
dpc-4248	210	1	in	in	ADP
dpc-4248	210	2	addition	addition	NOUN
dpc-4248	210	3	,	,	PUNCT
dpc-4248	210	4	torres	torre	VERB
dpc-4248	210	5	et	et	NOUN
dpc-4248	210	6	 	 	SPACE
dpc-4248	210	7	al	al	PROPN
dpc-4248	210	8	analyzed	analyze	VERB
dpc-4248	210	9	the	the	DET
dpc-4248	210	10	drug	drug	NOUN
dpc-4248	210	11	survival	survival	NOUN
dpc-4248	210	12	of	of	ADP
dpc-4248	210	13	different	different	ADJ
dpc-4248	210	14	il-17	il-17	NOUN
dpc-4248	210	15	and	and	CCONJ
dpc-4248	210	16	il-23	il-23	VERB
dpc-4248	210	17	inhibitors	inhibitor	NOUN
dpc-4248	210	18	,	,	PUNCT
dpc-4248	210	19	and	and	CCONJ
dpc-4248	210	20	brodalumab	brodalumab	NOUN
dpc-4248	210	21	resulted	result	VERB
dpc-4248	210	22	the	the	DET
dpc-4248	210	23	il-17	il-17	NUM
dpc-4248	210	24	inhibitor	inhibitor	NOUN
dpc-4248	210	25	with	with	ADP
dpc-4248	210	26	the	the	DET
dpc-4248	210	27	highest	high	ADJ
dpc-4248	210	28	drug	drug	NOUN
dpc-4248	210	29	survival	survival	NOUN
dpc-4248	210	30	at	at	ADP
dpc-4248	210	31	24	24	NUM
dpc-4248	210	32	months	month	NOUN
dpc-4248	210	33	(	(	PUNCT
dpc-4248	210	34	overall	overall	ADJ
dpc-4248	210	35	probability	probability	NOUN
dpc-4248	210	36	of	of	ADP
dpc-4248	210	37	drug	drug	NOUN
dpc-4248	210	38	survival	survival	NOUN
dpc-4248	210	39	of	of	ADP
dpc-4248	210	40	0.80	0.80	NUM
dpc-4248	210	41	compared	compare	VERB
dpc-4248	210	42	to	to	ADP
dpc-4248	210	43	0.79	0.79	NUM
dpc-4248	210	44	for	for	ADP
dpc-4248	210	45	ixekizumab	ixekizumab	NOUN
dpc-4248	210	46	,	,	PUNCT
dpc-4248	210	47	and	and	CCONJ
dpc-4248	210	48	0.75	0.75	NUM
dpc-4248	210	49	for	for	ADP
dpc-4248	210	50	secukinumab	secukinumab	NOUN
dpc-4248	210	51	)	)	PUNCT
dpc-4248	210	52	.	.	PUNCT
dpc-4248	211	1	the	the	DET
dpc-4248	211	2	higher	high	ADJ
dpc-4248	211	3	drug	drug	NOUN
dpc-4248	211	4	survival	survival	NOUN
dpc-4248	211	5	of	of	ADP
dpc-4248	211	6	brodalumab	brodalumab	NOUN
dpc-4248	211	7	compared	compare	VERB
dpc-4248	211	8	to	to	ADP
dpc-4248	211	9	other	other	ADJ
dpc-4248	211	10	il-17	il-17	ADP
dpc-4248	211	11	inhibitors	inhibitor	NOUN
dpc-4248	211	12	,	,	PUNCT
dpc-4248	211	13	although	although	SCONJ
dpc-4248	211	14	with	with	ADP
dpc-4248	211	15	no	no	DET
dpc-4248	211	16	statistical	statistical	ADJ
dpc-4248	211	17	significance	significance	NOUN
dpc-4248	211	18	,	,	PUNCT
dpc-4248	211	19	appeared	appear	VERB
dpc-4248	211	20	also	also	ADV
dpc-4248	211	21	in	in	ADP
dpc-4248	211	22	the	the	DET
dpc-4248	211	23	recent	recent	ADJ
dpc-4248	211	24	real	real	ADJ
dpc-4248	211	25	-	-	PUNCT
dpc-4248	211	26	world	world	NOUN
dpc-4248	211	27	analysis	analysis	NOUN
dpc-4248	211	28	conducted	conduct	VERB
dpc-4248	211	29	in	in	ADP
dpc-4248	211	30	the	the	DET
dpc-4248	211	31	czech	czech	PROPN
dpc-4248	211	32	republic	republic	NOUN
dpc-4248	211	33	[	[	X
dpc-4248	211	34	18	18	NUM
dpc-4248	211	35	,	,	PUNCT
dpc-4248	211	36	19	19	NUM
dpc-4248	211	37	]	]	PUNCT
dpc-4248	211	38	.	.	PUNCT
dpc-4248	212	1	finally	finally	ADV
dpc-4248	212	2	,	,	PUNCT
dpc-4248	212	3	gargiulo	gargiulo	NOUN
dpc-4248	212	4	et	et	PROPN
dpc-4248	212	5	al	al	PROPN
dpc-4248	212	6	.	.	PROPN
dpc-4248	213	1	recently	recently	ADV
dpc-4248	213	2	published	publish	VERB
dpc-4248	213	3	an	an	DET
dpc-4248	213	4	italian	italian	ADJ
dpc-4248	213	5	study	study	NOUN
dpc-4248	213	6	that	that	PRON
dpc-4248	213	7	involved	involve	VERB
dpc-4248	213	8	606	606	NUM
dpc-4248	213	9	patients	patient	NOUN
dpc-4248	213	10	treated	treat	VERB
dpc-4248	213	11	with	with	ADP
dpc-4248	213	12	brodalumab	brodalumab	NOUN
dpc-4248	213	13	,	,	PUNCT
dpc-4248	213	14	out	out	ADP
dpc-4248	213	15	of	of	ADP
dpc-4248	213	16	which	which	PRON
dpc-4248	213	17	115	115	NUM
dpc-4248	213	18	completed	complete	VERB
dpc-4248	213	19	a	a	DET
dpc-4248	213	20	3	3	NUM
dpc-4248	213	21	-	-	PUNCT
dpc-4248	213	22	year	year	NOUN
dpc-4248	213	23	follow	follow	NOUN
dpc-4248	213	24	-	-	PUNCT
dpc-4248	213	25	up	up	NOUN
dpc-4248	213	26	.	.	PUNCT
dpc-4248	214	1	the	the	DET
dpc-4248	214	2	study	study	NOUN
dpc-4248	214	3	confirmed	confirm	VERB
dpc-4248	214	4	the	the	DET
dpc-4248	214	5	high	high	ADJ
dpc-4248	214	6	persistence	persistence	NOUN
dpc-4248	214	7	in	in	ADP
dpc-4248	214	8	treatment	treatment	NOUN
dpc-4248	214	9	even	even	ADV
dpc-4248	214	10	at	at	ADP
dpc-4248	214	11	36	36	NUM
dpc-4248	214	12	months	month	NOUN
dpc-4248	214	13	,	,	PUNCT
dpc-4248	214	14	with	with	ADP
dpc-4248	214	15	a	a	DET
dpc-4248	214	16	notable	notable	ADJ
dpc-4248	214	17	survival	survival	NOUN
dpc-4248	214	18	rate	rate	NOUN
dpc-4248	214	19	of	of	ADP
dpc-4248	214	20	85.64	85.64	NUM
dpc-4248	214	21	%	%	NOUN
dpc-4248	214	22	[	[	X
dpc-4248	214	23	20	20	NUM
dpc-4248	214	24	]	]	PUNCT
dpc-4248	214	25	.	.	PUNCT
dpc-4248	215	1	discontinuation	discontinuation	NOUN
dpc-4248	215	2	of	of	ADP
dpc-4248	215	3	brodalumab	brodalumab	NOUN
dpc-4248	215	4	in	in	ADP
dpc-4248	215	5	our	our	PRON
dpc-4248	215	6	study	study	NOUN
dpc-4248	215	7	primarily	primarily	ADV
dpc-4248	215	8	occurred	occur	VERB
dpc-4248	215	9	due	due	ADP
dpc-4248	215	10	to	to	ADP
dpc-4248	215	11	adverse	adverse	ADJ
dpc-4248	215	12	events	event	NOUN
dpc-4248	215	13	.	.	PUNCT
dpc-4248	216	1	the	the	DET
dpc-4248	216	2	most	most	ADV
dpc-4248	216	3	frequent	frequent	ADJ
dpc-4248	216	4	in	in	ADP
dpc-4248	216	5	our	our	PRON
dpc-4248	216	6	patients	patient	NOUN
dpc-4248	216	7	was	be	AUX
dpc-4248	216	8	the	the	DET
dpc-4248	216	9	onset	onset	NOUN
dpc-4248	216	10	of	of	ADP
dpc-4248	216	11	an	an	DET
dpc-4248	216	12	eczematous	eczematous	ADJ
dpc-4248	216	13	eruption	eruption	NOUN
dpc-4248	216	14	,	,	PUNCT
dpc-4248	216	15	occurring	occur	VERB
dpc-4248	216	16	in	in	ADP
dpc-4248	216	17	2/90	2/90	NUM
dpc-4248	216	18	patients	patient	NOUN
dpc-4248	216	19	(	(	PUNCT
dpc-4248	216	20	2.22	2.22	NUM
dpc-4248	216	21	%	%	NOUN
dpc-4248	216	22	)	)	PUNCT
dpc-4248	216	23	.	.	PUNCT
dpc-4248	217	1	this	this	PRON
dpc-4248	217	2	is	be	AUX
dpc-4248	217	3	a	a	DET
dpc-4248	217	4	well	well	ADV
dpc-4248	217	5	-	-	PUNCT
dpc-4248	217	6	known	know	VERB
dpc-4248	217	7	adverse	adverse	ADJ
dpc-4248	217	8	event	event	NOUN
dpc-4248	217	9	which	which	PRON
dpc-4248	217	10	can	can	AUX
dpc-4248	217	11	occur	occur	VERB
dpc-4248	217	12	during	during	ADP
dpc-4248	217	13	anti	anti	ADJ
dpc-4248	217	14	il-17	il-17	ADP
dpc-4248	217	15	treatments	treatment	NOUN
dpc-4248	217	16	.	.	PUNCT
dpc-4248	218	1	although	although	SCONJ
dpc-4248	218	2	the	the	DET
dpc-4248	218	3	exact	exact	ADJ
dpc-4248	218	4	underlying	underlying	ADJ
dpc-4248	218	5	pathogenetic	pathogenetic	ADJ
dpc-4248	218	6	mechanism	mechanism	NOUN
dpc-4248	218	7	is	be	AUX
dpc-4248	218	8	not	not	PART
dpc-4248	218	9	yet	yet	ADV
dpc-4248	218	10	fully	fully	ADV
dpc-4248	218	11	understood	understand	VERB
dpc-4248	218	12	,	,	PUNCT
dpc-4248	218	13	it	it	PRON
dpc-4248	218	14	has	have	AUX
dpc-4248	218	15	been	be	AUX
dpc-4248	218	16	hypothesized	hypothesize	VERB
dpc-4248	218	17	that	that	SCONJ
dpc-4248	218	18	the	the	DET
dpc-4248	218	19	incidence	incidence	NOUN
dpc-4248	218	20	of	of	ADP
dpc-4248	218	21	eczematous	eczematous	ADJ
dpc-4248	218	22	eruptions	eruption	NOUN
dpc-4248	218	23	is	be	AUX
dpc-4248	218	24	mainly	mainly	ADV
dpc-4248	218	25	linked	link	VERB
dpc-4248	218	26	to	to	ADP
dpc-4248	218	27	the	the	DET
dpc-4248	218	28	overexpression	overexpression	NOUN
dpc-4248	218	29	of	of	ADP
dpc-4248	218	30	il-17	il-17	PRON
dpc-4248	218	31	c.	c.	PROPN
dpc-4248	218	32	brodalumab	brodalumab	PROPN
dpc-4248	218	33	,	,	PUNCT
dpc-4248	218	34	acting	act	VERB
dpc-4248	218	35	on	on	ADP
dpc-4248	218	36	il-17ra	il-17ra	PROPN
dpc-4248	218	37	and	and	CCONJ
dpc-4248	218	38	blocking	block	VERB
dpc-4248	218	39	il17a	il17a	NOUN
dpc-4248	218	40	,	,	PUNCT
dpc-4248	218	41	il-17	il-17	ADP
dpc-4248	218	42	f	f	NOUN
dpc-4248	218	43	,	,	PUNCT
dpc-4248	218	44	and	and	CCONJ
dpc-4248	218	45	il-17	il-17	ADP
dpc-4248	218	46	c	c	X
dpc-4248	218	47	,	,	PUNCT
dpc-4248	218	48	does	do	AUX
dpc-4248	218	49	not	not	PART
dpc-4248	218	50	result	result	VERB
dpc-4248	218	51	in	in	ADP
dpc-4248	218	52	an	an	DET
dpc-4248	218	53	increase	increase	NOUN
dpc-4248	218	54	of	of	ADP
dpc-4248	218	55	il-17	il-17	NOUN
dpc-4248	218	56	c	c	PROPN
dpc-4248	218	57	and	and	CCONJ
dpc-4248	218	58	this	this	PRON
dpc-4248	218	59	may	may	AUX
dpc-4248	218	60	explain	explain	VERB
dpc-4248	218	61	the	the	DET
dpc-4248	218	62	lower	low	ADJ
dpc-4248	218	63	prevalence	prevalence	NOUN
dpc-4248	218	64	of	of	ADP
dpc-4248	218	65	this	this	DET
dpc-4248	218	66	side	side	ADJ
dpc-4248	218	67	effect	effect	NOUN
dpc-4248	218	68	in	in	ADP
dpc-4248	218	69	our	our	PRON
dpc-4248	218	70	population	population	NOUN
dpc-4248	218	71	respect	respect	NOUN
dpc-4248	218	72	to	to	ADP
dpc-4248	218	73	what	what	PRON
dpc-4248	218	74	is	be	AUX
dpc-4248	218	75	reported	report	VERB
dpc-4248	218	76	for	for	ADP
dpc-4248	218	77	other	other	ADJ
dpc-4248	218	78	anti	anti	ADJ
dpc-4248	218	79	il17	il17	PROPN
dpc-4248	218	80	agents	agent	NOUN
dpc-4248	218	81	(	(	PUNCT
dpc-4248	218	82	2.2	2.2	NUM
dpc-4248	218	83	%	%	NOUN
dpc-4248	218	84	vs	vs	ADP
dpc-4248	218	85	5.8	5.8	NUM
dpc-4248	218	86	%	%	NOUN
dpc-4248	218	87	)	)	PUNCT
dpc-4248	219	1	[	[	X
dpc-4248	219	2	21	21	NUM
dpc-4248	219	3	]	]	PUNCT
dpc-4248	219	4	.	.	PUNCT
dpc-4248	220	1	several	several	ADJ
dpc-4248	220	2	cases	case	NOUN
dpc-4248	220	3	have	have	AUX
dpc-4248	220	4	been	be	AUX
dpc-4248	220	5	described	describe	VERB
dpc-4248	220	6	that	that	SCONJ
dpc-4248	220	7	support	support	VERB
dpc-4248	220	8	this	this	DET
dpc-4248	220	9	hypothesis	hypothesis	NOUN
dpc-4248	220	10	.	.	PUNCT
dpc-4248	221	1	for	for	ADP
dpc-4248	221	2	instance	instance	NOUN
dpc-4248	221	3	,	,	PUNCT
dpc-4248	221	4	a	a	DET
dpc-4248	221	5	patient	patient	NOUN
dpc-4248	221	6	with	with	ADP
dpc-4248	221	7	an	an	DET
dpc-4248	221	8	eczematous	eczematous	ADJ
dpc-4248	221	9	eruption	eruption	NOUN
dpc-4248	221	10	induced	induce	VERB
dpc-4248	221	11	by	by	ADP
dpc-4248	221	12	ixekizumab	ixekizumab	NOUN
dpc-4248	221	13	was	be	AUX
dpc-4248	221	14	treated	treat	VERB
dpc-4248	221	15	with	with	ADP
dpc-4248	221	16	brodalumab	brodalumab	NOUN
dpc-4248	221	17	with	with	ADP
dpc-4248	221	18	success	success	NOUN
dpc-4248	221	19	,	,	PUNCT
dpc-4248	221	20	and	and	CCONJ
dpc-4248	221	21	a	a	DET
dpc-4248	221	22	patient	patient	NOUN
dpc-4248	221	23	with	with	ADP
dpc-4248	221	24	concurrent	concurrent	ADJ
dpc-4248	221	25	atopic	atopic	NOUN
dpc-4248	221	26	dermatitis	dermatitis	NOUN
dpc-4248	221	27	and	and	CCONJ
dpc-4248	221	28	psoriasis	psoriasis	NOUN
dpc-4248	221	29	was	be	AUX
dpc-4248	221	30	managed	manage	VERB
dpc-4248	221	31	with	with	ADP
dpc-4248	221	32	brodalumab	brodalumab	NOUN
dpc-4248	221	33	achieving	achieve	VERB
dpc-4248	221	34	a	a	DET
dpc-4248	221	35	complete	complete	ADJ
dpc-4248	221	36	clinical	clinical	ADJ
dpc-4248	221	37	response	response	NOUN
dpc-4248	222	1	[	[	X
dpc-4248	222	2	22	22	NUM
dpc-4248	222	3	,	,	PUNCT
dpc-4248	222	4	23	23	NUM
dpc-4248	222	5	]	]	PUNCT
dpc-4248	222	6	.	.	PUNCT
dpc-4248	223	1	otherwise	otherwise	ADV
dpc-4248	223	2	,	,	PUNCT
dpc-4248	223	3	brodalumab	brodalumab	NOUN
dpc-4248	223	4	was	be	AUX
dpc-4248	223	5	well	well	ADV
dpc-4248	223	6	tolerated	tolerate	VERB
dpc-4248	223	7	in	in	ADP
dpc-4248	223	8	our	our	PRON
dpc-4248	223	9	population	population	NOUN
dpc-4248	223	10	and	and	CCONJ
dpc-4248	223	11	only	only	ADV
dpc-4248	223	12	one	one	NUM
dpc-4248	223	13	patient	patient	NOUN
dpc-4248	223	14	(	(	PUNCT
dpc-4248	223	15	1/90	1/90	NUM
dpc-4248	223	16	)	)	PUNCT
dpc-4248	223	17	experienced	experience	VERB
dpc-4248	223	18	another	another	DET
dpc-4248	223	19	well	well	ADV
dpc-4248	223	20	-	-	PUNCT
dpc-4248	223	21	known	know	VERB
dpc-4248	223	22	il17	il17	PROPN
dpc-4248	223	23	agent	agent	NOUN
dpc-4248	223	24	side	side	NOUN
dpc-4248	223	25	effect	effect	NOUN
dpc-4248	223	26	,	,	PUNCT
dpc-4248	223	27	such	such	ADJ
dpc-4248	223	28	as	as	ADP
dpc-4248	223	29	recurrent	recurrent	ADJ
dpc-4248	223	30	candidiasis	candidiasis	NOUN
dpc-4248	223	31	.	.	PUNCT
dpc-4248	224	1	this	this	PRON
dpc-4248	224	2	is	be	AUX
dpc-4248	224	3	in	in	ADP
dpc-4248	224	4	line	line	NOUN
dpc-4248	224	5	with	with	ADP
dpc-4248	224	6	the	the	DET
dpc-4248	224	7	role	role	NOUN
dpc-4248	224	8	of	of	ADP
dpc-4248	224	9	il-17	il-17	NUM
dpc-4248	224	10	in	in	ADP
dpc-4248	224	11	host	host	NOUN
dpc-4248	224	12	defence	defence	NOUN
dpc-4248	224	13	against	against	ADP
dpc-4248	224	14	mucocutaneous	mucocutaneous	ADJ
dpc-4248	224	15	candidiasis	candidiasis	NOUN
dpc-4248	224	16	[	[	X
dpc-4248	224	17	24	24	NUM
dpc-4248	224	18	]	]	PUNCT
dpc-4248	224	19	.	.	PUNCT
dpc-4248	225	1	predictive	predictive	ADJ
dpc-4248	225	2	factors	factor	NOUN
dpc-4248	225	3	associated	associate	VERB
dpc-4248	225	4	with	with	ADP
dpc-4248	225	5	suspension	suspension	NOUN
dpc-4248	225	6	due	due	ADP
dpc-4248	225	7	to	to	ADP
dpc-4248	225	8	adverse	adverse	ADJ
dpc-4248	225	9	events	event	NOUN
dpc-4248	225	10	in	in	ADP
dpc-4248	225	11	the	the	DET
dpc-4248	225	12	univariable	univariable	ADJ
dpc-4248	225	13	logistic	logistic	ADJ
dpc-4248	225	14	regression	regression	NOUN
dpc-4248	225	15	were	be	AUX
dpc-4248	225	16	bmi	bmi	NOUN
dpc-4248	225	17	,	,	PUNCT
dpc-4248	225	18	scalp	scalp	NOUN
dpc-4248	225	19	psoriasis	psoriasis	NOUN
dpc-4248	225	20	,	,	PUNCT
dpc-4248	225	21	and	and	CCONJ
dpc-4248	225	22	genital	genital	ADJ
dpc-4248	225	23	psoriasis	psoriasis	NOUN
dpc-4248	225	24	.	.	PUNCT
dpc-4248	226	1	it	it	PRON
dpc-4248	226	2	’s	’s	AUX
dpc-4248	226	3	now	now	ADV
dpc-4248	226	4	well	well	ADV
dpc-4248	226	5	established	establish	VERB
dpc-4248	226	6	that	that	SCONJ
dpc-4248	226	7	a	a	DET
dpc-4248	226	8	higher	high	ADJ
dpc-4248	226	9	bmi	bmi	NOUN
dpc-4248	226	10	is	be	AUX
dpc-4248	226	11	associated	associate	VERB
dpc-4248	226	12	with	with	ADP
dpc-4248	226	13	increased	increase	VERB
dpc-4248	226	14	comorbidities	comorbiditie	NOUN
dpc-4248	226	15	and	and	CCONJ
dpc-4248	226	16	adverse	adverse	ADJ
dpc-4248	226	17	events	event	NOUN
dpc-4248	226	18	,	,	PUNCT
dpc-4248	226	19	even	even	ADV
dpc-4248	226	20	not	not	PART
dpc-4248	226	21	directly	directly	ADV
dpc-4248	226	22	related	relate	VERB
dpc-4248	226	23	to	to	ADP
dpc-4248	226	24	psoriatic	psoriatic	ADJ
dpc-4248	226	25	therapy	therapy	NOUN
dpc-4248	226	26	,	,	PUNCT
dpc-4248	226	27	while	while	SCONJ
dpc-4248	226	28	we	we	PRON
dpc-4248	226	29	do	do	AUX
dpc-4248	226	30	not	not	PART
dpc-4248	226	31	clinically	clinically	ADV
dpc-4248	226	32	correlate	correlate	VERB
dpc-4248	226	33	scalp	scalp	NOUN
dpc-4248	226	34	psoriasis	psoriasis	NOUN
dpc-4248	226	35	and	and	CCONJ
dpc-4248	226	36	genital	genital	ADJ
dpc-4248	226	37	psoriasis	psoriasis	NOUN
dpc-4248	226	38	with	with	ADP
dpc-4248	226	39	adverse	adverse	ADJ
dpc-4248	226	40	events	event	NOUN
dpc-4248	226	41	.	.	PUNCT
dpc-4248	227	1	these	these	DET
dpc-4248	227	2	predictive	predictive	ADJ
dpc-4248	227	3	factors	factor	NOUN
dpc-4248	227	4	were	be	AUX
dpc-4248	227	5	not	not	PART
dpc-4248	227	6	confirmed	confirm	VERB
dpc-4248	227	7	in	in	ADP
dpc-4248	227	8	the	the	DET
dpc-4248	227	9	multivariable	multivariable	ADJ
dpc-4248	227	10	analysis	analysis	NOUN
dpc-4248	227	11	.	.	PUNCT
dpc-4248	228	1	10	10	NUM
dpc-4248	228	2	original	original	ADJ
dpc-4248	228	3	article	article	NOUN
dpc-4248	228	4	|	|	ADV
dpc-4248	228	5	dermatol	dermatol	ADJ
dpc-4248	228	6	pract	pract	NOUN
dpc-4248	228	7	concept	concept	NOUN
dpc-4248	228	8	.	.	PUNCT
dpc-4248	229	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	229	2	7	7	NUM
dpc-4248	229	3	.	.	PUNCT
dpc-4248	230	1	bettencourt	bettencourt	PROPN
dpc-4248	230	2	ms	ms	PROPN
dpc-4248	230	3	.	.	PROPN
dpc-4248	230	4	real	real	ADJ
dpc-4248	230	5	-	-	PUNCT
dpc-4248	230	6	world	world	NOUN
dpc-4248	230	7	clinical	clinical	ADJ
dpc-4248	230	8	experience	experience	NOUN
dpc-4248	230	9	with	with	ADP
dpc-4248	230	10	the	the	DET
dpc-4248	230	11	il-17	il-17	NUM
dpc-4248	230	12	receptor	receptor	NOUN
dpc-4248	230	13	a	a	DET
dpc-4248	230	14	antagonist	antagonist	NOUN
dpc-4248	230	15	brodalumab	brodalumab	NOUN
dpc-4248	230	16	.	.	PUNCT
dpc-4248	231	1	j	j	PROPN
dpc-4248	231	2	drugs	drug	NOUN
dpc-4248	231	3	dermatol	dermatol	NOUN
dpc-4248	231	4	.	.	PUNCT
dpc-4248	232	1	2020	2020	NUM
dpc-4248	232	2	feb	feb	PROPN
dpc-4248	232	3	1;19(2):132–136	1;19(2):132–136	NUM
dpc-4248	232	4	.	.	PUNCT
dpc-4248	233	1	doi	doi	NOUN
dpc-4248	233	2	:	:	PUNCT
dpc-4248	233	3	10.36849	10.36849	NUM
dpc-4248	233	4	/	/	SYM
dpc-4248	233	5	jdd.2020.4774	jdd.2020.4774	NOUN
dpc-4248	233	6	.	.	PUNCT
dpc-4248	234	1	pmid	pmid	NOUN
dpc-4248	234	2	:	:	PUNCT
dpc-4248	234	3	32129956	32129956	NUM
dpc-4248	234	4	.	.	PUNCT
dpc-4248	235	1	8	8	X
dpc-4248	235	2	.	.	X
dpc-4248	235	3	fargnoli	fargnoli	PROPN
dpc-4248	235	4	mc	mc	PROPN
dpc-4248	235	5	,	,	PUNCT
dpc-4248	235	6	esposito	esposito	PROPN
dpc-4248	235	7	m	m	PROPN
dpc-4248	235	8	,	,	PUNCT
dpc-4248	235	9	dapavo	dapavo	VERB
dpc-4248	235	10	p	p	NOUN
dpc-4248	235	11	,	,	PUNCT
dpc-4248	235	12	parodi	parodi	X
dpc-4248	235	13	a	a	PRON
dpc-4248	235	14	,	,	PUNCT
dpc-4248	235	15	rossi	rossi	PROPN
dpc-4248	235	16	m	m	PROPN
dpc-4248	235	17	,	,	PUNCT
dpc-4248	235	18	tiberio	tiberio	PROPN
dpc-4248	235	19	r	r	PROPN
dpc-4248	235	20	,	,	PUNCT
dpc-4248	235	21	dastoli	dastoli	PROPN
dpc-4248	235	22	s	s	PROPN
dpc-4248	235	23	,	,	PUNCT
dpc-4248	235	24	offidani	offidani	NOUN
dpc-4248	235	25	am	be	AUX
dpc-4248	235	26	,	,	PUNCT
dpc-4248	235	27	argenziano	argenziano	ADJ
dpc-4248	235	28	g	g	NOUN
dpc-4248	235	29	,	,	PUNCT
dpc-4248	235	30	gisondi	gisondi	NOUN
dpc-4248	235	31	p	p	NOUN
dpc-4248	235	32	,	,	PUNCT
dpc-4248	235	33	lo	lo	PROPN
dpc-4248	235	34	schiavo	schiavo	PROPN
dpc-4248	235	35	a	a	PROPN
dpc-4248	235	36	,	,	PUNCT
dpc-4248	235	37	loconsole	loconsole	NOUN
dpc-4248	236	1	f	f	X
dpc-4248	236	2	,	,	PUNCT
dpc-4248	236	3	pella	pella	PROPN
dpc-4248	236	4	p	p	PROPN
dpc-4248	236	5	,	,	PUNCT
dpc-4248	236	6	bardazzi	bardazzi	NOUN
dpc-4248	236	7	f	f	PROPN
dpc-4248	236	8	,	,	PUNCT
dpc-4248	236	9	cusano	cusano	ADJ
dpc-4248	236	10	f	f	X
dpc-4248	236	11	,	,	PUNCT
dpc-4248	236	12	gattoni	gattoni	PROPN
dpc-4248	236	13	m	m	PROPN
dpc-4248	236	14	,	,	PUNCT
dpc-4248	236	15	nacca	nacca	ADJ
dpc-4248	236	16	m	m	PROPN
dpc-4248	236	17	,	,	PUNCT
dpc-4248	236	18	cannavò	cannavò	VERB
dpc-4248	236	19	sp	sp	NOUN
dpc-4248	236	20	,	,	PUNCT
dpc-4248	236	21	pellegrini	pellegrini	PROPN
dpc-4248	236	22	c	c	PROPN
dpc-4248	236	23	,	,	PUNCT
dpc-4248	236	24	costanzo	costanzo	PROPN
dpc-4248	236	25	a	a	NOUN
dpc-4248	236	26	;	;	PUNCT
dpc-4248	236	27	brilliant	brilliant	ADJ
dpc-4248	236	28	working	working	NOUN
dpc-4248	236	29	group	group	NOUN
dpc-4248	236	30	.	.	PUNCT
dpc-4248	237	1	brodalumab	brodalumab	NOUN
dpc-4248	237	2	for	for	ADP
dpc-4248	237	3	the	the	DET
dpc-4248	237	4	treatment	treatment	NOUN
dpc-4248	237	5	of	of	ADP
dpc-4248	237	6	moderate	moderate	ADJ
dpc-4248	237	7	-	-	PUNCT
dpc-4248	237	8	to	to	ADP
dpc-4248	237	9	-	-	PUNCT
dpc-4248	237	10	severe	severe	ADJ
dpc-4248	237	11	plaque	plaque	NOUN
dpc-4248	237	12	-	-	PUNCT
dpc-4248	237	13	type	type	NOUN
dpc-4248	237	14	psoriasis	psoriasis	NOUN
dpc-4248	237	15	:	:	PUNCT
dpc-4248	237	16	a	a	DET
dpc-4248	237	17	real	real	ADJ
dpc-4248	237	18	-	-	PUNCT
dpc-4248	237	19	life	life	NOUN
dpc-4248	237	20	,	,	PUNCT
dpc-4248	237	21	retrospective	retrospective	ADJ
dpc-4248	237	22	24	24	NUM
dpc-4248	237	23	-	-	PUNCT
dpc-4248	237	24	week	week	NOUN
dpc-4248	237	25	experience	experience	NOUN
dpc-4248	237	26	.	.	PUNCT
dpc-4248	238	1	j	j	PROPN
dpc-4248	238	2	eur	eur	PROPN
dpc-4248	238	3	acad	acad	PROPN
dpc-4248	238	4	dermatol	dermatol	NOUN
dpc-4248	238	5	venereol	venereol	NOUN
dpc-4248	238	6	.	.	PUNCT
dpc-4248	239	1	2021	2021	NUM
dpc-4248	239	2	mar;35(3):693–700	mar;35(3):693–700	NOUN
dpc-4248	239	3	.	.	PUNCT
dpc-4248	239	4	doi	doi	NOUN
dpc-4248	239	5	:	:	PUNCT
dpc-4248	239	6	10.1111	10.1111	NUM
dpc-4248	239	7	/	/	SYM
dpc-4248	239	8	jdv.16931	jdv.16931	ADJ
dpc-4248	239	9	.	.	PUNCT
dpc-4248	240	1	epub	epub	PROPN
dpc-4248	240	2	2020	2020	NUM
dpc-4248	240	3	oct	oct	PROPN
dpc-4248	240	4	13	13	NUM
dpc-4248	240	5	.	.	PUNCT
dpc-4248	241	1	pmid	pmid	NOUN
dpc-4248	241	2	:	:	PUNCT
dpc-4248	241	3	32916767	32916767	NUM
dpc-4248	241	4	.	.	PUNCT
dpc-4248	242	1	9	9	X
dpc-4248	242	2	.	.	X
dpc-4248	242	3	megna	megna	PROPN
dpc-4248	242	4	m	m	PROPN
dpc-4248	242	5	,	,	PUNCT
dpc-4248	242	6	potestio	potestio	VERB
dpc-4248	242	7	l	l	NOUN
dpc-4248	242	8	,	,	PUNCT
dpc-4248	242	9	camela	camela	ADP
dpc-4248	242	10	e	e	NOUN
dpc-4248	242	11	,	,	PUNCT
dpc-4248	242	12	fabbrocini	fabbrocini	NOUN
dpc-4248	242	13	g	g	NOUN
dpc-4248	242	14	,	,	PUNCT
dpc-4248	242	15	ruggiero	ruggiero	PROPN
dpc-4248	242	16	a.	a.	NOUN
dpc-4248	242	17	ixekizumab	ixekizumab	NOUN
dpc-4248	242	18	and	and	CCONJ
dpc-4248	242	19	brodalumab	brodalumab	VERB
dpc-4248	242	20	indirect	indirect	ADJ
dpc-4248	242	21	comparison	comparison	NOUN
dpc-4248	242	22	in	in	ADP
dpc-4248	242	23	the	the	DET
dpc-4248	242	24	treatment	treatment	NOUN
dpc-4248	242	25	of	of	ADP
dpc-4248	242	26	moderate	moderate	ADJ
dpc-4248	242	27	to	to	ADP
dpc-4248	242	28	severe	severe	ADJ
dpc-4248	242	29	psoriasis	psoriasis	NOUN
dpc-4248	242	30	:	:	PUNCT
dpc-4248	242	31	results	result	VERB
dpc-4248	242	32	from	from	ADP
dpc-4248	242	33	an	an	DET
dpc-4248	242	34	italian	italian	ADJ
dpc-4248	242	35	single	single	ADJ
dpc-4248	242	36	-	-	PUNCT
dpc-4248	242	37	center	center	NOUN
dpc-4248	242	38	retrospective	retrospective	ADJ
dpc-4248	242	39	study	study	NOUN
dpc-4248	242	40	in	in	ADP
dpc-4248	242	41	a	a	DET
dpc-4248	242	42	real	real	ADJ
dpc-4248	242	43	-	-	PUNCT
dpc-4248	242	44	life	life	NOUN
dpc-4248	242	45	setting	setting	NOUN
dpc-4248	242	46	.	.	PUNCT
dpc-4248	243	1	dermatol	dermatol	NOUN
dpc-4248	243	2	ther	ther	ADV
dpc-4248	243	3	.	.	PUNCT
dpc-4248	244	1	2022	2022	NUM
dpc-4248	244	2	sep;35(9):e15667	sep;35(9):e15667	NOUN
dpc-4248	244	3	.	.	PUNCT
dpc-4248	245	1	doi	doi	NOUN
dpc-4248	245	2	:	:	PUNCT
dpc-4248	245	3	10.1111	10.1111	NUM
dpc-4248	245	4	/	/	SYM
dpc-4248	245	5	dth.15667	dth.15667	NUM
dpc-4248	245	6	.	.	PUNCT
dpc-4248	246	1	epub	epub	NOUN
dpc-4248	246	2	2022	2022	NUM
dpc-4248	246	3	jul	jul	PROPN
dpc-4248	246	4	11	11	NUM
dpc-4248	246	5	.	.	PUNCT
dpc-4248	247	1	pmid	pmid	NOUN
dpc-4248	247	2	:	:	PUNCT
dpc-4248	247	3	35762107	35762107	NUM
dpc-4248	247	4	;	;	PUNCT
dpc-4248	247	5	pmcid	pmcid	NOUN
dpc-4248	247	6	:	:	PUNCT
dpc-4248	247	7	pmc9540270	pmc9540270	ADJ
dpc-4248	247	8	.	.	PUNCT
dpc-4248	248	1	10	10	NUM
dpc-4248	248	2	.	.	X
dpc-4248	249	1	gaudet	gaudet	PROPN
dpc-4248	249	2	v	v	PROPN
dpc-4248	249	3	,	,	PUNCT
dpc-4248	249	4	yap	yap	PROPN
dpc-4248	249	5	b	b	PROPN
dpc-4248	249	6	,	,	PUNCT
dpc-4248	249	7	hassan	hassan	PROPN
dpc-4248	249	8	s	s	PROPN
dpc-4248	249	9	,	,	PUNCT
dpc-4248	249	10	barbeau	barbeau	PROPN
dpc-4248	249	11	m.	m.	PROPN
dpc-4248	249	12	brodalumab	brodalumab	PROPN
dpc-4248	249	13	for	for	ADP
dpc-4248	249	14	plaque	plaque	NOUN
dpc-4248	249	15	psoriasis	psoriasis	NOUN
dpc-4248	249	16	:	:	PUNCT
dpc-4248	249	17	a	a	DET
dpc-4248	249	18	canadian	canadian	ADJ
dpc-4248	249	19	real	real	ADJ
dpc-4248	249	20	-	-	PUNCT
dpc-4248	249	21	world	world	NOUN
dpc-4248	249	22	experience	experience	NOUN
dpc-4248	249	23	at	at	ADP
dpc-4248	249	24	2	2	NUM
dpc-4248	249	25	-	-	PUNCT
dpc-4248	249	26	years	year	NOUN
dpc-4248	249	27	postlaunch	postlaunch	NOUN
dpc-4248	249	28	.	.	PUNCT
dpc-4248	250	1	j	j	PROPN
dpc-4248	250	2	cutan	cutan	PROPN
dpc-4248	250	3	med	med	ADJ
dpc-4248	250	4	surg	surg	NOUN
dpc-4248	250	5	.	.	PUNCT
dpc-4248	251	1	2023	2023	NUM
dpc-4248	251	2	may	may	AUX
dpc-4248	251	3	-	-	PUNCT
dpc-4248	251	4	jun;27(3):226–235	jun;27(3):226–235	PROPN
dpc-4248	251	5	.	.	PUNCT
dpc-4248	252	1	doi	doi	NOUN
dpc-4248	252	2	:	:	PUNCT
dpc-4248	252	3	10.1177/12034754231168851	10.1177/12034754231168851	NUM
dpc-4248	252	4	.	.	PUNCT
dpc-4248	253	1	epub	epub	NOUN
dpc-4248	253	2	2023	2023	NUM
dpc-4248	253	3	apr	apr	NOUN
dpc-4248	253	4	21	21	NUM
dpc-4248	253	5	.	.	PUNCT
dpc-4248	254	1	pmid	pmid	NOUN
dpc-4248	254	2	:	:	PUNCT
dpc-4248	254	3	37083148	37083148	NUM
dpc-4248	254	4	.	.	PUNCT
dpc-4248	255	1	11	11	NUM
dpc-4248	255	2	.	.	PUNCT
dpc-4248	256	1	galluzzo	galluzzo	NOUN
dpc-4248	256	2	m	m	PROPN
dpc-4248	256	3	,	,	PUNCT
dpc-4248	256	4	caldarola	caldarola	PROPN
dpc-4248	256	5	g	g	PROPN
dpc-4248	256	6	,	,	PUNCT
dpc-4248	256	7	de	de	PROPN
dpc-4248	256	8	simone	simone	PROPN
dpc-4248	256	9	c	c	NOUN
dpc-4248	256	10	,	,	PUNCT
dpc-4248	256	11	bernardini	bernardini	X
dpc-4248	256	12	n	n	CCONJ
dpc-4248	256	13	,	,	PUNCT
dpc-4248	256	14	moretta	moretta	VERB
dpc-4248	256	15	g	g	PROPN
dpc-4248	256	16	,	,	PUNCT
dpc-4248	256	17	pallotta	pallotta	NOUN
dpc-4248	256	18	s	s	PART
dpc-4248	256	19	,	,	PUNCT
dpc-4248	256	20	botti	botti	PROPN
dpc-4248	256	21	e	e	NOUN
dpc-4248	256	22	,	,	PUNCT
dpc-4248	256	23	campione	campione	PROPN
dpc-4248	256	24	e	e	NOUN
dpc-4248	256	25	,	,	PUNCT
dpc-4248	256	26	pirro	pirro	PROPN
dpc-4248	256	27	f	f	PROPN
dpc-4248	256	28	,	,	PUNCT
dpc-4248	256	29	potenza	potenza	PROPN
dpc-4248	256	30	c	c	PROPN
dpc-4248	256	31	,	,	PUNCT
dpc-4248	256	32	bianchi	bianchi	PROPN
dpc-4248	256	33	l	l	PROPN
dpc-4248	256	34	,	,	PUNCT
dpc-4248	256	35	peris	peris	PROPN
dpc-4248	256	36	k.	k.	PROPN
dpc-4248	256	37	use	use	NOUN
dpc-4248	256	38	of	of	ADP
dpc-4248	256	39	brodalumab	brodalumab	NOUN
dpc-4248	256	40	for	for	ADP
dpc-4248	256	41	the	the	DET
dpc-4248	256	42	treatment	treatment	NOUN
dpc-4248	256	43	of	of	ADP
dpc-4248	256	44	chronic	chronic	ADJ
dpc-4248	256	45	plaque	plaque	NOUN
dpc-4248	256	46	psoriasis	psoriasis	NOUN
dpc-4248	256	47	:	:	PUNCT
dpc-4248	256	48	a	a	DET
dpc-4248	256	49	one	one	NUM
dpc-4248	256	50	-	-	PUNCT
dpc-4248	256	51	year	year	NOUN
dpc-4248	256	52	real	real	ADJ
dpc-4248	256	53	-	-	PUNCT
dpc-4248	256	54	life	life	NOUN
dpc-4248	256	55	study	study	NOUN
dpc-4248	256	56	in	in	ADP
dpc-4248	256	57	the	the	DET
dpc-4248	256	58	lazio	lazio	PROPN
dpc-4248	256	59	region	region	PROPN
dpc-4248	256	60	,	,	PUNCT
dpc-4248	256	61	italy	italy	PROPN
dpc-4248	256	62	.	.	PUNCT
dpc-4248	257	1	expert	expert	PROPN
dpc-4248	257	2	opin	opin	NOUN
dpc-4248	257	3	biol	biol	NOUN
dpc-4248	257	4	ther	ther	ADV
dpc-4248	257	5	.	.	PUNCT
dpc-4248	258	1	2021	2021	NUM
dpc-4248	258	2	sep;21(9):1299–1310	sep;21(9):1299–1310	NOUN
dpc-4248	258	3	.	.	PUNCT
dpc-4248	259	1	doi	doi	NOUN
dpc-4248	259	2	:	:	PUNCT
dpc-4248	259	3	10.1080/14712598.2021.1941862	10.1080/14712598.2021.1941862	NUM
dpc-4248	259	4	.	.	PUNCT
dpc-4248	260	1	epub	epub	NOUN
dpc-4248	260	2	2021	2021	NUM
dpc-4248	260	3	jun	jun	PROPN
dpc-4248	260	4	28	28	NUM
dpc-4248	260	5	.	.	PUNCT
dpc-4248	261	1	pmid	pmid	NOUN
dpc-4248	261	2	:	:	PUNCT
dpc-4248	261	3	34114515	34114515	NUM
dpc-4248	261	4	.	.	PUNCT
dpc-4248	262	1	12	12	NUM
dpc-4248	262	2	.	.	PUNCT
dpc-4248	263	1	no	no	DET
dpc-4248	263	2	dj	dj	NOUN
dpc-4248	263	3	,	,	PUNCT
dpc-4248	263	4	inkeles	inkele	NOUN
dpc-4248	263	5	ms	ms	PROPN
dpc-4248	263	6	,	,	PUNCT
dpc-4248	263	7	amin	amin	PROPN
dpc-4248	263	8	m	m	PROPN
dpc-4248	263	9	,	,	PUNCT
dpc-4248	263	10	wu	wu	PROPN
dpc-4248	263	11	jj	jj	PROPN
dpc-4248	263	12	.	.	PROPN
dpc-4248	263	13	drug	drug	PROPN
dpc-4248	263	14	survival	survival	NOUN
dpc-4248	263	15	of	of	ADP
dpc-4248	263	16	biologic	biologic	NOUN
dpc-4248	263	17	treatments	treatment	NOUN
dpc-4248	263	18	in	in	ADP
dpc-4248	263	19	psoriasis	psoriasis	NOUN
dpc-4248	263	20	:	:	PUNCT
dpc-4248	263	21	a	a	DET
dpc-4248	263	22	systematic	systematic	ADJ
dpc-4248	263	23	review	review	NOUN
dpc-4248	263	24	.	.	PUNCT
dpc-4248	264	1	j	j	PROPN
dpc-4248	264	2	dermatolog	dermatolog	PROPN
dpc-4248	264	3	treat	treat	NOUN
dpc-4248	264	4	.	.	PUNCT
dpc-4248	265	1	2018	2018	NUM
dpc-4248	265	2	aug;29(5):460–466	aug;29(5):460–466	NOUN
dpc-4248	265	3	.	.	PUNCT
dpc-4248	266	1	doi	doi	NOUN
dpc-4248	266	2	:	:	PUNCT
dpc-4248	266	3	10.1080/09546634.2017.1398393	10.1080/09546634.2017.1398393	NUM
dpc-4248	266	4	.	.	PUNCT
dpc-4248	267	1	epub	epub	PROPN
dpc-4248	267	2	2017	2017	NUM
dpc-4248	267	3	nov	nov	PROPN
dpc-4248	267	4	10	10	NUM
dpc-4248	267	5	.	.	PUNCT
dpc-4248	268	1	pmid	pmid	NOUN
dpc-4248	268	2	:	:	PUNCT
dpc-4248	268	3	29076754	29076754	NUM
dpc-4248	268	4	.	.	PUNCT
dpc-4248	269	1	13	13	NUM
dpc-4248	269	2	.	.	X
dpc-4248	269	3	rompoti	rompoti	PROPN
dpc-4248	269	4	n	n	CCONJ
dpc-4248	269	5	,	,	PUNCT
dpc-4248	269	6	politou	politou	PROPN
dpc-4248	269	7	m	m	PROPN
dpc-4248	269	8	,	,	PUNCT
dpc-4248	269	9	stefanaki	stefanaki	PROPN
dpc-4248	269	10	i	i	PRON
dpc-4248	269	11	,	,	PUNCT
dpc-4248	269	12	vavouli	vavouli	PROPN
dpc-4248	269	13	c	c	PROPN
dpc-4248	269	14	,	,	PUNCT
dpc-4248	269	15	papoutsaki	papoutsaki	PROPN
dpc-4248	269	16	m	m	PROPN
dpc-4248	269	17	,	,	PUNCT
dpc-4248	269	18	neofotistou	neofotistou	VERB
dpc-4248	269	19	a	a	PRON
dpc-4248	269	20	,	,	PUNCT
dpc-4248	269	21	rigopoulos	rigopoulos	PROPN
dpc-4248	269	22	d	d	PROPN
dpc-4248	269	23	,	,	PUNCT
dpc-4248	269	24	stratigos	stratigos	PROPN
dpc-4248	269	25	a	a	PRON
dpc-4248	269	26	,	,	PUNCT
dpc-4248	269	27	nicolaidou	nicolaidou	PROPN
dpc-4248	269	28	e.	e.	PROPN
dpc-4248	269	29	brodalumab	brodalumab	PROPN
dpc-4248	269	30	in	in	ADP
dpc-4248	269	31	plaque	plaque	NOUN
dpc-4248	269	32	psoriasis	psoriasis	NOUN
dpc-4248	269	33	:	:	PUNCT
dpc-4248	269	34	real	real	ADJ
dpc-4248	269	35	-	-	PUNCT
dpc-4248	269	36	world	world	NOUN
dpc-4248	269	37	data	datum	NOUN
dpc-4248	269	38	on	on	ADP
dpc-4248	269	39	effectiveness	effectiveness	NOUN
dpc-4248	269	40	,	,	PUNCT
dpc-4248	269	41	safety	safety	NOUN
dpc-4248	269	42	and	and	CCONJ
dpc-4248	269	43	clinical	clinical	ADJ
dpc-4248	269	44	predictive	predictive	ADJ
dpc-4248	269	45	factors	factor	NOUN
dpc-4248	269	46	of	of	ADP
dpc-4248	269	47	initial	initial	ADJ
dpc-4248	269	48	response	response	NOUN
dpc-4248	269	49	and	and	CCONJ
dpc-4248	269	50	drug	drug	NOUN
dpc-4248	269	51	survival	survival	NOUN
dpc-4248	269	52	over	over	ADP
dpc-4248	269	53	a	a	DET
dpc-4248	269	54	period	period	NOUN
dpc-4248	269	55	of	of	ADP
dpc-4248	269	56	104	104	NUM
dpc-4248	269	57	weeks	week	NOUN
dpc-4248	269	58	.	.	PUNCT
dpc-4248	270	1	j	j	PROPN
dpc-4248	270	2	eur	eur	PROPN
dpc-4248	270	3	acad	acad	PROPN
dpc-4248	270	4	dermatol	dermatol	NOUN
dpc-4248	270	5	venereol	venereol	NOUN
dpc-4248	270	6	.	.	PUNCT
dpc-4248	271	1	2023	2023	NUM
dpc-4248	271	2	apr;37(4):689–697	apr;37(4):689–697	PROPN
dpc-4248	271	3	.	.	PUNCT
dpc-4248	272	1	doi	doi	NOUN
dpc-4248	272	2	:	:	PUNCT
dpc-4248	272	3	10.1111	10.1111	NUM
dpc-4248	272	4	/	/	SYM
dpc-4248	272	5	jdv.18825	jdv.18825	PROPN
dpc-4248	272	6	.	.	PUNCT
dpc-4248	273	1	epub	epub	PROPN
dpc-4248	273	2	2023	2023	NUM
dpc-4248	273	3	jan	jan	PROPN
dpc-4248	273	4	4	4	NUM
dpc-4248	273	5	.	.	PUNCT
dpc-4248	273	6	pmid	pmid	NOUN
dpc-4248	273	7	:	:	PUNCT
dpc-4248	273	8	36562663	36562663	NUM
dpc-4248	273	9	.	.	PUNCT
dpc-4248	274	1	14	14	NUM
dpc-4248	274	2	.	.	X
dpc-4248	274	3	dapavo	dapavo	VERB
dpc-4248	274	4	p	p	NOUN
dpc-4248	274	5	,	,	PUNCT
dpc-4248	274	6	siliquini	siliquini	PROPN
dpc-4248	274	7	n	n	CCONJ
dpc-4248	274	8	,	,	PUNCT
dpc-4248	274	9	mastorino	mastorino	ADJ
dpc-4248	274	10	l	l	NOUN
dpc-4248	274	11	,	,	PUNCT
dpc-4248	274	12	avallone	avallone	NOUN
dpc-4248	274	13	g	g	PROPN
dpc-4248	274	14	,	,	PUNCT
dpc-4248	274	15	merli	merli	PROPN
dpc-4248	274	16	m	m	PROPN
dpc-4248	274	17	,	,	PUNCT
dpc-4248	274	18	agostini	agostini	PROPN
dpc-4248	274	19	a	a	PROPN
dpc-4248	274	20	,	,	PUNCT
dpc-4248	274	21	cariti	cariti	PROPN
dpc-4248	274	22	c	c	NOUN
dpc-4248	274	23	,	,	PUNCT
dpc-4248	274	24	viola	viola	PROPN
dpc-4248	274	25	r	r	PROPN
dpc-4248	274	26	,	,	PUNCT
dpc-4248	274	27	stroppiana	stroppiana	PROPN
dpc-4248	274	28	e	e	PROPN
dpc-4248	274	29	,	,	PUNCT
dpc-4248	274	30	verrone	verrone	NOUN
dpc-4248	274	31	a	a	X
dpc-4248	274	32	,	,	PUNCT
dpc-4248	274	33	ortoncelli	ortoncelli	PROPN
dpc-4248	274	34	m	m	PROPN
dpc-4248	274	35	,	,	PUNCT
dpc-4248	274	36	quaglino	quaglino	VERB
dpc-4248	274	37	p	p	X
dpc-4248	274	38	,	,	PUNCT
dpc-4248	275	1	ribero	ribero	PROPN
dpc-4248	275	2	s.	s.	PROPN
dpc-4248	275	3	efficacy	efficacy	PROPN
dpc-4248	275	4	,	,	PUNCT
dpc-4248	275	5	safety	safety	NOUN
dpc-4248	275	6	,	,	PUNCT
dpc-4248	275	7	and	and	CCONJ
dpc-4248	275	8	drug	drug	NOUN
dpc-4248	275	9	survival	survival	NOUN
dpc-4248	275	10	of	of	ADP
dpc-4248	275	11	il-23	il-23	NOUN
dpc-4248	275	12	,	,	PUNCT
dpc-4248	275	13	il-17	il-17	X
dpc-4248	275	14	,	,	PUNCT
dpc-4248	275	15	and	and	CCONJ
dpc-4248	275	16	tnf	tnf	PROPN
dpc-4248	275	17	-	-	PUNCT
dpc-4248	275	18	alpha	alpha	NOUN
dpc-4248	275	19	inhibitors	inhibitor	NOUN
dpc-4248	275	20	for	for	ADP
dpc-4248	275	21	psoriasis	psoriasis	NOUN
dpc-4248	275	22	treatment	treatment	NOUN
dpc-4248	275	23	:	:	PUNCT
dpc-4248	275	24	a	a	DET
dpc-4248	275	25	retrospective	retrospective	ADJ
dpc-4248	275	26	study	study	NOUN
dpc-4248	275	27	.	.	PUNCT
dpc-4248	276	1	j	j	PROPN
dpc-4248	276	2	dermatolog	dermatolog	PROPN
dpc-4248	276	3	treat	treat	NOUN
dpc-4248	276	4	.	.	PUNCT
dpc-4248	277	1	2022	2022	NUM
dpc-4248	277	2	jun;33(4):2352–2357	jun;33(4):2352–2357	NOUN
dpc-4248	277	3	.	.	PUNCT
dpc-4248	278	1	doi	doi	NOUN
dpc-4248	278	2	:	:	PUNCT
dpc-4248	278	3	10.1080/09546634.2021.1961998	10.1080/09546634.2021.1961998	NUM
dpc-4248	278	4	.	.	PUNCT
dpc-4248	279	1	epub	epub	NOUN
dpc-4248	279	2	2021	2021	NUM
dpc-4248	279	3	aug	aug	PROPN
dpc-4248	279	4	13	13	NUM
dpc-4248	279	5	.	.	PUNCT
dpc-4248	280	1	pmid	pmid	NOUN
dpc-4248	280	2	:	:	PUNCT
dpc-4248	280	3	34315331	34315331	NUM
dpc-4248	280	4	.	.	PUNCT
dpc-4248	281	1	15	15	NUM
dpc-4248	281	2	.	.	X
dpc-4248	281	3	galan	galan	PROPN
dpc-4248	281	4	-	-	PUNCT
dpc-4248	281	5	gutierrez	gutierrez	PROPN
dpc-4248	281	6	m	m	NOUN
dpc-4248	281	7	,	,	PUNCT
dpc-4248	281	8	font	font	NOUN
dpc-4248	281	9	-	-	PUNCT
dpc-4248	281	10	ugalde	ugalde	VERB
dpc-4248	281	11	p	p	NOUN
dpc-4248	281	12	,	,	PUNCT
dpc-4248	281	13	padilla	padilla	PROPN
dpc-4248	281	14	l	l	PROPN
dpc-4248	281	15	,	,	PUNCT
dpc-4248	281	16	hernandez	hernandez	PROPN
dpc-4248	281	17	-	-	PUNCT
dpc-4248	281	18	montoya	montoya	PROPN
dpc-4248	281	19	c	c	PROPN
dpc-4248	281	20	,	,	PUNCT
dpc-4248	281	21	godoy	godoy	PROPN
dpc-4248	281	22	d	d	PROPN
dpc-4248	281	23	,	,	PUNCT
dpc-4248	281	24	armario	armario	PROPN
dpc-4248	281	25	-	-	PUNCT
dpc-4248	281	26	hita	hita	PROPN
dpc-4248	281	27	jc	jc	PROPN
dpc-4248	281	28	,	,	PUNCT
dpc-4248	281	29	ruiz	ruiz	NOUN
dpc-4248	281	30	-	-	PUNCT
dpc-4248	281	31	villaverde	villaverde	NOUN
dpc-4248	281	32	r.	r.	PROPN
dpc-4248	281	33	brodalumab	brodalumab	PROPN
dpc-4248	281	34	:	:	PUNCT
dpc-4248	281	35	efficacy	efficacy	NOUN
dpc-4248	281	36	,	,	PUNCT
dpc-4248	281	37	safety	safety	NOUN
dpc-4248	281	38	,	,	PUNCT
dpc-4248	281	39	and	and	CCONJ
dpc-4248	281	40	survival	survival	NOUN
dpc-4248	281	41	in	in	ADP
dpc-4248	281	42	mid	mid	ADJ
dpc-4248	281	43	-	-	NOUN
dpc-4248	281	44	term	term	NOUN
dpc-4248	281	45	(	(	PUNCT
dpc-4248	281	46	52	52	NUM
dpc-4248	281	47	weeks	week	NOUN
dpc-4248	281	48	)	)	PUNCT
dpc-4248	281	49	on	on	ADP
dpc-4248	281	50	real	real	ADJ
dpc-4248	281	51	clinical	clinical	ADJ
dpc-4248	281	52	practice	practice	NOUN
dpc-4248	281	53	in	in	ADP
dpc-4248	281	54	andalucia	andalucia	PROPN
dpc-4248	281	55	,	,	PUNCT
dpc-4248	281	56	spain	spain	PROPN
dpc-4248	281	57	.	.	PUNCT
dpc-4248	282	1	int	int	PROPN
dpc-4248	282	2	j	j	PROPN
dpc-4248	282	3	dermatol	dermatol	NOUN
dpc-4248	282	4	.	.	PUNCT
dpc-4248	283	1	2023	2023	NUM
dpc-4248	283	2	may;62(5):700–706	may;62(5):700–706	PROPN
dpc-4248	283	3	.	.	PUNCT
dpc-4248	283	4	doi	doi	PROPN
dpc-4248	283	5	:	:	PUNCT
dpc-4248	283	6	10.1111	10.1111	NUM
dpc-4248	283	7	/	/	SYM
dpc-4248	283	8	ijd.16527	ijd.16527	NOUN
dpc-4248	283	9	.	.	PUNCT
dpc-4248	284	1	epub	epub	NOUN
dpc-4248	284	2	2022	2022	NUM
dpc-4248	284	3	dec	dec	PROPN
dpc-4248	284	4	10	10	NUM
dpc-4248	284	5	.	.	PUNCT
dpc-4248	285	1	pmid	pmid	NOUN
dpc-4248	285	2	:	:	PUNCT
dpc-4248	285	3	36495585	36495585	NUM
dpc-4248	285	4	.	.	PUNCT
dpc-4248	286	1	16	16	NUM
dpc-4248	286	2	.	.	PUNCT
dpc-4248	287	1	caldarola	caldarola	PROPN
dpc-4248	287	2	g	g	PROPN
dpc-4248	287	3	,	,	PUNCT
dpc-4248	287	4	mariani	mariani	PROPN
dpc-4248	287	5	m	m	PROPN
dpc-4248	287	6	,	,	PUNCT
dpc-4248	287	7	pirro	pirro	PROPN
dpc-4248	287	8	f	f	PROPN
dpc-4248	287	9	,	,	PUNCT
dpc-4248	287	10	nicolotti	nicolotti	VERB
dpc-4248	287	11	n	n	CCONJ
dpc-4248	287	12	,	,	PUNCT
dpc-4248	287	13	burlando	burlando	PROPN
dpc-4248	287	14	m	m	PROPN
dpc-4248	287	15	,	,	PUNCT
dpc-4248	287	16	calabrese	calabrese	ADJ
dpc-4248	287	17	l	l	NOUN
dpc-4248	287	18	,	,	PUNCT
dpc-4248	287	19	parodi	parodi	PROPN
dpc-4248	287	20	a	a	X
dpc-4248	287	21	,	,	PUNCT
dpc-4248	287	22	peris	peris	PROPN
dpc-4248	287	23	k	k	PROPN
dpc-4248	287	24	,	,	PUNCT
dpc-4248	287	25	de	de	PROPN
dpc-4248	287	26	simone	simone	PROPN
dpc-4248	287	27	c.	c.	PROPN
dpc-4248	287	28	comparison	comparison	NOUN
dpc-4248	287	29	of	of	ADP
dpc-4248	287	30	shortand	shortand	NOUN
dpc-4248	287	31	long	long	ADJ
dpc-4248	287	32	-	-	PUNCT
dpc-4248	287	33	term	term	NOUN
dpc-4248	287	34	effectiveness	effectiveness	NOUN
dpc-4248	287	35	of	of	ADP
dpc-4248	287	36	ixekizumab	ixekizumab	NOUN
dpc-4248	287	37	and	and	CCONJ
dpc-4248	287	38	secukinumab	secukinumab	NOUN
dpc-4248	287	39	in	in	ADP
dpc-4248	287	40	real	real	ADJ
dpc-4248	287	41	-	-	PUNCT
dpc-4248	287	42	world	world	NOUN
dpc-4248	287	43	practice	practice	NOUN
dpc-4248	287	44	.	.	PUNCT
dpc-4248	288	1	expert	expert	NOUN
dpc-4248	288	2	opin	opin	NOUN
dpc-4248	288	3	biol	biol	NOUN
dpc-4248	288	4	ther	ther	ADV
dpc-4248	288	5	.	.	PUNCT
dpc-4248	289	1	2021	2021	NUM
dpc-4248	289	2	feb;21(2):279–286	feb;21(2):279–286	NOUN
dpc-4248	289	3	.	.	PUNCT
dpc-4248	289	4	doi	doi	NOUN
dpc-4248	289	5	:	:	PUNCT
dpc-4248	289	6	10.1080/14712598.2021.1849133	10.1080/14712598.2021.1849133	NUM
dpc-4248	289	7	.	.	PUNCT
dpc-4248	290	1	epub	epub	NOUN
dpc-4248	290	2	2021	2021	NUM
dpc-4248	290	3	jan	jan	PROPN
dpc-4248	290	4	20	20	NUM
dpc-4248	290	5	.	.	PUNCT
dpc-4248	291	1	pmid	pmid	NOUN
dpc-4248	291	2	:	:	PUNCT
dpc-4248	291	3	33170052	33170052	NUM
dpc-4248	291	4	.	.	PUNCT
dpc-4248	292	1	limitations	limitation	VERB
dpc-4248	292	2	the	the	DET
dpc-4248	292	3	limitations	limitation	NOUN
dpc-4248	292	4	of	of	ADP
dpc-4248	292	5	our	our	PRON
dpc-4248	292	6	study	study	NOUN
dpc-4248	292	7	are	be	AUX
dpc-4248	292	8	the	the	DET
dpc-4248	292	9	retrospective	retrospective	ADJ
dpc-4248	292	10	study	study	NOUN
dpc-4248	292	11	design	design	NOUN
dpc-4248	292	12	and	and	CCONJ
dpc-4248	292	13	the	the	DET
dpc-4248	292	14	size	size	NOUN
dpc-4248	292	15	of	of	ADP
dpc-4248	292	16	the	the	DET
dpc-4248	292	17	study	study	NOUN
dpc-4248	292	18	population	population	NOUN
dpc-4248	292	19	.	.	PUNCT
dpc-4248	293	1	however	however	ADV
dpc-4248	293	2	,	,	PUNCT
dpc-4248	293	3	the	the	DET
dpc-4248	293	4	long	long	ADJ
dpc-4248	293	5	observation	observation	NOUN
dpc-4248	293	6	period	period	NOUN
dpc-4248	293	7	provide	provide	VERB
dpc-4248	293	8	important	important	ADJ
dpc-4248	293	9	evidence	evidence	NOUN
dpc-4248	293	10	in	in	ADP
dpc-4248	293	11	a	a	DET
dpc-4248	293	12	real	real	ADJ
dpc-4248	293	13	-	-	PUNCT
dpc-4248	293	14	world	world	NOUN
dpc-4248	293	15	setting	setting	NOUN
dpc-4248	293	16	.	.	PUNCT
dpc-4248	294	1	conclusions	conclusion	NOUN
dpc-4248	294	2	brodalumab	brodalumab	NOUN
dpc-4248	294	3	has	have	AUX
dpc-4248	294	4	shown	show	VERB
dpc-4248	294	5	promising	promising	ADJ
dpc-4248	294	6	long	long	ADJ
dpc-4248	294	7	-	-	PUNCT
dpc-4248	294	8	term	term	NOUN
dpc-4248	294	9	efficacy	efficacy	NOUN
dpc-4248	294	10	in	in	ADP
dpc-4248	294	11	the	the	DET
dpc-4248	294	12	management	management	NOUN
dpc-4248	294	13	of	of	ADP
dpc-4248	294	14	moderate	moderate	ADJ
dpc-4248	294	15	to	to	ADP
dpc-4248	294	16	severe	severe	ADJ
dpc-4248	294	17	plaque	plaque	NOUN
dpc-4248	294	18	psoriasis	psoriasis	NOUN
dpc-4248	294	19	,	,	PUNCT
dpc-4248	294	20	in	in	ADP
dpc-4248	294	21	a	a	DET
dpc-4248	294	22	period	period	NOUN
dpc-4248	294	23	up	up	ADP
dpc-4248	294	24	to	to	PART
dpc-4248	294	25	3	3	NUM
dpc-4248	294	26	years	year	NOUN
dpc-4248	294	27	.	.	PUNCT
dpc-4248	295	1	the	the	DET
dpc-4248	295	2	data	datum	NOUN
dpc-4248	295	3	presented	present	VERB
dpc-4248	295	4	in	in	ADP
dpc-4248	295	5	our	our	PRON
dpc-4248	295	6	study	study	NOUN
dpc-4248	295	7	contribute	contribute	VERB
dpc-4248	295	8	to	to	ADP
dpc-4248	295	9	the	the	DET
dpc-4248	295	10	better	well	ADJ
dpc-4248	295	11	understanding	understanding	NOUN
dpc-4248	295	12	of	of	ADP
dpc-4248	295	13	brodalumab	brodalumab	NOUN
dpc-4248	295	14	’s	’s	PART
dpc-4248	295	15	success	success	NOUN
dpc-4248	295	16	in	in	ADP
dpc-4248	295	17	real	real	ADJ
dpc-4248	295	18	world	world	NOUN
dpc-4248	295	19	.	.	PUNCT
dpc-4248	296	1	consideration	consideration	NOUN
dpc-4248	296	2	of	of	ADP
dpc-4248	296	3	baseline	baseline	ADJ
dpc-4248	296	4	disease	disease	NOUN
dpc-4248	296	5	severity	severity	NOUN
dpc-4248	296	6	,	,	PUNCT
dpc-4248	296	7	comorbidities	comorbiditie	NOUN
dpc-4248	296	8	,	,	PUNCT
dpc-4248	296	9	and	and	CCONJ
dpc-4248	296	10	bmi	bmi	NOUN
dpc-4248	296	11	can	can	AUX
dpc-4248	296	12	help	help	VERB
dpc-4248	296	13	in	in	ADP
dpc-4248	296	14	predicting	predict	VERB
dpc-4248	296	15	patient	patient	ADJ
dpc-4248	296	16	adherence	adherence	NOUN
dpc-4248	296	17	and	and	CCONJ
dpc-4248	296	18	optimizing	optimize	VERB
dpc-4248	296	19	the	the	DET
dpc-4248	296	20	long	long	ADJ
dpc-4248	296	21	-	-	PUNCT
dpc-4248	296	22	term	term	NOUN
dpc-4248	296	23	management	management	NOUN
dpc-4248	296	24	of	of	ADP
dpc-4248	296	25	moderate	moderate	ADJ
dpc-4248	296	26	to	to	ADP
dpc-4248	296	27	severe	severe	ADJ
dpc-4248	296	28	plaque	plaque	NOUN
dpc-4248	296	29	psoriasis	psoriasis	NOUN
dpc-4248	296	30	with	with	ADP
dpc-4248	296	31	brodalumab	brodalumab	NOUN
dpc-4248	296	32	.	.	PUNCT
dpc-4248	297	1	references	reference	NOUN
dpc-4248	297	2	1	1	NUM
dpc-4248	297	3	.	.	PUNCT
dpc-4248	297	4	blair	blair	PROPN
dpc-4248	297	5	ha	ha	PROPN
dpc-4248	297	6	.	.	PROPN
dpc-4248	297	7	brodalumab	brodalumab	PROPN
dpc-4248	297	8	:	:	PUNCT
dpc-4248	297	9	a	a	DET
dpc-4248	297	10	review	review	NOUN
dpc-4248	297	11	in	in	ADP
dpc-4248	297	12	moderate	moderate	ADJ
dpc-4248	297	13	to	to	ADP
dpc-4248	297	14	severe	severe	ADJ
dpc-4248	297	15	plaque	plaque	NOUN
dpc-4248	297	16	psoriasis	psoriasis	NOUN
dpc-4248	297	17	.	.	PUNCT
dpc-4248	298	1	drugs	drug	NOUN
dpc-4248	298	2	.	.	PUNCT
dpc-4248	299	1	2018;78(4):495–504	2018;78(4):495–504	NUM
dpc-4248	299	2	.	.	NOUN
dpc-4248	299	3	2	2	NUM
dpc-4248	299	4	.	.	PUNCT
dpc-4248	299	5	russell	russell	PROPN
dpc-4248	299	6	cb	cb	PROPN
dpc-4248	299	7	,	,	PUNCT
dpc-4248	299	8	rand	rand	PROPN
dpc-4248	299	9	h.	h.	PROPN
dpc-4248	299	10	gene	gene	NOUN
dpc-4248	299	11	expression	expression	NOUN
dpc-4248	299	12	profiles	profile	NOUN
dpc-4248	299	13	normalized	normalize	VERB
dpc-4248	299	14	in	in	ADP
dpc-4248	299	15	psoriatic	psoriatic	ADJ
dpc-4248	299	16	skin	skin	NOUN
dpc-4248	299	17	by	by	ADP
dpc-4248	299	18	treatment	treatment	NOUN
dpc-4248	299	19	with	with	ADP
dpc-4248	299	20	brodalumab	brodalumab	NOUN
dpc-4248	299	21	,	,	PUNCT
dpc-4248	299	22	a	a	DET
dpc-4248	299	23	human	human	ADJ
dpc-4248	299	24	anti	anti	ADJ
dpc-4248	299	25	-	-	ADJ
dpc-4248	299	26	il-17	il-17	ADV
dpc-4248	299	27	receptor	receptor	NOUN
dpc-4248	299	28	monoclonal	monoclonal	NOUN
dpc-4248	299	29	antibody	antibody	NOUN
dpc-4248	299	30	.	.	PUNCT
dpc-4248	300	1	j	j	PROPN
dpc-4248	300	2	immunol	immunol	NOUN
dpc-4248	300	3	.	.	PUNCT
dpc-4248	301	1	2014;192(8):3828–3836	2014;192(8):3828–3836	NUM
dpc-4248	301	2	.	.	NOUN
dpc-4248	301	3	3	3	X
dpc-4248	301	4	.	.	X
dpc-4248	301	5	papp	papp	PROPN
dpc-4248	301	6	ka	ka	PROPN
dpc-4248	301	7	,	,	PUNCT
dpc-4248	301	8	reich	reich	PROPN
dpc-4248	301	9	k	k	PROPN
dpc-4248	301	10	,	,	PUNCT
dpc-4248	301	11	paul	paul	PROPN
dpc-4248	301	12	c	c	PROPN
dpc-4248	301	13	,	,	PUNCT
dpc-4248	301	14	blauvelt	blauvelt	VERB
dpc-4248	301	15	a	a	PRON
dpc-4248	301	16	,	,	PUNCT
dpc-4248	301	17	baran	baran	NOUN
dpc-4248	301	18	w	w	PROPN
dpc-4248	301	19	,	,	PUNCT
dpc-4248	301	20	bolduc	bolduc	PROPN
dpc-4248	301	21	c	c	AUX
dpc-4248	301	22	,	,	PUNCT
dpc-4248	301	23	toth	toth	PROPN
dpc-4248	301	24	d	d	PROPN
dpc-4248	301	25	,	,	PUNCT
dpc-4248	301	26	langley	langley	PROPN
dpc-4248	301	27	rg	rg	PROPN
dpc-4248	301	28	,	,	PUNCT
dpc-4248	301	29	cather	cather	PROPN
dpc-4248	301	30	j	j	PROPN
dpc-4248	301	31	,	,	PUNCT
dpc-4248	301	32	gottlieb	gottlieb	PROPN
dpc-4248	301	33	ab	ab	PROPN
dpc-4248	301	34	,	,	PUNCT
dpc-4248	301	35	thaçi	thaçi	PROPN
dpc-4248	301	36	d	d	PROPN
dpc-4248	301	37	,	,	PUNCT
dpc-4248	301	38	krueger	krueger	PROPN
dpc-4248	301	39	jg	jg	PROPN
dpc-4248	301	40	,	,	PUNCT
dpc-4248	301	41	russell	russell	PROPN
dpc-4248	301	42	cb	cb	PROPN
dpc-4248	301	43	,	,	PUNCT
dpc-4248	301	44	milmont	milmont	PROPN
dpc-4248	301	45	ce	ce	PROPN
dpc-4248	301	46	,	,	PUNCT
dpc-4248	301	47	li	li	PROPN
dpc-4248	301	48	j	j	PROPN
dpc-4248	301	49	,	,	PUNCT
dpc-4248	301	50	klekotka	klekotka	PROPN
dpc-4248	301	51	pa	pa	PROPN
dpc-4248	301	52	,	,	PUNCT
dpc-4248	301	53	kricorian	kricorian	PROPN
dpc-4248	301	54	g	g	PROPN
dpc-4248	301	55	,	,	PUNCT
dpc-4248	301	56	nirula	nirula	ADJ
dpc-4248	301	57	a.	a.	PROPN
dpc-4248	301	58	a	a	DET
dpc-4248	301	59	 	 	SPACE
dpc-4248	301	60	prospective	prospective	ADJ
dpc-4248	301	61	phase	phase	NOUN
dpc-4248	301	62	iii	iii	NOUN
dpc-4248	301	63	,	,	PUNCT
dpc-4248	301	64	randomized	randomize	VERB
dpc-4248	301	65	,	,	PUNCT
dpc-4248	301	66	double	double	ADJ
dpc-4248	301	67	-	-	PUNCT
dpc-4248	301	68	blind	blind	ADJ
dpc-4248	301	69	,	,	PUNCT
dpc-4248	301	70	placebo	placebo	NOUN
dpc-4248	301	71	-	-	PUNCT
dpc-4248	301	72	controlled	control	VERB
dpc-4248	301	73	study	study	NOUN
dpc-4248	301	74	of	of	ADP
dpc-4248	301	75	brodalumab	brodalumab	NOUN
dpc-4248	301	76	in	in	ADP
dpc-4248	301	77	patients	patient	NOUN
dpc-4248	301	78	with	with	ADP
dpc-4248	301	79	moderate	moderate	ADJ
dpc-4248	301	80	-	-	PUNCT
dpc-4248	301	81	to	to	ADP
dpc-4248	301	82	-	-	PUNCT
dpc-4248	301	83	severe	severe	ADJ
dpc-4248	301	84	plaque	plaque	NOUN
dpc-4248	301	85	psoriasis	psoriasis	NOUN
dpc-4248	301	86	.	.	PUNCT
dpc-4248	302	1	br	br	PROPN
dpc-4248	302	2	j	j	PROPN
dpc-4248	302	3	dermatol	dermatol	NOUN
dpc-4248	302	4	.	.	PUNCT
dpc-4248	303	1	2016	2016	NUM
dpc-4248	303	2	aug;175(2):273–86	aug;175(2):273–86	NOUN
dpc-4248	303	3	.	.	PUNCT
dpc-4248	304	1	doi	doi	NOUN
dpc-4248	304	2	:	:	PUNCT
dpc-4248	304	3	10.1111	10.1111	NUM
dpc-4248	304	4	/bjd.14493	/bjd.14493	NOUN
dpc-4248	304	5	.	.	PUNCT
dpc-4248	305	1	epub	epub	PROPN
dpc-4248	305	2	2016	2016	NUM
dpc-4248	305	3	jun	jun	PROPN
dpc-4248	305	4	23	23	NUM
dpc-4248	305	5	.	.	PUNCT
dpc-4248	306	1	pmid	pmid	NOUN
dpc-4248	306	2	:	:	PUNCT
dpc-4248	306	3	26914406	26914406	NUM
dpc-4248	306	4	.	.	PUNCT
dpc-4248	307	1	4	4	X
dpc-4248	307	2	.	.	X
dpc-4248	307	3	lebwohl	lebwohl	PROPN
dpc-4248	307	4	m	m	PROPN
dpc-4248	307	5	,	,	PUNCT
dpc-4248	307	6	strober	strober	ADV
dpc-4248	307	7	b	b	NUM
dpc-4248	307	8	,	,	PUNCT
dpc-4248	307	9	menter	menter	X
dpc-4248	307	10	a	a	NOUN
dpc-4248	307	11	,	,	PUNCT
dpc-4248	307	12	gordon	gordon	PROPN
dpc-4248	307	13	k	k	PROPN
dpc-4248	307	14	,	,	PUNCT
dpc-4248	307	15	weglowska	weglowska	PROPN
dpc-4248	307	16	j	j	PROPN
dpc-4248	307	17	,	,	PUNCT
dpc-4248	307	18	puig	puig	PROPN
dpc-4248	307	19	l	l	PROPN
dpc-4248	307	20	,	,	PUNCT
dpc-4248	307	21	papp	papp	PROPN
dpc-4248	307	22	k	k	PROPN
dpc-4248	307	23	,	,	PUNCT
dpc-4248	307	24	spelman	spelman	PROPN
dpc-4248	307	25	l	l	PROPN
dpc-4248	307	26	,	,	PUNCT
dpc-4248	307	27	toth	toth	PROPN
dpc-4248	307	28	d	d	PROPN
dpc-4248	307	29	,	,	PUNCT
dpc-4248	307	30	kerdel	kerdel	PROPN
dpc-4248	307	31	f	f	PROPN
dpc-4248	307	32	,	,	PUNCT
dpc-4248	307	33	armstrong	armstrong	PROPN
dpc-4248	307	34	aw	aw	PROPN
dpc-4248	307	35	,	,	PUNCT
dpc-4248	307	36	stingl	stingl	NOUN
dpc-4248	307	37	g	g	PROPN
dpc-4248	307	38	,	,	PUNCT
dpc-4248	307	39	kimball	kimball	PROPN
dpc-4248	307	40	ab	ab	PROPN
dpc-4248	307	41	,	,	PUNCT
dpc-4248	307	42	bachelez	bachelez	PROPN
dpc-4248	307	43	h	h	PROPN
dpc-4248	307	44	,	,	PUNCT
dpc-4248	307	45	wu	wu	PROPN
dpc-4248	307	46	jj	jj	PROPN
dpc-4248	307	47	,	,	PUNCT
dpc-4248	307	48	crowley	crowley	PROPN
dpc-4248	307	49	j	j	PROPN
dpc-4248	307	50	,	,	PUNCT
dpc-4248	307	51	langley	langley	PROPN
dpc-4248	307	52	rg	rg	PROPN
dpc-4248	307	53	,	,	PUNCT
dpc-4248	307	54	blicharski	blicharski	PROPN
dpc-4248	307	55	t	t	PROPN
dpc-4248	307	56	,	,	PUNCT
dpc-4248	307	57	paul	paul	PROPN
dpc-4248	307	58	c	c	PROPN
dpc-4248	307	59	,	,	PUNCT
dpc-4248	307	60	lacour	lacour	PROPN
dpc-4248	307	61	jp	jp	NOUN
dpc-4248	307	62	,	,	PUNCT
dpc-4248	307	63	tyring	tyre	VERB
dpc-4248	307	64	s	s	PRON
dpc-4248	307	65	,	,	PUNCT
dpc-4248	307	66	kircik	kircik	PROPN
dpc-4248	307	67	l	l	PROPN
dpc-4248	307	68	,	,	PUNCT
dpc-4248	307	69	chimenti	chimenti	PROPN
dpc-4248	307	70	s	s	PROPN
dpc-4248	307	71	,	,	PUNCT
dpc-4248	307	72	callis	calli	VERB
dpc-4248	307	73	duffin	duffin	PROPN
dpc-4248	307	74	k	k	PROPN
dpc-4248	307	75	,	,	PUNCT
dpc-4248	307	76	bagel	bagel	PROPN
dpc-4248	307	77	j	j	PROPN
dpc-4248	307	78	,	,	PUNCT
dpc-4248	307	79	koo	koo	PROPN
dpc-4248	307	80	j	j	PROPN
dpc-4248	307	81	,	,	PUNCT
dpc-4248	307	82	aras	aras	PROPN
dpc-4248	307	83	g	g	PROPN
dpc-4248	307	84	,	,	PUNCT
dpc-4248	307	85	li	li	PROPN
dpc-4248	307	86	j	j	PROPN
dpc-4248	307	87	,	,	PUNCT
dpc-4248	307	88	song	song	PROPN
dpc-4248	307	89	w	w	PROPN
dpc-4248	307	90	,	,	PUNCT
dpc-4248	307	91	milmont	milmont	PROPN
dpc-4248	307	92	ce	ce	PROPN
dpc-4248	307	93	,	,	PUNCT
dpc-4248	307	94	shi	shi	PROPN
dpc-4248	307	95	y	y	PROPN
dpc-4248	307	96	,	,	PUNCT
dpc-4248	307	97	erondu	erondu	NOUN
dpc-4248	307	98	n	n	PROPN
dpc-4248	307	99	,	,	PUNCT
dpc-4248	307	100	klekotka	klekotka	PROPN
dpc-4248	307	101	p	p	X
dpc-4248	307	102	,	,	PUNCT
dpc-4248	307	103	kotzin	kotzin	PROPN
dpc-4248	307	104	b	b	PROPN
dpc-4248	307	105	,	,	PUNCT
dpc-4248	307	106	nirula	nirula	ADJ
dpc-4248	307	107	a.	a.	NOUN
dpc-4248	307	108	phase	phase	NOUN
dpc-4248	307	109	3	3	NUM
dpc-4248	307	110	studies	study	NOUN
dpc-4248	307	111	comparing	compare	VERB
dpc-4248	307	112	brodalumab	brodalumab	NOUN
dpc-4248	307	113	with	with	ADP
dpc-4248	307	114	ustekinumab	ustekinumab	NOUN
dpc-4248	307	115	in	in	ADP
dpc-4248	307	116	psoriasis	psoriasis	NOUN
dpc-4248	307	117	.	.	PUNCT
dpc-4248	308	1	n	n	CCONJ
dpc-4248	308	2	engl	engl	PROPN
dpc-4248	308	3	j	j	PROPN
dpc-4248	308	4	med	med	PROPN
dpc-4248	308	5	.	.	PUNCT
dpc-4248	309	1	2015	2015	NUM
dpc-4248	309	2	oct;373(14):1318–28	oct;373(14):1318–28	NOUN
dpc-4248	309	3	.	.	PUNCT
dpc-4248	310	1	doi	doi	NOUN
dpc-4248	310	2	:	:	PUNCT
dpc-4248	310	3	10.1056	10.1056	NUM
dpc-4248	310	4	/	/	SYM
dpc-4248	310	5	nejmoa1503824	nejmoa1503824	PROPN
dpc-4248	310	6	.	.	PUNCT
dpc-4248	311	1	pmid	pmid	NOUN
dpc-4248	311	2	:	:	PUNCT
dpc-4248	311	3	26422722	26422722	NUM
dpc-4248	311	4	.	.	PUNCT
dpc-4248	312	1	5	5	X
dpc-4248	312	2	.	.	X
dpc-4248	312	3	puig	puig	PROPN
dpc-4248	312	4	l	l	PROPN
dpc-4248	312	5	,	,	PUNCT
dpc-4248	312	6	lebwohl	lebwohl	PROPN
dpc-4248	312	7	m	m	PROPN
dpc-4248	312	8	,	,	PUNCT
dpc-4248	312	9	bachelez	bachelez	PROPN
dpc-4248	312	10	h	h	PROPN
dpc-4248	312	11	,	,	PUNCT
dpc-4248	312	12	sobell	sobell	PROPN
dpc-4248	312	13	j	j	PROPN
dpc-4248	312	14	,	,	PUNCT
dpc-4248	312	15	jacobson	jacobson	PROPN
dpc-4248	312	16	aa	aa	PROPN
dpc-4248	312	17	.	.	PUNCT
dpc-4248	313	1	long	long	ADJ
dpc-4248	313	2	-	-	PUNCT
dpc-4248	313	3	term	term	NOUN
dpc-4248	313	4	efficacy	efficacy	NOUN
dpc-4248	313	5	and	and	CCONJ
dpc-4248	313	6	safety	safety	NOUN
dpc-4248	313	7	of	of	ADP
dpc-4248	313	8	brodalumab	brodalumab	NOUN
dpc-4248	313	9	in	in	ADP
dpc-4248	313	10	the	the	DET
dpc-4248	313	11	treatment	treatment	NOUN
dpc-4248	313	12	of	of	ADP
dpc-4248	313	13	psoriasis	psoriasis	NOUN
dpc-4248	313	14	:	:	PUNCT
dpc-4248	313	15	120	120	NUM
dpc-4248	313	16	-	-	PUNCT
dpc-4248	313	17	week	week	NOUN
dpc-4248	313	18	results	result	NOUN
dpc-4248	313	19	from	from	ADP
dpc-4248	313	20	the	the	DET
dpc-4248	313	21	randomized	randomized	ADJ
dpc-4248	313	22	,	,	PUNCT
dpc-4248	313	23	double	double	ADJ
dpc-4248	313	24	-	-	PUNCT
dpc-4248	313	25	blind	blind	ADJ
dpc-4248	313	26	,	,	PUNCT
dpc-4248	313	27	placebo	placebo	NOUN
dpc-4248	313	28	and	and	CCONJ
dpc-4248	313	29	active	active	ADJ
dpc-4248	313	30	comparator	comparator	NOUN
dpc-4248	313	31	-	-	PUNCT
dpc-4248	313	32	controlled	control	VERB
dpc-4248	313	33	phase	phase	NOUN
dpc-4248	313	34	3	3	NUM
dpc-4248	313	35	amagine-2	amagine-2	NUM
dpc-4248	313	36	trial	trial	NOUN
dpc-4248	313	37	.	.	PUNCT
dpc-4248	314	1	j	j	PROPN
dpc-4248	314	2	am	be	AUX
dpc-4248	314	3	acad	acad	ADJ
dpc-4248	314	4	dermatol	dermatol	NOUN
dpc-4248	314	5	.	.	PUNCT
dpc-4248	315	1	2020	2020	NUM
dpc-4248	316	1	feb;82(2):352–359	feb;82(2):352–359	PROPN
dpc-4248	316	2	.	.	PUNCT
dpc-4248	317	1	doi	doi	NOUN
dpc-4248	317	2	:	:	PUNCT
dpc-4248	317	3	10.1016	10.1016	NUM
dpc-4248	317	4	/j.jaad.2019.05.095	/j.jaad.2019.05.095	NOUN
dpc-4248	317	5	.	.	PUNCT
dpc-4248	318	1	epub	epub	PROPN
dpc-4248	318	2	2019	2019	NUM
dpc-4248	318	3	jun	jun	PROPN
dpc-4248	318	4	5	5	NUM
dpc-4248	318	5	.	.	PUNCT
dpc-4248	319	1	pmid	pmid	NOUN
dpc-4248	319	2	:	:	PUNCT
dpc-4248	319	3	31175909	31175909	NUM
dpc-4248	319	4	.	.	PUNCT
dpc-4248	320	1	6	6	X
dpc-4248	320	2	.	.	X
dpc-4248	320	3	papadavid	papadavid	PROPN
dpc-4248	320	4	e	e	NOUN
dpc-4248	320	5	,	,	PUNCT
dpc-4248	320	6	zafeiriou	zafeiriou	NOUN
dpc-4248	320	7	e	e	PROPN
dpc-4248	320	8	,	,	PUNCT
dpc-4248	320	9	georgiou	georgiou	PROPN
dpc-4248	320	10	s	s	PROPN
dpc-4248	320	11	,	,	PUNCT
dpc-4248	320	12	roussaki	roussaki	NOUN
dpc-4248	320	13	-	-	PUNCT
dpc-4248	320	14	schulze	schulze	NOUN
dpc-4248	320	15	av	av	PROPN
dpc-4248	320	16	,	,	PUNCT
dpc-4248	320	17	spiliopoulos	spiliopoulos	PROPN
dpc-4248	320	18	t	t	PROPN
dpc-4248	320	19	,	,	PUNCT
dpc-4248	320	20	vryzaki	vryzaki	PROPN
dpc-4248	320	21	e	e	NOUN
dpc-4248	320	22	,	,	PUNCT
dpc-4248	320	23	oikonomou	oikonomou	ADP
dpc-4248	320	24	c	c	NOUN
dpc-4248	320	25	,	,	PUNCT
dpc-4248	320	26	drongoula	drongoula	NOUN
dpc-4248	320	27	o	o	NOUN
dpc-4248	320	28	,	,	PUNCT
dpc-4248	320	29	boziou	boziou	PROPN
dpc-4248	320	30	m	m	PROPN
dpc-4248	320	31	,	,	PUNCT
dpc-4248	320	32	goudouras	goudoura	VERB
dpc-4248	320	33	g	g	NOUN
dpc-4248	320	34	,	,	PUNCT
dpc-4248	320	35	sfaelos	sfaelo	NOUN
dpc-4248	320	36	k	k	NOUN
dpc-4248	320	37	,	,	PUNCT
dpc-4248	320	38	apalla	apalla	PROPN
dpc-4248	320	39	z	z	PROPN
dpc-4248	320	40	,	,	PUNCT
dpc-4248	320	41	lazaridou	lazaridou	PROPN
dpc-4248	320	42	e.	e.	PROPN
dpc-4248	320	43	real	real	PROPN
dpc-4248	320	44	-	-	PUNCT
dpc-4248	320	45	world	world	NOUN
dpc-4248	320	46	clinical	clinical	ADJ
dpc-4248	320	47	outcomes	outcome	NOUN
dpc-4248	320	48	of	of	ADP
dpc-4248	320	49	treatment	treatment	NOUN
dpc-4248	320	50	with	with	ADP
dpc-4248	320	51	brodalumab	brodalumab	NOUN
dpc-4248	320	52	in	in	ADP
dpc-4248	320	53	patients	patient	NOUN
dpc-4248	320	54	with	with	ADP
dpc-4248	320	55	moderate	moderate	ADJ
dpc-4248	320	56	-	-	PUNCT
dpc-4248	320	57	to	to	ADP
dpc-4248	320	58	-	-	PUNCT
dpc-4248	320	59	severe	severe	ADJ
dpc-4248	320	60	psoriasis	psoriasis	NOUN
dpc-4248	320	61	:	:	PUNCT
dpc-4248	320	62	a	a	DET
dpc-4248	320	63	retrospective	retrospective	ADJ
dpc-4248	320	64	,	,	PUNCT
dpc-4248	320	65	24	24	NUM
dpc-4248	320	66	-	-	PUNCT
dpc-4248	320	67	month	month	NOUN
dpc-4248	320	68	experience	experience	NOUN
dpc-4248	320	69	from	from	ADP
dpc-4248	320	70	four	four	NUM
dpc-4248	320	71	academic	academic	ADJ
dpc-4248	320	72	dermatology	dermatology	NOUN
dpc-4248	320	73	centers	center	NOUN
dpc-4248	320	74	in	in	ADP
dpc-4248	320	75	greece	greece	PROPN
dpc-4248	320	76	.	.	PUNCT
dpc-4248	321	1	j	j	PROPN
dpc-4248	321	2	dermatolog	dermatolog	PROPN
dpc-4248	321	3	treat	treat	NOUN
dpc-4248	321	4	.	.	PUNCT
dpc-4248	322	1	2022	2022	NUM
dpc-4248	322	2	nov;33(7):3053–3059	nov;33(7):3053–3059	NOUN
dpc-4248	322	3	.	.	PUNCT
dpc-4248	323	1	doi	doi	NOUN
dpc-4248	323	2	:	:	PUNCT
dpc-4248	323	3	10.1080/09546634.2022.2110836	10.1080/09546634.2022.2110836	NUM
dpc-4248	323	4	.	.	PUNCT
dpc-4248	324	1	epub	epub	NOUN
dpc-4248	324	2	2022	2022	NUM
dpc-4248	324	3	aug	aug	PROPN
dpc-4248	324	4	23	23	NUM
dpc-4248	324	5	.	.	PUNCT
dpc-4248	325	1	pmid	pmid	NOUN
dpc-4248	325	2	:	:	PUNCT
dpc-4248	325	3	36000186	36000186	NUM
dpc-4248	325	4	.	.	PUNCT
dpc-4248	326	1	original	original	ADJ
dpc-4248	326	2	article	article	NOUN
dpc-4248	326	3	|	|	ADV
dpc-4248	326	4	dermatol	dermatol	ADJ
dpc-4248	326	5	pract	pract	NOUN
dpc-4248	326	6	concept	concept	NOUN
dpc-4248	326	7	.	.	PUNCT
dpc-4248	327	1	2024;14(2):e2024152	2024;14(2):e2024152	NUM
dpc-4248	327	2	11	11	NUM
dpc-4248	327	3	arthritis	arthritis	NOUN
dpc-4248	327	4	in	in	ADP
dpc-4248	327	5	patients	patient	NOUN
dpc-4248	327	6	with	with	ADP
dpc-4248	327	7	psoriasis	psoriasis	NOUN
dpc-4248	327	8	:	:	PUNCT
dpc-4248	327	9	a	a	DET
dpc-4248	327	10	prospective	prospective	ADJ
dpc-4248	327	11	cohort	cohort	NOUN
dpc-4248	327	12	study	study	NOUN
dpc-4248	327	13	.	.	PUNCT
dpc-4248	328	1	arthritis	arthritis	NOUN
dpc-4248	328	2	rheumatol	rheumatol	NOUN
dpc-4248	328	3	.	.	PUNCT
dpc-4248	329	1	2016	2016	NUM
dpc-4248	329	2	apr;68(4):915–23	apr;68(4):915–23	ADJ
dpc-4248	329	3	.	.	PUNCT
dpc-4248	330	1	doi	doi	NOUN
dpc-4248	330	2	:	:	PUNCT
dpc-4248	330	3	10.1002	10.1002	NUM
dpc-4248	330	4	/	/	SYM
dpc-4248	330	5	art	art	NOUN
dpc-4248	330	6	.39494	.39494	PROPN
dpc-4248	330	7	.	.	PUNCT
dpc-4248	331	1	pmid	pmid	NOUN
dpc-4248	331	2	:	:	PUNCT
dpc-4248	331	3	26555117	26555117	NUM
dpc-4248	331	4	.	.	PUNCT
dpc-4248	332	1	26	26	NUM
dpc-4248	332	2	.	.	PUNCT
dpc-4248	333	1	mease	mease	PROPN
dpc-4248	333	2	pj	pj	PROPN
dpc-4248	333	3	,	,	PUNCT
dpc-4248	333	4	helliwell	helliwell	PROPN
dpc-4248	333	5	ps	ps	PROPN
dpc-4248	333	6	,	,	PUNCT
dpc-4248	333	7	hjuler	hjuler	NOUN
dpc-4248	333	8	kf	kf	PROPN
dpc-4248	333	9	,	,	PUNCT
dpc-4248	333	10	et	et	PROPN
dpc-4248	333	11	al	al	PROPN
dpc-4248	333	12	.	.	PROPN
dpc-4248	333	13	brodalumab	brodalumab	PROPN
dpc-4248	333	14	in	in	ADP
dpc-4248	333	15	psoriatic	psoriatic	ADJ
dpc-4248	333	16	arthritis	arthritis	NOUN
dpc-4248	333	17	:	:	PUNCT
dpc-4248	333	18	results	result	NOUN
dpc-4248	333	19	from	from	ADP
dpc-4248	333	20	the	the	DET
dpc-4248	333	21	randomised	randomised	ADJ
dpc-4248	333	22	phase	phase	NOUN
dpc-4248	333	23	iii	iii	NUM
dpc-4248	333	24	amvision-1	amvision-1	NUM
dpc-4248	333	25	and	and	CCONJ
dpc-4248	333	26	amvision-2	amvision-2	NUM
dpc-4248	333	27	trials	trial	NOUN
dpc-4248	333	28	.	.	PUNCT
dpc-4248	334	1	ann	ann	PROPN
dpc-4248	334	2	rheum	rheum	PROPN
dpc-4248	334	3	dis	dis	PROPN
dpc-4248	334	4	.	.	PUNCT
dpc-4248	335	1	2021;80(2):185–93	2021;80(2):185–93	NUM
dpc-4248	335	2	.	.	NOUN
dpc-4248	336	1	27	27	NUM
dpc-4248	336	2	.	.	PUNCT
dpc-4248	337	1	gkanti	gkanti	PROPN
dpc-4248	337	2	v	v	PROPN
dpc-4248	337	3	,	,	PUNCT
dpc-4248	337	4	dalamaga	dalamaga	PROPN
dpc-4248	337	5	m	m	PROPN
dpc-4248	337	6	,	,	PUNCT
dpc-4248	337	7	papadavid	papadavid	PROPN
dpc-4248	337	8	e.	e.	PROPN
dpc-4248	337	9	drug	drug	PROPN
dpc-4248	337	10	survival	survival	PROPN
dpc-4248	337	11	of	of	ADP
dpc-4248	337	12	brodalumab	brodalumab	NOUN
dpc-4248	337	13	is	be	AUX
dpc-4248	337	14	greater	great	ADJ
dpc-4248	337	15	in	in	ADP
dpc-4248	337	16	patients	patient	NOUN
dpc-4248	337	17	with	with	ADP
dpc-4248	337	18	psoriasis	psoriasis	NOUN
dpc-4248	337	19	and	and	CCONJ
dpc-4248	337	20	psoriatic	psoriatic	ADJ
dpc-4248	337	21	arthritis	arthritis	NOUN
dpc-4248	337	22	in	in	ADP
dpc-4248	337	23	a	a	DET
dpc-4248	337	24	real	real	ADJ
dpc-4248	337	25	-	-	PUNCT
dpc-4248	337	26	world	world	NOUN
dpc-4248	337	27	setting	setting	NOUN
dpc-4248	337	28	.	.	PUNCT
dpc-4248	338	1	int	int	NOUN
dpc-4248	338	2	j	j	PROPN
dpc-4248	338	3	dermatol	dermatol	NOUN
dpc-4248	338	4	.	.	PUNCT
dpc-4248	339	1	2023	2023	NUM
dpc-4248	339	2	jan;62(1):e31	jan;62(1):e31	NUM
dpc-4248	339	3	-	-	PUNCT
dpc-4248	339	4	e34	e34	NOUN
dpc-4248	339	5	.	.	PUNCT
dpc-4248	340	1	doi	doi	NOUN
dpc-4248	340	2	:	:	PUNCT
dpc-4248	340	3	10.1111	10.1111	NUM
dpc-4248	340	4	/	/	SYM
dpc-4248	340	5	ijd.16408	ijd.16408	X
dpc-4248	340	6	.	.	PUNCT
dpc-4248	341	1	epub	epub	VERB
dpc-4248	341	2	2022	2022	NUM
dpc-4248	341	3	sep	sep	PROPN
dpc-4248	341	4	10	10	NUM
dpc-4248	341	5	.	.	PUNCT
dpc-4248	342	1	pmid	pmid	NOUN
dpc-4248	342	2	:	:	PUNCT
dpc-4248	342	3	36087047	36087047	NUM
dpc-4248	342	4	.	.	PUNCT
dpc-4248	343	1	28	28	NUM
dpc-4248	343	2	.	.	PUNCT
dpc-4248	344	1	reich	reich	PROPN
dpc-4248	344	2	k	k	PROPN
dpc-4248	344	3	,	,	PUNCT
dpc-4248	344	4	mrowietz	mrowietz	PROPN
dpc-4248	344	5	u	u	NOUN
dpc-4248	344	6	,	,	PUNCT
dpc-4248	344	7	menter	menter	PROPN
dpc-4248	344	8	a	a	X
dpc-4248	344	9	,	,	PUNCT
dpc-4248	344	10	griffiths	griffiths	PROPN
dpc-4248	344	11	cem	cem	PROPN
dpc-4248	344	12	,	,	PUNCT
dpc-4248	344	13	bagel	bagel	NOUN
dpc-4248	344	14	j	j	PROPN
dpc-4248	344	15	,	,	PUNCT
dpc-4248	344	16	strober	strober	ADV
dpc-4248	344	17	b	b	NUM
dpc-4248	344	18	,	,	PUNCT
dpc-4248	344	19	nunez	nunez	PROPN
dpc-4248	344	20	gomez	gomez	PROPN
dpc-4248	344	21	n	n	PROPN
dpc-4248	344	22	,	,	PUNCT
dpc-4248	344	23	shi	shi	PROPN
dpc-4248	344	24	r	r	PROPN
dpc-4248	344	25	,	,	PUNCT
dpc-4248	344	26	guerette	guerette	NOUN
dpc-4248	344	27	b	b	PROPN
dpc-4248	344	28	,	,	PUNCT
dpc-4248	344	29	lebwohl	lebwohl	VERB
dpc-4248	344	30	m.	m.	NOUN
dpc-4248	344	31	effect	effect	NOUN
dpc-4248	344	32	of	of	ADP
dpc-4248	344	33	baseline	baseline	NOUN
dpc-4248	344	34	disease	disease	NOUN
dpc-4248	344	35	severity	severity	NOUN
dpc-4248	344	36	on	on	ADP
dpc-4248	344	37	achievement	achievement	NOUN
dpc-4248	344	38	of	of	ADP
dpc-4248	344	39	treatment	treatment	NOUN
dpc-4248	344	40	target	target	NOUN
dpc-4248	344	41	with	with	ADP
dpc-4248	344	42	apremilast	apremilast	ADJ
dpc-4248	344	43	:	:	PUNCT
dpc-4248	344	44	results	result	NOUN
dpc-4248	344	45	from	from	ADP
dpc-4248	344	46	a	a	DET
dpc-4248	344	47	pooled	pooled	ADJ
dpc-4248	344	48	analysis	analysis	NOUN
dpc-4248	344	49	.	.	PUNCT
dpc-4248	345	1	j	j	PROPN
dpc-4248	345	2	eur	eur	PROPN
dpc-4248	345	3	acad	acad	PROPN
dpc-4248	345	4	dermatol	dermatol	NOUN
dpc-4248	345	5	venereol	venereol	NOUN
dpc-4248	345	6	.	.	PUNCT
dpc-4248	346	1	2021	2021	NUM
dpc-4248	346	2	dec;35(12):2409–2414	dec;35(12):2409–2414	NOUN
dpc-4248	346	3	.	.	PUNCT
dpc-4248	347	1	doi	doi	NOUN
dpc-4248	347	2	:	:	PUNCT
dpc-4248	347	3	10.1111	10.1111	NUM
dpc-4248	347	4	/	/	SYM
dpc-4248	347	5	jdv.17520	jdv.17520	PROPN
dpc-4248	347	6	.	.	PUNCT
dpc-4248	348	1	epub	epub	PROPN
dpc-4248	348	2	2021	2021	NUM
dpc-4248	348	3	aug	aug	PROPN
dpc-4248	348	4	23	23	NUM
dpc-4248	348	5	.	.	PUNCT
dpc-4248	349	1	pmid	pmid	NOUN
dpc-4248	349	2	:	:	PUNCT
dpc-4248	349	3	34255891	34255891	NUM
dpc-4248	349	4	.	.	PUNCT
dpc-4248	350	1	29	29	NUM
dpc-4248	350	2	.	.	PUNCT
dpc-4248	351	1	merola	merola	PROPN
dpc-4248	351	2	jf	jf	PROPN
dpc-4248	351	3	,	,	PUNCT
dpc-4248	351	4	kavanaugh	kavanaugh	PROPN
dpc-4248	351	5	a	a	PROPN
dpc-4248	351	6	,	,	PUNCT
dpc-4248	351	7	lebwohl	lebwohl	ADJ
dpc-4248	351	8	mg	mg	PROPN
dpc-4248	351	9	,	,	PUNCT
dpc-4248	351	10	et	et	PROPN
dpc-4248	351	11	al	al	PROPN
dpc-4248	351	12	.	.	PROPN
dpc-4248	351	13	clinical	clinical	ADJ
dpc-4248	351	14	efcacy	efcacy	NOUN
dpc-4248	351	15	and	and	CCONJ
dpc-4248	351	16	safety	safety	NOUN
dpc-4248	351	17	of	of	ADP
dpc-4248	351	18	psoriasis	psoriasis	NOUN
dpc-4248	351	19	treatments	treatment	NOUN
dpc-4248	351	20	in	in	ADP
dpc-4248	351	21	patients	patient	NOUN
dpc-4248	351	22	with	with	ADP
dpc-4248	351	23	concomitant	concomitant	ADJ
dpc-4248	351	24	metabolic	metabolic	NOUN
dpc-4248	351	25	syndrome	syndrome	NOUN
dpc-4248	351	26	:	:	PUNCT
dpc-4248	351	27	a	a	DET
dpc-4248	351	28	narrative	narrative	NOUN
dpc-4248	351	29	review	review	NOUN
dpc-4248	351	30	.	.	PUNCT
dpc-4248	352	1	dermatol	dermatol	NOUN
dpc-4248	352	2	ther	ther	ADV
dpc-4248	352	3	(	(	PUNCT
dpc-4248	352	4	heidelb	heidelb	NOUN
dpc-4248	352	5	)	)	PUNCT
dpc-4248	352	6	.	.	PUNCT
dpc-4248	353	1	2022	2022	NUM
dpc-4248	353	2	.	.	PUNCT
dpc-4248	354	1	30	30	NUM
dpc-4248	354	2	.	.	PUNCT
dpc-4248	355	1	hsu	hsu	PROPN
dpc-4248	355	2	s	s	PROPN
dpc-4248	355	3	,	,	PUNCT
dpc-4248	355	4	green	green	PROPN
dpc-4248	355	5	lj	lj	PROPN
dpc-4248	355	6	,	,	PUNCT
dpc-4248	355	7	lebwohl	lebwohl	VERB
dpc-4248	355	8	mg	mg	PROPN
dpc-4248	355	9	,	,	PUNCT
dpc-4248	355	10	wu	wu	PROPN
dpc-4248	355	11	jj	jj	PROPN
dpc-4248	355	12	,	,	PUNCT
dpc-4248	355	13	blauvelt	blauvelt	VERB
dpc-4248	355	14	a	a	DET
dpc-4248	355	15	,	,	PUNCT
dpc-4248	355	16	jacobson	jacobson	PROPN
dpc-4248	355	17	aa	aa	PROPN
dpc-4248	355	18	.	.	PUNCT
dpc-4248	355	19	comparable	comparable	ADJ
dpc-4248	355	20	efficacy	efficacy	NOUN
dpc-4248	355	21	and	and	CCONJ
dpc-4248	355	22	safety	safety	NOUN
dpc-4248	355	23	of	of	ADP
dpc-4248	355	24	brodalumab	brodalumab	NOUN
dpc-4248	355	25	in	in	ADP
dpc-4248	355	26	obese	obese	NOUN
dpc-4248	355	27	and	and	CCONJ
dpc-4248	355	28	nonobese	nonobese	ADJ
dpc-4248	355	29	patients	patient	NOUN
dpc-4248	355	30	with	with	ADP
dpc-4248	355	31	psoriasis	psoriasis	NOUN
dpc-4248	355	32	:	:	PUNCT
dpc-4248	355	33	analysis	analysis	NOUN
dpc-4248	355	34	of	of	ADP
dpc-4248	355	35	two	two	NUM
dpc-4248	355	36	randomized	randomized	ADJ
dpc-4248	355	37	controlled	control	VERB
dpc-4248	355	38	trials	trial	NOUN
dpc-4248	355	39	.	.	PUNCT
dpc-4248	356	1	br	br	PROPN
dpc-4248	356	2	j	j	PROPN
dpc-4248	356	3	dermatol	dermatol	NOUN
dpc-4248	356	4	.	.	PUNCT
dpc-4248	356	5	2020	2020	NUM
dpc-4248	357	1	apr;182(4):880–888	apr;182(4):880–888	PROPN
dpc-4248	357	2	.	.	PROPN
dpc-4248	357	3	doi	doi	PROPN
dpc-4248	357	4	:	:	PUNCT
dpc-4248	357	5	10.1111	10.1111	NUM
dpc-4248	357	6	/	/	SYM
dpc-4248	357	7	bjd.18327	bjd.18327	NOUN
dpc-4248	357	8	.	.	PUNCT
dpc-4248	358	1	epub	epub	PROPN
dpc-4248	358	2	2019	2019	NUM
dpc-4248	358	3	oct	oct	NOUN
dpc-4248	358	4	16	16	NUM
dpc-4248	358	5	.	.	PUNCT
dpc-4248	359	1	pmid	pmid	NOUN
dpc-4248	359	2	:	:	PUNCT
dpc-4248	359	3	31276189	31276189	NUM
dpc-4248	359	4	.	.	PUNCT
dpc-4248	360	1	31	31	NUM
dpc-4248	360	2	.	.	PUNCT
dpc-4248	361	1	chiricozzi	chiricozzi	PROPN
dpc-4248	361	2	a	a	NOUN
dpc-4248	361	3	,	,	PUNCT
dpc-4248	361	4	balato	balato	NOUN
dpc-4248	361	5	a	a	PRON
dpc-4248	361	6	,	,	PUNCT
dpc-4248	361	7	conrad	conrad	PROPN
dpc-4248	361	8	c	c	PROPN
dpc-4248	361	9	,	,	PUNCT
dpc-4248	361	10	conti	conti	PROPN
dpc-4248	361	11	a	a	X
dpc-4248	361	12	,	,	PUNCT
dpc-4248	361	13	dapavo	dapavo	ADJ
dpc-4248	361	14	p	p	NOUN
dpc-4248	361	15	,	,	PUNCT
dpc-4248	361	16	ferreira	ferreira	PROPN
dpc-4248	361	17	p	p	PROPN
dpc-4248	361	18	,	,	PUNCT
dpc-4248	361	19	gaiani	gaiani	PROPN
dpc-4248	361	20	fm	fm	PROPN
dpc-4248	361	21	,	,	PUNCT
dpc-4248	361	22	leite	leite	PROPN
dpc-4248	361	23	l	l	PROPN
dpc-4248	361	24	,	,	PUNCT
dpc-4248	361	25	malagoli	malagoli	NOUN
dpc-4248	361	26	p	p	NOUN
dpc-4248	361	27	,	,	PUNCT
dpc-4248	361	28	mendes	mende	NOUN
dpc-4248	361	29	-	-	PUNCT
dpc-4248	361	30	bastos	bastos	PROPN
dpc-4248	361	31	p	p	NOUN
dpc-4248	361	32	,	,	PUNCT
dpc-4248	361	33	megna	megna	PROPN
dpc-4248	361	34	m	m	PROPN
dpc-4248	361	35	,	,	PUNCT
dpc-4248	361	36	messina	messina	PROPN
dpc-4248	361	37	f	f	PROPN
dpc-4248	361	38	,	,	PUNCT
dpc-4248	361	39	nidegger	nidegger	PROPN
dpc-4248	361	40	a	a	PRON
dpc-4248	361	41	,	,	PUNCT
dpc-4248	361	42	odorici	odorici	NOUN
dpc-4248	361	43	g	g	PROPN
dpc-4248	361	44	,	,	PUNCT
dpc-4248	361	45	panduri	panduri	PROPN
dpc-4248	361	46	s	s	PROPN
dpc-4248	361	47	,	,	PUNCT
dpc-4248	361	48	piaserico	piaserico	PROPN
dpc-4248	361	49	s	s	PART
dpc-4248	361	50	,	,	PUNCT
dpc-4248	361	51	piscitelli	piscitelli	ADV
dpc-4248	361	52	l	l	NOUN
dpc-4248	361	53	,	,	PUNCT
dpc-4248	361	54	prignano	prignano	PROPN
dpc-4248	361	55	f	f	PROPN
dpc-4248	361	56	,	,	PUNCT
dpc-4248	361	57	ribero	ribero	PROPN
dpc-4248	361	58	s	s	PROPN
dpc-4248	361	59	,	,	PUNCT
dpc-4248	361	60	valerio	valerio	PROPN
dpc-4248	361	61	j	j	PROPN
dpc-4248	361	62	,	,	PUNCT
dpc-4248	361	63	torres	torre	VERB
dpc-4248	361	64	t.	t.	PROPN
dpc-4248	361	65	secukinumab	secukinumab	NOUN
dpc-4248	361	66	demonstrates	demonstrate	VERB
dpc-4248	361	67	improvements	improvement	NOUN
dpc-4248	361	68	in	in	ADP
dpc-4248	361	69	absolute	absolute	ADJ
dpc-4248	361	70	and	and	CCONJ
dpc-4248	361	71	relative	relative	ADJ
dpc-4248	361	72	psoriasis	psoriasis	NOUN
dpc-4248	361	73	area	area	NOUN
dpc-4248	361	74	severity	severity	NOUN
dpc-4248	361	75	indices	indice	VERB
dpc-4248	361	76	in	in	ADP
dpc-4248	361	77	moderate	moderate	ADJ
dpc-4248	361	78	-	-	PUNCT
dpc-4248	361	79	to	to	ADP
dpc-4248	361	80	-	-	PUNCT
dpc-4248	361	81	severe	severe	ADJ
dpc-4248	361	82	plaque	plaque	NOUN
dpc-4248	361	83	psoriasis	psoriasis	NOUN
dpc-4248	361	84	:	:	PUNCT
dpc-4248	361	85	results	result	VERB
dpc-4248	361	86	from	from	ADP
dpc-4248	361	87	a	a	DET
dpc-4248	361	88	european	european	ADJ
dpc-4248	361	89	,	,	PUNCT
dpc-4248	361	90	multicentric	multicentric	ADJ
dpc-4248	361	91	,	,	PUNCT
dpc-4248	361	92	retrospective	retrospective	ADJ
dpc-4248	361	93	,	,	PUNCT
dpc-4248	361	94	real	real	ADJ
dpc-4248	361	95	-	-	PUNCT
dpc-4248	361	96	world	world	NOUN
dpc-4248	361	97	study	study	NOUN
dpc-4248	361	98	.	.	PUNCT
dpc-4248	362	1	j	j	PROPN
dpc-4248	362	2	dermatolog	dermatolog	PROPN
dpc-4248	362	3	treat	treat	NOUN
dpc-4248	362	4	.	.	PUNCT
dpc-4248	363	1	2020	2020	NUM
dpc-4248	364	1	aug;31(5):476–483	aug;31(5):476–483	PROPN
dpc-4248	364	2	.	.	PUNCT
dpc-4248	364	3	doi	doi	PROPN
dpc-4248	364	4	:	:	PUNCT
dpc-4248	364	5	10.1080/09546634.2019.1671577	10.1080/09546634.2019.1671577	NUM
dpc-4248	364	6	.	.	PUNCT
dpc-4248	365	1	epub	epub	NOUN
dpc-4248	365	2	2019	2019	NUM
dpc-4248	365	3	oct	oct	PROPN
dpc-4248	365	4	2	2	NUM
dpc-4248	365	5	.	.	PUNCT
dpc-4248	365	6	pmid	pmid	NOUN
dpc-4248	365	7	:	:	PUNCT
dpc-4248	365	8	31557063	31557063	NUM
dpc-4248	365	9	.	.	PUNCT
dpc-4248	366	1	32	32	NUM
dpc-4248	366	2	.	.	PUNCT
dpc-4248	367	1	thein	thein	PROPN
dpc-4248	367	2	d	d	PROPN
dpc-4248	367	3	,	,	PUNCT
dpc-4248	367	4	rosenø	rosenø	VERB
dpc-4248	367	5	nal	nal	NOUN
dpc-4248	367	6	,	,	PUNCT
dpc-4248	367	7	maul	maul	PROPN
dpc-4248	367	8	jt	jt	PROPN
dpc-4248	367	9	,	,	PUNCT
dpc-4248	367	10	wu	wu	PROPN
dpc-4248	367	11	jj	jj	PROPN
dpc-4248	367	12	,	,	PUNCT
dpc-4248	367	13	skov	skov	PROPN
dpc-4248	367	14	l	l	NOUN
dpc-4248	367	15	,	,	PUNCT
dpc-4248	367	16	bryld	bryld	NOUN
dpc-4248	367	17	le	le	X
dpc-4248	367	18	,	,	PUNCT
dpc-4248	367	19	rasmussen	rasmussen	PROPN
dpc-4248	367	20	mk	mk	PROPN
dpc-4248	367	21	,	,	PUNCT
dpc-4248	367	22	ajgeiy	ajgeiy	PROPN
dpc-4248	367	23	kk	kk	PROPN
dpc-4248	367	24	,	,	PUNCT
dpc-4248	367	25	thomsen	thomsen	PROPN
dpc-4248	367	26	sf	sf	PROPN
dpc-4248	367	27	,	,	PUNCT
dpc-4248	367	28	thyssen	thyssen	PROPN
dpc-4248	367	29	jp	jp	PROPN
dpc-4248	367	30	,	,	PUNCT
dpc-4248	367	31	egeberg	egeberg	PROPN
dpc-4248	367	32	a.	a.	PROPN
dpc-4248	367	33	drug	drug	PROPN
dpc-4248	367	34	survival	survival	NOUN
dpc-4248	367	35	of	of	ADP
dpc-4248	367	36	adalimumab	adalimumab	PROPN
dpc-4248	367	37	,	,	PUNCT
dpc-4248	367	38	secukinumab	secukinumab	NOUN
dpc-4248	367	39	,	,	PUNCT
dpc-4248	367	40	and	and	CCONJ
dpc-4248	367	41	ustekinumab	ustekinumab	NOUN
dpc-4248	367	42	in	in	ADP
dpc-4248	367	43	psoriasis	psoriasis	NOUN
dpc-4248	367	44	as	as	SCONJ
dpc-4248	367	45	determined	determine	VERB
dpc-4248	367	46	by	by	ADP
dpc-4248	367	47	either	either	CCONJ
dpc-4248	367	48	dose	dose	NOUN
dpc-4248	367	49	escalation	escalation	NOUN
dpc-4248	367	50	or	or	CCONJ
dpc-4248	367	51	drug	drug	NOUN
dpc-4248	367	52	discontinuation	discontinuation	NOUN
dpc-4248	367	53	during	during	ADP
dpc-4248	367	54	the	the	DET
dpc-4248	367	55	first	first	ADJ
dpc-4248	367	56	3	3	NUM
dpc-4248	367	57	years	year	NOUN
dpc-4248	367	58	of	of	ADP
dpc-4248	367	59	treatment	treatment	NOUN
dpc-4248	367	60	a	a	DET
dpc-4248	367	61	nationwide	nationwide	ADJ
dpc-4248	367	62	cohort	cohort	NOUN
dpc-4248	367	63	study	study	NOUN
dpc-4248	367	64	.	.	PUNCT
dpc-4248	368	1	j	j	PROPN
dpc-4248	368	2	invest	invest	VERB
dpc-4248	368	3	dermatol	dermatol	NOUN
dpc-4248	368	4	.	.	PUNCT
dpc-4248	369	1	2023	2023	NUM
dpc-4248	369	2	apr	apr	NOUN
dpc-4248	369	3	27	27	NUM
dpc-4248	369	4	:	:	PUNCT
dpc-4248	369	5	s0022	s0022	NOUN
dpc-4248	369	6	–	–	PUNCT
dpc-4248	369	7	202x(23)02041	202x(23)02041	NUM
dpc-4248	369	8	-	-	SYM
dpc-4248	369	9	9	9	NUM
dpc-4248	369	10	.	.	PUNCT
dpc-4248	369	11	doi	doi	NOUN
dpc-4248	369	12	:	:	PUNCT
dpc-4248	369	13	10.1016	10.1016	NUM
dpc-4248	369	14	/	/	SYM
dpc-4248	369	15	j.jid.2023.04.009	j.jid.2023.04.009	NOUN
dpc-4248	369	16	.	.	PUNCT
dpc-4248	370	1	epub	epub	NOUN
dpc-4248	370	2	ahead	ahead	ADV
dpc-4248	370	3	of	of	ADP
dpc-4248	370	4	print	print	NOUN
dpc-4248	370	5	.	.	PUNCT
dpc-4248	371	1	pmid	pmid	NOUN
dpc-4248	371	2	:	:	PUNCT
dpc-4248	371	3	37119965	37119965	NUM
dpc-4248	371	4	.	.	PUNCT
dpc-4248	372	1	33	33	NUM
dpc-4248	372	2	.	.	NOUN
dpc-4248	372	3	mastorino	mastorino	PROPN
dpc-4248	372	4	l	l	PROPN
dpc-4248	372	5	,	,	PUNCT
dpc-4248	372	6	castelli	castelli	PROPN
dpc-4248	372	7	f	f	PROPN
dpc-4248	372	8	,	,	PUNCT
dpc-4248	372	9	stroppiana	stroppiana	PROPN
dpc-4248	372	10	e	e	PROPN
dpc-4248	372	11	,	,	PUNCT
dpc-4248	372	12	verrone	verrone	NOUN
dpc-4248	372	13	a	a	X
dpc-4248	372	14	,	,	PUNCT
dpc-4248	372	15	ortoncelli	ortoncelli	PROPN
dpc-4248	372	16	m	m	PROPN
dpc-4248	372	17	,	,	PUNCT
dpc-4248	372	18	susca	susca	PROPN
dpc-4248	372	19	s	s	PART
dpc-4248	372	20	,	,	PUNCT
dpc-4248	372	21	boskovic	boskovic	PROPN
dpc-4248	372	22	s	s	PROPN
dpc-4248	372	23	,	,	PUNCT
dpc-4248	372	24	passerini	passerini	ADJ
dpc-4248	372	25	sg	sg	PROPN
dpc-4248	372	26	,	,	PUNCT
dpc-4248	372	27	macagno	macagno	NOUN
dpc-4248	372	28	n	n	CCONJ
dpc-4248	372	29	,	,	PUNCT
dpc-4248	372	30	cariti	cariti	PROPN
dpc-4248	372	31	c	c	NOUN
dpc-4248	372	32	,	,	PUNCT
dpc-4248	372	33	licciardello	licciardello	PROPN
dpc-4248	372	34	m	m	PROPN
dpc-4248	372	35	,	,	PUNCT
dpc-4248	372	36	solaroli	solaroli	PROPN
dpc-4248	372	37	c	c	PROPN
dpc-4248	372	38	,	,	PUNCT
dpc-4248	372	39	pertusi	pertusi	VERB
dpc-4248	372	40	g	g	NOUN
dpc-4248	372	41	,	,	PUNCT
dpc-4248	372	42	aragone	aragone	NOUN
dpc-4248	372	43	mg	mg	PROPN
dpc-4248	372	44	,	,	PUNCT
dpc-4248	372	45	baggini	baggini	NOUN
dpc-4248	372	46	g	g	PROPN
dpc-4248	372	47	,	,	PUNCT
dpc-4248	372	48	addese	addese	PROPN
dpc-4248	372	49	c	c	PROPN
dpc-4248	372	50	,	,	PUNCT
dpc-4248	372	51	leporati	leporati	PROPN
dpc-4248	372	52	c	c	NOUN
dpc-4248	372	53	,	,	PUNCT
dpc-4248	372	54	peila	peila	NOUN
dpc-4248	372	55	r	r	NOUN
dpc-4248	372	56	,	,	PUNCT
dpc-4248	372	57	giura	giura	PROPN
dpc-4248	372	58	mt	mt	PROPN
dpc-4248	372	59	,	,	PUNCT
dpc-4248	372	60	rossotto	rossotto	ADJ
dpc-4248	372	61	g	g	PROPN
dpc-4248	372	62	,	,	PUNCT
dpc-4248	372	63	pella	pella	PROPN
dpc-4248	372	64	p	p	PROPN
dpc-4248	372	65	,	,	PUNCT
dpc-4248	372	66	mocci	mocci	PROPN
dpc-4248	372	67	l	l	PROPN
dpc-4248	372	68	,	,	PUNCT
dpc-4248	372	69	merlo	merlo	PROPN
dpc-4248	372	70	g	g	PROPN
dpc-4248	372	71	,	,	PUNCT
dpc-4248	372	72	tiberio	tiberio	NOUN
dpc-4248	372	73	r	r	PROPN
dpc-4248	372	74	,	,	PUNCT
dpc-4248	372	75	graziola	graziola	NOUN
dpc-4248	372	76	f	f	AUX
dpc-4248	372	77	,	,	PUNCT
dpc-4248	372	78	quaglino	quaglino	PROPN
dpc-4248	372	79	p	p	X
dpc-4248	372	80	,	,	PUNCT
dpc-4248	372	81	dapavo	dapavo	ADJ
dpc-4248	372	82	p	p	NOUN
dpc-4248	372	83	,	,	PUNCT
dpc-4248	372	84	ribero	ribero	PROPN
dpc-4248	372	85	s.	s.	PROPN
dpc-4248	372	86	risankizumab	risankizumab	PROPN
dpc-4248	372	87	shows	show	VERB
dpc-4248	372	88	faster	fast	ADJ
dpc-4248	372	89	response	response	NOUN
dpc-4248	372	90	in	in	ADP
dpc-4248	372	91	bio	bio	PROPN
dpc-4248	372	92	naïve	naïve	PROPN
dpc-4248	372	93	than	than	ADP
dpc-4248	372	94	in	in	ADP
dpc-4248	372	95	bio	bio	ADJ
dpc-4248	372	96	-	-	ADJ
dpc-4248	372	97	experienced	experienced	ADJ
dpc-4248	372	98	psoriatic	psoriatic	ADJ
dpc-4248	372	99	patients	patient	NOUN
dpc-4248	372	100	.	.	PUNCT
dpc-4248	373	1	j	j	PROPN
dpc-4248	373	2	eur	eur	PROPN
dpc-4248	373	3	acad	acad	PROPN
dpc-4248	373	4	dermatol	dermatol	NOUN
dpc-4248	373	5	venereol	venereol	NOUN
dpc-4248	373	6	.	.	PUNCT
dpc-4248	374	1	2022	2022	NUM
dpc-4248	374	2	oct;36(10):e838	oct;36(10):e838	NOUN
dpc-4248	374	3	-	-	PUNCT
dpc-4248	374	4	e841	e841	PROPN
dpc-4248	374	5	.	.	PUNCT
dpc-4248	374	6	doi	doi	NOUN
dpc-4248	374	7	:	:	PUNCT
dpc-4248	374	8	10.1111	10.1111	NUM
dpc-4248	374	9	/	/	SYM
dpc-4248	374	10	jdv.18314	jdv.18314	PROPN
dpc-4248	374	11	.	.	PUNCT
dpc-4248	375	1	epub	epub	PROPN
dpc-4248	375	2	2022	2022	NUM
dpc-4248	375	3	jun	jun	PROPN
dpc-4248	375	4	22	22	NUM
dpc-4248	375	5	.	.	PUNCT
dpc-4248	376	1	pmid	pmid	NOUN
dpc-4248	376	2	:	:	PUNCT
dpc-4248	376	3	35686942	35686942	NUM
dpc-4248	376	4	.	.	PUNCT
dpc-4248	377	1	34	34	NUM
dpc-4248	377	2	.	.	PUNCT
dpc-4248	378	1	kimmel	kimmel	PROPN
dpc-4248	378	2	g	g	PROPN
dpc-4248	378	3	,	,	PUNCT
dpc-4248	378	4	chima	chima	PROPN
dpc-4248	378	5	m	m	PROPN
dpc-4248	378	6	,	,	PUNCT
dpc-4248	378	7	kim	kim	PROPN
dpc-4248	378	8	hj	hj	PROPN
dpc-4248	378	9	,	,	PUNCT
dpc-4248	378	10	et	et	PROPN
dpc-4248	378	11	al	al	PROPN
dpc-4248	378	12	.	.	PUNCT
dpc-4248	378	13	brodalumab	brodalumab	PROPN
dpc-4248	378	14	in	in	ADP
dpc-4248	378	15	the	the	DET
dpc-4248	378	16	treatment	treatment	NOUN
dpc-4248	378	17	of	of	ADP
dpc-4248	378	18	moderate	moderate	ADJ
dpc-4248	378	19	to	to	ADP
dpc-4248	378	20	severe	severe	ADJ
dpc-4248	378	21	psoriasis	psoriasis	NOUN
dpc-4248	378	22	in	in	ADP
dpc-4248	378	23	patients	patient	NOUN
dpc-4248	378	24	when	when	SCONJ
dpc-4248	378	25	previous	previous	ADJ
dpc-4248	378	26	anti	anti	ADJ
dpc-4248	378	27	-	-	ADJ
dpc-4248	378	28	interleukin	interleukin	ADJ
dpc-4248	378	29	17a	17a	X
dpc-4248	378	30	therapies	therapy	NOUN
dpc-4248	378	31	have	have	AUX
dpc-4248	378	32	failed	fail	VERB
dpc-4248	378	33	.	.	PUNCT
dpc-4248	379	1	j	j	PROPN
dpc-4248	379	2	am	be	AUX
dpc-4248	379	3	acad	acad	ADJ
dpc-4248	379	4	dermatol	dermatol	NOUN
dpc-4248	379	5	.	.	PUNCT
dpc-4248	380	1	2019;81(3):857–859	2019;81(3):857–859	NUM
dpc-4248	380	2	.	.	NOUN
dpc-4248	380	3	35	35	NUM
dpc-4248	380	4	.	.	PUNCT
dpc-4248	381	1	kromer	kromer	PROPN
dpc-4248	381	2	c	c	PROPN
dpc-4248	381	3	,	,	PUNCT
dpc-4248	381	4	wilsmann	wilsmann	PROPN
dpc-4248	381	5	-	-	PUNCT
dpc-4248	381	6	theis	theis	PROPN
dpc-4248	381	7	d	d	PROPN
dpc-4248	381	8	,	,	PUNCT
dpc-4248	381	9	gerdes	gerdes	PROPN
dpc-4248	381	10	s	s	PROPN
dpc-4248	381	11	,	,	PUNCT
dpc-4248	381	12	et	et	PROPN
dpc-4248	381	13	al	al	PROPN
dpc-4248	381	14	.	.	PUNCT
dpc-4248	382	1	changing	change	VERB
dpc-4248	382	2	within	within	ADP
dpc-4248	382	3	the	the	DET
dpc-4248	382	4	same	same	ADJ
dpc-4248	382	5	class	class	NOUN
dpc-4248	382	6	:	:	PUNCT
dpc-4248	382	7	efficacy	efficacy	NOUN
dpc-4248	382	8	of	of	ADP
dpc-4248	382	9	brodalumab	brodalumab	NOUN
dpc-4248	382	10	in	in	ADP
dpc-4248	382	11	plaque	plaque	NOUN
dpc-4248	382	12	psoriasis	psoriasis	NOUN
dpc-4248	382	13	after	after	ADP
dpc-4248	382	14	treatment	treatment	NOUN
dpc-4248	382	15	with	with	ADP
dpc-4248	382	16	an	an	DET
dpc-4248	382	17	il-17a	il-17a	PROPN
dpc-4248	382	18	blocker	blocker	NOUN
dpc-4248	382	19	a	a	DET
dpc-4248	382	20	retrospective	retrospective	ADJ
dpc-4248	382	21	multicenter	multicenter	NOUN
dpc-4248	382	22	study	study	NOUN
dpc-4248	382	23	.	.	PUNCT
dpc-4248	383	1	j	j	PROPN
dpc-4248	383	2	dermatolog	dermatolog	PROPN
dpc-4248	383	3	treat	treat	NOUN
dpc-4248	383	4	.	.	PUNCT
dpc-4248	384	1	2020	2020	NUM
dpc-4248	384	2	.	.	PUNCT
dpc-4248	385	1	p.	p.	NOUN
dpc-4248	385	2	1–5	1–5	NUM
dpc-4248	385	3	.	.	PROPN
dpc-4248	385	4	17	17	NUM
dpc-4248	385	5	.	.	PUNCT
dpc-4248	386	1	elgaard	elgaard	PROPN
dpc-4248	386	2	cdb	cdb	PROPN
dpc-4248	386	3	,	,	PUNCT
dpc-4248	386	4	iversen	iversen	PROPN
dpc-4248	386	5	l	l	PROPN
dpc-4248	386	6	,	,	PUNCT
dpc-4248	386	7	hjuler	hjuler	PROPN
dpc-4248	386	8	kf	kf	PROPN
dpc-4248	386	9	.	.	PUNCT
dpc-4248	387	1	single	single	ADJ
dpc-4248	387	2	-	-	PUNCT
dpc-4248	387	3	centre	centre	NOUN
dpc-4248	387	4	real	real	ADJ
dpc-4248	387	5	-	-	PUNCT
dpc-4248	387	6	world	world	NOUN
dpc-4248	387	7	study	study	NOUN
dpc-4248	387	8	on	on	ADP
dpc-4248	387	9	drug	drug	NOUN
dpc-4248	387	10	survival	survival	NOUN
dpc-4248	387	11	and	and	CCONJ
dpc-4248	387	12	effectiveness	effectiveness	NOUN
dpc-4248	387	13	of	of	ADP
dpc-4248	387	14	brodalumab	brodalumab	NOUN
dpc-4248	387	15	for	for	ADP
dpc-4248	387	16	treatment	treatment	NOUN
dpc-4248	387	17	of	of	ADP
dpc-4248	387	18	psoriasis	psoriasis	NOUN
dpc-4248	387	19	and	and	CCONJ
dpc-4248	387	20	psoriatic	psoriatic	ADJ
dpc-4248	387	21	arthritis	arthritis	NOUN
dpc-4248	387	22	.	.	PUNCT
dpc-4248	388	1	drugs	drug	NOUN
dpc-4248	388	2	r	r	PROPN
dpc-4248	388	3	d.	d.	PROPN
dpc-4248	388	4	2023	2023	NUM
dpc-4248	388	5	may	may	AUX
dpc-4248	388	6	8	8	NUM
dpc-4248	388	7	.	.	PUNCT
dpc-4248	389	1	doi	doi	NOUN
dpc-4248	389	2	:	:	PUNCT
dpc-4248	389	3	10.1007	10.1007	NUM
dpc-4248	389	4	/	/	SYM
dpc-4248	389	5	s40268	s40268	NOUN
dpc-4248	389	6	-	-	PUNCT
dpc-4248	389	7	023	023	NUM
dpc-4248	389	8	-	-	PUNCT
dpc-4248	389	9	00422	00422	NUM
dpc-4248	389	10	-	-	PUNCT
dpc-4248	389	11	w.	w.	NOUN
dpc-4248	389	12	epub	epub	PROPN
dpc-4248	389	13	ahead	ahead	ADV
dpc-4248	389	14	of	of	ADP
dpc-4248	389	15	print	print	NOUN
dpc-4248	389	16	.	.	PUNCT
dpc-4248	390	1	pmid	pmid	NOUN
dpc-4248	390	2	:	:	PUNCT
dpc-4248	390	3	37155121	37155121	NUM
dpc-4248	390	4	.	.	PUNCT
dpc-4248	391	1	18	18	NUM
dpc-4248	391	2	.	.	PUNCT
dpc-4248	392	1	kojanova	kojanova	PROPN
dpc-4248	392	2	m	m	PROPN
dpc-4248	392	3	,	,	PUNCT
dpc-4248	392	4	hugo	hugo	PROPN
dpc-4248	392	5	j	j	PROPN
dpc-4248	392	6	,	,	PUNCT
dpc-4248	392	7	velackova	velackova	PROPN
dpc-4248	392	8	b	b	X
dpc-4248	392	9	,	,	PUNCT
dpc-4248	392	10	cetkovska	cetkovska	PROPN
dpc-4248	392	11	p	p	NOUN
dpc-4248	392	12	,	,	PUNCT
dpc-4248	392	13	fialova	fialova	PROPN
dpc-4248	392	14	j	j	PROPN
dpc-4248	392	15	,	,	PUNCT
dpc-4248	392	16	dolezal	dolezal	PROPN
dpc-4248	392	17	t	t	PROPN
dpc-4248	392	18	,	,	PUNCT
dpc-4248	392	19	tichy	tichy	PROPN
dpc-4248	392	20	m	m	PROPN
dpc-4248	392	21	,	,	PUNCT
dpc-4248	392	22	gkalpakiotis	gkalpakiotis	PROPN
dpc-4248	392	23	s	s	PROPN
dpc-4248	392	24	;	;	PUNCT
dpc-4248	392	25	biorep	biorep	PROPN
dpc-4248	392	26	study	study	NOUN
dpc-4248	392	27	group	group	NOUN
dpc-4248	392	28	.	.	PUNCT
dpc-4248	393	1	efficacy	efficacy	NOUN
dpc-4248	393	2	,	,	PUNCT
dpc-4248	393	3	safety	safety	NOUN
dpc-4248	393	4	,	,	PUNCT
dpc-4248	393	5	and	and	CCONJ
dpc-4248	393	6	drug	drug	NOUN
dpc-4248	393	7	survival	survival	NOUN
dpc-4248	393	8	of	of	ADP
dpc-4248	393	9	patients	patient	NOUN
dpc-4248	393	10	with	with	ADP
dpc-4248	393	11	psoriasis	psoriasis	NOUN
dpc-4248	393	12	treated	treat	VERB
dpc-4248	393	13	with	with	ADP
dpc-4248	393	14	il-17	il-17	NUM
dpc-4248	393	15	inhibitors	inhibitor	NOUN
dpc-4248	393	16	brodalumab	brodalumab	NOUN
dpc-4248	393	17	,	,	PUNCT
dpc-4248	393	18	ixekizumab	ixekizumab	NOUN
dpc-4248	393	19	,	,	PUNCT
dpc-4248	393	20	and	and	CCONJ
dpc-4248	393	21	secukinumab	secukinumab	NOUN
dpc-4248	393	22	:	:	PUNCT
dpc-4248	393	23	real	real	ADJ
dpc-4248	393	24	-	-	PUNCT
dpc-4248	393	25	world	world	NOUN
dpc-4248	393	26	data	datum	NOUN
dpc-4248	393	27	from	from	ADP
dpc-4248	393	28	the	the	DET
dpc-4248	393	29	czech	czech	PROPN
dpc-4248	393	30	republic	republic	NOUN
dpc-4248	393	31	biorep	biorep	PROPN
dpc-4248	393	32	registry	registry	PROPN
dpc-4248	393	33	.	.	PUNCT
dpc-4248	394	1	j	j	PROPN
dpc-4248	394	2	dermatolog	dermatolog	PROPN
dpc-4248	394	3	treat	treat	NOUN
dpc-4248	394	4	.	.	PUNCT
dpc-4248	395	1	2022	2022	NUM
dpc-4248	395	2	sep;33(6):2827–2837	sep;33(6):2827–2837	PRON
dpc-4248	395	3	.	.	PUNCT
dpc-4248	396	1	doi	doi	NOUN
dpc-4248	396	2	:	:	PUNCT
dpc-4248	396	3	10.1080/09546634.2022.2082354	10.1080/09546634.2022.2082354	NUM
dpc-4248	396	4	.	.	PUNCT
dpc-4248	397	1	epub	epub	NOUN
dpc-4248	397	2	2022	2022	NUM
dpc-4248	397	3	may	may	AUX
dpc-4248	397	4	29	29	NUM
dpc-4248	397	5	.	.	PUNCT
dpc-4248	398	1	pmid	pmid	NOUN
dpc-4248	398	2	:	:	PUNCT
dpc-4248	398	3	35635185	35635185	NUM
dpc-4248	398	4	.	.	PUNCT
dpc-4248	399	1	19	19	NUM
dpc-4248	399	2	.	.	NOUN
dpc-4248	399	3	torres	torres	PROPN
dpc-4248	399	4	t	t	PROPN
dpc-4248	399	5	,	,	PUNCT
dpc-4248	399	6	puig	puig	PROPN
dpc-4248	399	7	l	l	NOUN
dpc-4248	399	8	,	,	PUNCT
dpc-4248	399	9	vender	vender	PROPN
dpc-4248	399	10	r	r	PROPN
dpc-4248	399	11	,	,	PUNCT
dpc-4248	399	12	yeung	yeung	PROPN
dpc-4248	399	13	j	j	PROPN
dpc-4248	399	14	,	,	PUNCT
dpc-4248	399	15	carrascosa	carrascosa	PROPN
dpc-4248	399	16	jm	jm	PROPN
dpc-4248	399	17	,	,	PUNCT
dpc-4248	399	18	piaserico	piaserico	PROPN
dpc-4248	399	19	s	s	PART
dpc-4248	399	20	,	,	PUNCT
dpc-4248	399	21	gisondi	gisondi	NOUN
dpc-4248	399	22	p	p	NOUN
dpc-4248	399	23	,	,	PUNCT
dpc-4248	399	24	lynde	lynde	PROPN
dpc-4248	399	25	c	c	PROPN
dpc-4248	399	26	,	,	PUNCT
dpc-4248	399	27	ferreira	ferreira	PROPN
dpc-4248	399	28	p	p	PROPN
dpc-4248	399	29	,	,	PUNCT
dpc-4248	399	30	bastos	bastos	PROPN
dpc-4248	399	31	pm	pm	NOUN
dpc-4248	399	32	,	,	PUNCT
dpc-4248	399	33	dauden	dauden	ADJ
dpc-4248	399	34	e	e	NOUN
dpc-4248	399	35	,	,	PUNCT
dpc-4248	399	36	leite	leite	PROPN
dpc-4248	399	37	l	l	PROPN
dpc-4248	399	38	,	,	PUNCT
dpc-4248	399	39	valerio	valerio	PROPN
dpc-4248	399	40	j	j	PROPN
dpc-4248	399	41	,	,	PUNCT
dpc-4248	399	42	del	del	PROPN
dpc-4248	399	43	alcázar	alcázar	PROPN
dpc-4248	399	44	-	-	PROPN
dpc-4248	399	45	viladomiu	viladomiu	PROPN
dpc-4248	399	46	e	e	PROPN
dpc-4248	399	47	,	,	PUNCT
dpc-4248	399	48	rull	rull	PROPN
dpc-4248	399	49	ev	ev	NOUN
dpc-4248	399	50	,	,	PUNCT
dpc-4248	399	51	llamas	llamas	PROPN
dpc-4248	399	52	-	-	PUNCT
dpc-4248	399	53	velasco	velasco	PROPN
dpc-4248	399	54	m	m	PROPN
dpc-4248	399	55	,	,	PUNCT
dpc-4248	399	56	pirro	pirro	PROPN
dpc-4248	399	57	f	f	PROPN
dpc-4248	399	58	,	,	PUNCT
dpc-4248	399	59	messina	messina	PROPN
dpc-4248	399	60	f	f	PROPN
dpc-4248	399	61	,	,	PUNCT
dpc-4248	399	62	bruni	bruni	PROPN
dpc-4248	399	63	m	m	PROPN
dpc-4248	399	64	,	,	PUNCT
dpc-4248	399	65	licata	licata	VERB
dpc-4248	399	66	g	g	PROPN
dpc-4248	399	67	,	,	PUNCT
dpc-4248	399	68	ricceri	ricceri	PROPN
dpc-4248	399	69	f	f	PROPN
dpc-4248	399	70	,	,	PUNCT
dpc-4248	399	71	nidegger	nidegger	PROPN
dpc-4248	399	72	a	a	X
dpc-4248	399	73	,	,	PUNCT
dpc-4248	399	74	hugo	hugo	PROPN
dpc-4248	399	75	j	j	PROPN
dpc-4248	399	76	,	,	PUNCT
dpc-4248	399	77	mufti	mufti	PROPN
dpc-4248	399	78	a	a	PROPN
dpc-4248	399	79	,	,	PUNCT
dpc-4248	399	80	daponte	daponte	NOUN
dpc-4248	399	81	ai	ai	PROPN
dpc-4248	399	82	,	,	PUNCT
dpc-4248	399	83	teixeira	teixeira	PROPN
dpc-4248	399	84	l	l	PROPN
dpc-4248	399	85	,	,	PUNCT
dpc-4248	399	86	balato	balato	VERB
dpc-4248	399	87	a	a	PRON
dpc-4248	399	88	,	,	PUNCT
dpc-4248	399	89	romanelli	romanelli	NOUN
dpc-4248	399	90	m	m	PROPN
dpc-4248	399	91	,	,	PUNCT
dpc-4248	400	1	prignano	prignano	PROPN
dpc-4248	400	2	f	f	PROPN
dpc-4248	400	3	,	,	PUNCT
dpc-4248	400	4	gkalpakiotis	gkalpakiotis	PROPN
dpc-4248	400	5	s	s	PROPN
dpc-4248	400	6	,	,	PUNCT
dpc-4248	400	7	conrad	conrad	PROPN
dpc-4248	400	8	c	c	PROPN
dpc-4248	400	9	,	,	PUNCT
dpc-4248	400	10	lazaridou	lazaridou	PROPN
dpc-4248	400	11	e	e	PROPN
dpc-4248	400	12	,	,	PUNCT
dpc-4248	400	13	rompoti	rompoti	PROPN
dpc-4248	400	14	n	n	CCONJ
dpc-4248	400	15	,	,	PUNCT
dpc-4248	400	16	papoutsaki	papoutsaki	PROPN
dpc-4248	400	17	m	m	PROPN
dpc-4248	400	18	,	,	PUNCT
dpc-4248	400	19	nogueira	nogueira	PROPN
dpc-4248	400	20	m	m	PROPN
dpc-4248	400	21	,	,	PUNCT
dpc-4248	400	22	chiricozzi	chiricozzi	PROPN
dpc-4248	400	23	a.	a.	NOUN
dpc-4248	400	24	drug	drug	PROPN
dpc-4248	400	25	survival	survival	NOUN
dpc-4248	400	26	of	of	ADP
dpc-4248	400	27	interleukin	interleukin	NOUN
dpc-4248	400	28	(	(	PUNCT
dpc-4248	400	29	il	il	PROPN
dpc-4248	400	30	)	)	PUNCT
dpc-4248	400	31	17	17	NUM
dpc-4248	400	32	and	and	CCONJ
dpc-4248	400	33	il	il	PROPN
dpc-4248	400	34	23	23	NUM
dpc-4248	400	35	inhibitors	inhibitor	NOUN
dpc-4248	400	36	for	for	ADP
dpc-4248	400	37	the	the	DET
dpc-4248	400	38	treatment	treatment	NOUN
dpc-4248	400	39	of	of	ADP
dpc-4248	400	40	psoriasis	psoriasis	NOUN
dpc-4248	400	41	:	:	PUNCT
dpc-4248	400	42	a	a	DET
dpc-4248	400	43	retrospective	retrospective	ADJ
dpc-4248	400	44	multi	multi	ADJ
dpc-4248	400	45	country	country	NOUN
dpc-4248	400	46	,	,	PUNCT
dpc-4248	400	47	multicentric	multicentric	ADJ
dpc-4248	400	48	cohort	cohort	NOUN
dpc-4248	400	49	study	study	NOUN
dpc-4248	400	50	.	.	PUNCT
dpc-4248	401	1	am	be	AUX
dpc-4248	401	2	j	j	PROPN
dpc-4248	401	3	clin	clin	PROPN
dpc-4248	401	4	dermatol	dermatol	NOUN
dpc-4248	401	5	.	.	PUNCT
dpc-4248	402	1	2022	2022	NUM
dpc-4248	402	2	nov;23(6):891–904	nov;23(6):891–904	VERB
dpc-4248	402	3	.	.	PUNCT
dpc-4248	403	1	doi	doi	NOUN
dpc-4248	403	2	:	:	PUNCT
dpc-4248	403	3	10.1007	10.1007	NUM
dpc-4248	403	4	/	/	SYM
dpc-4248	403	5	s40257	s40257	NOUN
dpc-4248	403	6	-022	-022	PROPN
dpc-4248	403	7	-	-	PUNCT
dpc-4248	403	8	00722	00722	NUM
dpc-4248	403	9	-	-	PUNCT
dpc-4248	403	10	y.	y.	NOUN
dpc-4248	403	11	epub	epub	PROPN
dpc-4248	403	12	2022	2022	NUM
dpc-4248	403	13	aug	aug	PROPN
dpc-4248	403	14	17	17	NUM
dpc-4248	403	15	.	.	PUNCT
dpc-4248	404	1	pmid	pmid	NOUN
dpc-4248	404	2	:	:	PUNCT
dpc-4248	404	3	35976568	35976568	NUM
dpc-4248	404	4	.	.	PUNCT
dpc-4248	405	1	20	20	NUM
dpc-4248	405	2	.	.	PUNCT
dpc-4248	406	1	gargiulo	gargiulo	PROPN
dpc-4248	406	2	l	l	NOUN
dpc-4248	406	3	,	,	PUNCT
dpc-4248	406	4	ibba	ibba	ADJ
dpc-4248	406	5	l	l	NOUN
dpc-4248	406	6	,	,	PUNCT
dpc-4248	406	7	malagoli	malagoli	NOUN
dpc-4248	406	8	p	p	NOUN
dpc-4248	406	9	,	,	PUNCT
dpc-4248	406	10	amoruso	amoruso	PROPN
dpc-4248	406	11	f	f	PROPN
dpc-4248	406	12	,	,	PUNCT
dpc-4248	406	13	argenziano	argenziano	ADJ
dpc-4248	406	14	g	g	NOUN
dpc-4248	406	15	,	,	PUNCT
dpc-4248	406	16	balato	balato	NOUN
dpc-4248	406	17	a	a	DET
dpc-4248	406	18	,	,	PUNCT
dpc-4248	406	19	bardazzi	bardazzi	NOUN
dpc-4248	406	20	f	f	NOUN
dpc-4248	406	21	,	,	PUNCT
dpc-4248	406	22	burlando	burlando	PROPN
dpc-4248	406	23	m	m	PROPN
dpc-4248	406	24	,	,	PUNCT
dpc-4248	406	25	carrera	carrera	PROPN
dpc-4248	406	26	cg	cg	PROPN
dpc-4248	406	27	,	,	PUNCT
dpc-4248	406	28	damiani	damiani	PROPN
dpc-4248	406	29	g	g	PROPN
dpc-4248	406	30	,	,	PUNCT
dpc-4248	406	31	dapavo	dapavo	VERB
dpc-4248	406	32	p	p	NOUN
dpc-4248	406	33	,	,	PUNCT
dpc-4248	406	34	dini	dini	NOUN
dpc-4248	406	35	v	v	NOUN
dpc-4248	406	36	,	,	PUNCT
dpc-4248	406	37	fabbrocini	fabbrocini	NOUN
dpc-4248	406	38	g	g	NOUN
dpc-4248	406	39	,	,	PUNCT
dpc-4248	406	40	franchi	franchi	PROPN
dpc-4248	406	41	c	c	PROPN
dpc-4248	406	42	,	,	PUNCT
dpc-4248	406	43	gaiani	gaiani	PROPN
dpc-4248	406	44	fm	fm	PROPN
dpc-4248	406	45	,	,	PUNCT
dpc-4248	406	46	girolomoni	girolomoni	VERB
dpc-4248	406	47	g	g	NOUN
dpc-4248	406	48	,	,	PUNCT
dpc-4248	406	49	guarneri	guarneri	ADJ
dpc-4248	406	50	c	c	NOUN
dpc-4248	406	51	,	,	PUNCT
dpc-4248	406	52	lasagni	lasagni	NOUN
dpc-4248	406	53	c	c	NOUN
dpc-4248	406	54	,	,	PUNCT
dpc-4248	406	55	loconsole	loconsole	NOUN
dpc-4248	406	56	f	f	X
dpc-4248	406	57	,	,	PUNCT
dpc-4248	406	58	marzano	marzano	PROPN
dpc-4248	406	59	av	av	PROPN
dpc-4248	406	60	,	,	PUNCT
dpc-4248	406	61	megna	megna	PROPN
dpc-4248	406	62	m	m	PROPN
dpc-4248	406	63	,	,	PUNCT
dpc-4248	406	64	sampogna	sampogna	PROPN
dpc-4248	406	65	f	f	NOUN
dpc-4248	406	66	,	,	PUNCT
dpc-4248	406	67	travaglini	travaglini	ADJ
dpc-4248	406	68	m	m	PROPN
dpc-4248	406	69	,	,	PUNCT
dpc-4248	406	70	costanzo	costanzo	PROPN
dpc-4248	406	71	a	a	DET
dpc-4248	406	72	,	,	PUNCT
dpc-4248	406	73	narcisi	narcisi	ADJ
dpc-4248	406	74	a.	a.	NOUN
dpc-4248	406	75	brodalumab	brodalumab	NOUN
dpc-4248	406	76	for	for	ADP
dpc-4248	406	77	the	the	DET
dpc-4248	406	78	treatment	treatment	NOUN
dpc-4248	406	79	of	of	ADP
dpc-4248	406	80	plaque	plaque	NOUN
dpc-4248	406	81	psoriasis	psoriasis	NOUN
dpc-4248	406	82	in	in	ADP
dpc-4248	406	83	a	a	DET
dpc-4248	406	84	real	real	ADJ
dpc-4248	406	85	-	-	PUNCT
dpc-4248	406	86	life	life	NOUN
dpc-4248	406	87	setting	setting	NOUN
dpc-4248	406	88	:	:	PUNCT
dpc-4248	406	89	a	a	DET
dpc-4248	406	90	3	3	NUM
dpc-4248	406	91	  	  	SPACE
dpc-4248	406	92	years	year	NOUN
dpc-4248	406	93	multicenter	multicenter	NOUN
dpc-4248	406	94	retrospective	retrospective	ADJ
dpc-4248	406	95	study	study	NOUN
dpc-4248	406	96	-	-	PUNCT
dpc-4248	406	97	il	il	PROPN
dpc-4248	406	98	pso	pso	PROPN
dpc-4248	406	99	(	(	PUNCT
dpc-4248	406	100	italian	italian	ADJ
dpc-4248	406	101	landscape	landscape	NOUN
dpc-4248	406	102	psoriasis	psoriasis	NOUN
dpc-4248	406	103	)	)	PUNCT
dpc-4248	406	104	.	.	PUNCT
dpc-4248	407	1	front	front	PROPN
dpc-4248	407	2	med	med	PROPN
dpc-4248	407	3	(	(	PUNCT
dpc-4248	407	4	lausanne	lausanne	PROPN
dpc-4248	407	5	)	)	PUNCT
dpc-4248	407	6	.	.	PUNCT
dpc-4248	408	1	2023	2023	NUM
dpc-4248	408	2	jul	jul	PROPN
dpc-4248	408	3	3;10:1196966	3;10:1196966	NUM
dpc-4248	408	4	.	.	PUNCT
dpc-4248	409	1	doi	doi	NOUN
dpc-4248	409	2	:	:	PUNCT
dpc-4248	409	3	10.3389	10.3389	NUM
dpc-4248	409	4	/	/	SYM
dpc-4248	409	5	fmed.2023.1196966	fmed.2023.1196966	NUM
dpc-4248	409	6	.	.	PUNCT
dpc-4248	410	1	pmid	pmid	NOUN
dpc-4248	410	2	:	:	PUNCT
dpc-4248	410	3	37469659	37469659	NUM
dpc-4248	410	4	;	;	PUNCT
dpc-4248	410	5	pmcid	pmcid	ADJ
dpc-4248	410	6	:	:	PUNCT
dpc-4248	410	7	pmc10352451	pmc10352451	NOUN
dpc-4248	410	8	.	.	PUNCT
dpc-4248	411	1	21	21	NUM
dpc-4248	411	2	.	.	X
dpc-4248	411	3	caldarola	caldarola	PROPN
dpc-4248	411	4	g	g	PROPN
dpc-4248	411	5	,	,	PUNCT
dpc-4248	411	6	pirro	pirro	PROPN
dpc-4248	411	7	f	f	PROPN
dpc-4248	411	8	,	,	PUNCT
dpc-4248	411	9	di	di	PROPN
dpc-4248	411	10	stefani	stefani	PROPN
dpc-4248	411	11	a	a	PRON
dpc-4248	411	12	,	,	PUNCT
dpc-4248	411	13	talamonti	talamonti	PROPN
dpc-4248	411	14	m	m	PROPN
dpc-4248	411	15	,	,	PUNCT
dpc-4248	411	16	galluzzo	galluzzo	PROPN
dpc-4248	411	17	m	m	PROPN
dpc-4248	411	18	,	,	PUNCT
dpc-4248	411	19	d’adamio	d’adamio	PROPN
dpc-4248	411	20	s	s	PART
dpc-4248	411	21	,	,	PUNCT
dpc-4248	411	22	magnano	magnano	PROPN
dpc-4248	411	23	m	m	PROPN
dpc-4248	411	24	,	,	PUNCT
dpc-4248	411	25	bernardini	bernardini	PROPN
dpc-4248	411	26	n	n	CCONJ
dpc-4248	411	27	,	,	PUNCT
dpc-4248	411	28	malagoli	malagoli	NOUN
dpc-4248	411	29	p	p	NOUN
dpc-4248	411	30	,	,	PUNCT
dpc-4248	411	31	bardazzi	bardazzi	NOUN
dpc-4248	411	32	f	f	NOUN
dpc-4248	411	33	,	,	PUNCT
dpc-4248	411	34	potenza	potenza	PROPN
dpc-4248	411	35	c	c	PROPN
dpc-4248	411	36	,	,	PUNCT
dpc-4248	411	37	bianchi	bianchi	PROPN
dpc-4248	411	38	l	l	PROPN
dpc-4248	411	39	,	,	PUNCT
dpc-4248	411	40	peris	peris	PROPN
dpc-4248	411	41	k	k	PROPN
dpc-4248	411	42	,	,	PUNCT
dpc-4248	411	43	de	de	PROPN
dpc-4248	411	44	simone	simone	PROPN
dpc-4248	411	45	c.	c.	PROPN
dpc-4248	411	46	clinical	clinical	ADJ
dpc-4248	411	47	and	and	CCONJ
dpc-4248	411	48	histopathological	histopathological	ADJ
dpc-4248	411	49	characterization	characterization	NOUN
dpc-4248	411	50	of	of	ADP
dpc-4248	411	51	eczematous	eczematous	ADJ
dpc-4248	411	52	eruptions	eruption	NOUN
dpc-4248	411	53	occurring	occur	VERB
dpc-4248	411	54	in	in	ADP
dpc-4248	411	55	course	course	NOUN
dpc-4248	411	56	of	of	ADP
dpc-4248	411	57	anti	anti	ADJ
dpc-4248	411	58	il-17	il-17	ADP
dpc-4248	411	59	treatment	treatment	NOUN
dpc-4248	411	60	:	:	PUNCT
dpc-4248	411	61	a	a	DET
dpc-4248	411	62	case	case	NOUN
dpc-4248	411	63	series	series	NOUN
dpc-4248	411	64	and	and	CCONJ
dpc-4248	411	65	review	review	NOUN
dpc-4248	411	66	of	of	ADP
dpc-4248	411	67	the	the	DET
dpc-4248	411	68	literature	literature	NOUN
dpc-4248	411	69	.	.	PUNCT
dpc-4248	412	1	expert	expert	NOUN
dpc-4248	412	2	opin	opin	NOUN
dpc-4248	412	3	biol	biol	NOUN
dpc-4248	412	4	ther	ther	ADV
dpc-4248	412	5	.	.	PUNCT
dpc-4248	413	1	2020	2020	NUM
dpc-4248	414	1	jun;20(6):665–672	jun;20(6):665–672	VERB
dpc-4248	414	2	.	.	PUNCT
dpc-4248	414	3	doi	doi	NOUN
dpc-4248	414	4	:	:	PUNCT
dpc-4248	414	5	10.1080/14712598.2020.1727439	10.1080/14712598.2020.1727439	NUM
dpc-4248	414	6	.	.	PUNCT
dpc-4248	415	1	epub	epub	PROPN
dpc-4248	415	2	2020	2020	NUM
dpc-4248	415	3	feb	feb	PROPN
dpc-4248	415	4	17	17	NUM
dpc-4248	415	5	.	.	PUNCT
dpc-4248	416	1	pmid	pmid	NOUN
dpc-4248	416	2	:	:	PUNCT
dpc-4248	416	3	32045273	32045273	NUM
dpc-4248	416	4	.	.	PUNCT
dpc-4248	417	1	22	22	NUM
dpc-4248	417	2	.	.	PUNCT
dpc-4248	418	1	kimura	kimura	NOUN
dpc-4248	418	2	r	r	NOUN
dpc-4248	418	3	,	,	PUNCT
dpc-4248	418	4	sugita	sugita	PROPN
dpc-4248	418	5	k	k	PROPN
dpc-4248	418	6	,	,	PUNCT
dpc-4248	418	7	yamamoto	yamamoto	PROPN
dpc-4248	418	8	o.	o.	PROPN
dpc-4248	418	9	successful	successful	PROPN
dpc-4248	418	10	switching	switch	VERB
dpc-4248	418	11	to	to	PART
dpc-4248	418	12	brodalumab	brodalumab	VERB
dpc-4248	418	13	in	in	ADP
dpc-4248	418	14	a	a	DET
dpc-4248	418	15	patient	patient	NOUN
dpc-4248	418	16	with	with	ADP
dpc-4248	418	17	severe	severe	ADJ
dpc-4248	418	18	psoriasis	psoriasis	NOUN
dpc-4248	418	19	developing	develop	VERB
dpc-4248	418	20	ixekizumab	ixekizumab	NOUN
dpc-4248	418	21	-	-	PUNCT
dpc-4248	418	22	induced	induce	VERB
dpc-4248	418	23	eczema	eczema	NOUN
dpc-4248	418	24	.	.	PUNCT
dpc-4248	419	1	eur	eur	PROPN
dpc-4248	419	2	j	j	PROPN
dpc-4248	419	3	dermatol	dermatol	NOUN
dpc-4248	419	4	.	.	PUNCT
dpc-4248	420	1	2020	2020	NUM
dpc-4248	420	2	dec	dec	PROPN
dpc-4248	420	3	1;30(6	1;30(6	NUM
dpc-4248	420	4	):	):	PUNCT
dpc-4248	421	1	732–734	732–734	NUM
dpc-4248	421	2	.	.	PUNCT
dpc-4248	421	3	doi	doi	NOUN
dpc-4248	421	4	:	:	PUNCT
dpc-4248	421	5	10.1684	10.1684	NUM
dpc-4248	421	6	/	/	SYM
dpc-4248	421	7	ejd.2020.3904	ejd.2020.3904	NOUN
dpc-4248	421	8	.	.	PUNCT
dpc-4248	422	1	pmid	pmid	NOUN
dpc-4248	422	2	:	:	PUNCT
dpc-4248	422	3	33237034	33237034	NUM
dpc-4248	422	4	.	.	PUNCT
dpc-4248	423	1	23	23	NUM
dpc-4248	423	2	.	.	PUNCT
dpc-4248	424	1	gambardella	gambardella	PROPN
dpc-4248	424	2	a	a	PRON
dpc-4248	424	3	,	,	PUNCT
dpc-4248	424	4	licata	licata	NOUN
dpc-4248	424	5	g	g	PROPN
dpc-4248	424	6	,	,	PUNCT
dpc-4248	424	7	de	de	PROPN
dpc-4248	424	8	rosa	rosa	PROPN
dpc-4248	424	9	a	a	PROPN
dpc-4248	424	10	,	,	PUNCT
dpc-4248	424	11	pagliuca	pagliuca	PROPN
dpc-4248	424	12	f	f	PROPN
dpc-4248	424	13	,	,	PUNCT
dpc-4248	424	14	calabrese	calabrese	ADJ
dpc-4248	424	15	g	g	NOUN
dpc-4248	424	16	,	,	PUNCT
dpc-4248	424	17	alfano	alfano	NOUN
dpc-4248	424	18	r	r	NOUN
dpc-4248	424	19	,	,	PUNCT
dpc-4248	424	20	argenziano	argenziano	ADJ
dpc-4248	424	21	g.	g.	PROPN
dpc-4248	424	22	concurrent	concurrent	ADJ
dpc-4248	424	23	atopic	atopic	NOUN
dpc-4248	424	24	dermatitis	dermatitis	NOUN
dpc-4248	424	25	and	and	CCONJ
dpc-4248	424	26	psoriasis	psoriasis	NOUN
dpc-4248	424	27	successfully	successfully	ADV
dpc-4248	424	28	treated	treat	VERB
dpc-4248	424	29	with	with	ADP
dpc-4248	424	30	brodalumab	brodalumab	NOUN
dpc-4248	424	31	.	.	PUNCT
dpc-4248	425	1	dermatitis	dermatitis	NOUN
dpc-4248	425	2	.	.	PUNCT
dpc-4248	426	1	2021	2021	NUM
dpc-4248	426	2	oct	oct	NOUN
dpc-4248	426	3	1;32(1s):e86	1;32(1s):e86	NUM
dpc-4248	426	4	-	-	PUNCT
dpc-4248	426	5	e88	e88	NOUN
dpc-4248	426	6	.	.	PUNCT
dpc-4248	427	1	doi	doi	NOUN
dpc-4248	427	2	:	:	PUNCT
dpc-4248	427	3	10.1097	10.1097	NUM
dpc-4248	427	4	/	/	SYM
dpc-4248	427	5	der.0000000000000645	der.0000000000000645	NOUN
dpc-4248	427	6	.	.	PUNCT
dpc-4248	428	1	pmid	pmid	NOUN
dpc-4248	428	2	:	:	PUNCT
dpc-4248	428	3	33208631	33208631	NUM
dpc-4248	428	4	.	.	PUNCT
dpc-4248	429	1	24	24	NUM
dpc-4248	429	2	.	.	PUNCT
dpc-4248	429	3	davidson	davidson	PROPN
dpc-4248	429	4	l	l	PROPN
dpc-4248	429	5	,	,	PUNCT
dpc-4248	429	6	van	van	PROPN
dpc-4248	429	7	den	den	PROPN
dpc-4248	429	8	reek	reek	PROPN
dpc-4248	429	9	jmpa	jmpa	PROPN
dpc-4248	429	10	,	,	PUNCT
dpc-4248	429	11	bruno	bruno	PROPN
dpc-4248	429	12	m	m	PROPN
dpc-4248	429	13	,	,	PUNCT
dpc-4248	429	14	van	van	PROPN
dpc-4248	429	15	hunsel	hunsel	PROPN
dpc-4248	429	16	f	f	PROPN
dpc-4248	429	17	,	,	PUNCT
dpc-4248	429	18	herings	hering	NOUN
dpc-4248	429	19	rmc	rmc	PROPN
dpc-4248	429	20	,	,	PUNCT
dpc-4248	429	21	matzaraki	matzaraki	PROPN
dpc-4248	429	22	v	v	NOUN
dpc-4248	429	23	,	,	PUNCT
dpc-4248	429	24	boahen	boahen	NOUN
dpc-4248	429	25	ck	ck	PROPN
dpc-4248	429	26	,	,	PUNCT
dpc-4248	429	27	kumar	kumar	PROPN
dpc-4248	429	28	v	v	PROPN
dpc-4248	429	29	,	,	PUNCT
dpc-4248	429	30	groenewoud	groenewoud	ADJ
dpc-4248	429	31	hmm	hmm	NOUN
dpc-4248	429	32	,	,	PUNCT
dpc-4248	429	33	van	van	PROPN
dpc-4248	429	34	de	de	PROPN
dpc-4248	429	35	veerdonk	veerdonk	PROPN
dpc-4248	429	36	fl	fl	PROPN
dpc-4248	429	37	,	,	PUNCT
dpc-4248	429	38	netea	netea	NOUN
dpc-4248	429	39	mg	mg	PROPN
dpc-4248	429	40	,	,	PUNCT
dpc-4248	429	41	de	de	PROPN
dpc-4248	429	42	jong	jong	PROPN
dpc-4248	429	43	emgj	emgj	PROPN
dpc-4248	429	44	,	,	PUNCT
dpc-4248	429	45	kullberg	kullberg	PROPN
dpc-4248	429	46	bj	bj	VERB
dpc-4248	429	47	.	.	PUNCT
dpc-4248	430	1	risk	risk	NOUN
dpc-4248	430	2	of	of	ADP
dpc-4248	430	3	candidiasis	candidiasis	NOUN
dpc-4248	430	4	associated	associate	VERB
dpc-4248	430	5	with	with	ADP
dpc-4248	430	6	interleukin-17	interleukin-17	PROPN
dpc-4248	430	7	inhibitors	inhibitor	NOUN
dpc-4248	430	8	:	:	PUNCT
dpc-4248	430	9	a	a	DET
dpc-4248	430	10	real	real	ADJ
dpc-4248	430	11	-	-	PUNCT
dpc-4248	430	12	world	world	NOUN
dpc-4248	430	13	observational	observational	ADJ
dpc-4248	430	14	study	study	NOUN
dpc-4248	430	15	of	of	ADP
dpc-4248	430	16	multiple	multiple	ADJ
dpc-4248	430	17	independent	independent	ADJ
dpc-4248	430	18	sources	source	NOUN
dpc-4248	430	19	.	.	PUNCT
dpc-4248	431	1	lancet	lancet	VERB
dpc-4248	431	2	reg	reg	PROPN
dpc-4248	431	3	health	health	PROPN
dpc-4248	431	4	eur	eur	PROPN
dpc-4248	431	5	.	.	PROPN
dpc-4248	432	1	2021	2021	NUM
dpc-4248	432	2	nov	nov	NOUN
dpc-4248	432	3	22;13:100266	22;13:100266	NUM
dpc-4248	432	4	.	.	PUNCT
dpc-4248	433	1	doi	doi	NOUN
dpc-4248	433	2	:	:	PUNCT
dpc-4248	433	3	10.1016	10.1016	NUM
dpc-4248	433	4	/	/	SYM
dpc-4248	433	5	j.lanepe.2021.100266	j.lanepe.2021.100266	PROPN
dpc-4248	433	6	.	.	PUNCT
dpc-4248	434	1	pmid	pmid	NOUN
dpc-4248	434	2	:	:	PUNCT
dpc-4248	434	3	34950923	34950923	NUM
dpc-4248	434	4	;	;	PUNCT
dpc-4248	434	5	pmcid	pmcid	PROPN
dpc-4248	434	6	:	:	PUNCT
dpc-4248	434	7	pmc8671639	pmc8671639	PROPN
dpc-4248	434	8	.	.	PUNCT
dpc-4248	435	1	25	25	NUM
dpc-4248	435	2	.	.	PUNCT
dpc-4248	435	3	eder	eder	NOUN
dpc-4248	435	4	l	l	NOUN
dpc-4248	435	5	,	,	PUNCT
dpc-4248	435	6	haddad	haddad	PROPN
dpc-4248	435	7	a	a	PROPN
dpc-4248	435	8	,	,	PUNCT
dpc-4248	435	9	rosen	rosen	PROPN
dpc-4248	435	10	cf	cf	PROPN
dpc-4248	435	11	,	,	PUNCT
dpc-4248	435	12	lee	lee	PROPN
dpc-4248	435	13	ka	ka	PROPN
dpc-4248	435	14	,	,	PUNCT
dpc-4248	435	15	chandran	chandran	PROPN
dpc-4248	435	16	v	v	PROPN
dpc-4248	435	17	,	,	PUNCT
dpc-4248	435	18	cook	cook	VERB
dpc-4248	435	19	r	r	NOUN
dpc-4248	435	20	,	,	PUNCT
dpc-4248	435	21	gladman	gladman	NOUN
dpc-4248	435	22	dd	dd	NOUN
dpc-4248	435	23	.	.	PUNCT
dpc-4248	436	1	the	the	DET
dpc-4248	436	2	incidence	incidence	NOUN
dpc-4248	436	3	and	and	CCONJ
dpc-4248	436	4	risk	risk	NOUN
dpc-4248	436	5	factors	factor	NOUN
dpc-4248	436	6	for	for	ADP
dpc-4248	436	7	psoriatic	psoriatic	ADJ